0001723128-24-000021.txt : 20240508 0001723128-24-000021.hdr.sgml : 20240508 20240508164614 ACCESSION NUMBER: 0001723128-24-000021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 24927030 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 10-Q 1 amrx-20240331.htm 10-Q amrx-20240331
000172312812-312024Q1falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURamrx:productamrx:representativeamrx:medicationamrx:stateamrx:actionamrx:caseiso4217:USDamrx:twinPackamrx:segmentiso4217:INR00017231282024-01-012024-03-3100017231282024-04-3000017231282023-01-012023-03-310001723128amrx:OpanaERAntitrustLitigationMember2023-01-012023-03-3100017231282024-03-3100017231282023-12-310001723128us-gaap:NonrelatedPartyMember2024-03-310001723128us-gaap:NonrelatedPartyMember2023-12-310001723128us-gaap:RelatedPartyMember2024-03-310001723128us-gaap:RelatedPartyMember2023-12-310001723128us-gaap:CommonClassAMember2023-12-310001723128us-gaap:CommonClassAMember2024-03-310001723128us-gaap:CommonClassBMember2024-03-310001723128us-gaap:CommonClassBMember2023-12-3100017231282022-12-3100017231282023-03-310001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001723128us-gaap:AdditionalPaidInCapitalMember2023-12-310001723128us-gaap:RetainedEarningsMember2023-12-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001723128us-gaap:NoncontrollingInterestMember2023-12-310001723128us-gaap:RetainedEarningsMember2024-01-012024-03-310001723128us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001723128us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-03-310001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-310001723128us-gaap:AdditionalPaidInCapitalMember2024-03-310001723128us-gaap:RetainedEarningsMember2024-03-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001723128us-gaap:NoncontrollingInterestMember2024-03-310001723128us-gaap:CommonStockMemberamrx:OldPubCoCommonClassAMember2022-12-310001723128us-gaap:CommonStockMemberamrx:OldPubCoCommonClassBMember2022-12-310001723128us-gaap:AdditionalPaidInCapitalMember2022-12-310001723128us-gaap:RetainedEarningsMember2022-12-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001723128us-gaap:NoncontrollingInterestMember2022-12-310001723128us-gaap:RetainedEarningsMember2023-01-012023-03-310001723128us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001723128us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001723128us-gaap:CommonStockMemberamrx:OldPubCoCommonClassAMember2023-01-012023-03-310001723128us-gaap:CommonStockMemberamrx:OldPubCoCommonClassAMember2023-03-310001723128us-gaap:CommonStockMemberamrx:OldPubCoCommonClassBMember2023-03-310001723128us-gaap:AdditionalPaidInCapitalMember2023-03-310001723128us-gaap:RetainedEarningsMember2023-03-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001723128us-gaap:NoncontrollingInterestMember2023-03-310001723128amrx:AmnealPharmaceuticalsLLCMember2024-03-310001723128amrx:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001723128amrx:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001723128amrx:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001723128amrx:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001723128us-gaap:RevenueFromContractWithCustomerMemberamrx:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001723128us-gaap:RevenueFromContractWithCustomerMemberamrx:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerDMember2024-01-012024-03-310001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerDMember2023-01-012023-03-310001723128country:USamrx:GenericsSegmentMemberamrx:AntiInfectiveMember2024-01-012024-03-310001723128country:USamrx:GenericsSegmentMemberamrx:AntiInfectiveMember2023-01-012023-03-310001723128amrx:HormonalAllergyMembercountry:USamrx:GenericsSegmentMember2024-01-012024-03-310001723128amrx:HormonalAllergyMembercountry:USamrx:GenericsSegmentMember2023-01-012023-03-310001723128country:USamrx:GenericsSegmentMemberamrx:AntiviralMember2024-01-012024-03-310001723128country:USamrx:GenericsSegmentMemberamrx:AntiviralMember2023-01-012023-03-310001723128country:USamrx:GenericsSegmentMemberamrx:CentralNervousSystemMember2024-01-012024-03-310001723128country:USamrx:GenericsSegmentMemberamrx:CentralNervousSystemMember2023-01-012023-03-310001723128country:USamrx:CardiovascularSystemMemberamrx:GenericsSegmentMember2024-01-012024-03-310001723128country:USamrx:CardiovascularSystemMemberamrx:GenericsSegmentMember2023-01-012023-03-310001723128amrx:GastroenterologyMembercountry:USamrx:GenericsSegmentMember2024-01-012024-03-310001723128amrx:GastroenterologyMembercountry:USamrx:GenericsSegmentMember2023-01-012023-03-310001723128amrx:OncologyMembercountry:USamrx:GenericsSegmentMember2024-01-012024-03-310001723128amrx:OncologyMembercountry:USamrx:GenericsSegmentMember2023-01-012023-03-310001723128amrx:MetabolicDiseaseEndocrineMembercountry:USamrx:GenericsSegmentMember2024-01-012024-03-310001723128amrx:MetabolicDiseaseEndocrineMembercountry:USamrx:GenericsSegmentMember2023-01-012023-03-310001723128country:USamrx:GenericsSegmentMemberamrx:RespiratoryMember2024-01-012024-03-310001723128country:USamrx:GenericsSegmentMemberamrx:RespiratoryMember2023-01-012023-03-310001723128country:USamrx:GenericsSegmentMemberamrx:DermatologyMember2024-01-012024-03-310001723128country:USamrx:GenericsSegmentMemberamrx:DermatologyMember2023-01-012023-03-310001723128country:USamrx:GenericsSegmentMemberamrx:OtherTherapeuticClassesMember2024-01-012024-03-310001723128country:USamrx:GenericsSegmentMemberamrx:OtherTherapeuticClassesMember2023-01-012023-03-310001723128us-gaap:NonUsMemberamrx:GenericsSegmentMember2024-01-012024-03-310001723128us-gaap:NonUsMemberamrx:GenericsSegmentMember2023-01-012023-03-310001723128amrx:GenericsSegmentMember2024-01-012024-03-310001723128amrx:GenericsSegmentMember2023-01-012023-03-310001723128amrx:HormonalAllergyMembercountry:USamrx:SpecialtySegmentMember2024-01-012024-03-310001723128amrx:HormonalAllergyMembercountry:USamrx:SpecialtySegmentMember2023-01-012023-03-310001723128country:USamrx:CentralNervousSystemMemberamrx:SpecialtySegmentMember2024-01-012024-03-310001723128country:USamrx:CentralNervousSystemMemberamrx:SpecialtySegmentMember2023-01-012023-03-310001723128country:USamrx:LicenseAgreementMemberamrx:SpecialtySegmentMember2024-01-012024-03-310001723128country:USamrx:LicenseAgreementMemberamrx:SpecialtySegmentMember2023-01-012023-03-310001723128country:USamrx:OtherTherapeuticClassesMemberamrx:SpecialtySegmentMember2024-01-012024-03-310001723128country:USamrx:OtherTherapeuticClassesMemberamrx:SpecialtySegmentMember2023-01-012023-03-310001723128amrx:SpecialtySegmentMember2024-01-012024-03-310001723128amrx:SpecialtySegmentMember2023-01-012023-03-310001723128country:USus-gaap:DistributionServiceMemberamrx:AvKARESegmentMember2024-01-012024-03-310001723128country:USus-gaap:DistributionServiceMemberamrx:AvKARESegmentMember2023-01-012023-03-310001723128country:USamrx:GovernmentLabelMemberamrx:AvKARESegmentMember2024-01-012024-03-310001723128country:USamrx:GovernmentLabelMemberamrx:AvKARESegmentMember2023-01-012023-03-310001723128country:USamrx:InstitutionalMemberamrx:AvKARESegmentMember2024-01-012024-03-310001723128country:USamrx:InstitutionalMemberamrx:AvKARESegmentMember2023-01-012023-03-310001723128country:USus-gaap:ProductAndServiceOtherMemberamrx:AvKARESegmentMember2024-01-012024-03-310001723128country:USus-gaap:ProductAndServiceOtherMemberamrx:AvKARESegmentMember2023-01-012023-03-310001723128amrx:AvKARESegmentMember2024-01-012024-03-310001723128amrx:AvKARESegmentMember2023-01-012023-03-310001723128amrx:ContractChargebacksAndSalesVolumeAllowancesMember2023-12-310001723128amrx:CashDiscountAllowancesMember2023-12-310001723128us-gaap:SalesReturnsAndAllowancesMember2023-12-310001723128amrx:AccruedMedicaidAndCommercialRebatesMember2023-12-310001723128amrx:ContractChargebacksAndSalesVolumeAllowancesMember2024-01-012024-03-310001723128amrx:CashDiscountAllowancesMember2024-01-012024-03-310001723128us-gaap:SalesReturnsAndAllowancesMember2024-01-012024-03-310001723128amrx:AccruedMedicaidAndCommercialRebatesMember2024-01-012024-03-310001723128amrx:ContractChargebacksAndSalesVolumeAllowancesMember2024-03-310001723128amrx:CashDiscountAllowancesMember2024-03-310001723128us-gaap:SalesReturnsAndAllowancesMember2024-03-310001723128amrx:AccruedMedicaidAndCommercialRebatesMember2024-03-310001723128amrx:LicenseAgreementWithOrionCorporationMember2022-12-282022-12-280001723128amrx:LicenseAgreementWithOrionCorporationMember2023-01-012023-03-310001723128amrx:LicenseAgreementWithOrionCorporationMember2024-01-012024-03-310001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-03-310001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001723128amrx:ONGENTYSLicenseAgreementMember2023-12-050001723128amrx:ONGENTYSLicenseAgreementMember2023-12-012023-12-310001723128amrx:KnightTherapeuticsInternationalS.A.LicenseAgreementMember2024-01-242024-01-240001723128amrx:KnightTherapeuticsInternationalS.A.LicenseAgreementMember2024-02-260001723128amrx:KnightTherapeuticsInternationalS.A.LicenseAgreementMember2024-02-262024-02-260001723128amrx:LicenseAgreementWithZambonBiotechMember2024-02-232024-02-230001723128amrx:LicenseAgreementWithZambonBiotechMember2024-02-230001723128amrx:LicenseAgreementWithZambonBiotechMember2024-01-012024-03-310001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2018-05-072018-05-070001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2022-01-012022-12-310001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2022-12-310001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2024-01-012024-03-310001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2023-10-122023-10-120001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2023-01-012023-12-310001723128amrx:DevelopmentMilestonesMemberamrx:BiosimilarLicensingAndSupplyAgreementMember2023-01-012023-12-310001723128amrx:RegulatoryApprovalMemberamrx:BiosimilarLicensingAndSupplyAgreementMember2023-01-012023-12-310001723128amrx:AchievementOfCumulativeNetSalesMemberamrx:BiosimilarLicensingAndSupplyAgreementMember2023-01-012023-03-3100017231282018-01-012018-12-3100017231282019-01-012019-12-3100017231282023-01-012023-11-0600017231282023-11-072023-11-070001723128us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001723128us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001723128us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001723128us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001723128us-gaap:PerformanceSharesMember2024-01-012024-03-310001723128us-gaap:PerformanceSharesMember2023-01-012023-03-310001723128us-gaap:CommonClassBMember2024-01-012024-03-310001723128us-gaap:CommonClassBMember2023-01-012023-03-310001723128amrx:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-03-310001723128amrx:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-06-300001723128amrx:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-03-310001723128amrx:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-06-300001723128amrx:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-03-310001723128amrx:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-06-3000017231282023-01-012023-06-300001723128amrx:SpecialtySegmentMember2024-03-310001723128amrx:GenericsSegmentMember2024-03-310001723128amrx:AvKARESegmentMember2024-03-310001723128amrx:SpecialtySegmentMember2023-12-310001723128amrx:GenericsSegmentMember2023-12-310001723128amrx:AvKARESegmentMember2023-12-310001723128us-gaap:ContractualRightsMember2024-03-310001723128us-gaap:ContractualRightsMember2023-12-310001723128us-gaap:TradeNamesMember2024-03-310001723128us-gaap:TradeNamesMember2023-12-310001723128us-gaap:InterestRateSwapMember2024-03-310001723128us-gaap:InterestRateSwapMember2023-12-310001723128amrx:SecurityDepositsMember2024-03-310001723128amrx:SecurityDepositsMember2023-12-310001723128amrx:LongTermPrepaidExpensesMember2024-03-310001723128amrx:LongTermPrepaidExpensesMember2023-12-310001723128amrx:DeferredRevolvingCreditFacilityCostsMember2024-03-310001723128amrx:DeferredRevolvingCreditFacilityCostsMember2023-12-310001723128us-gaap:OtherNoncurrentAssetsMember2024-03-310001723128us-gaap:OtherNoncurrentAssetsMember2023-12-310001723128amrx:TermLoanDue2025Member2024-03-310001723128amrx:TermLoanDue2025Member2023-12-310001723128amrx:TermLoanDue2028Member2024-03-310001723128amrx:TermLoanDue2028Member2023-12-310001723128amrx:AmendedNewRevolvingCreditFacilityMember2024-01-012024-03-310001723128amrx:AmendedRondoCreditFacilityMember2024-01-012024-03-310001723128amrx:AmendedNewRevolvingCreditFacilityMember2023-12-310001723128amrx:AmendedRondoCreditFacilityMember2024-03-310001723128amrx:UncertainTaxPositionNoncurrentMember2024-03-310001723128amrx:UncertainTaxPositionNoncurrentMember2023-12-310001723128amrx:LongTermCompensationMember2024-03-310001723128amrx:LongTermCompensationMember2023-12-310001723128amrx:ContingentConsiderationMember2024-03-310001723128amrx:ContingentConsiderationMember2023-12-310001723128us-gaap:OtherNoncurrentLiabilitiesMember2024-03-310001723128us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001723128us-gaap:FairValueInputsLevel1Member2024-03-310001723128us-gaap:FairValueInputsLevel2Member2024-03-310001723128us-gaap:FairValueInputsLevel3Member2024-03-310001723128us-gaap:FairValueInputsLevel1Member2023-12-310001723128us-gaap:FairValueInputsLevel2Member2023-12-310001723128us-gaap:FairValueInputsLevel3Member2023-12-310001723128us-gaap:FairValueInputsLevel2Memberamrx:SeniorSecuredCreditFacilityTermLoanDueMay2025Memberamrx:SeniorSecuredCreditFacilityMember2024-03-310001723128us-gaap:FairValueInputsLevel2Memberamrx:SeniorSecuredCreditFacilityTermLoanDueMay2025Memberamrx:SeniorSecuredCreditFacilityMember2023-12-310001723128amrx:TermLoanDueMay2028Memberus-gaap:FairValueInputsLevel2Memberamrx:SeniorSecuredCreditFacilityMember2024-03-310001723128us-gaap:FairValueInputsLevel2Memberamrx:SeniorSecuredCreditFacilityMember2023-12-310001723128amrx:LongTermPromissoryNotesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001723128amrx:LongTermPromissoryNotesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001723128amrx:InterestRateLockAgreementMember2019-10-310001723128amrx:AmendedOctober2019SwapMember2023-11-140001723128amrx:November2023SwapMember2023-11-140001723128amrx:AmendedOctober2019SwapMember2023-11-142023-11-140001723128us-gaap:OtherAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamrx:VariableToFixedInterestRateSwapMember2024-03-310001723128us-gaap:OtherAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamrx:VariableToFixedInterestRateSwapMember2023-12-310001723128amrx:OpanaERAntitrustLitigationMember2024-03-310001723128amrx:OpanaERAntitrustLitigationMember2023-12-310001723128amrx:OpanaERAccruedInterestMember2024-03-310001723128amrx:OpanaERAccruedInterestMember2023-12-310001723128amrx:CivilPrescriptionOpioidLitigationMember2024-03-310001723128amrx:CivilPrescriptionOpioidLitigationMember2023-12-310001723128amrx:OtherMember2024-03-310001723128amrx:OtherMember2023-12-310001723128amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember2014-11-062014-11-060001723128amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember2015-03-132015-03-130001723128amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember2023-05-150001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2019-05-100001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2019-11-010001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2020-06-100001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2020-06-102020-06-100001723128amrx:CivilPrescriptionOpioidLitigationMember2023-05-312023-05-310001723128amrx:CivilPrescriptionOpioidLitigationMemberus-gaap:SubsequentEventMember2024-04-302024-04-300001723128amrx:LitigationSettlementOptionOneMemberamrx:CivilPrescriptionOpioidLitigationMemberus-gaap:SubsequentEventMember2024-04-302024-04-300001723128amrx:LitigationSettlementOptionOneMemberamrx:CivilPrescriptionOpioidLitigationMemberus-gaap:SubsequentEventMember2024-04-300001723128amrx:LitigationSettlementOptionTwoMemberamrx:CivilPrescriptionOpioidLitigationMemberus-gaap:SubsequentEventMember2024-04-300001723128amrx:LitigationSettlementOptionTwoMemberamrx:CivilPrescriptionOpioidLitigationMemberus-gaap:SubsequentEventMember2024-04-302024-04-300001723128srt:MaximumMemberamrx:LitigationSettlementOptionOneMemberamrx:CivilPrescriptionOpioidLitigationMemberus-gaap:SubsequentEventMember2024-04-302024-04-300001723128amrx:CivilPrescriptionOpioidLitigationMember2024-01-012024-03-310001723128amrx:RanitidineLitigationMember2023-12-310001723128amrx:MetforminLitigationMemberamrx:LitigationSettlementOptionOneMemberus-gaap:SubsequentEventMember2024-05-022024-05-020001723128amrx:LitigationSettlementOptionTwoMemberamrx:MetforminLitigationMemberus-gaap:SubsequentEventMember2024-05-022024-05-020001723128amrx:XyremSodiumOxybateAntitrustLitigationMember2023-02-282023-02-280001723128amrx:XyremSodiumOxybateAntitrustLitigationMember2023-12-182023-12-180001723128amrx:XyremSodiumOxybateAntitrustLitigationMember2023-12-012023-12-310001723128amrx:XyremSodiumOxybateAntitrustLitigationMember2023-12-310001723128amrx:UFCWLocal1500WelfareFundV.TakedaPharmaceuticalsU.S.A.Inc.Member2024-02-282024-02-280001723128amrx:AmnealPharmaceuticalsLLCMember2023-11-070001723128us-gaap:CommonClassBMember2023-11-070001723128amrx:KashivSpecialtyPharmaceuticalsLLCMember2021-04-020001723128amrx:SellersOfKSPMemberamrx:KashivSpecialtyPharmaceuticalsLLCMember2021-04-020001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2021-12-310001723128amrx:RondoPartnersLLCMemberamrx:AvKareIncorporationAndRAndSNortheastLLCMember2020-01-310001723128amrx:RondoPartnersLLCMemberamrx:AvKareIncorporationAndRAndSNortheastLLCMember2024-03-310001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2024-01-012024-03-310001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2023-01-012023-03-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310001723128amrx:ResearchAndDevelopmentParkingSpaceLeaseMemberamrx:KashivBioSciencesLLCMember2024-01-012024-03-310001723128amrx:ResearchAndDevelopmentParkingSpaceLeaseMemberamrx:KashivBioSciencesLLCMember2023-01-012023-03-310001723128amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMemberamrx:KashivBioSciencesLLCMember2024-01-012024-03-310001723128amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMemberamrx:KashivBioSciencesLLCMember2023-01-012023-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember2024-01-012024-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember2023-01-012023-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentStorageIncomeMember2024-01-012024-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentStorageIncomeMember2023-01-012023-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2024-01-012024-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentGenericDevelopmentSupplyAgreementResearchAndDevelopmentMaterialMember2024-01-012024-03-310001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentGenericDevelopmentSupplyAgreementResearchAndDevelopmentMaterialMember2023-01-012023-03-310001723128amrx:DeferredRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMemberamrx:KashivBioSciencesLLCMember2024-01-012024-03-310001723128amrx:DeferredRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMemberamrx:KashivBioSciencesLLCMember2023-01-012023-03-310001723128amrx:ResearchAndDevelopmentMember2024-01-012024-03-310001723128amrx:ResearchAndDevelopmentMember2023-01-012023-03-310001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:KananLLCMember2024-01-012024-03-310001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:KananLLCMember2023-01-012023-03-310001723128amrx:SutariaFamilyRealtyLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2024-01-012024-03-310001723128amrx:SutariaFamilyRealtyLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-03-310001723128amrx:ApaceKYLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2024-01-012024-03-310001723128amrx:ApaceKYLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-03-310001723128amrx:SellingGeneralAndAdministrativeOperatingLeaseMemberamrx:TracyPropertiesLLCMember2024-01-012024-03-310001723128amrx:SellingGeneralAndAdministrativeOperatingLeaseMemberamrx:TracyPropertiesLLCMember2023-01-012023-03-310001723128amrx:AzaTechPharmaLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2024-01-012024-03-310001723128amrx:AzaTechPharmaLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-03-310001723128amrx:AvPropLLCMemberamrx:SellingGeneralAndAdministrativeOperatingLeaseMember2024-01-012024-03-310001723128amrx:AvPropLLCMemberamrx:SellingGeneralAndAdministrativeOperatingLeaseMember2023-01-012023-03-310001723128amrx:AvtarInvestmentsLLCMemberamrx:ResearchAndDevelopmentMember2024-01-012024-03-310001723128amrx:AvtarInvestmentsLLCMemberamrx:ResearchAndDevelopmentMember2023-01-012023-03-310001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:AlkermesMember2024-01-012024-03-310001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:AlkermesMember2023-01-012023-03-310001723128amrx:RSSolutionsMemberamrx:SellingGeneralAndAdministrativeLogisticsServicesMember2024-01-012024-03-310001723128amrx:RSSolutionsMemberamrx:SellingGeneralAndAdministrativeLogisticsServicesMember2023-01-012023-03-310001723128amrx:MembersTaxReceivableAgreementMemberamrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember2024-01-012024-03-310001723128amrx:MembersTaxReceivableAgreementMemberamrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember2023-01-012023-03-310001723128amrx:KashivBioSciencesLLCMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:KashivBioSciencesLLCMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:ApaceKYLLCMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:ApaceKYLLCMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:AlkermesMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:AlkermesMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:AzaTechPharmaLLCMember2024-03-310001723128amrx:AzaTechPharmaLLCMember2023-12-310001723128amrx:AzaTechPharmaLLCMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:AzaTechPharmaLLCMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:AvtarInvestmentsLLCMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:AvtarInvestmentsLLCMemberus-gaap:RelatedPartyMember2023-12-310001723128us-gaap:RelatedPartyMemberamrx:SellersOfAvKARELLCAndRSMember2024-03-310001723128us-gaap:RelatedPartyMemberamrx:SellersOfAvKARELLCAndRSMember2023-12-310001723128amrx:MembersTaxReceivableAgreementMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:MembersTaxReceivableAgreementMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:RondoClassBUnitHoldersTaxDistributionsMember2024-03-310001723128amrx:RondoClassBUnitHoldersTaxDistributionsMember2023-12-310001723128amrx:AlkermesPlcMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:AlkermesPlcMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:RondoPartnersLLCMemberus-gaap:RelatedPartyMember2024-03-310001723128amrx:RondoPartnersLLCMemberus-gaap:RelatedPartyMember2023-12-310001723128amrx:KashivBioSciencesLLCMember2024-03-012024-03-310001723128amrx:KashivBioSciencesLicenseAndCommercializationAgreementMemberamrx:DevelopmentMilestonesMember2024-03-012024-03-310001723128amrx:RegulatoryApprovalMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-03-012024-03-310001723128amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-03-012024-03-310001723128amrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2022-12-012022-12-310001723128amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-01-012024-03-310001723128srt:MaximumMemberamrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMember2024-01-012024-03-310001723128amrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMemberamrx:DevelopmentMilestonesMember2024-01-012024-03-310001723128amrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMemberamrx:RegulatoryApprovalMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-01-012024-03-310001723128amrx:InitialCommercialLaunchMilestonesMemberamrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-01-012024-03-310001723128amrx:AchievementOfAnnualCommercialMilestoneMemberamrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-01-012024-03-310001723128amrx:ResearchAndDevelopmentReimbursementMembersrt:AffiliatedEntityMemberamrx:KashivBioSciencesLicenseAndCommercializationAgreementMember2024-03-310001723128us-gaap:OperatingSegmentsMemberamrx:GenericsSegmentMember2024-01-012024-03-310001723128us-gaap:OperatingSegmentsMemberamrx:AmnealSpecialtyPharmaSegmentMember2024-01-012024-03-310001723128us-gaap:OperatingSegmentsMemberamrx:AvKARESegmentMember2024-01-012024-03-310001723128us-gaap:CorporateNonSegmentMember2024-01-012024-03-310001723128us-gaap:OperatingSegmentsMemberamrx:GenericsSegmentMember2023-01-012023-03-310001723128us-gaap:OperatingSegmentsMemberamrx:AmnealSpecialtyPharmaSegmentMember2023-01-012023-03-310001723128us-gaap:OperatingSegmentsMemberamrx:AvKARESegmentMember2023-01-012023-03-310001723128us-gaap:CorporateNonSegmentMember2023-01-012023-03-310001723128us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberamrx:SubsidiaryInIndiaMemberus-gaap:SubsequentEventMember2024-04-300001723128us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberamrx:SubsidiaryInIndiaMemberus-gaap:SubsequentEventMember2024-04-302024-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                        to                       
Commission file number 001-38485
Amneal Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
93-4225266
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
Amneal Pharmaceuticals, Inc.
400 Crossing Boulevard, Bridgewater, NJ
08807
(Address of principal executive offices)(Zip Code)
(908) 947-3120
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No
As of April 30, 2024, there were 308,651,373 shares of the registrant’s Class A common stock outstanding, with a par value of $0.01.



Amneal Pharmaceuticals, Inc.
Table of Contents
1


Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q and other publicly available documents of Amneal Pharmaceuticals, Inc. contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States (“U.S.”) Private Securities Litigation Reform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries (“the Company”, “we”, “us”, or “our”) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “targets,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements.


Summary of Material Risks

Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to:

our ability to successfully develop, license, acquire and commercialize new products on a timely basis;
the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices;
our ability to obtain exclusive marketing rights for our products;
our revenues derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers;
the impact of a prolonged business interruption within our supply chain;
the continuing trend of consolidation of certain customer groups;
our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods;
legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives;
our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents;
our ability to attract, hire and retain highly skilled personnel;
risks related to federal regulation of arrangements between manufacturers of branded and generic products;
our reliance on certain licenses to proprietary technologies from time to time;
the significant amount of resources we expend on research and development (“R&D”);
the risk of claims brought against us by third parties such as those described in Note 17. Commitments and Contingencies - Other Litigation Related to the Company’s Business;
risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws;
changes to Food and Drug Administration (“FDA”) product approval requirements;
the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers;
our dependence on third-party agreements for a portion of our product offerings;
our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness;
our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties;
our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms;
the impact of global economic, political or other catastrophic events;
our obligations under a tax receivable agreement may be significant;
the high concentration of ownership of our Class A common stock and the fact that we are controlled by the Amneal Group (as defined in Item 1. Business in the Company’s 2023 Annual Report on Form 10-K); and
2


such other factors as may be set forth elsewhere in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, particularly in the section entitled 1A. Risk Factors and our public filings with the SEC.
Investors should carefully read our Annual Report on Form 10-K for the year ended December 31, 2023, including the section 1A. Risk Factors, for a description of certain risks that could, among other things, cause our actual results to differ materially from those expressed in our forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described herein and in our Annual Report to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.
3


PART I - FINANCIAL INFORMATION
Item 1.    Financial Statements (Unaudited)
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited; in thousands, except per share amounts)


Three Months Ended March 31,
20242023
Net revenue$659,191 $557,540 
Cost of goods sold421,131 379,354 
Gross profit238,060 178,186 
Selling, general and administrative112,595 102,096 
Research and development39,298 38,690 
Intellectual property legal development expenses984 1,644 
Restructuring and other charges1,470 510 
Change in fair value of contingent consideration100 2,457 
Charges (credit) related to legal matters, net94,359 (436)
Other operating income (1,224)
Operating (loss) income(10,746)34,449 
Other (expense) income:
Interest expense, net(65,703)(49,315)
Foreign exchange (loss) gain, net(1,197)1,901 
Increase in tax receivable agreement liability(1,948)(826)
Other income, net4,072 4,365 
Total other expense, net(64,776)(43,875)
Loss before income taxes(75,522)(9,426)
Provision for income taxes6,156 668 
Net loss(81,678)(10,094)
Less: Net (income) loss attributable to non-controlling interests(9,965)3,151 
Net loss attributable to Amneal Pharmaceuticals, Inc.
$(91,643)$(6,943)
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
   Basic and diluted
$(0.30)$(0.05)
Weighted-average common shares outstanding:
   Basic and diluted
307,279 152,109 







The accompanying notes are an integral part of these consolidated financial statements.
4


Amneal Pharmaceuticals, Inc.
Consolidated Statements of Comprehensive Loss
(unaudited; in thousands)



Three Months Ended March 31,
20242023
Net loss$(81,678)$(10,094)
Less: Net (income) loss attributable to non-controlling interests(9,965)3,151 
Net loss attributable to Amneal Pharmaceuticals, Inc.(91,643)(6,943)
Other comprehensive (loss) income:
Foreign currency translation adjustments arising during the period(390)1,797 
Unrealized gain (loss) on cash flow hedge, net of tax of $0
15,543 (14,270)
Reclassification of cash flow hedge to earnings, net of tax of $0
(6,515) 
Less: Other comprehensive loss attributable to non-controlling interests 6,236 
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.8,638 (6,237)
Comprehensive loss attributable to Amneal Pharmaceuticals, Inc.$(83,005)$(13,180)



















The accompanying notes are an integral part of these consolidated financial statements.
5


Amneal Pharmaceuticals, Inc.
Consolidated Balance Sheets
(unaudited; in thousands, except per share amounts)
March 31, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$46,520 $91,542 
Restricted cash5,097 7,565 
Trade accounts receivable, net668,955 613,732 
Inventories570,653 581,384 
Prepaid expenses and other current assets87,298 82,685 
Related party receivables1,521 955 
Total current assets1,380,044 1,377,863 
Property, plant and equipment, net439,815 447,574 
Goodwill598,549 598,629 
Intangible assets, net859,272 890,423 
Operating lease right-of-use assets32,970 30,329 
Operating lease right-of-use assets - related party12,468 12,954 
Financing lease right-of-use assets59,532 59,280 
Other assets73,747 55,517 
Total assets$3,456,397 $3,472,569 
Liabilities and Stockholders' (Deficiency) Equity
Current liabilities:
Accounts payable and accrued expenses$558,518 $534,662 
Current portion of liabilities for legal matters30,130 76,988 
Revolving credit facility179,000 179,000 
Current portion of long-term debt, net33,660 34,125 
Current portion of operating lease liabilities9,508 9,207 
Current portion of operating lease liabilities - related party3,192 2,825 
Current portion of financing lease liabilities3,305 2,467 
Related party payables - short term17,075 7,321 
Total current liabilities834,388 846,595 
Long-term debt, net2,377,707 2,386,004 
Note payable - related party41,893 41,447 
Operating lease liabilities26,786 24,095 
Operating lease liabilities - related party11,969 12,787 
Financing lease liabilities58,809 58,566 
Related party payables - long term11,394 11,776 
Liabilities for legal matters - long term85,479 316 
Other long-term liabilities24,579 29,679 
Total long-term liabilities2,638,616 2,564,670 
Commitments and contingencies (Notes 4 and 17)
Redeemable non-controlling interests47,022 41,293 
Stockholders' (Deficiency) Equity
Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023
  
Class A common stock, $0.01 par value, 900,000 shares authorized at both March 31, 2024 and December 31, 2023; 308,623 and 306,565 shares issued at March 31, 2024 and December 31, 2023, respectively
3,086 3,066 
Class B common stock, $0.01 par value, 300,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023
  
Additional paid-in capital538,720 539,240 
Stockholders' accumulated deficit(581,819)(490,176)
Accumulated other comprehensive loss(23,711)(32,349)
Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity(63,724)19,781 
Non-controlling interests95 230 
Total stockholders' (deficiency) equity(63,629)20,011 
Total liabilities and stockholders' (deficiency) equity$3,456,397 $3,472,569 
The accompanying notes are an integral part of these consolidated financial statements.
6


Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(unaudited; in thousands)
Three Months Ended March 31,
20242023
Cash flows from operating activities:
Net loss$(81,678)$(10,094)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization55,528 58,150 
Unrealized foreign currency loss (gain)1,511 (1,987)
Amortization of debt issuance costs and discount288 2,058 
Intangible asset impairment charges920  
Change in fair value of contingent consideration100 2,457 
Stock-based compensation6,722 7,596 
Inventory provision22,923 25,204 
Other operating charges and credits, net1,250 2,047 
Changes in assets and liabilities:
Trade accounts receivable, net(55,173)195,970 
Inventories(12,200)(22,508)
Prepaid expenses, other current assets and other assets(11,708)29,160 
Related party receivables(562)470 
Accounts payable, accrued expenses and other liabilities62,174 (150,483)
Related party payables5,495 1,672 
Net cash (used in) provided by operating activities(4,410)139,712 
Cash flows from investing activities:
Purchases of property, plant and equipment(9,198)(9,688)
Acquisition of intangible assets(9,700)(338)
Deposits for future acquisition of property, plant and equipment(862)(1,711)
Net cash used in investing activities(19,760)(11,737)
Cash flows from financing activities:
Payments of principal on debt, revolving credit facilities, financing leases and other(63,377)(72,659)
Borrowings on revolving credit facilities48,000 80,000 
Proceeds from exercise of stock options28  
Employee payroll tax withholding on restricted stock unit vesting(7,212)(2,022)
Tax distributions to non-controlling interests(594)(18,219)
Net cash used in financing activities(23,155)(12,900)
Effect of foreign exchange rate on cash(165)767 
Net (decrease) increase in cash, cash equivalents, and restricted cash(47,490)115,842 
Cash, cash equivalents, and restricted cash - beginning of period99,107 35,227 
Cash, cash equivalents, and restricted cash - end of period$51,617 $151,069 
Cash and cash equivalents - end of period$46,520 $144,674 
Restricted cash - end of period5,097 6,395 
Cash, cash equivalents, and restricted cash - end of period$51,617 $151,069 














The accompanying notes are an integral part of these consolidated financial statements.
7


Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows (continued)
(unaudited; in thousands)

Three Months Ended March 31,
20242023
Supplemental disclosure of cash flow information:
Cash paid for interest$64,514 $41,066 
Cash (paid) received, net for income taxes$(4,567)$3,421 
Supplemental disclosure of non-cash investing and financing activity:
Tax distributions to non-controlling interests$3,777 $11,548 
















































The accompanying notes are an integral part of these consolidated financial statements.
8


Amneal Pharmaceuticals, Inc.
Consolidated Statements of Changes in Stockholders’ Equity (Deficiency)
(unaudited; in thousands)

New PubCo
Class A Common StockAdditional
Paid-in Capital
Stockholders'
Accumulated Deficit
Accumulated
Other
Comprehensive Loss
Non-
Controlling Interests
Total Equity (Deficiency)Redeemable Non-Controlling Interests
SharesAmount
Balance at December 31, 2023306,565 $3,066 $539,240 $(490,176)$(32,349)$230 $20,011 $41,293 
Net (loss) income— — — (91,643)— (135)(91,778)10,100 
Foreign currency translation adjustments— — — — (390)— (390)— 
Stock-based compensation— — 6,722 — — — 6,722 — 
Exercise of stock options10 — 28 — — — 28 — 
Restricted stock unit vesting, net of shares withheld to cover payroll taxes2,048 20 (7,270)— — — (7,250)— 
Unrealized gain on cash flow hedge, net of tax of $0
— — — — 15,543 — 15,543 — 
Tax distributions, net— — — — — — — (4,371)
Reclassification of cash flow hedge to earnings, net of tax of $0
— — — — (6,515)— (6,515)— 
Balance at March 31, 2024308,623 $3,086 $538,720 $(581,819)$(23,711)$95 $(63,629)$47,022 


Old PubCo
Class A Common
Stock
Class B Common
Stock
Additional
Paid-in Capital
Stockholders'
Accumulated Deficit
Accumulated
Other
Comprehensive Income
Non-
Controlling Interests
Total EquityRedeemable Non-Controlling Interests
SharesAmountSharesAmount
Balance at December 31, 2022151,490 $1,514 152,117 $1,522 $691,629 $(406,183)$9,939 $(114,442)$183,979 $24,949 
Net (loss) income— — — — — (6,943)— (8,688)(15,631)5,537 
Foreign currency translation adjustments— — — — — — 898 899 1,797 — 
Stock-based compensation— — — — 7,596 — — — 7,596 — 
Restricted stock unit vesting, net of shares withheld to cover payroll taxes1,831 18 — — 1,497 — 62 (3,572)(1,995)— 
Unrealized loss on cash flow hedge, net of tax of $0
— — — — — — (7,135)(7,135)(14,270)— 
Tax distributions— — — — — — — (26,808)(26,808)(2,959)
Balance at March 31, 2023153,321 $1,532 152,117 $1,522 $700,722 $(413,126)$3,764 $(159,746)$134,668 $27,527 





















The accompanying notes are an integral part of these consolidated financial statements.
9


Amneal Pharmaceuticals, Inc.
Notes to Consolidated Financial Statements
(unaudited)
1. Nature of Operations
Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, and biosimilars in our Generics segment and specialty branded pharmaceuticals. The Company operates principally in the United States (“U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company whose principal assets are 100% of the common units of Amneal Pharmaceuticals, LLC (“Amneal”).
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.
Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2023 Annual Report on Form 10-K.
Use of Estimates
The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Reclassification
The prior period balance related to the TRA (as defined in Note 5. Income Taxes) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss.
The prior period balance related to long-term liabilities for legal matters of $0.3 million, formerly included in other long-term liabilities as of December 31, 2023, has been reclassified to the balance sheet caption “liabilities for legal matters - long term” to conform to the current period presentation in the consolidated balance sheets. This reclassification did not impact total long-term liabilities or total liabilities.
10


Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
3. Revenue Recognition
The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
License Agreements
Refer to Note 4. Alliance and Collaboration for further information related to revenue recognition associated with license agreements.
Concentration of Revenue
The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue:
Three Months Ended March 31,
20242023
Customer A21 %22 %
Customer B15 %14 %
Customer C23 %20 %
Customer D10 %9 %
11


Disaggregated Revenue
The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands):
Three Months Ended March 31,
20242023
Generics
Anti-infective$6,110 $5,174 
Hormonal / allergy107,714 104,851 
Antiviral3,866 25,474 
Central nervous system109,456 84,582 
Cardiovascular system45,878 32,503 
Gastroenterology18,197 14,364 
Oncology38,533 10,578 
Metabolic disease / endocrine
11,185 9,265 
Respiratory11,136 12,815 
Dermatology18,975 18,004 
Other therapeutic classes18,523 25,895 
International and other1,721 301 
Total Generics net revenue391,294 343,806 
Specialty
Hormonal / allergy29,375 24,763 
Central nervous system66,276 60,139 
License agreement (1)
4,479  
Other therapeutic classes5,104 6,776 
Total Specialty net revenue105,234 91,678 
AvKARE
Distribution109,713 83,230 
Government label34,952 24,516 
Institutional10,858 8,862 
Other7,140 5,448 
Total AvKARE net revenue162,663 122,056 
Total net revenue$659,191 $557,540 
(1)Refer to Note 4. Alliance and Collaboration for information on revenue recognized under a license agreement.
A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2023$559,334 $23,892 $136,486 $90,690 
Provision related to sales recorded in the period885,322 30,073 16,220 61,271 
Credits/payments issued during the period(987,202)(26,550)(15,598)(55,250)
Balance at March 31, 2024$457,454 $27,415 $137,108 $96,711 
12


4. Alliance and Collaboration
The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide R&D services over multiple periods. The Company’s significant arrangements are discussed below.
Orion Corporation License Agreement
On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of its complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance.
During both the three months ended March 31, 2024 and 2023, the Company recognized $0.6 million as a reduction to R&D expense related to services performed under the Orion Agreement. As of March 31, 2024, deferred income of $10.7 million and $1.2 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of December 31, 2023, deferred income of $7.8 million and $4.7 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of March 31, 2024, no products have been supplied by Amneal under the Orion Agreement. Refer to Note 5. Alliance and Collaboration in our 2023 Annual Report on Form 10-K for additional information.
ONGENTYS® License Agreement
On December 5, 2023, the Company entered into a license agreement with BIAL-Portela & Ca., S.A. (“BIAL”) for the exclusive royalty-free right to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023 and ending at such time when generic opicapone sales reach certain predetermined thresholds (the “BIAL License Agreement”). ONGENTYS® is BIAL’s proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes. Under the BIAL Agreement, the Company is responsible for commercialization and marketing of ONGENTYS® in the U.S. and BIAL is responsible for manufacturing and supply. The BIAL Agreement also requires the Company to spend a minimum of $6.0 million in medical and marketing activities directly related to ONGENTYS®. The Company commenced distribution of ONGENTYS® during the three months ended March 31, 2024.
During December 2023, the Company paid a nonrefundable license fee of $12.5 million to BIAL, which was capitalized as an intangible asset and will be amortized to cost of sales over a period of eight years. The BIAL License Agreement provides for potential future milestone payments totaling $22.5 million, depending on cumulative net sales of ONGENTYS®.
Knight Therapeutics International S.A. License Agreement
On January 24, 2024, the Company entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. (“Knight”) granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the “Knight License Agreement”). The Knight License Agreement will automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal.
Knight will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight.
On February 26, 2024, the Company received a nonrefundable license fee of $1.0 million from Knight, which was recorded as net revenue for the three months ended March 31, 2024. The Knight License Agreement provides for potential future milestone payments totaling $10.5 million, contingent upon regulatory approval, launch dates and cumulative net sales targets by Knight. The agreement also includes low-double digit royalty payments based on net sales of IPX203.
13


License Agreement with Zambon Biotech
On February 23, 2024, the Company entered into a license, distribution and supply agreement with Zambon Biotech S.A. (“Zambon”) granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the “Zambon License Agreement”). The term for the Zambon License Agreement is 15 years commencing from the commercial launch of the product, which can automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Zambon will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Zambon.
In connection with the execution of the agreement, the Company was entitled to a non-refundable license fee of €5.0 million, or $5.4 million, which was received in April 2024. Of the license fee, the Company allocated €3.2 million, or $3.5 million, to the delivery of a functional license, which was recorded as net revenue during the three months ended March 31, 2024. In addition, the Company is eligible to receive future milestone payments totaling €71.5 million, or $77.2 million, from Zambon, contingent upon regulatory approval of the product, and achievement of certain annual net sales targets by Zambon. The Zambon License Agreement also includes single-digit to low-double digit royalty payments based on net sales of IPX203.
Biosimilar Licensing and Supply Agreement
Bevacizumab
On May 7, 2018, the Company entered into a licensing and supply agreement with mAbxience S.L. (“mAbxience”), for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. Pursuant to the agreement, the Company will be the exclusive partner in the U.S. market and pay up-front, development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to mAbxience, up to $78.3 million.
On April 13, 2022, the FDA approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million during the year ended December 31, 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of seven years. During the three months ended March 31, 2024, the Company paid a sales-based milestone of $9.5 million, which was capitalized as a product rights intangible asset and is being amortized to cost of sales.
Denosumab
On October 12, 2023, the Company entered into a licensing and supply agreement with mAbxience to be the exclusive U.S. partner for two denosumab biosimilars referencing both Prolia® and XGEVA®. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. mAbxience is responsible for the clinical and regulatory approval for the two products and regulatory fees will be shared by the parties. Upon approval of each product, mAbxience will be responsible for supply and the Company will be responsible for commercialization.
During the year ended December 31, 2023, the Company recorded R&D expense for a $2.5 million payment made upon execution of the agreement and an additional $2.5 million for a developmental milestone. During the three months ended March 31, 2024, the Company recorded R&D expense for a $3.0 million payment made for a clinical milestone. The agreement provides for potential future milestone payments to mAbxience of up to $66.0 million as follows: (i) up to $3.5 million relating to clinical and developmental milestones; (ii) up to $15.0 million for regulatory approval and initial commercial launch milestones; and (iii) up to $47.5 million for the achievement of annual commercial milestones.
Agreements with Kashiv Biosciences, LLC
For details on the Company’s related party agreements with Kashiv Biosciences, LLC (“Kashiv”), refer to Note 19. Related Party Transactions in this Form 10-Q and Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K.
14


5. Income Taxes
For the three months ended March 31, 2024, the Company’s provision for income taxes and effective tax rate were $6.2 million and (8.2)%, respectively, as compared to $0.7 million and (7.1)%, respectively, for the three months ended March 31, 2023. For the three months ended March 31, 2024, the period-over-period change in the provision for income taxes was primarily related to changes in the jurisdictional mix of income.
The Company recorded deferred tax assets for (i) its outside basis difference in its investment in Amneal on May 4, 2018, (ii) the net operating loss of Impax Laboratories, Inc., which was acquired by the Company in 2018, from January 1, 2018 through May 4, 2018, (iii) certain federal and state credits, and (iv) interest carryforwards of Impax that were attributable to the Company.
The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others.
The Company established a valuation allowance on its DTAs based upon all available objective and verifiable evidence, both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three-year pre-tax losses through March 31, 2024. As a result of the losses through March 31, 2024, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of March 31, 2024 and December 31, 2023, this valuation allowance was $566.0 million and $566.5 million, respectively, and reduced the carrying value of these gross DTAs to zero.
In 2018, the Company entered into a tax receivable agreement (“TRA”) for which it was generally required to pay the holders of Amneal common units on a one-to-one basis, 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal common units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal common units for shares of Class A common stock of the Company prior to the Reorganization (as defined in Note 1. Nature of Operations in our 2023 Annual Report on Form 10-K) and (ii) tax benefits attributable to payments made under the TRA. In conjunction with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million during 2019. As part of the Reorganization, the TRA was amended to reduce the Company’s future obligation to pay 85% of the tax benefits subject to the TRA to 75% of such realized benefits. This agreement will not cause the acceleration of payments under the TRA.
As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize its DTAs subject to the TRA; therefore, as of March 31, 2024 and December 31, 2023, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more-likely-than-not in the future, at such time, these TRA liabilities (which amounted to approximately $185.0 million at March 31, 2024 and December 31, 2023) will be recorded through charges in the Company’s consolidated statements of operations.
The timing and amount of any payments under the TRA may vary depending on the timing of the Company’s taxable income and the tax rate in effect at the time of realization of the Company’s taxable income. Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. Payments could also be in excess of the tax savings that the Company may ultimately realize.
Although the DTAs were not determined to be realizable as of March 31, 2024 and December 31, 2023, the Company assessed that a TRA liability of $5.7 million and $3.8 million at those dates, respectively, had become probable. For the three months ended March 31, 2024 and 2023, the Company recorded expenses associated with the TRA of $1.9 million and $0.8 million, respectively. In future periods, the Company will continue to evaluate whether any future TRA payments become probable and can be estimated and, if so, an estimate of payment will be accrued.
Any future recognition of these TRA liabilities will be recorded through charges in the Company’s consolidated statements of operations. However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA in excess of the $5.7 million accrued as of March 31, 2024. Should the Company determine that a DTA with a
15


valuation allowance is realizable in a subsequent period, the related valuation allowance will be reversed and, if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded.
The Company continuously monitors government proposals to make changes to tax laws, including proposed legislation in certain foreign jurisdictions resulting from the adoption of the Organization for Economic Cooperation and Development (“OECD”) policies (refer to Note 7. Income Taxes in the Company’s 2023 Annual Report on Form 10-K). The OECD has issued a two-pillar approach to global taxation, focusing on global profit allocation and a global minimum tax rate of at least 15%. Legislation for the “Pillar Two” proposal, applying to the Company, has been enacted in Ireland, and it is effective with the financial year beginning on January 1, 2024. As the tax rates the other jurisdictions in which the Company operates exceed 15%, the Company does not believe there is any potential additional exposure besides in Ireland.
Since Pillar Two taxes are an alternative minimum tax, deferred taxes will not need to be recorded or remeasured as a result of Pillar Two taxes. Instead, Pillar Two taxes will be expensed as incurred. For interim tax provision purposes, the Pillar Two tax related to Ireland taxes is included in the calculation of the Company’s provision for income taxes.

6. Loss per Share
Following the implementation of the Reorganization on November 7, 2023, all outstanding shares of Old PubCo Class A common stock and Old PubCo Class B common stock were exchanged for an equivalent number of shares of Class A common stock of the Company.
Basic loss per share of the Company’s Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share of Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding, adjusted to give effect to potentially dilutive securities. The weighted-average number of shares of Class A common stock for all periods prior to the Reorganization includes shares of Old PubCo Class A common stock.
The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts):
Three Months Ended
March 31,
20242023
Numerator:
Net loss attributable to Amneal Pharmaceuticals, Inc.
$(91,643)$(6,943)
Denominator:
Weighted-average shares outstanding - basic and diluted
307,279 152,109 
Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic and diluted
$(0.30)$(0.05)
Prior to the Reorganization, shares of Old PubCo Class B common stock did not share in the losses of the Company and, therefore, were not participating securities. As such, separate presentation of basic and diluted loss per share of Old PubCo Class B common stock under the two-class method was not presented. Effective with the Reorganization, all outstanding shares of Old PubCo Class B common stock were surrendered and canceled.
The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands):
Three Months Ended
March 31,
20242023
Stock options
2,406 (1)2,632 (1)
Restricted stock units
10,837 (1)11,576 (1)
Performance stock units
7,827 (1)7,018 (1)
Shares of Old PubCo Class B common stock
 152,117 (2)
16


(1)Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.
(2)Shares of Old PubCo Class B common stock were considered potentially dilutive shares of Old PubCo Class A common stock. Shares of Old PubCo Class B common stock were excluded from the computations of diluted loss per share of Class A common stock for the three months ended March 31, 2023 because the effect of their inclusion would have been anti-dilutive under the if-converted method.
7. Trade Accounts Receivable, Net
Trade accounts receivable, net was comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Gross accounts receivable$1,156,861 $1,199,980 
Allowance for credit losses(3,037)(3,022)
Contract charge-backs and sales volume allowances(457,454)(559,334)
Cash discount allowances(27,415)(23,892)
Subtotal(487,906)(586,248)
Trade accounts receivable, net$668,955 $613,732 
Concentration of Receivables
Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows:
March 31,
2024
December 31,
2023
Customer A32 %40 %
Customer B29 %24 %
Customer C23 %22 %
8. Inventories
Inventories were comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Raw materials
$196,737 $217,744 
Work in process
57,924 59,563 
Finished goods
315,992 304,077 
Total inventories$570,653 $581,384 
17


9. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets were comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Deposits and advances$1,935 $2,200 
Prepaid insurance4,780 8,334 
Prepaid regulatory fees4,219 6,331 
Income and other tax receivables12,198 13,168 
Prepaid taxes9,205 11,899 
Other current receivables
12,802 9,929 
Chargebacks receivable (1)
8,575 7,876 
Other prepaid assets33,584 22,948 
Total prepaid expenses and other current assets$87,298 $82,685 
(1)When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.
10. Goodwill and Other Intangible Assets
The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands):
March 31,
2024
December 31,
2023
Balance, beginning of period$598,629 $598,853 
Currency translation(80)(224)
Balance, end of period$598,549 $598,629 
As of March 31, 2024, $366.3 million, $162.7 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2023, $366.3 million, $162.8 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively.
Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights6.2$1,207,469 $(739,351)$468,118 $1,198,971 $(703,297)$495,674 
Other intangible assets3.1111,800 (76,491)35,309 111,800 (72,896)38,904 
Subtotal1,319,269 (815,842)503,427 1,310,771 (776,193)534,578 
In-process research and development355,845 — 355,845 355,845 — 355,845 
Total intangible assets$1,675,114 $(815,842)$859,272 $1,666,616 $(776,193)$890,423 
Amortization expense related to intangible assets for the three months ended March 31, 2024 and 2023 was $39.9 million and $41.1 million, respectively.
18


The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&D”) intangible assets (in thousands):
Future
Amortization
Remainder of 2024$119,432 
2025121,638 
202673,115 
202752,606 
202833,263 
202926,484 
Thereafter76,889 
   Total$503,427 
The Company reviews intangible assets with finite lives for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Indefinite-lived intangible assets, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. Intangible asset impairments were immaterial for the three months ended March 31, 2024 (none for the three months ended March 31, 2023).
On June 30, 2023, the Company received a complete response letter (“CRL”) from the FDA regarding its new drug application (“NDA”) for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that, although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. During October 2023, the Company met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked the Company to perform a QT study, a routine cardiac safety study that is required for new drugs. On February 7, 2024, the Company provided a complete response resubmission to the FDA for IPX203. IPX203 has a Prescription Drug User Fee Act (PDUFA) decision date of August 7, 2024.
No indicators of impairment of the Company’s IPX203 IPR&D intangible asset were identified during 2024. Additionally, there was no impairment recorded during 2023. While management believes the assumptions used in the Company’s 2023 annual impairment test of its IPX203 IPR&D intangible asset were reasonable and continue to be commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin, delaying the potential launch date, and lowering the probability of technical and regulatory success, could result in material future impairments of the Company’s IPX203 IPR&D intangible asset. Refer to Note 13. Goodwill and Other Intangible Assets in the Company’s Annual Report on Form 10-K for additional information.

11. Other Assets

Other assets were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Interest rate swap (1)
$52,632 $37,089 
Security deposits 3,616 3,602 
Long-term prepaid expenses3,099 3,273 
Deferred revolving credit facility costs4,007 4,427 
Other long term assets10,393 7,126 
Total $73,747 $55,517 

(1)Refer to Note 15. Fair Value Measurements and Note 16. Financial Instruments for information about the Company’s interest rate swap.
19


12. Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Accounts payable$175,325 $143,572 
Accrued returns allowance (1)
137,108 136,486 
Accrued compensation44,806 71,122 
Accrued Medicaid and commercial rebates (1)
96,711 90,690 
Accrued royalties19,779 23,342 
Commercial chargebacks and rebates10,226 10,226 
Accrued professional fees14,598 11,005 
Accrued other59,965 48,219 
Total accounts payable and accrued expenses$558,518 $534,662 
(1)Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2023 to March 31, 2024.
13. Debt
There have been no material changes in the Company’s long-term debt since December 31, 2023, except as disclosed below. Refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for additional information and definitions of terms used in this note.
The following is a summary of the Company’s indebtedness under its term loans (in thousands):
March 31, 2024December 31, 2023
Term Loan Due May 2025$191,979 $191,979 
Term Loan Due May 20282,336,949 2,351,647 
Total debt2,528,928 2,543,626 
Less: debt issuance costs(117,561)(123,497)
Total debt, net of debt issuance costs2,411,367 2,420,129 
Less: current portion of long-term debt(33,660)(34,125)
Total long-term debt, net$2,377,707 $2,386,004 
During the three months ended March 31, 2024, the Company (i) borrowed and repaid $20.0 million under the Amended New Revolving Credit Facility and (ii) borrowed and repaid $28.0 million under the Amended Rondo Revolving Credit Facility. As of each of March 31, 2024 and December 31, 2023, $179.0 million was outstanding on the Amended New Revolving Credit Facility.

14. Other Long-Term Liabilities

Other long-term liabilities were comprised of the following (in thousands):

March 31, 2024December 31, 2023
Uncertain tax positions$504 $497 
Long-term compensation18,073 21,283 
Contingent consideration (1)
433 433 
Other long-term liabilities5,569 7,466 
Total other long-term liabilities$24,579 $29,679 
(1)    Refer to Note 15. Fair Value Measurements for additional information.
20


15. Fair Value Measurements
Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):
Fair Value Measurement Based on
March 31, 2024TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Assets
Interest rate swap (1)
$52,632 $ $52,632 $ 
Liabilities
Deferred compensation plan liabilities (2)
$9,668 $ $9,668 $ 
Contingent consideration liabilities (3)
$1,021 $ $ $1,021 
December 31, 2023
Assets
Interest rate swap (1)
$37,089 $ $37,089 $ 
Liabilities
Deferred compensation plan liabilities (2)
$9,100 $ $9,100 $ 
Contingent consideration liability (3)
$921 $ $ $921 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 16. Financial Instruments for information on the Company's interest rate swap.
(2)These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.
21


(3)The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. For the three months ended March 31, 2024, there was no material activity or payments related to the contingent consideration liabilities.
There were no transfers between levels in the fair value hierarchy during the three months ended March 31, 2024.
Assets and Liabilities Not Measured at Fair Value on a Recurring Basis
The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments.
The following is a summary of the Company’s indebtedness at fair value (in thousands):
March 31, 2024December 31, 2023
Term Loan Due 2025$192,099 $190,779 
Term Loan Due 2028$2,339,870 $2,328,130 
Sellers Notes$41,944 $41,033 
The Term Loan Due 2025 and Term Loan Due 2028 are in the Level 2 category within the fair value level hierarchy. The fair values were determined using market data for valuation. The Sellers Notes are in the Level 2 category within the fair value level hierarchy.
Refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for detailed information about its indebtedness, including definitions of terms.
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
There were no non-recurring fair value measurements during the three months ended March 31, 2024 and 2023.
16. Financial Instruments
The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates.
Interest Rate Risk
Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company’s debt obligations consist of variable-rate and fixed-rate debt instruments. The Company’s primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. To achieve this objective, the Company initially entered into an interest rate swap on the Term Loan Due 2025. On November 14, 2023, in connection with the refinancing of the Term Loan Due 2025, the Company novated its swap agreement to another counterparty and, in connection with such novation, amended the interest rate swap agreement. Refer to the section “Interest Rate Derivative - Cash Flow Hedge” below and in Note 20. Financial Instruments in the Company’s 2023 Annual Report on Form 10-K for additional information and the definition of certain terms.
Interest Rate Derivative – Cash Flow Hedge
The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month London interbank offered rate (“LIBOR”) associated with the Term Loan Due 2025 (the “October 2019 Swap”). On May 31, 2023, the Company executed an amendment to the October 2019 Swap that, among other things, changed the variable reference rate from LIBOR to the one-month secured overnight financing rate (“SOFR”) (the “Amended October 2019 Swap”). On November 14, 2023, in connection with the Company’s refinancing of the Term Loan Due 2025 and the New Credit Facility
22


(refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for definitions and additional information), the Company novated the Amended October 2019 Swap to another counterparty and subsequently amended the interest rate agreement. Specifically, the amendments modified (i) the fixed rate payable by the counterparty from 1.3660% to a new fixed rate of 2.7877% and (ii) extended the termination date through May 4, 2027 (i.e., one year before the Term Loan Due 2028 matures) (the “November 2023 Swap”). The amendments did not change the notional amount of $1.3 billion. The purpose of the November 2023 Swap is to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month SOFR associated with the Term Loan Due 2028.
The Company used a strategy commonly referred to as “blend and extend,” which allows the existing asset position of the swap agreement to be effectively blended into the new interest rate swap agreement. As a result of this transaction, on November 14, 2023, the Amended October 2019 Swap was de-designated and the unrealized gain of $66.7 million was recorded within accumulated other comprehensive (loss) income and will be amortized as a reduction of interest expense, net, over the original term of the of the Amended October 2019 Swap (until May 2025), as the hedged transactions affect earnings. Additionally, the November 2023 Swap had a fair value of $66.7 million at inception and will be ratably recorded to accumulated other comprehensive (loss) income and reclassified to interest expense, net, over the term of the November 2023 Swap, as the hedged transactions affect earnings.
During the three months ended March 31, 2024, the Company reclassified a gain of $6.5 million from accumulated other comprehensive loss to interest expense, net. Approximately $26.1 million of net gains included in accumulated other comprehensive loss as of March 31, 2024 are expected to be reclassified into earnings within the next 12 months as interest payments are made on the Company’s Term Loan Due 2028 and amortization of the amounts included in accumulated other comprehensive loss occurs.
As of March 31, 2024, the total gain, net of income taxes, related to the Company’s cash flow hedge of $42.8 million, was recognized in accumulated other comprehensive loss.
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
March 31, 2024December 31, 2023
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther Assets$52,632 Other Assets$37,089 
17. Commitments and Contingencies
Commitments
Commercial Manufacturing, Collaboration, License, and Distribution Agreements
The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered with third parties. The Company has also licensed certain technologies or IP from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 4. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 19. Related Party Transactions for additional information.
23


Contingencies
Legal Proceedings
The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies.
For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized.
For the three months ended March 31, 2024, charges related to legal matters, net of $94.4 million were associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. (refer to the section Civil Prescription Opioid Litigation below). For the three months ended March 31, 2023, credit related to legal matters, net of $0.4 million was comprised of a litigation settlement gain, partially offset by charges for legal proceedings.
Liabilities for legal matters were comprised of the following (in thousands):
MatterMarch 31, 2024December 31, 2023
Opana ER® antitrust litigation$ $50,000 
Opana ER® antitrust litigation-accrued interest
 2,347 
Civil prescription opioid litigation30,130 21,189 
Other
 3,452 
Current portion of liabilities for legal matters$30,130 $76,988 
Civil prescription opioid litigation (Liabilities for legal matters - long term)$85,479 $316 
Refer to the respective discussions below for additional information about the significant matters in the tables above.
Refer to Note 21. Commitments and Contingencies in our Annual Report on Form 10-K for a general discussion of Medicaid Reimbursement and Price Reporting Matters and Patent Litigation.
Other Litigation Related to the Company’s Business
Opana ER® Antitrust Litigation

From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out
24


plaintiffs”) of Opana ER® were filed against Endo Pharmaceuticals Inc. and Impax Laboratories, Inc. (“Impax”) and consolidated into multi-district litigation (“MDL”) in the U.S. District Court for the Northern District of Illinois.

Impax subsequently entered into settlement agreements with all of the plaintiffs that were subsequently approved by the court. Pursuant to the settlement agreements, the Company agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all of the plaintiffs’ claims. As of December 31, 2023, the liability for the final settlement payment of $50.0 million, plus 3% stated interest thereon, was included in the current portion of liabilities for legal matters and was paid in January 2024 with cash on hand. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved.
United States Department of Justice Investigations

On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation.

On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.

On May 15, 2023, Amneal received a CID from the Civil Division requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only” after the reference listed drug’s label was converted to over-the-counter. The Company is cooperating with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.
In Re Generic Pharmaceuticals Pricing Antitrust Litigation
Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania (In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa.)) (“MDL No. 2724”).
On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original plaintiff states.
Both the May 10, 2019 and June 10, 2020 lawsuits seek unspecified monetary damages and penalties and equitable relief including disgorgement and restitution, and both were incorporated into MDL No. 2724. The June 10, 2020 lawsuit was selected for bellwether status. The States of Alabama, Hawaii and Arkansas, and the Territory of Guam voluntarily dismissed all of their claims in the two actions against all defendants, including the Company. American Samoa voluntarily dismissed its claims in the May 10, 2019 action and was not named as a plaintiff in the June 10, 2020 action. On February 27, 2023, the Court addressed defendants’ motions to dismiss the June 10, 2020 action, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. On November 1, 2023, the Attorneys
25


General filed a Motion to Remand their cases to the State of Connecticut. On January 21, 2024, the Joint Panel on Multidistrict Litigation (“JPML”) granted the motion, and these cases were formally remanded in April 2024. See Connecticut, et al. v. Teva Pharmaceuticals USA, Inc., et al., 3:19-cv-00710-MPS and Connecticut, et al. v. Sandoz, Inc. et al., 3:20-cv-00803-MPS.
Fact discovery in MDL No. 2724 is proceeding as to both bellwether and non-bellwether cases, and expert discovery as to bellwether cases is also underway. No trial date has been set. No schedule has yet been issued in the May 10, 2019 and June 10, 2020 actions brought by the State Attorneys General, which have now been remanded to the District of Connecticut.
On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present (Kathryn Eaton v. Teva Canada Limited, et. al., No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, the plaintiff filed a second amended complaint. On May 30, 2023, the plaintiff served materials for their motion to certify the action as a class proceeding, define the class and certify the common questions to be decided, among other things. The certification hearing date is scheduled for December 2024, but subject to court approval, the hearing date may be rescheduled on consent to May 2025. The Company is preparing a response to the motion to certify in advance of that date.
Civil Prescription Opioid Litigation
The Company and certain of its affiliates are named as defendants in over 900 cases filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors, and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act, state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors, and retail pharmacies as defendants, and there have been numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors, and retail pharmacies in which the Company and its affiliates are not named. Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804) (the “Opioid MDL”). The Company is also named in various state court cases pending in seven states. No firm trial dates have been set except in Texas (January 31, 2025, trial-ready date (Dallas County)).
The Company reached a settlement agreement with the New Mexico Attorney General to resolve its claims against the Company, which was finalized on April 24, 2023. A Consent Judgment dismissing the case was entered on May 15, 2023.

The Company reached a settlement agreement to resolve all pending litigation brought by West Virginia political subdivisions, which was signed on May 25, 2023. The two neonatal abstinence syndrome cases in West Virginia state court were dismissed on May 31, 2023 and were subsequently appealed by the plaintiffs. These appeals remain pending. The hospital cases pending in West Virginia state court were dismissed on May 2, 2023.

The Company reached a preliminary settlement with a group of private hospitals in Alabama in June 2023 to resolve the hospitals’ claims against the Company. The Company anticipates a final determination approving the settlement by the end of the second quarter of 2024. On February 7, 2024, the Company was dismissed from the Mobile County Board of Health case. The Company previously reported an August 12, 2024 trial date for that case.

On January 13, 2023, the Company received a subpoena from the New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information. On January 4, 2024, the Company received a CID issued by the Alaska Attorney General seeking information regarding its business concerning opioid-containing products. The Company is evaluating the CID.

In late April 2024, the Company reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. The settlement in principle is subject to the negotiation and execution of a definitive settlement agreement between the parties. The settlement would be payable over ten years. Under the settlement in principle, the Company would agree to pay $92.5 million in cash and provide $180.0 million (valued at $125/ twin pack) in naloxone nasal spray to help treat opioid overdoses. In lieu of receiving product, the settling parties can opt to receive 25% of the naloxone nasal spray’s value (up to $45.0 million) in cash during the last four years of the ten years payment term, which could increase the total amount of cash the Company would agree to pay up to $137.5 million.

26


As of March 31, 2024, the Company concluded the loss related to the opioid litigation was probable, and the related loss was reasonably estimable considering the settlement in principle. As a result, the Company recorded a charge of $94.4 million associated with the settlement in principle during the three months ended March 31, 2024 to increase the liability as of March 31, 2024, to $115.6 million, of which $85.5 million was classified as long-term. While this liability has been deemed reasonable by the Company’s management, it could significantly change as the definitive settlement agreement is finalized. As of December 31, 2023, the Company had a liability of $21.5 million related to its prescription opioid litigation, of which $0.3 million was classified as long-term. For the remaining cases not covered by the settlement in principle, primarily brought by other hospitals, schools and individuals, the Company has not recorded a liability as of March 31, 2024 or December 31, 2023, because it concluded that a loss was not probable and estimable.
United States Department of Justice / Drug Enforcement Administration Subpoenas

On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered civil and criminal tolling agreements with the USAO through May 15, 2024. It is not possible to determine the exact outcome of these investigations.

On March 14, 2019, Amneal received a subpoena from an Assistant U.S. Attorney for the Southern District of Florida (the “AUSA”). The subpoena requested information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation.

On October 7, 2019, Amneal received a subpoena from the New York State Department of Financial Services seeking documents and information related to sales of opioid products in the state of New York. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact outcome of this investigation.

Ranitidine Litigation

The Company and its affiliates were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers, including the Company, without leave to file further amended complaints, holding all claims were preempted. Plaintiffs appealed the MDL Court’s dismissals to the 11th Circuit Court of Appeals. On November 7, 2022, the 11th Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The 11th Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Plaintiffs filed their merits brief on April 10, 2024.

The Company and its affiliates have also been named as defendants in various state lawsuits in five states in which the Company has filed motions to dismiss or plans to file motions to dismiss in the future. On August 17, 2023, the judge in the consolidated Illinois state court cases granted a motion to dismiss all such cases in which the Company and affiliates had been named, holding all claims preempted. There are no trial dates involving the Company in any of the state court cases.
Metformin Litigation

Amneal and AvKARE, LLC (improperly named as AvKARE, Inc.) were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey, consolidated as In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH) (“In re Metformin”). The lawsuits allege economic loss in connection with their purchase or reimbursements due to the alleged contamination of generic metformin products with NDMA. Plaintiffs have voluntarily dismissed their claims seeking medical monitoring or evaluation due to their consummation of allegedly contaminated metformin. The parties are currently engaged in discovery. On October 17, 2023, co-defendant Rite-Aid filed a suggestion of bankruptcy and automatic stay of proceeding. AvKARE, LLC has been dismissed from this action. Three additional similar putative class action lawsuits filed against Amneal and AvKARE, LLC have been consolidated for discovery and pretrial purposes only, Marcia E. Brice v. Amneal Pharmaceuticals, Inc., No. 2:20-cv-13728 (D.N.J.), Michael Hann v. Amneal
27


Pharmaceuticals of New York, LLC et al., No. 2:23-cv-22902 (D.N.J.), and In re Metformin: County of Monmouth, et al. v. Apotex Inc., et al., No. 2:23-cv-21001-MAC-MAH (D.N.J.) (“County of Monmouth”).

Pursuant to a Stipulation and Order entered on the docket on May 2, 2024, plaintiffs will file a third amended complaint in In re Metformin which includes the claims and parties in County of Monmouth. The third amended complaint must be filed within three days of entry of the Stipulation and Order. Immediately preceding the filing of the third amended complaint, the County of Monmouth First Amended Complaint will be voluntarily dismissed without prejudice. Defendants may file a motion to dismiss the third amended complaint within thirty days of the filing of the third amended complaint.

On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of valsartan, losartan, and metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern metformin (Davis v. Camber Pharmaceuticals, Inc., et al., C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation transferred the Davis Action into the In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation multi-district litigation for pretrial proceedings.

Xyrem® (Sodium Oxybate) Antitrust Litigation

Amneal was named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with the settlement of patent litigation related to Xyrem®. The actions were consolidated in the United States District Court for the Northern District of California for pretrial proceedings (In re Xyrem (Sodium Oxybate) Antitrust Litigation, No. 5:20-md-02966-LHK (N.D. Cal.)).

Amneal was also named as a defendant in a similar action filed by Aetna Inc. (“Aetna”) in California state court (Aetna Inc. v. Jazz Pharms., Inc. et. al, No. 22CV010951 (Cal. Super. Ct.). The California state court held that it lacks jurisdiction over several defendants, including Amneal, on December 27, 2022, and later issued an order dismissing Amneal without prejudice. On August 25, 2023, Aetna filed a motion seeking leave to file a second amended complaint adding Amneal as a defendant, which the Court tentatively granted on October 20, 2023. Aetna filed a second amended complaint naming Amneal on November 17, 2023.

On February 28, 2023, Amneal executed a $1.9 million settlement agreement with class plaintiffs in the federal litigation. Class plaintiffs filed a motion for final approval of the settlement on November 10, 2023, and entered an order granting final approval, certifying settlement class, and dismissing class plaintiffs’ against Amneal with prejudice on April 17, 2024. On December 18, 2023, Amneal executed a $4.0 million settlement with Aetna, United Healthcare Services, Inc. (“United”), Humana Inc. (“Humana”), Molina Healthcare Inc. (“Molina”), and Health Care Service Corporation (“HCSC”). Pursuant to that settlement, the federal court dismissed United, Humana, Molina and HCSC’s claims against Amneal, with prejudice, on February 26, 2024, and the California state court dismissed Aetna’s claims against Amneal, with prejudice, on February 29, 2024. Thus, all claims against Amneal in the federal and state court have been voluntarily dismissed with prejudice pursuant to settlements. In December 2023, the Company recorded $3.0 million for the settlement of claims associated with Xyrem® antitrust litigation. As of December 31, 2023, the Company had a liability of $2.0 million associated with this settlement, which was paid in January 2024.

UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.

On November 14, 2023, UFCW Local 1500 Welfare Fund and other health plans filed a purported class action lawsuit in the United States District Court for the Southern District of New York against Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) and other manufacturers of generic versions of Takeda’s Colcrys® (colchicine), including Amneal (UFCW Local 1500 Welfare Fund et al. v. Takeda Pharma. U.S.A., Inc. et al, No. 1:23-cv-10030 (S.D.N.Y.). The plaintiff health plans seek to represent a class of third party payers and alleging that the generic manufacturers conspired with Takeda to restrict output of generic Colcrys® to maintain higher prices, in violation of the antitrust laws. On February 28, 2024, Takeda filed a motion to transfer the case to the United States District Court for the Eastern District of Pennsylvania. On March 13, 2024 and March 27, 2024, Amneal submitted a letter and brief, respectively, informing the Court of its position that the Eastern District of Pennsylvania lacks personal jurisdiction over Amneal. The deadline for defendants to respond to the complaint is 45 days after the date on which the motion to transfer is resolved.

28


Indian Tax Authority Matters

Amneal Pharmaceuticals Pvt. Ltd., RAKS Pharmaceuticals Pvt. Ltd., and Puniska Healthcare Pvt. Ltd., which are subsidiaries of the Company, are currently involved in litigations with Indian tax authorities concerning Central Excise Tax, Service Tax, Goods & Services Tax, and Value Added Tax for various periods of time between 2014 and 2017. These subsidiaries have contested certain of these assessments, which are at various stages of the administrative process. The Company strongly believes its Indian subsidiaries have meritorious defenses in the matter.
18. Stockholders’ Equity and Redeemable Non-Controlling Interests
Effective with the Reorganization on November 7, 2023, the Company holds 100% of the Amneal Common Units.
In connection with the Reorganization, the Company amended and restated its certificate of incorporation. The voting rights, dividend rights and participation rights of holders of Class A common stock of the Company did not materially change as a result of the amendment. There were no shares of Class B common stock of the Company outstanding as of December 31, 2023.
Non-Controlling Interests
The consolidated financial statements of the Company include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold. Prior to the Reorganization, non-controlling interests were adjusted for capital transactions that impact the non-publicly held economic interests in Amneal.
Prior to the Reorganization, Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”). During the three months ended March 31, 2023, the Company recorded net tax distributions to the Members of $26.8 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members.
The Company acquired a 98% interest in KSP on April 2, 2021. The sellers of KSP, a related party, hold the remaining interests. The Company attributes 2% of the net income or loss of KSP to non-controlling interests.
Redeemable Non-Controlling Interests
The Company acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”), in 2020.  The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest (“Rondo Class B Units”) in the holding company that directly owns the acquired companies (“Rondo”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. Because the redemption of the Rondo Class B Units is outside of the Company’s control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests.

The Company attributes 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption probable. For the three months ended March 31, 2024 and 2023, the Company recorded tax distributions of $4.4 million and $3.0 million, respectively, as a reduction of redeemable non-controlling interests, respectively.
29


Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands):
Foreign
currency
translation
adjustments
Unrealized gain (loss) on cash
flow hedge, net
of tax
Accumulated
other
comprehensive (loss) income
Balance December 31, 2023$(66,072)$33,723 $(32,349)
Other comprehensive loss before reclassification(390)15,543 15,153 
Reclassification of cash flow hedge to earnings, net of tax of $0
 (6,515)(6,515)
Balance March 31, 2024$(66,462)$42,751 $(23,711)
Balance December 31, 2022$(32,382)$42,321 $9,939 
Other comprehensive loss before reclassification898 (7,135)(6,237)
Reallocation of ownership interests
(195)257 62 
Balance March 31, 2023$(31,679)$35,443 $3,764 
19. Related Party Transactions
The Company has various business agreements with certain parties in which there is some common ownership. However, the Company does not directly own or manage any of such related parties. Except as disclosed below, as of and for the three months ended March 31, 2024, there were no material changes to our related party agreements or relationships as described in Note 24. Related Party Transactions and Note 22. Stockholders’ Equity in our 2023 Annual Report on Form 10-K.
The following table summarizes the Company’s related party transactions (in thousands):
Three Months Ended March 31,
Related Party and Nature of TransactionCaption in Balance Sheet and Statement of Operations20242023
Kashiv Biosciences LLC
Parking space leaseResearch and development$25 $17 
Development and commercialization agreement - Ganirelix Acetate and Cetrorelix AcetateResearch and development$ $50 
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)Cost of goods sold$4,526 $144 
Storage agreementResearch and development$(77)$(48)
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)Inventory and cost of goods sold$1,216 $ 
Generic development supply agreement - research and development materialResearch and development$(48)$ 
Generic development supply agreement - development activity deferred incomeDeferred revenue and net revenue$(422)$ 
Development and commercialization agreement - Long-acting injectableResearch and development$500 $ 
Other Related Parties
Kanan, LLC - operating leaseInventory and cost of goods sold$592 $566 
Sutaria Family Realty, LLC - operating leaseInventory and cost of goods sold$314 $305 
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreementInventory and cost of goods sold$5,001 $1,836 
Tracy Properties LLC - operating leaseSelling, general and administrative$143 $169 
AzaTech Pharma LLC - supply agreementInventory and cost of goods sold$2,312 $575 
AvPROP, LLC - operating leaseSelling, general and administrative$44 $47 
Avtar Investments, LLC - consulting servicesResearch and development$69 $188 
AlkermesInventory and cost of goods sold$12 $2 
R&S Solutions - logistics servicesSelling, general and administrative$ $20 
Members - tax receivable agreement (TRA liability)Other expense$1,948 $826 
30


The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):
March 31, 2024December 31, 2023
Kashiv - various agreements$1,434 $954 
Apace Packaging, LLC - packaging agreement9  
Alkermes 1 
AzaTech Pharma LLC78  
Related party receivables - short term $1,521 $955 
Kashiv - various agreements$5,773 $3,179 
Apace Packaging, LLC - packaging agreement1,863 1,091 
AzaTech Pharma LLC - supply agreement1,650 1,958 
Avtar Investments LLC - consulting services22 100 
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
442 442 
Members - tax receivable agreement3,532 549 
Rondo Class B unit holders - tax distributions3,777  
Alkermes Plc16 2 
Related party payables - short term $17,075 $7,321 
Kashiv - contingent consideration
$530 $430 
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
8,691 8,139 
Members - tax receivable agreement2,173 3,207 
Related party payables - long term $11,394 $11,776 
Kashiv Biosciences
Amendment to Biosimilar License Agreement
In March 2024, the Company amended the Kashiv Biosimilar Agreement (as defined in Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K) to include two additional in-development products, a pre-filled auto-injector delivery system for peg-filgrastim and a pre-filled on-body injector (OBI) delivery system for peg-filgrastim. Consistent with the existing terms, Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling, and pricing activities of these product candidates. The amendment did not change the contractual terms related to existing commercialized biosimilar products.
The amendment provides an incremental $14.5 million in potential future milestone payments specific to these in-development products, including $7.0 million for clinical and developmental milestones and $7.5 million for regulatory approval and first commercial-sales milestones. In addition, the amendment clarifies that future net sales milestones payments of up to $37.5 million, which did not change, shall be contingent upon reaching certain commercial sales volume objectives for the aggregate of all products under the amended agreement. The agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.
No amounts were paid or recognized during the three months ended March 31, 2024 pursuant to this amendment.

Long-Acting Injectable License and Supply Agreement
In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal is responsible for manufacturing batch products and performing certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, is responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services.

Pursuant to the development supply agreement, Amneal maintained a right of first offer and negotiation to the licensing of each generic product candidate. In March 2024, Amneal and Kashiv entered into a license and supply agreement for the development and commercialization of a long-acting injectable (the “Injectable License and Supply Agreement"). The existing development supply agreement remains effective for the remaining three generic product candidates.

31


Subject to the terms of the Injectable License and Supply Agreement, Amneal is responsible for development, regulatory approval, and commercialization of the product candidate in the U.S., whereas Kashiv is responsible for development and regulatory approval of the product candidate for all other territories outside the U.S. Contingent upon Kashiv obtaining regulatory approval outside the U.S., Amneal shall manufacture the commercial supply for Kashiv at a stated price. The term of the agreement is 10 years from the respective product’s launch date in the U.S.

During the three months ended March 31, 2024, the Company recorded R&D expense for a $0.5 million payment made upon execution of the license and supply agreement. The agreement provides for potential future milestone payments to Kashiv of up to $35.0 million as follows: (i) up to $10.0 million relating to developmental milestones; (ii) up to $20.0 million for U.S. regulatory approval and initial commercial launch milestones; and (iii) up to $5.0 million for the achievement of annual commercial milestones. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.
Refer to Note 3. Acquisitions and Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K for information on the Company’s agreements with Kashiv.
20. Segment Information
The Company has three reportable segments: Generics, Specialty, and AvKARE.
Generics
The Company’s Generics segment includes a retail and institutional portfolio of over 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals.
Specialty
The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders.
AvKARE
The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.
Chief Operating Decision Makers
The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, because they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment because it is not reviewed by the Company’s chief operating decision makers.
32


The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Three Months Ended March 31, 2024
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$391,294 $105,234 $162,663 $ $659,191 
Cost of goods sold239,922 44,800 136,409  421,131 
Gross profit151,372 60,434 26,254  238,060 
Selling, general and administrative33,085 25,196 14,907 39,407 112,595 
Research and development34,371 4,927   39,298 
Intellectual property legal development expenses960 24   984 
Restructuring and other charges 946  524 1,470 
Change in fair value of contingent consideration 100   100 
Charges related to legal matters, net94,359    94,359 
Operating (loss) income$(11,403)$29,241 $11,347 $(39,931)$(10,746)

Three Months Ended March 31, 2023
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$343,806 $91,678 $122,056 $ $557,540 
Cost of goods sold230,551 43,191 105,612  379,354 
Gross profit113,255 48,487 16,444  178,186 
Selling, general and administrative27,600 22,379 12,940 39,177 102,096 
Research and development32,359 6,331   38,690 
Intellectual property legal development expenses1,624 20   1,644 
Restructuring and other charges99   411 510 
Change in fair value of contingent consideration 2,457   2,457 
(Credit) charges related to legal matters, net(2,444)  2,008 (436)
Other operating income(1,224)   (1,224)
Operating income (loss)
$55,241 $17,300 $3,504 $(41,596)$34,449 
(1)Operating results for the sale of Amneal products by AvKARE are included in Generics.
21. Subsequent Event

On April 30, 2024, Amneal closed on the sale of a wholly owned subsidiary in India to Kashiv for total consideration of ₹1 billion, or approximately $12 million. Total consideration consisted of a ₹416 million, or approximately $5 million, cash payment at closing and the assumption of a loan payable of approximately ₹600 million, or approximately $7 million, payable to another subsidiary of Amneal in India. The loan payable bears interest of 11% on the unpaid principal and is due on or before December 31, 2024. The Company is permitted to offset royalties or other amounts payable to Kashiv with any overdue principal on the loan payable. The subsidiary’s assets and liabilities were primarily comprised of a building under construction and a note payable, respectively. The subsidiary had no business activity, other than the construction of the building.
33


Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals. We operate principally in the United States (“U.S.”), India, and Ireland, and sell to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly.
The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. Risk Factors in our 2023 Annual Report on Form 10-K and under the heading Cautionary Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q.
The following discussion and analysis for the three months ended March 31, 2024 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.
Overview
We have three reportable segments: Generics, Specialty, and AvKARE.  
Generics
Our Generics segment includes approximately 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals. We focus on developing products with substantial barriers-to-entry due to complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on our financial results. The entrance into the market of additional competition generally has a negative impact on the volume and/or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of our control.
Specialty
Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system (“CNS”) disorders, including Parkinson’s disease, and endocrine disorders. Our portfolio of products includes RYTARY®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to RYTARY®, our promoted Specialty portfolio also includes UNITHROID® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., and ONGENTYS® (opicapone), an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes, which we commenced selling in early 2024 under a license agreement with BIAL-Portela & Ca., S.A.
On June 30, 2023, we received a complete response letter (“CRL”) from the FDA regarding our new drug application (“NDA”) for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that, although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. During October 2023, we met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked us to complete a QT study, a routine cardiac safety study that is required for new drugs. We completed the QT study and resubmitted our NDA for IPX203 on February 7, 2024. IPX203 has a Prescription Drug User Fee Act (PDUFA) decision date of August 7, 2024. However, we can provide no assurance that the FDA will approve our NDA for IPX203 timely or at all.
Our Specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Our Specialty segment also has a number of product candidates that are in varying stages of development.
34



For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S., when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.
AvKARE
Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.
The Pharmaceutical Industry
The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our 2023 Annual Report on Form 10-K, as supplemented by Part II, Item 1A Risk Factors of our subsequent Quarterly Reports on Form 10-Q.
Inflation

While it is difficult to accurately measure the impact of inflation, we estimate our business will experience an increase in costs due to inflation of approximately $15.0 million to $20.0 million for the year ending December 31, 2024, excluding the impact of rising interest rates. Notwithstanding our estimates, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.


35


Results of Operations
Consolidated Results
The following table sets forth our summarized, consolidated results of operations for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,Increase (Decrease)
20242023$%
Net revenue$659,191 $557,540 $101,651 18.2 %
Cost of goods sold421,131 379,354 41,777 11.0 %
Gross profit238,060 178,186 59,874 33.6 %
Selling, general and administrative112,595 102,096 10,499 10.3 %
Research and development39,298 38,690 608 1.6 %
Intellectual property legal development expenses984 1,644 (660)(40.1)%
Restructuring and other charges1,470 510 960 188.2 %
Change in fair value of contingent consideration100 2,457 (2,357)(95.9)%
Charges (credit) related to legal matters, net94,359 (436)94,795 nm
Other operating income— (1,224)1,224 (100.0)%
Operating (loss) income(10,746)34,449 (45,195)nm
Total other expense, net(64,776)(43,875)(20,901)47.6 %
Loss before income taxes(75,522)(9,426)(66,096)nm
Provision for income taxes
6,156 668 5,488 nm
Net loss$(81,678)$(10,094)$(71,584)nm
nm - not meaningful
Net Revenue

Net revenue for the three months ended March 31, 2024 increased 18.2% from the prior year period primarily due to:

Growth in our Generics segment net revenue of $47.5 million primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $24.6 million and other new generic products that contributed $19.2 million of year-over-year growth and strong volume growth, partially offset by price erosion. Net revenue for the three months ended March 31, 2023 included a non-recurring customer order of $21.0 million.

Growth in our AvKARE segment net revenue of $40.6 million, primarily driven by growth in our distribution and government label channels resulting from growth in new product introductions.

Growth in our Specialty segment net revenue of $13.6 million primarily driven by a $9.4 million increase in our promoted neurology portfolio, of which $4.0 million was comprised of sales of ONGENTYS®, which launched during the first quarter of 2024, and growth in our promoted endocrinology portfolio of $4.6 million, partially offset by declines in our non-promoted products.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased 11.0% for the three months ended March 31, 2024 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE and Generics volume and increased plant costs, partially offset by efficiencies in our supply costs. Cost of goods sold for the three months ended March 31, 2023 included $11.0 million associated with the non-recurring customer order in our Generics segment discussed above.

Gross profit as a percentage of net revenue increased to 36.1% for the three months ended March 31, 2024 from 32.0% in the prior year period primarily as a result of the factors noted above.
Selling, General, and Administrative
Selling, general, and administrative (“SG&A”) expenses for the three months ended March 31, 2024 increased 10.3% as compared to the prior year period primarily due to increases in employee compensation, promotion associated with
36


ONGENTYS® and our planned launch of IPX203, and annual fees assessed on branded prescription drug manufacturers, which are also applicable to certain of our generic products.
Research and Development
Research and development (“R&D”) expenses for the three months ended March 31, 2024 increased 1.6% as compared to the prior year period primarily due to an increase in in-licensing and upfront milestone payments of $3.5 million, partially offset by lower project spend of $1.4 million and operating efficiencies in our infrastructure.
Change in Fair Value of Contingent Consideration
Refer to Note 15. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The change in the fair value of contingent consideration for the three months ended March 31, 2024 was immaterial. The $2.5 million change in the fair value of contingent consideration for the three months ended March 31, 2023 was primarily driven by a decrease in our cost of debt and the passage of time.
Charges (Credit) Related to Legal Matters, Net
For the three months ended March 31, 2024, we recorded a charge for Generics civil prescription opioid litigation of $94.4 million. For the three months ended March 31, 2023, we recorded a net credit of $0.4 million for a litigation settlement gain, partially offset by charges for legal proceedings. Refer to Note 17. Commitments and Contingencies for additional information.
Total Other Expense, Net
Total other expense, net for the three months ended March 31, 2024 increased 47.6% as compared to the prior year period. The increase was primarily driven by a $16.4 million increase in interest expense as a result of higher rates on our variable-rate debt.
Provision For Income Taxes
For the three months ended March 31, 2024, our provision for income taxes and effective tax rate were $6.2 million and (8.2)%, respectively, as compared to a provision for income taxes of $0.7 million and an effective tax rate of (7.1)% for the three months ended March 31, 2023. The period-over-period changes in the provision for income taxes and effective tax rate were primarily related to changes in the jurisdictional mix of income.
Generics
The following table sets forth results of operations for our Generics segment for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,Increase (Decrease)
20242023$%
Net revenue$391,294 $343,806 $47,488 13.8 %
Cost of goods sold239,922 230,551 9,371 4.1 %
Gross profit151,372 113,255 38,117 33.7 %
Selling, general and administrative33,085 27,600 5,485 19.9 %
Research and development34,371 32,359 2,012 6.2 %
Intellectual property legal development expenses960 1,624 (664)(40.9)%
Restructuring and other charges— 99 (99)(100.0)%
Charges (credit) related to legal matters, net
94,359 (2,444)96,803 nm
Other operating income— (1,224)1,224 (100.0)%
Operating (loss) income
$(11,403)$55,241 $(66,644)(120.6)%
nm - not meaningful
37


Net Revenue
Generics net revenue for the three months ended March 31, 2024 increased 13.8% as compared to the prior year period primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $24.6 million and other new generic products that contributed $19.2 million of year-over-year growth and strong volume growth, partially offset by price erosion. Net revenue for the three months ended March 31, 2023 included a non-recurring customer order of $21.0 million.
Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the three months ended March 31, 2024 increased 4.1% as compared to the prior year period primarily due to costs associated with increased sales volume and increased plant costs, partially offset by efficiencies in our supply costs. Cost of goods sold for the three months ended March 31, 2023 included $11.0 million associated with the non-recurring customer order discussed above.

Generics gross profit as a percentage of net revenue increased to 38.7% for the three months ended March 31, 2024 from 32.9% in the prior year period primarily as a result of the factors noted above.
Selling, General, and Administrative
Generics SG&A expense for the three months ended March 31, 2024 increased 19.9% as compared to the prior year period primarily due to increases in employee compensation, promotion associated with our biosimilars, and the annual fees assessed on branded prescription drug manufacturers.
Research and Development
Generics R&D expenses for the three months ended March 31, 2024 increased 6.2% as compared to the prior year period primarily due to an increase in in-licensing and upfront milestone payments of $3.5 million, partially offset by reduced project spend of $0.8 million and operating efficiencies in our infrastructure.
Charges (Credit) Related to Legal Matters, Net
For the three months ended March 31, 2024, we recorded a charge for Generics civil prescription opioid litigation of $94.4 million. For the three months ended March 31, 2023, a litigation settlement gain was partially offset by charges for legal proceedings. Refer to Note 17. Commitments and Contingencies for additional information.
Specialty
The following table sets forth results of operations for our Specialty segment for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,Increase (Decrease)
20242023$%
Net revenue$105,234 $91,678 $13,556 14.8 %
Cost of goods sold44,800 43,191 1,609 3.7 %
Gross profit60,434 48,487 11,947 24.6 %
Selling, general and administrative25,196 22,379 2,817 12.6 %
Research and development4,927 6,331 (1,404)(22.2)%
Intellectual property legal development expenses24 20 20.0 %
Restructuring and other charges946 — 946 nm
Change in fair value of contingent consideration100 2,457 (2,357)(95.9)%
Operating income$29,241 $17,300 $11,941 69.0 %
nm - not meaningful
38


Net Revenue

Specialty net revenue for the three months ended March 31, 2024 increased 14.8% compared to the prior year period, primarily driven by a $9.4 million increase in our promoted neurology portfolio, of which $4.0 million was comprised of sales of ONGENTYS®, which launched during the first quarter of 2024, and growth in our promoted endocrinology portfolio of $4.6 million, partially offset by declines in our non-promoted products.

Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended March 31, 2024 increased 3.7% as compared to the prior year period, primarily due to an increase in volumes, partially offset by favorable product mix. Specialty gross profit as a percentage of net revenue increased to 57.4% for the three months ended March 31, 2024 as compared to 52.9% in the prior year period due to growth in our higher margin promoted products.
Selling, General, and Administrative
Specialty SG&A expense for the three months ended March 31, 2024 increased 12.6% as compared to the prior year period primarily due to increases in promotional costs associated with ONGENTYS® and our planned launch of IPX203 and an increase in the annual fees assessed on branded prescription drug manufacturers.
Research and Development
Specialty R&D expenses for the three months ended March 31, 2024 decreased 22.2% as compared to the prior year period primarily due to reduced project spend of $0.6 million and reduced infrastructure costs.
Change in Fair Value of Contingent Consideration
Refer to Note 15. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The change in the fair value of contingent consideration for the three months ended March 31, 2024 was immaterial. The $2.5 million change in the fair value of contingent consideration for the three months ended March 31, 2023 was primarily driven by a decrease in our cost of debt and the passage of time.
AvKARE
The following table sets forth results of operations for our AvKARE segment for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,Increase (Decrease)
20242023$%
Net revenue$162,663 $122,056 $40,607 33.3 %
Cost of goods sold136,409 105,612 30,797 29.2 %
Gross profit26,254 16,444 9,810 59.7 %
Selling, general and administrative14,907 12,940 1,967 15.2 %
Operating income$11,347 $3,504 $7,843 223.8 %
Net Revenue
AvKARE net revenue for the three months ended March 31, 2024 increased 33.3% as compared to the prior year period primarily driven by growth in our distribution and government label channels resulting from growth in new product introductions.
Cost of Goods Sold and Gross Profit
AvKARE cost of goods sold for the three months ended March 31, 2024 increased 29.2% as compared to the prior year period, and gross profit as a percentage of net revenue increased to 16.1% for the three months ended March 31, 2024 from 13.5% in the prior year period, primarily due to the increase in sales through our higher margin government channel, including higher margin new product introductions.
39


Selling, General and Administrative
AvKARE SG&A expense for the three months ended March 31, 2024 increased 15.2% as compared to the prior year period primarily due to higher employee compensation and sales-related expenses.
Liquidity and Capital Resources
Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements (as defined and discussed in Note 16. Debt in our 2023 Annual Report on Form 10-K). We have access to $397.7 million of available capacity under the Amended New Revolving Credit Facility and $28.0 million of available capacity under the Amended Rondo Revolving Credit Facility as of March 31, 2024. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control. Our primary uses of capital resources are to fund operating activities, including R&D expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, spending on production facility expansions, capital equipment, acquisitions, and legal settlements.
We estimate that we will invest approximately $60.0 million to $70.0 million during 2024 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology and facilities.
Debt Instruments
Over the next 12 months, we expect to make substantial payments, including monthly interest and quarterly principal amounts due for our Term Loan Due 2028, monthly interest on our Term Loan Due 2025 and Amended New Credit Facility, and contractual payments for leased premises. Refer to Note 16. Debt, Note 18. Leases, and Commitments and Contractual Obligations under Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 Annual Report on Form 10-K for additional information on our indebtedness and leases, respectively.
Settlement in Principle on Nationwide Civil Prescription Opioid Litigation
In late April 2024, we reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by states, counties, municipalities, and Native American tribes across the U.S. Refer to Note 17. Commitments and Contingencies for additional information.
Tax Receivable Agreement
In 2018, we entered into a tax receivable agreement (“TRA”) for which we were generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that we were deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to us (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A common stock and (ii) tax benefits attributable to payments made under the TRA. As part of the Reorganization (as defined in Note 1. Nature of Operations in our 2023 Annual Report on Form 10-K), the TRA was amended to reduce our future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. As of December 31, 2023, the contingent TRA liability, including the impact of the amendment, was approximately $185.0 million.
The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and amount of our taxable income, and the corporate tax rate in effect at the time of realization of our taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA’s attributes). Because the Amneal Group (as defined in Item 1. Business in the Company’s 2023 Annual Report on Form 10-K) has exchanged all of its Amneal Common Units pursuant to the Reorganization, the primary remaining factor that could increase the contingent TRA liability is an increase in the effective tax rate. Since the combined rate for federal and state and local income taxes, as of March 31, 2024, has not changed significantly since December 31, 2023, the contingent TRA liability has not changed significantly from the year end amount described above. In addition, any future payments under the TRA may create additional basis adjustments, which may result in an additional layer of depreciation and amortization allocable to the Company, resulting in additional TRA payments. The timing and amount of payments may also be accelerated under certain conditions, such as a change of control or other early termination event, which could give rise to our obligation to make TRA payments in advance of
40


tax benefits being realized. For further information, refer to Item 1A. Risk Factors in our 2023 Annual Report on Form 10-K and Note 5. Income Taxes in this Form 10-Q.

Tax-Related Distributions
Prior to the Reorganization, Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”). During the three months ended March 31, 2023, the Company recorded net tax distributions to the Members of $26.8 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members.
In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the three months ended March 31, 2024 and 2023, we made cash tax distributions of $0.6 million and $0.2 million, respectively, to the AvKARE Sellers. During April 2024, we made cash tax distributions of $3.7 million to the AvKARE Sellers.
Cash Balances
As of March 31, 2024, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.
Cash Flows
The following table sets forth our summarized, consolidated cash flows for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended
March 31,
Increase (Decrease)
20242023$%
Net cash (used in) provided by:
Operating activities$(4,410)$139,712 $(144,122)(103.2)%
Investing activities(19,760)(11,737)(8,023)68.4 %
Financing activities(23,155)(12,900)(10,255)79.5 %
Effect of exchange rate changes on cash(165)767 (932)(121.5)%
Net (decrease) increase in cash, cash equivalents, and restricted cash
$(47,490)$115,842 $(163,332)nm
nm - not meaningful
Cash Flows from Operating Activities
Net cash used in operating activities was $4.4 million for the three months ended March 31, 2024 as compared to net cash provided by operating activities of $139.7 million in the prior year period. The decrease in net operating cash flows in the three months ended March 31, 2024 as compared to the prior year period was primarily driven by (i) lower collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, which benefited the three months ended March 31, 2023 and (ii) receipt of a $21.4 million upfront payment associated with the license agreement with Orion Corporation in the three months ended March 31, 2023, partially offset by (i) lower period over period payments associated with the Opana ER® antitrust litigation settlement and (ii) favorable working capital movements.
Cash Flows from Investing Activities
Net cash used in investing activities for the three months ended March 31, 2024 was $19.8 million as compared to $11.7 million in the prior year period. The period over period increase in net cash used in investing activities was primarily due to the
41


payment of a sales-based milestone related to the licensing and supply agreement with mAbxience S.L. for its biosimilar candidate for Avastin® (bevacizumab).
Cash Flows from Financing Activities
Net cash used in financing activities was $23.2 million for the three months ended March 31, 2024 as compared to $12.9 million in the prior year period. The period over period increase in net cash used in financing activities was primarily due to (i) net payments of principal on debt and other financing liabilities in the three months ended March 31, 2024 as compared to net borrowings in the prior year period and (ii) an increase in employee payroll tax withholding on restricted stock unit vesting, partially offset by a period over period decrease in tax distributions to non-controlling interests.
Commitments and Contractual Obligations
Our contractual obligations are set forth in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2023 Annual Report on Form 10-K. As of March 31, 2024, there have been no material changes to the disclosure presented in our 2023 Annual Report on Form 10-K.
Off-Balance Sheet Arrangements
We did not have any off-balance sheet arrangements as of March 31, 2024.
Critical Accounting Policies and Estimates
For a discussion of our critical accounting policies and estimates, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2023 Annual Report on Form 10-K.
Recently Issued Accounting Standards
Recently issued accounting standards are discussed in Note 2. Summary of Significant Accounting Policies.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
There has not been any material change in our assessment of market risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our 2023 Annual Report on Form 10-K. 
Item 4.    Controls and Procedures
Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2024.

Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2024, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
42



Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.
Part II – OTHER INFORMATION
Item 1.    Legal Proceedings
Information pertaining to legal proceedings can be found in Note 17. Commitments and Contingencies and is incorporated by reference herein.
Item 1A.    Risk Factors
There have been no material changes to the disclosures presented in our 2023 Annual Report on Form 10-K under Item 1A. Risk Factors.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3.    Defaults Upon Senior Securities
None.
Item 4.    Mine Safety Disclosures
Not applicable.
Item 5.    Other Information
None.



43


Item 6.    Exhibits
Exhibit No.Description of Document
101
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for each of the three months ended March 31, 2024 and 2023, (ii) Consolidated Statements of Comprehensive Loss for each of the three months ended March 31, 2024 and 2023, (iii) Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023, (v) Consolidated Statements of Changes in Stockholders' Equity (Deficiency) for each of the three months ended March 31, 2024 and 2023 and (vi) Notes to Consolidated Financial Statements.*
104
Cover Page Interactive Data File – The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 is formatted in Inline XBRL (included as Exhibit 101).
*Filed herewith
**This certificate is being furnished solely to accompany the report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
44


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 8, 2024Amneal Pharmaceuticals, Inc.
(Registrant)
By:/s/ Anastasios Konidaris
Anastasios Konidaris
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
45
EX-31.1 2 amrx-2024033110xqexx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Chirag Patel, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 of Amneal Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 8, 2024By:/s/ Chirag Patel
Chirag Patel
President and Co-Chief Executive Officer
(Co-Principal Executive Officer)

EX-31.2 3 amrx-2024033110xqexx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Chintu Patel, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 of Amneal Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 8, 2024By:/s/ Chintu Patel
Chintu Patel
Co-Chief Executive Officer
(Co-Principal Executive Officer)

EX-31.3 4 amrx-2024033110xqexx313.htm EX-31.3 Document

Exhibit 31.3
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Anastasios Konidaris, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 of Amneal Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 8, 2024By:/s/ Anastasios Konidaris
Anastasios Konidaris
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 5 amrx-2024033110xqexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Amneal Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended March 31, 2024 (the “Report”), Chirag Patel, President and Co-Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
May 8, 2024By:/s/ Chirag Patel
Chirag Patel
President and Co-Chief Executive Officer
(Co-Principal Executive Officer)
A signed original of this written statement required by Section 906 has been provided to Amneal Pharmaceuticals, Inc. and will be retained by Amneal Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 amrx-2024033110xqexx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Amneal Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended March 31, 2024 (the “Report”), Chintu Patel, Co-Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
May 8, 2024By:/s/ Chintu Patel
Chintu Patel
Co-Chief Executive Officer
(Co-Principal Executive Officer)
A signed original of this written statement required by Section 906 has been provided to Amneal Pharmaceuticals, Inc. and will be retained by Amneal Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.3 7 amrx-2024033110xqexx323.htm EX-32.3 Document

Exhibit 32.3
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Amneal Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended March 31, 2024 (the “Report”), Anastasios Konidaris, Executive Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
May 8, 2024By:/s/ Anastasios Konidaris
Anastasios Konidaris
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
A signed original of this written statement required by Section 906 has been provided to Amneal Pharmaceuticals, Inc. and will be retained by Amneal Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 8 amrx-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Alliance and Collaboration link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Trade Accounts Receivable, Net link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Stockholders’ Equity and Redeemable Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Trade Accounts Receivable, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Stockholders’ Equity and Redeemable Non-Controlling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Nature of Operations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Revenue Recognition - Concentration of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Alliance and Collaboration - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Loss per Share - Computation of Basic and Diluted Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Trade Accounts Receivable, Net - Concentration of Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Inventories - Components of Inventories, Net of Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Goodwill and Other Intangible Assets - Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Other Assets - Schedule of Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Debt - Summary of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Debt - Summary of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Other Long-Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Fair Value Measurements - Summary of the Company’s Indebtedness at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Related Party Transactions - Related Party Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Related Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Segment Information - Schedules of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 amrx-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 amrx-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 amrx-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Less: Net (income) loss attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Change in fair value of contingent consideration Change in fair value during the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Other long-term liabilities Other Noncurrent Liabilities [Member] Statistical Measurement Statistical Measurement [Domain] Summary of the Company’s Indebtedness at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Research and development Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Achievement Of Annual Commercial Milestone Achievement Of Annual Commercial Milestone [Member] Achievement Of Annual Commercial Milestone Accrued royalties Accrued Royalties, Current Award Type Award Type [Domain] Debt Debt Disclosure [Text Block] Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Liabilities for legal matters - long term Estimated Litigation Liability, Noncurrent Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Collaborative arrangement maximum contingent payments amount Collaborative Arrangement Contingent Payments Amount Collaborative Arrangement, Contingent Payments, Amount Effect of foreign exchange rate on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Performance stock units Performance Shares [Member] Accounts payable Accounts Payable, Current Segment Reporting [Abstract] Segment Reporting [Abstract] Total other expense, net Nonoperating Income (Expense) Commitments and contingencies (Notes 4 and 17) Commitments and Contingencies Intangible asset impairment charges, indefinite-lived Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Apace Packaging, LLC - packaging agreement Apace K Y L L C [Member] Apace KY, LLC. Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Litigation settlement, interest rate Litigation Settlement, Interest Rate Litigation Settlement, Interest Rate Stockholders’ Equity and Redeemable Non-Controlling Interests Equity [Text Block] Litigation Settlement, Option One Litigation Settlement, Option One [Member] Litigation Settlement, Option One Schedule of Goodwill [Table] Schedule of Goodwill [Table] Customer D Customer D [Member] Customer D [Member] Geographical Geographical [Axis] Inventory provision Inventory Write-down Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Ownership Ownership [Axis] Generic Digoxin and Doxycycline Antitrust Litigation Generic Digoxin And Doxycycline Antitrust Litigation [Member] Generic Digoxin and Doxycycline Antitrust Litigation. Concentration Risk [Line Items] Concentration Risk [Line Items] Other Assets [Table] Other Assets [Table] Other assets. Customer Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Alkermes Plc Alkermes Plc [Member] Alkermes Plc Research and Development Storage Income Research and Development Storage Income [Member] Research and Development Storage Income Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Proceeds from divestiture of businesses Proceeds from Divestiture of Businesses Subsequent Event Type Subsequent Event Type [Domain] Senior Secured Credit Facility Senior Secured Credit Facility [Member] Senior Secured Credit Facility [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in dollars per share) Earnings Per Share, Diluted Trade accounts receivable, net Trade accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Goodwill [Roll Forward] Goodwill [Roll Forward] Reclassification of cash flow hedge to earnings, net of tax of $0 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Reclassification of cash flow hedge to earnings, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Collaborative arrangement non-refundable license fee Collaborative Arrangement, Non-Refundable License Fee Collaborative Arrangement, Non-Refundable License Fee Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Loss contingency civil lawsuit filed number of additional states Loss Contingency Civil Lawsuit Filed Number Of Additional States Loss contingency civil lawsuit filed number of additional states. Deferred compensation plan liabilities Deferred Compensation Plan Liabilities Fair Value Disclosures Deferred Compensation Plan Liabilities, Fair Value Disclosures Collaborative arrangement maximum milestone paid Collaborative Arrangement Maximum Milestone Paid Collaborative Arrangement Maximum Milestone Paid Estimated litigation liability Estimated Litigation Liability Litigation Case Litigation Case [Axis] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Related party receivables Increase (Decrease) in Due from Related Parties Long-term debt fair value Long-Term Debt, Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss attributable to Amneal Pharmaceuticals, Inc. Net Income (Loss) Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Total current liabilities Liabilities, Current Derivative Contract Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Collaborative arrangement net revenue agreement Collaborative Arrangement Net Revenue Agreement Collaborative Arrangement Net Revenue Agreement Intangible assets, cost Intangible Assets, Gross (Excluding Goodwill) Liabilities and Stockholders' (Deficiency) Equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Accrued Medicaid and Commercial Rebates Accrued Medicaid And Commercial Rebates [Member] Accrued Medicaid And Commercial Rebates [Member] Collaborative arrangement upfront payment Collaborative Arrangement Upfront Payment Collaborative arrangement, up-front payment. Prepaid taxes Prepaid Taxes Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Unrealized gain recorded within accumulated other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Av Kare Incorporation And R And S Northeast L L C Av Kare Incorporation And R And S Northeast L L C [Member] Av Kare Incorporation And R And S Northeast L L C Other Assets [Abstract] Other Assets [Abstract] Schedule of Loss per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of goods sold Cost of goods sold Cost of Goods and Services Sold Amounts of transaction with related party Related Party Transaction, Amounts of Transaction Common Class B Shares of Old PubCo Class B common stock Common Class B [Member] Customer B Customer B Customer B [Member] Customer B [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Goodwill Balance, beginning of period Balance, end of period Goodwill Equity Components Equity Components [Axis] Reallocation of ownership interests Changes In Reallocation Of Ownership Interests Changes in reallocation of ownership interests. Term Loan Due May 2028 Term Loan Due 2028 [Member] Term Loan Due 2028 Term Loan Due May 2025 Term Loan Due 2025 [Member] Term Loan Due 2025 Percentage Of Prescribed Label Percentage Of Prescribed Label Percentage Of Prescribed Label Variable to Fixed Interest Rate Swap Variable To Fixed Interest Rate Swap [Member] Variable-to-fixed interest rate swap. Entity Small Business Entity Small Business Generics Generics Segment [Member] Generics Segment [Member] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Trade accounts receivable, net Increase (Decrease) in Accounts Receivable Unrealized foreign currency loss (gain) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Amended October 2019 Swap Amended October 2019 Swap [Member] Amended October 2019 Swap Notional amount Derivative, Notional Amount Accounts Receivable Accounts Receivable [Member] Operating lease liabilities Operating Lease, Liability, Noncurrent Restricted cash Restricted cash - end of period Restricted Cash and Cash Equivalents, Current Restricted stock units Restricted Stock Units (RSUs) [Member] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Debt Instrument, Name Debt Instrument, Name [Domain] Amended New Revolving Credit Facility Amended New Revolving Credit Facility [Member] Amended New Revolving Credit Facility Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Amended Rondo Credit Facility Amended Rondo Credit Facility [Member] Amended Rondo Credit Facility Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Amneal Pharmaceuticals, LLC Amneal Pharmaceuticals, LLC [Member] Amneal Pharmaceuticals, LLC Deadline period for defendants Loss Contingency, Deadline Period For Defendants To Respond To Complaint Loss Contingency, Deadline Period For Defendants To Respond To Complaint Commercial chargebacks and rebates Rebates And Chargebacks Rebates and chargebacks. Payables and Accruals [Abstract] Tax distributions to non-controlling interests Noncash or Part Noncash Acquisition, Tax Distributions to Noncontrolling Interests Noncash or Part Noncash Acquisition, Tax Distributions to Noncontrolling Interests Product and Service Product and Service [Domain] Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Cash Discount Allowances Cash Discount Allowances [Member] Cash Discount Allowances [Member] Inventories Increase (Decrease) in Inventories Deposits and advances Contract with Customer, Asset, after Allowance for Credit Loss, Current Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Potentially dilutive securities excluded from earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Supplemental disclosure of non-cash investing and financing activity: Noncash Investing and Financing Items [Abstract] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Hedging Designation Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Remainder of 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Related Party Transactions Related Party Transactions Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Long-term Debt, Type Long-Term Debt, Type [Domain] Cash discount allowances Cash Discount Allowances Current Cash Discount Allowances, Current Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Specialty Specialty Segment [Member] Specialty Segment [Member] Number of states, filed civil lawsuit Loss Contingency Civil Lawsuit Filed Number Of States Loss Contingency, Civil Lawsuit Filed, Number Of States Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Dermatology Dermatology [Member] Dermatology. Current portion of operating lease liabilities Operating Lease, Liability, Current Fair Value Interest Rate Cash Flow Hedge Liability at Fair Value Schedule of Prepaid Expenses and Other Current Assets Schedule of Other Assets [Table Text Block] Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company R&S Solutions - logistics services R&S Solutions [Member] R&S Solutions Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Net Finite-Lived Intangible Assets, Net Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Tax receivable agreement liability Tax Receivable Agreement Liability Tax Receivable Agreement Liability Counterparty Name Counterparty Name [Domain] Cash, cash equivalents, and restricted cash - beginning of period Cash, cash equivalents, and restricted cash - end of period Cash, cash equivalents, and restricted cash - end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Restricted stock unit vesting, net of shares withheld to cover payroll taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Tax receivable agreement, payment ratio Tax Receivable Agreement, Payment Ratio Tax Receivable Agreement, Payment Ratio Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Gross profit Gross Profit Security Exchange Name Security Exchange Name Total debt, net of debt issuance costs Long-Term Debt Number of cases filed Loss Contingency, Number Of Cases Loss Contingency, Number Of Cases Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Alkermes Alkermes [Member] Alkermes Other comprehensive loss before reclassification Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Alliance and Collaboration Collaborative Arrangement Disclosure [Text Block] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Stock options Employee Stock Option [Member] Interest Rate Lock Agreement Interest Rate Lock Agreement [Member] Interest rate lock agreement. Balance, beginning of period Balance, end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Other Assets [Line Items] Other Assets [Line Items] Other assets. Common Class A Common Class A [Member] Maximum Maximum [Member] Comprehensive loss attributable to Amneal Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] License Agreement with Orion Corporation License Agreement with Orion Corporation [Member] License Agreement with Orion Corporation Collaborative arrangement license revenue agreement Collaborative Arrangement License Revenue Agreement Collaborative Arrangement License Revenue Agreement Note payable - related party Other Notes Payable Entity Address, Address Line One Entity Address, Address Line One Customer A Customer A Customer A [Member] Customer A [Member] Initial Commercial Launch Milestones Initial Commercial Launch Milestones [Member] Initial Commercial Launch Milestones Knight Therapeutics International S.A. License Agreement Knight Therapeutics International S.A. License Agreement [Member] Knight Therapeutics International S.A. License Agreement Development Milestones Development Milestones [Member] Development Milestones Subsequent Event [Table] Subsequent Event [Table] Ownership by parent (percent) Subsidiary, Ownership Percentage, Parent Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other operating charges and credits, net Other Noncash Income (Expense) Old PubCo, Common Class B Old PubCo, Common Class B [Member] Old PubCo, Common Class B Long-term compensation Long Term Compensation [Member] Long-term compensation. Business Acquisition Business Acquisition [Axis] Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Derivative [Table] Derivative [Table] Customer Concentration Risk Customer Concentration Risk [Member] Percentage of tax receivable agreement paid to other holders of Amneal common units (percent) Percentage Of Tax Benefits Under Tax Receivable Agreement Percentage of tax benefits under tax receivable agreement. Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Number of actions Loss Contingency, Number of Legal Actions Loss Contingency, Number of Legal Actions Title of 12(b) Security Title of 12(b) Security Contract charge-backs and sales volume allowances Contract Charge Backs And Sales Volume Allowances Current Contract Charge-Backs And Sales Volume Allowances, Current Government label Government Label [Member] Government label. Related Party Related Party, Type [Domain] Less: Other comprehensive loss attributable to non-controlling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest In-process research and development Indefinite-Lived Intangible Assets (Excluding Goodwill) Ownership percentage by noncontrolling owners (percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Operating Segments Operating Segments [Member] Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Old PubCo, Common Class A Old PubCo, Common Class A [Member] Old PubCo, Common Class A AvKARE AvKARE Segment [Member] AvKARE segment. Derivative, fixed interest rate Derivative, Fixed Interest Rate Schedule of Trade Accounts Receivable, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Financial Instruments Financial Instruments Disclosure [Text Block] Entity Tax Identification Number Entity Tax Identification Number Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Inventories Total inventories Inventory, Net Milestone Payment Milestone Payment [Domain] [Domain] for Milestone Payment [Axis] Statistical Measurement Statistical Measurement [Axis] Other long term liabilities Collaborative Arrangement Other Long Term Liabilities Collaborative Arrangement Other Long Term Liabilities Balance Sheet Location Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Research and Development Research and Development [Member] Research and Development Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding License supply agreement, potential future milestone payments License Supply Agreement, Potential Future Milestone Payments License Supply Agreement, Potential Future Milestone Payments Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Other Assets Other Assets [Member] Segments Segments [Domain] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Consolidation Items Consolidation Items [Domain] Stockholders' accumulated deficit Retained Earnings (Accumulated Deficit) Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: Earnings Per Share Basic And Diluted EPS [Abstract] Earnings Per Share Basic And Diluted EPS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Charges (credit) related to legal matters, net (Credit) charges related to legal matters, net (Credit) charges related to legal matters, net Gain (Loss) Related to Litigation Settlement Performance Obligations Revenue from Contract with Customer [Policy Text Block] Opana ER® antitrust litigation-accrued interest Opana ER Accrued Interest [Member] Opana ER Accrued Interest Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. [Member] UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. Current assets: Assets, Current [Abstract] Uncertain tax positions Uncertain Tax Position Noncurrent [Member] Uncertain tax position noncurrent. Gross accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Distribution Distribution Service [Member] Entity Address, State or Province Entity Address, State or Province Counterparty Name Counterparty Name [Axis] Other Other [Member] Other Metformin Litigation Metformin Litigation [Member] Metformin Litigation Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes Rondo Partners L L C [Member] Rondo Partners, LLC. Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Specialty Amneal Specialty Pharma Segment [Member] Amneal Specialty Pharma Segment [Member] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Shares beginning balance (in shares) Shares ending balance (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Disposal Group Name Disposal Group Name [Domain] Denominator: Earnings Per Share, Basic [Abstract] Contract Charge - Backs and Sales Volume Allowances Contract Chargebacks And Sales Volume Allowances [Member] Contract Charge-backs And Sales Volume Allowances [Member] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Sellers Notes Long Term Promissory Notes [Member] Long term promissory notes. Schedule of Charges and Liabilities Related to Legal Matters Schedule of Loss Contingencies by Contingency [Table Text Block] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Collaborative arrangement term Collaborative Arrangement Term Collaborative Arrangement, Term Current portion of liabilities for legal matters Estimated Litigation Liability, Current Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock Class of Stock [Domain] Customer Customer [Domain] Derivative gain reclassified from accumulated OCI into income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Net loss attributable to Amneal Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Interest rate swap Interest Rate Swap [Member] Debt Instrument Debt Instrument [Axis] Litigation settlement expense Litigation Settlement, Expense Litigation settlement, product supply amount Litigation Settlement, Product Supply Amount Litigation Settlement, Product Supply Amount Effective tax rate (percent) Effective Income Tax Rate Reconciliation, Percent Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Consideration on sale of subsidiary Disposal Group, Including Discontinued Operation, Consideration November 2023 Swap November 2023 Swap [Member] November 2023 Swap License Agreement with Zambon Biotech License Agreement with Zambon Biotech [Member] License Agreement with Zambon Biotech Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Accumulated Other Comprehensive Income Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Prepaid expenses, other current assets and other assets Increase (Decrease) in Prepaid Expense and Other Assets Provision related to sales recorded in the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Kanan, LLC - operating lease Kanan L L C [Member] Kanan, LLC [Member] Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Related Party Transaction Related Party Transaction [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Number of reportable segments Number of Reportable Segments Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Chargebacks receivable Chargebacks Receivable, Current Chargebacks Receivable, Current Related Party Affiliated Entity [Member] Common stock Common Stock, Value, Issued Ranitidine Litigation Ranitidine Litigation [Member] Ranitidine Litigation Number of generic prescription medications Number of Generic Prescription Medications Number of Generic Prescription Medications Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other intangible assets Trade Names [Member] Accrued professional fees Accrued Professional Fees, Current AzaTech Pharma LLC - supply agreement Aza Tech Pharma L L C [Member] AzaTech Pharma LLC. Total current assets Assets, Current Contingent consideration liabilities Business Combination, Contingent Consideration, Liability Schedules of Percent of Gross Trade Receivables Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Increase in tax receivable agreement liability Increase in tax receivable agreement liability Increase (Decrease) in Tax Receivable Agreement Liability Increase (Decrease) in Tax Receivable Agreement Liability Kashiv Bio Sciences License and Commercialization Agreement Kashiv Bio Sciences License And Commercialization Agreement [Member] Kashiv Bio Sciences license and commercialization agreement. Litigation Case Litigation Case [Domain] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Redeemable non-controlling interests Redeemable Non-Controlling Interests, beginning balance Redeemable Non-Controlling Interests, ending balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Statement [Table] Statement [Table] Litigation Settlement, Option Two Litigation Settlement, Option Two [Member] Litigation Settlement, Option Two Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Term Loan Due 2025 Senior Secured Credit Facility, Term Loan Due May 2025 [Member] Senior Secured Credit Facility, Term Loan Due May 2025 License agreement License Agreement [Member] License Agreement Concentration risk (percent) Concentration Risk, Percentage Interest rate swap Interest Rate Cash Flow Hedge Asset at Fair Value Schedule of Changes in Accumulated Other Comprehensive (Loss) Income by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Loan payable, interest rate Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable, Interest Rate Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable, Interest Rate Prepaid insurance Prepaid Insurance Schedule of Goodwill Schedule of Goodwill [Table Text Block] Product rights Contractual Rights [Member] Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Credits/payments issued during the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock Class of Stock [Axis] Anti-infective Anti Infective [Member] Anti infective. Entities [Table] Entities [Table] Accrued other Other Accrued Liabilities, Current Corporate and Other Corporate, Non-Segment [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Revolving credit facility Line of Credit, Current Litigation settlement amount Litigation Settlement, Amount Awarded to Other Party Litigation settlement, percentage of product value Litigation Settlement, Percentage Of Product Value Litigation Settlement, Percentage Of Product Value Other operating income Other Operating Income (Expense), Net Accounts payable and accrued expenses Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Members - tax receivable agreement Members - Tax Receivable Agreement [Member] Members - Tax Receivable Agreement Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income [Member] Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity Equity, Attributable to Parent Consolidation Items Consolidation Items [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Net (loss) income Temporary Equity, Net Income Respiratory Respiratory [Member] Respiratory. Valuation allowance Deferred Tax Assets, Valuation Allowance Subtotal Allowance For Accounts Receivable Current Allowance For Accounts Receivable, Current Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Payments of principal on debt, revolving credit facilities, financing leases and other Repayments Of Long Term Debt, Revolving Credit Facility And Financing Lease Obligations Repayments of long term debt and financing lease obligations. Number of claims dismissed Loss Contingency, Claims Dismissed, Number Unrealized gain (loss) on cash flow hedge, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Concentration Risk Type Concentration Risk Type [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Acquisition of intangible assets Payments to Acquire Intangible Assets Deferred revolving credit facility costs Deferred Revolving Credit Facility Costs [Member] Deferred revolving credit facility costs. Regulatory Approval Regulatory Approval [Member] Regulatory Approval [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Research and Development - Generic Development Supply Agreement - Research and Development Material Research and Development - Generic Development Supply Agreement - Research and Development Material [Member] Research and Development - Generic Development Supply Agreement - Research and Development Material Hedging Designation Hedging Designation [Domain] Other Assets Other Assets Disclosure [Text Block] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Tax distributions, net Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders Tax Distribution Noncontrolling interest, decrease from distributions to noncontrolling interest holders, tax distribution. Entity Emerging Growth Company Entity Emerging Growth Company AvPROP, LLC - operating lease Av Prop L L C [Member] AvProp, LLC. Less: debt issuance costs Debt Issuance Costs, Net Nonrefundable license fee received, amount Collaborative Arrangement, Nonrefundable License Fee Received, Amount Collaborative Arrangement, Nonrefundable License Fee Received, Amount Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other long term assets Other Noncurrent Assets [Member] Hormonal / allergy Hormonal Allergy [Member] Hormonal allergy. Disposal Group Classification Disposal Group Classification [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Estimated useful life (in years) Weighted-Average Amortization Period (in years) Finite-Lived Intangible Asset, Useful Life Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Kashiv Biosciences LLC Kashiv Bio Sciences L L C [Member] Kashiv BioSciences LLC [Member] Selling, General and Administrative - Logistics Services Selling, General and Administrative - Logistics Services [Member] Selling, General and Administrative - Logistics Services Common Stock Common Stock [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service Product and Service [Axis] Loss per Share Earnings Per Share [Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical Geographical [Domain] Total stockholders' (deficiency) equity Stockholders' equity beginning balance Stockholders' equity ending balance Equity, Including Portion Attributable to Noncontrolling Interest Tax distribution Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Unrealized gain (loss) on cash flow hedge, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Selling, General and Administrative - Operating Lease Selling, General and Administrative - Operating Lease [Member] Selling, General and Administrative - Operating Lease Property, plant and equipment, net Property, Plant and Equipment, Net Receivables [Abstract] Receivables [Abstract] Inventory and Cost of Goods Sold Inventory and Cost of Goods Sold [Member] Inventory and Cost of Goods Sold Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Disposal Group Classification Disposal Group Classification [Axis] Cash flow hedge gain (loss) to be reclassified within 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Security deposits Security Deposits [Member] Security deposits. Assets Assets Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Foreign exchange (loss) gain, net Gain (Loss), Foreign Currency Transaction, before Tax Nonrelated Party Nonrelated Party [Member] Litigation settlement, product supply price (in USD per twin pack) Litigation Settlement, Product Supply Price Litigation Settlement, Product Supply Price Employee payroll tax withholding on restricted stock unit vesting Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Other Product and Service, Other [Member] Net loss Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Cash (paid) received, net for income taxes Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Foreign currency translation adjustments arising during the period Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes Sellers of AvKARE LLC and R&S [Member] Sellers of AvKARE LLC and R&S Voting interest acquired (percent) Business Acquisition, Percentage of Voting Interests Acquired Stockholders' Accumulated Deficit Retained Earnings [Member] Current portion of long-term debt, net Less: current portion of long-term debt Long-Term Debt, Current Maturities Civil prescription opioid litigation (Liabilities for legal matters - long term) Long-Term Portion of Liabilities For Legal Matters (Included In Other Long-Term Liabilities) Long-Term Portion of Liabilities For Legal Matters (Included In Other Long-Term Liabilities) Total liabilities and stockholders' (deficiency) equity Liabilities and Equity Other assets Other Assets, Noncurrent Other (expense) income: Nonoperating Income (Expense) [Abstract] Ownership Ownership [Domain] Unrealized gain (loss) on cash flow hedge, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Basic (in dollars per share) Basic (in dollars per share) Earnings Per Share, Basic Central nervous system Central Nervous System [Member] Central nervous system. Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of Other Assets Schedule of Other Assets, Noncurrent [Table Text Block] R&D Reimbursement Research And Development Reimbursement [Member] Research And Development Reimbursement [Member] Entity Address, City or Town Entity Address, City or Town Collaborative arrangement non-refundable license fee, amortization period Collaborative Arrangement, Non-Refundable License Fee, Amortization Period Collaborative Arrangement, Non-Refundable License Fee, Amortization Period Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Related Party Related Party [Member] Ownership interest (percent) Percentage Of Ownership Interest Percentage of ownership interest. Assumption of loan payable Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable Subsidiary In India Subsidiary In India [Member] Subsidiary In India Prepaid Expenses and Other Current Assets Supplemental Balance Sheet Disclosures [Text Block] Total long-term liabilities Liabilities, Noncurrent Restructuring and other charges Restructuring Charges Document Transition Report Document Transition Report Customer C Customer C Customer C [Member] Customer C [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Tax distributions, net Temporary Equity, Tax Distribution Temporary Equity, Tax Distribution Reclassification of cash flow hedge to earnings, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Income and other tax receivables Income And Other Taxes Receivable Income and other taxes receivable. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Revenue by Major Customers by Reporting Segments Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Current portion of operating lease liabilities - related party Operating And Finance Lease Liability Current Operating And Finance Lease, Liability, Current Other Liabilities Disclosure [Abstract] Derivative Instrument Derivative Instrument [Axis] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Total debt Long-Term Debt, Gross Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Derivative [Line Items] Derivative [Line Items] Intellectual property legal development expenses Intellectual property legal development expenses Royalty Expense Depreciation and amortization Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs Term Loan Due 2028 Term Loan Due May 2028 [Member] Term Loan Due May 2028 Additional paid-in capital Additional Paid in Capital Accrued Returns Allowance Sales Returns and Allowances [Member] United States Department of Justice Investigations United States Department of Justice Investigations [Member] United States Department of Justice Investigations Net (loss) income Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Achievement of Cumulative Net Sales Achievement Of Cumulative Net Sales [Member] Achievement Of Cumulative Net Sales [Member] Sutaria Family Realty, LLC - operating lease Sutaria Family Realty, LLC [Member] Sutaria Family Realty, LLC Subsequent Event Type Subsequent Event Type [Axis] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Collaborative arrangement, profit share (percent) Collaborative Arrangement Profit Share Percentage Collaborative Arrangement, Profit Share, Percentage Liabilities recorded under tax receivable agreement Liabilities Under Tax Receivable Agreement Noncurrent Liabilities Under Tax Receivable Agreement, Noncurrent Other therapeutic classes Other Therapeutic Classes [Member] Other therapeutic classes. Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Avtar Investments LLC - consulting services Avtar Investments, LLC [Member] Avtar Investments, LLC Other Liabilities [Table] Other Liabilities [Table] Other liabilities. Related Party Related Party, Type [Axis] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Other Expense Other Expense Tax Receivable Agreement T R A Liability [Member] Other Expense Tax Receivable Agreement T R A Liability Notice period Collaborative Arrangement, Renewal Decline Notice Period Collaborative Arrangement, Renewal Decline Notice Period Tax distributions to non-controlling interests Tax Distribution To Noncontrolling Interest Financing Activities Tax Distribution To Non-controlling Interest, Financing Activities Metabolic disease / endocrine Metabolic Disease Endocrine [Member] Metabolic disease endocrine. Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Non-controlling interests Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Antiviral Antiviral [Member] Antiviral. Borrowings on revolving credit facilities Proceeds from Lines of Credit Tax distribution recorded as a reduction to redeemable non-controlling interest Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders Disposal Group Name Disposal Group Name [Axis] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Repayment of outstanding principal Repayments of Long-Term Debt Financing lease liabilities Finance Lease, Liability, Noncurrent Accrued Medicaid and commercial rebates Accrued Sales Rebates Current Accrued sales rebates current. Entity Central Index Key Entity Central Index Key Amortization of debt issuance costs and discount Amortization of Debt Issuance Costs and Discounts Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Loss contingency accrual Loss Contingency Accrual Oncology Oncology [Member] Oncology. Cost Finite-Lived Intangible Assets, Gross Collaborative arrangement, number of products Collaborative Arrangement, Number Of Products Collaborative Arrangement, Number Of Products Provision for income taxes Income tax expense (benefit) Income Tax Expense (Benefit) Research and development - Parking Space Lease Research and development - Parking Space Lease [Member] Research and development - Parking Space Lease Finished goods Inventory, Finished Goods, Net of Reserves International and other Non-US [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Xyrem® (Sodium Oxybate) Antitrust Litigation Xyrem® (Sodium Oxybate) Antitrust Litigation [Member] Xyrem® (Sodium Oxybate) Antitrust Litigation Contingent Consideration Contingent Consideration [Member] Contingent Consideration Financing lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Accrued compensation Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Number of products families Number Of Products Families Number Of Products Families Milestone Payment Milestone Payment [Axis] Milestone Payment [Axis] Reclassification of cash flow hedge to earnings, net of tax of $0 Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Opana ER® antitrust litigation Opana ER Antitrust Litigation [Member] Opana ER Antitrust Litigation Collaborative arrangement, medical and marketing activities Collaborative Arrangement, Medical And Marketing Activities Collaborative Arrangement, Medical And Marketing Activities Gastroenterology Gastroenterology [Member] Gastroenterology. Schedule of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Rondo Class B unit holders - tax distributions Rondo Class B Unit Holders - Tax Distributions [Member] Rondo Class B Unit Holders - Tax Distributions Equity [Abstract] Equity [Abstract] Inventories Inventory Disclosure [Text Block] Prepaid taxes Other Receivables, Net, Current Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Long-term Debt, Type Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Cash and cash equivalents Cash and cash equivalents - end of period Cash and Cash Equivalents, at Carrying Value SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Prepaid regulatory fees Prepaid Regulatory Fees Current Prepaid Regulatory Fees, Current Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Long-term debt, net Total long-term debt, net Long-Term Debt, Excluding Current Maturities Collaborative arrangement aggregate sales-based milestone payment Collaborative Arrangement Aggregate Sales-Based Milestone Payment Collaborative Arrangement Aggregate Sales-Based Milestone Payment Litigation settlement agreement terms Litigation Settlement, Payment Terms Litigation Settlement, Payment Terms Diluted (in shares) Weighted-average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Reversal of accrued tax receivable agreement liability Reversal Of Accrued Tax Receivable Agreement Liability Reversal of accrued tax receivable agreement liability. Accrued returns allowance Accrued Sales Returns Allowance Current Accrued sales returns allowance current. Schedule of Major Categories of Sales-Related Deductions Summary of Valuation Allowance [Table Text Block] Schedule of Other Long-Term Liabilities Other Noncurrent Liabilities [Table Text Block] Interest expense, net Interest Income (Expense), Nonoperating, Net Sellers of KSP Sellers of KSP [Member] Sellers of KSP Revenue Recognition Revenue from Contract with Customer [Text Block] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid-in Capital Additional Paid-in Capital [Member] Unrealized gain (loss) on cash flow hedge, net of tax of $0 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Balance Sheet Location Balance Sheet Location [Axis] Total assets Assets Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Net of income taxes, recognized in accumulated other comprehensive income AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Litigation Settlement, Option [Domain] Litigation Settlement, Option [Domain] Litigation Settlement, Option [Domain] Deposits for future acquisition of property, plant and equipment Payments to Acquire Property, Plant, and Equipment, Deposits Payments to Acquire Property, Plant, and Equipment, Deposits Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate [Member] Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate Subsequent Events Subsequent Events [Text Block] Trade Accounts Receivable, Net Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Other prepaid assets Other Prepaid Expense, Current Kashiv Specialty Pharmaceuticals, LLC Kashiv Specialty Pharmaceuticals, LLC [Member] Kashiv Specialty Pharmaceuticals, LLC US UNITED STATES Other Liabilities [Line Items] Other Liabilities [Line Items] Other liabilities. Other Long-Term Liabilities Other Liabilities Disclosure [Text Block] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Other long-term liabilities Other Liabilities, Noncurrent Collaborative arrangement renew for successive term Collaborative Arrangement Renew for Successive Term Collaborative Arrangement Renew for Successive Term Segment Information Segment Reporting Disclosure [Text Block] Civil prescription opioid litigation Civil Prescription Opioid Litigation [Member] Civil Prescription Opioid Litigation ONGENTYS® License Agreement ONGENTYS® License Agreement [Member] ONGENTYS® License Agreement Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component Equity Component [Domain] Deferred income Deferred Income Current portion of financing lease liabilities Finance Lease, Liability, Current Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim [Member] Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim Number of sales representatives Number of Sales Representatives Number of Sales Representatives Long-term prepaid expenses Long Term Prepaid Expenses [Member] Long-term prepaid expenses. Work in process Inventory, Work in Process, Net of Reserves Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted-average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Entity Current Reporting Status Concentration Risk Type Concentration Risk Type [Domain] Operating (loss) income Operating Income (Loss) Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Statement of Other Comprehensive Income [Abstract] Statement of Other Comprehensive Income [Abstract] Cardiovascular system Cardiovascular System [Member] Cardiovascular system. Biosimilar Licensing and Supply Agreement Biosimilar Licensing And Supply Agreement [Member] Biosimilar Licensing And Supply Agreement [Member] Number of states with cases Loss Contingency, Number Of States with Cases Loss Contingency, Number Of States with Cases Related Party Transaction Related Party Transaction [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Segments Segments [Axis] Related party payables Increase (Decrease) in Due to Related Parties Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Litigation Settlement, Option [Axis] Litigation Settlement, Option [Axis] Litigation Settlement, Option Revolving credit facility Long-Term Line of Credit Institutional Institutional [Member] Institutional. Stockholders' (Deficiency) Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Non- Controlling Interests Noncontrolling Interest [Member] Tracy Properties LLC - operating lease Tracy Properties L L C [Member] Tracy Properties LLC. EX-101.PRE 12 amrx-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
3 Months Ended
Mar. 31, 2024
Apr. 30, 2024
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-38485  
Entity Registrant Name Amneal Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 93-4225266  
Entity Address, Address Line One 400 Crossing Boulevard,  
Entity Address, City or Town Bridgewater  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08807  
City Area Code 908  
Local Phone Number 947-3120  
Title of 12(b) Security Class A Common Stock, par value $0.01 per share  
Trading Symbol AMRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   308,651,373
Entity Central Index Key 0001723128  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net revenue $ 659,191 $ 557,540
Cost of goods sold 421,131 379,354
Gross profit 238,060 178,186
Selling, general and administrative 112,595 102,096
Research and development 39,298 38,690
Intellectual property legal development expenses 984 1,644
Restructuring and other charges 1,470 510
Change in fair value of contingent consideration 100 2,457
Charges (credit) related to legal matters, net 94,359 (436)
Other operating income 0 (1,224)
Operating (loss) income (10,746) 34,449
Other (expense) income:    
Interest expense, net (65,703) (49,315)
Foreign exchange (loss) gain, net (1,197) 1,901
Increase in tax receivable agreement liability (1,948) (826)
Other income, net 4,072 4,365
Total other expense, net (64,776) (43,875)
Loss before income taxes (75,522) (9,426)
Provision for income taxes 6,156 668
Net loss (81,678) (10,094)
Less: Net (income) loss attributable to non-controlling interests (9,965) 3,151
Net loss attributable to Amneal Pharmaceuticals, Inc. $ (91,643) $ (6,943)
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:    
Basic (in dollars per share) $ (0.30) $ (0.05)
Diluted (in dollars per share) $ (0.30) $ (0.05)
Weighted-average common shares outstanding:    
Basic (in shares) 307,279 152,109
Diluted (in shares) 307,279 152,109
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Other Comprehensive Income [Abstract]    
Net (loss) income $ (81,678) $ (10,094)
Less: Net (income) loss attributable to non-controlling interests (9,965) 3,151
Net loss attributable to Amneal Pharmaceuticals, Inc. (91,643) (6,943)
Other comprehensive (loss) income:    
Foreign currency translation adjustments arising during the period (390) 1,797
Unrealized gain (loss) on cash flow hedge, net of tax of $0 15,543 (14,270)
Reclassification of cash flow hedge to earnings, net of tax of $0 (6,515) 0
Less: Other comprehensive loss attributable to non-controlling interests 0 6,236
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. 8,638 (6,237)
Comprehensive loss attributable to Amneal Pharmaceuticals, Inc. $ (83,005) $ (13,180)
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Comprehensive Loss (Parentheticals) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Unrealized gain (loss) on cash flow hedge, net of tax $ 0 $ 0
Reclassification of cash flow hedge to earnings, net of tax $ 0 $ 0
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 46,520 $ 91,542
Restricted cash 5,097 7,565
Inventories 570,653 581,384
Prepaid expenses and other current assets 87,298 82,685
Total current assets 1,380,044 1,377,863
Property, plant and equipment, net 439,815 447,574
Goodwill 598,549 598,629
Intangible assets, net 859,272 890,423
Other assets 73,747 55,517
Total assets 3,456,397 3,472,569
Current liabilities:    
Current portion of liabilities for legal matters 30,130 76,988
Revolving credit facility 179,000 179,000
Current portion of long-term debt, net 33,660 34,125
Total current liabilities 834,388 846,595
Long-term debt, net 2,377,707 2,386,004
Note payable - related party 41,893 41,447
Liabilities for legal matters - long term 85,479 316
Total long-term liabilities 2,638,616 2,564,670
Commitments and contingencies (Notes 4 and 17)
Redeemable non-controlling interests 47,022 41,293
Stockholders' (Deficiency) Equity    
Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023 0 0
Additional paid-in capital 538,720 539,240
Stockholders' accumulated deficit (581,819) (490,176)
Accumulated other comprehensive loss (23,711) (32,349)
Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity (63,724) 19,781
Non-controlling interests 95 230
Total stockholders' (deficiency) equity (63,629) 20,011
Total liabilities and stockholders' (deficiency) equity 3,456,397 3,472,569
Related Party    
Current assets:    
Trade accounts receivable, net 1,521 955
Operating lease right-of-use assets 12,468 12,954
Current liabilities:    
Accounts payable and accrued expenses 17,075 7,321
Current portion of operating lease liabilities - related party 3,192 2,825
Operating lease liabilities 11,969 12,787
Other long-term liabilities 11,394 11,776
Nonrelated Party    
Current assets:    
Trade accounts receivable, net 668,955 613,732
Operating lease right-of-use assets 32,970 30,329
Financing lease right-of-use assets 59,532 59,280
Current liabilities:    
Accounts payable and accrued expenses 558,518 534,662
Current portion of operating lease liabilities 9,508 9,207
Current portion of financing lease liabilities 3,305 2,467
Operating lease liabilities 26,786 24,095
Financing lease liabilities 58,809 58,566
Other long-term liabilities 24,579 29,679
Common Class A    
Stockholders' (Deficiency) Equity    
Common stock 3,086 3,066
Common Class B    
Stockholders' (Deficiency) Equity    
Common stock $ 0 $ 0
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Common Class A    
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 900,000,000 900,000,000
Common stock, shares issued (in shares) 308,623,000 306,565,000
Common Class B    
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 0 0
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net (loss) income $ (81,678) $ (10,094)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation and amortization 55,528 58,150
Unrealized foreign currency loss (gain) 1,511 (1,987)
Amortization of debt issuance costs and discount 288 2,058
Intangible asset impairment charges 920 0
Change in fair value of contingent consideration 100 2,457
Stock-based compensation 6,722 7,596
Inventory provision 22,923 25,204
Other operating charges and credits, net 1,250 2,047
Changes in assets and liabilities:    
Trade accounts receivable, net (55,173) 195,970
Inventories (12,200) (22,508)
Prepaid expenses, other current assets and other assets (11,708) 29,160
Related party receivables (562) 470
Accounts payable, accrued expenses and other liabilities 62,174 (150,483)
Related party payables 5,495 1,672
Net cash (used in) provided by operating activities (4,410) 139,712
Cash flows from investing activities:    
Purchases of property, plant and equipment (9,198) (9,688)
Acquisition of intangible assets (9,700) (338)
Deposits for future acquisition of property, plant and equipment (862) (1,711)
Net cash used in investing activities (19,760) (11,737)
Cash flows from financing activities:    
Payments of principal on debt, revolving credit facilities, financing leases and other (63,377) (72,659)
Borrowings on revolving credit facilities 48,000 80,000
Proceeds from exercise of stock options 28 0
Employee payroll tax withholding on restricted stock unit vesting (7,212) (2,022)
Tax distributions to non-controlling interests (594) (18,219)
Net cash used in financing activities (23,155) (12,900)
Effect of foreign exchange rate on cash (165) 767
Net (decrease) increase in cash, cash equivalents, and restricted cash (47,490) 115,842
Cash, cash equivalents, and restricted cash - beginning of period 99,107 35,227
Cash, cash equivalents, and restricted cash - end of period 51,617 151,069
Cash and cash equivalents - end of period 46,520 144,674
Restricted cash - end of period 5,097 6,395
Cash, cash equivalents, and restricted cash - end of period 51,617 151,069
Supplemental disclosure of cash flow information:    
Cash paid for interest 64,514 41,066
Cash (paid) received, net for income taxes (4,567) 3,421
Supplemental disclosure of non-cash investing and financing activity:    
Tax distributions to non-controlling interests $ 3,777 $ 11,548
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Common Class A
Common Stock
Old PubCo, Common Class A
Common Stock
Old PubCo, Common Class B
Additional Paid-in Capital
Stockholders' Accumulated Deficit
Accumulated Other Comprehensive Income
Non- Controlling Interests
Shares beginning balance (in shares) at Dec. 31, 2022     151,490 152,117        
Stockholders' equity beginning balance at Dec. 31, 2022 $ 183,979   $ 1,514 $ 1,522 $ 691,629 $ (406,183) $ 9,939 $ (114,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net (loss) income (15,631)         (6,943)   (8,688)
Foreign currency translation adjustments 1,797           898 899
Stock-based compensation 7,596       7,596      
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)     1,831          
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (1,995)   $ 18   1,497   62 (3,572)
Unrealized gain (loss) on cash flow hedge, net of tax (14,270)           (7,135) (7,135)
Tax distributions, net (26,808)             (26,808)
Reclassification of cash flow hedge to earnings, net of tax of $0 0              
Shares ending balance (in shares) at Mar. 31, 2023     153,321 152,117        
Stockholders' equity ending balance at Mar. 31, 2023 134,668   $ 1,532 $ 1,522 700,722 (413,126) 3,764 (159,746)
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2022 24,949              
Increase (Decrease) in Temporary Equity [Roll Forward]                
Net (loss) income 5,537              
Tax distributions, net (2,959)              
Redeemable Non-Controlling Interests, ending balance at Mar. 31, 2023 27,527              
Shares beginning balance (in shares) at Dec. 31, 2023   306,565            
Stockholders' equity beginning balance at Dec. 31, 2023 20,011 $ 3,066     539,240 (490,176) (32,349) 230
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net (loss) income (91,778)         (91,643)   (135)
Foreign currency translation adjustments (390)           (390)  
Stock-based compensation 6,722       6,722      
Exercise of stock options (in shares)   10            
Exercise of stock options 28       28      
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)   2,048            
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (7,250) $ 20     (7,270)      
Unrealized gain (loss) on cash flow hedge, net of tax 15,543           15,543  
Reclassification of cash flow hedge to earnings, net of tax of $0 (6,515)           (6,515)  
Shares ending balance (in shares) at Mar. 31, 2024   308,623            
Stockholders' equity ending balance at Mar. 31, 2024 (63,629) $ 3,086     $ 538,720 $ (581,819) $ (23,711) $ 95
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2023 41,293              
Increase (Decrease) in Temporary Equity [Roll Forward]                
Net (loss) income 10,100              
Tax distributions, net (4,371)              
Redeemable Non-Controlling Interests, ending balance at Mar. 31, 2024 $ 47,022              
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) (Parenthetical)
3 Months Ended
Mar. 31, 2024
USD ($)
Statement of Stockholders' Equity [Abstract]  
Unrealized gain (loss) on cash flow hedge, net of tax $ 0
Reclassification of cash flow hedge to earnings, net of tax $ 0
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Operations
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations Nature of Operations
Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, and biosimilars in our Generics segment and specialty branded pharmaceuticals. The Company operates principally in the United States (“U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company whose principal assets are 100% of the common units of Amneal Pharmaceuticals, LLC (“Amneal”).
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.
Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2023 Annual Report on Form 10-K.
Use of Estimates
The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Reclassification
The prior period balance related to the TRA (as defined in Note 5. Income Taxes) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss.
The prior period balance related to long-term liabilities for legal matters of $0.3 million, formerly included in other long-term liabilities as of December 31, 2023, has been reclassified to the balance sheet caption “liabilities for legal matters - long term” to conform to the current period presentation in the consolidated balance sheets. This reclassification did not impact total long-term liabilities or total liabilities.
Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
License Agreements
Refer to Note 4. Alliance and Collaboration for further information related to revenue recognition associated with license agreements.
Concentration of Revenue
The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue:
Three Months Ended March 31,
20242023
Customer A21 %22 %
Customer B15 %14 %
Customer C23 %20 %
Customer D10 %%
Disaggregated Revenue
The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands):
Three Months Ended March 31,
20242023
Generics
Anti-infective$6,110 $5,174 
Hormonal / allergy107,714 104,851 
Antiviral3,866 25,474 
Central nervous system109,456 84,582 
Cardiovascular system45,878 32,503 
Gastroenterology18,197 14,364 
Oncology38,533 10,578 
Metabolic disease / endocrine
11,185 9,265 
Respiratory11,136 12,815 
Dermatology18,975 18,004 
Other therapeutic classes18,523 25,895 
International and other1,721 301 
Total Generics net revenue391,294 343,806 
Specialty
Hormonal / allergy29,375 24,763 
Central nervous system66,276 60,139 
License agreement (1)
4,479 — 
Other therapeutic classes5,104 6,776 
Total Specialty net revenue105,234 91,678 
AvKARE
Distribution109,713 83,230 
Government label34,952 24,516 
Institutional10,858 8,862 
Other7,140 5,448 
Total AvKARE net revenue162,663 122,056 
Total net revenue$659,191 $557,540 
(1)Refer to Note 4. Alliance and Collaboration for information on revenue recognized under a license agreement.
A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2023$559,334 $23,892 $136,486 $90,690 
Provision related to sales recorded in the period885,322 30,073 16,220 61,271 
Credits/payments issued during the period(987,202)(26,550)(15,598)(55,250)
Balance at March 31, 2024$457,454 $27,415 $137,108 $96,711 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Alliance and Collaboration
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Alliance and Collaboration Alliance and Collaboration
The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide R&D services over multiple periods. The Company’s significant arrangements are discussed below.
Orion Corporation License Agreement
On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of its complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance.
During both the three months ended March 31, 2024 and 2023, the Company recognized $0.6 million as a reduction to R&D expense related to services performed under the Orion Agreement. As of March 31, 2024, deferred income of $10.7 million and $1.2 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of December 31, 2023, deferred income of $7.8 million and $4.7 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of March 31, 2024, no products have been supplied by Amneal under the Orion Agreement. Refer to Note 5. Alliance and Collaboration in our 2023 Annual Report on Form 10-K for additional information.
ONGENTYS® License Agreement
On December 5, 2023, the Company entered into a license agreement with BIAL-Portela & Ca., S.A. (“BIAL”) for the exclusive royalty-free right to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023 and ending at such time when generic opicapone sales reach certain predetermined thresholds (the “BIAL License Agreement”). ONGENTYS® is BIAL’s proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes. Under the BIAL Agreement, the Company is responsible for commercialization and marketing of ONGENTYS® in the U.S. and BIAL is responsible for manufacturing and supply. The BIAL Agreement also requires the Company to spend a minimum of $6.0 million in medical and marketing activities directly related to ONGENTYS®. The Company commenced distribution of ONGENTYS® during the three months ended March 31, 2024.
During December 2023, the Company paid a nonrefundable license fee of $12.5 million to BIAL, which was capitalized as an intangible asset and will be amortized to cost of sales over a period of eight years. The BIAL License Agreement provides for potential future milestone payments totaling $22.5 million, depending on cumulative net sales of ONGENTYS®.
Knight Therapeutics International S.A. License Agreement
On January 24, 2024, the Company entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. (“Knight”) granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the “Knight License Agreement”). The Knight License Agreement will automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal.
Knight will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight.
On February 26, 2024, the Company received a nonrefundable license fee of $1.0 million from Knight, which was recorded as net revenue for the three months ended March 31, 2024. The Knight License Agreement provides for potential future milestone payments totaling $10.5 million, contingent upon regulatory approval, launch dates and cumulative net sales targets by Knight. The agreement also includes low-double digit royalty payments based on net sales of IPX203.
License Agreement with Zambon Biotech
On February 23, 2024, the Company entered into a license, distribution and supply agreement with Zambon Biotech S.A. (“Zambon”) granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the “Zambon License Agreement”). The term for the Zambon License Agreement is 15 years commencing from the commercial launch of the product, which can automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Zambon will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Zambon.
In connection with the execution of the agreement, the Company was entitled to a non-refundable license fee of €5.0 million, or $5.4 million, which was received in April 2024. Of the license fee, the Company allocated €3.2 million, or $3.5 million, to the delivery of a functional license, which was recorded as net revenue during the three months ended March 31, 2024. In addition, the Company is eligible to receive future milestone payments totaling €71.5 million, or $77.2 million, from Zambon, contingent upon regulatory approval of the product, and achievement of certain annual net sales targets by Zambon. The Zambon License Agreement also includes single-digit to low-double digit royalty payments based on net sales of IPX203.
Biosimilar Licensing and Supply Agreement
Bevacizumab
On May 7, 2018, the Company entered into a licensing and supply agreement with mAbxience S.L. (“mAbxience”), for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. Pursuant to the agreement, the Company will be the exclusive partner in the U.S. market and pay up-front, development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to mAbxience, up to $78.3 million.
On April 13, 2022, the FDA approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million during the year ended December 31, 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of seven years. During the three months ended March 31, 2024, the Company paid a sales-based milestone of $9.5 million, which was capitalized as a product rights intangible asset and is being amortized to cost of sales.
Denosumab
On October 12, 2023, the Company entered into a licensing and supply agreement with mAbxience to be the exclusive U.S. partner for two denosumab biosimilars referencing both Prolia® and XGEVA®. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. mAbxience is responsible for the clinical and regulatory approval for the two products and regulatory fees will be shared by the parties. Upon approval of each product, mAbxience will be responsible for supply and the Company will be responsible for commercialization.
During the year ended December 31, 2023, the Company recorded R&D expense for a $2.5 million payment made upon execution of the agreement and an additional $2.5 million for a developmental milestone. During the three months ended March 31, 2024, the Company recorded R&D expense for a $3.0 million payment made for a clinical milestone. The agreement provides for potential future milestone payments to mAbxience of up to $66.0 million as follows: (i) up to $3.5 million relating to clinical and developmental milestones; (ii) up to $15.0 million for regulatory approval and initial commercial launch milestones; and (iii) up to $47.5 million for the achievement of annual commercial milestones.
Agreements with Kashiv Biosciences, LLC
For details on the Company’s related party agreements with Kashiv Biosciences, LLC (“Kashiv”), refer to Note 19. Related Party Transactions in this Form 10-Q and Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
For the three months ended March 31, 2024, the Company’s provision for income taxes and effective tax rate were $6.2 million and (8.2)%, respectively, as compared to $0.7 million and (7.1)%, respectively, for the three months ended March 31, 2023. For the three months ended March 31, 2024, the period-over-period change in the provision for income taxes was primarily related to changes in the jurisdictional mix of income.
The Company recorded deferred tax assets for (i) its outside basis difference in its investment in Amneal on May 4, 2018, (ii) the net operating loss of Impax Laboratories, Inc., which was acquired by the Company in 2018, from January 1, 2018 through May 4, 2018, (iii) certain federal and state credits, and (iv) interest carryforwards of Impax that were attributable to the Company.
The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others.
The Company established a valuation allowance on its DTAs based upon all available objective and verifiable evidence, both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three-year pre-tax losses through March 31, 2024. As a result of the losses through March 31, 2024, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of March 31, 2024 and December 31, 2023, this valuation allowance was $566.0 million and $566.5 million, respectively, and reduced the carrying value of these gross DTAs to zero.
In 2018, the Company entered into a tax receivable agreement (“TRA”) for which it was generally required to pay the holders of Amneal common units on a one-to-one basis, 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal common units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal common units for shares of Class A common stock of the Company prior to the Reorganization (as defined in Note 1. Nature of Operations in our 2023 Annual Report on Form 10-K) and (ii) tax benefits attributable to payments made under the TRA. In conjunction with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million during 2019. As part of the Reorganization, the TRA was amended to reduce the Company’s future obligation to pay 85% of the tax benefits subject to the TRA to 75% of such realized benefits. This agreement will not cause the acceleration of payments under the TRA.
As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize its DTAs subject to the TRA; therefore, as of March 31, 2024 and December 31, 2023, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more-likely-than-not in the future, at such time, these TRA liabilities (which amounted to approximately $185.0 million at March 31, 2024 and December 31, 2023) will be recorded through charges in the Company’s consolidated statements of operations.
The timing and amount of any payments under the TRA may vary depending on the timing of the Company’s taxable income and the tax rate in effect at the time of realization of the Company’s taxable income. Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. Payments could also be in excess of the tax savings that the Company may ultimately realize.
Although the DTAs were not determined to be realizable as of March 31, 2024 and December 31, 2023, the Company assessed that a TRA liability of $5.7 million and $3.8 million at those dates, respectively, had become probable. For the three months ended March 31, 2024 and 2023, the Company recorded expenses associated with the TRA of $1.9 million and $0.8 million, respectively. In future periods, the Company will continue to evaluate whether any future TRA payments become probable and can be estimated and, if so, an estimate of payment will be accrued.
Any future recognition of these TRA liabilities will be recorded through charges in the Company’s consolidated statements of operations. However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA in excess of the $5.7 million accrued as of March 31, 2024. Should the Company determine that a DTA with a
valuation allowance is realizable in a subsequent period, the related valuation allowance will be reversed and, if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded.
The Company continuously monitors government proposals to make changes to tax laws, including proposed legislation in certain foreign jurisdictions resulting from the adoption of the Organization for Economic Cooperation and Development (“OECD”) policies (refer to Note 7. Income Taxes in the Company’s 2023 Annual Report on Form 10-K). The OECD has issued a two-pillar approach to global taxation, focusing on global profit allocation and a global minimum tax rate of at least 15%. Legislation for the “Pillar Two” proposal, applying to the Company, has been enacted in Ireland, and it is effective with the financial year beginning on January 1, 2024. As the tax rates the other jurisdictions in which the Company operates exceed 15%, the Company does not believe there is any potential additional exposure besides in Ireland.
Since Pillar Two taxes are an alternative minimum tax, deferred taxes will not need to be recorded or remeasured as a result of Pillar Two taxes. Instead, Pillar Two taxes will be expensed as incurred. For interim tax provision purposes, the Pillar Two tax related to Ireland taxes is included in the calculation of the Company’s provision for income taxes.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss per Share
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Loss per Share Loss per Share
Following the implementation of the Reorganization on November 7, 2023, all outstanding shares of Old PubCo Class A common stock and Old PubCo Class B common stock were exchanged for an equivalent number of shares of Class A common stock of the Company.
Basic loss per share of the Company’s Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share of Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding, adjusted to give effect to potentially dilutive securities. The weighted-average number of shares of Class A common stock for all periods prior to the Reorganization includes shares of Old PubCo Class A common stock.
The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts):
Three Months Ended
March 31,
20242023
Numerator:
Net loss attributable to Amneal Pharmaceuticals, Inc.
$(91,643)$(6,943)
Denominator:
Weighted-average shares outstanding - basic and diluted
307,279 152,109 
Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic and diluted
$(0.30)$(0.05)
Prior to the Reorganization, shares of Old PubCo Class B common stock did not share in the losses of the Company and, therefore, were not participating securities. As such, separate presentation of basic and diluted loss per share of Old PubCo Class B common stock under the two-class method was not presented. Effective with the Reorganization, all outstanding shares of Old PubCo Class B common stock were surrendered and canceled.
The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands):
Three Months Ended
March 31,
20242023
Stock options
2,406 (1)2,632 (1)
Restricted stock units
10,837 (1)11,576 (1)
Performance stock units
7,827 (1)7,018 (1)
Shares of Old PubCo Class B common stock
— 152,117 (2)
(1)Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.
(2)Shares of Old PubCo Class B common stock were considered potentially dilutive shares of Old PubCo Class A common stock. Shares of Old PubCo Class B common stock were excluded from the computations of diluted loss per share of Class A common stock for the three months ended March 31, 2023 because the effect of their inclusion would have been anti-dilutive under the if-converted method.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Trade Accounts Receivable, Net
3 Months Ended
Mar. 31, 2024
Receivables [Abstract]  
Trade Accounts Receivable, Net Trade Accounts Receivable, Net
Trade accounts receivable, net was comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Gross accounts receivable$1,156,861 $1,199,980 
Allowance for credit losses(3,037)(3,022)
Contract charge-backs and sales volume allowances(457,454)(559,334)
Cash discount allowances(27,415)(23,892)
Subtotal(487,906)(586,248)
Trade accounts receivable, net$668,955 $613,732 
Concentration of Receivables
Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows:
March 31,
2024
December 31,
2023
Customer A32 %40 %
Customer B29 %24 %
Customer C23 %22 %
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories
3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories were comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Raw materials
$196,737 $217,744 
Work in process
57,924 59,563 
Finished goods
315,992 304,077 
Total inventories$570,653 $581,384 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses and Other Current Assets
3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets were comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Deposits and advances$1,935 $2,200 
Prepaid insurance4,780 8,334 
Prepaid regulatory fees4,219 6,331 
Income and other tax receivables12,198 13,168 
Prepaid taxes9,205 11,899 
Other current receivables
12,802 9,929 
Chargebacks receivable (1)
8,575 7,876 
Other prepaid assets33,584 22,948 
Total prepaid expenses and other current assets$87,298 $82,685 
(1)When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets
3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands):
March 31,
2024
December 31,
2023
Balance, beginning of period$598,629 $598,853 
Currency translation(80)(224)
Balance, end of period$598,549 $598,629 
As of March 31, 2024, $366.3 million, $162.7 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2023, $366.3 million, $162.8 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively.
Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights6.2$1,207,469 $(739,351)$468,118 $1,198,971 $(703,297)$495,674 
Other intangible assets3.1111,800 (76,491)35,309 111,800 (72,896)38,904 
Subtotal1,319,269 (815,842)503,427 1,310,771 (776,193)534,578 
In-process research and development355,845 — 355,845 355,845 — 355,845 
Total intangible assets$1,675,114 $(815,842)$859,272 $1,666,616 $(776,193)$890,423 
Amortization expense related to intangible assets for the three months ended March 31, 2024 and 2023 was $39.9 million and $41.1 million, respectively.
The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&D”) intangible assets (in thousands):
Future
Amortization
Remainder of 2024$119,432 
2025121,638 
202673,115 
202752,606 
202833,263 
202926,484 
Thereafter76,889 
   Total$503,427 
The Company reviews intangible assets with finite lives for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Indefinite-lived intangible assets, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. Intangible asset impairments were immaterial for the three months ended March 31, 2024 (none for the three months ended March 31, 2023).
On June 30, 2023, the Company received a complete response letter (“CRL”) from the FDA regarding its new drug application (“NDA”) for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that, although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. During October 2023, the Company met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked the Company to perform a QT study, a routine cardiac safety study that is required for new drugs. On February 7, 2024, the Company provided a complete response resubmission to the FDA for IPX203. IPX203 has a Prescription Drug User Fee Act (PDUFA) decision date of August 7, 2024.
No indicators of impairment of the Company’s IPX203 IPR&D intangible asset were identified during 2024. Additionally, there was no impairment recorded during 2023. While management believes the assumptions used in the Company’s 2023 annual impairment test of its IPX203 IPR&D intangible asset were reasonable and continue to be commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin, delaying the potential launch date, and lowering the probability of technical and regulatory success, could result in material future impairments of the Company’s IPX203 IPR&D intangible asset. Refer to Note 13. Goodwill and Other Intangible Assets in the Company’s Annual Report on Form 10-K for additional information.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Assets
3 Months Ended
Mar. 31, 2024
Other Assets [Abstract]  
Other Assets Other Assets
Other assets were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Interest rate swap (1)
$52,632 $37,089 
Security deposits 3,616 3,602 
Long-term prepaid expenses3,099 3,273 
Deferred revolving credit facility costs4,007 4,427 
Other long term assets10,393 7,126 
Total $73,747 $55,517 
(1)Refer to Note 15. Fair Value Measurements and Note 16. Financial Instruments for information about the Company’s interest rate swap.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Expenses
3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Expenses Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Accounts payable$175,325 $143,572 
Accrued returns allowance (1)
137,108 136,486 
Accrued compensation44,806 71,122 
Accrued Medicaid and commercial rebates (1)
96,711 90,690 
Accrued royalties19,779 23,342 
Commercial chargebacks and rebates10,226 10,226 
Accrued professional fees14,598 11,005 
Accrued other59,965 48,219 
Total accounts payable and accrued expenses$558,518 $534,662 
(1)Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2023 to March 31, 2024.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt
3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Debt Debt
There have been no material changes in the Company’s long-term debt since December 31, 2023, except as disclosed below. Refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for additional information and definitions of terms used in this note.
The following is a summary of the Company’s indebtedness under its term loans (in thousands):
March 31, 2024December 31, 2023
Term Loan Due May 2025$191,979 $191,979 
Term Loan Due May 20282,336,949 2,351,647 
Total debt2,528,928 2,543,626 
Less: debt issuance costs(117,561)(123,497)
Total debt, net of debt issuance costs2,411,367 2,420,129 
Less: current portion of long-term debt(33,660)(34,125)
Total long-term debt, net$2,377,707 $2,386,004 
During the three months ended March 31, 2024, the Company (i) borrowed and repaid $20.0 million under the Amended New Revolving Credit Facility and (ii) borrowed and repaid $28.0 million under the Amended Rondo Revolving Credit Facility. As of each of March 31, 2024 and December 31, 2023, $179.0 million was outstanding on the Amended New Revolving Credit Facility.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Long-Term Liabilities
3 Months Ended
Mar. 31, 2024
Other Liabilities Disclosure [Abstract]  
Other Long-Term Liabilities Other Long-Term Liabilities
Other long-term liabilities were comprised of the following (in thousands):

March 31, 2024December 31, 2023
Uncertain tax positions$504 $497 
Long-term compensation18,073 21,283 
Contingent consideration (1)
433 433 
Other long-term liabilities5,569 7,466 
Total other long-term liabilities$24,579 $29,679 
(1)    Refer to Note 15. Fair Value Measurements for additional information.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):
Fair Value Measurement Based on
March 31, 2024TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Assets
Interest rate swap (1)
$52,632 $— $52,632 $— 
Liabilities
Deferred compensation plan liabilities (2)
$9,668 $— $9,668 $— 
Contingent consideration liabilities (3)
$1,021 $— $— $1,021 
December 31, 2023
Assets
Interest rate swap (1)
$37,089 $— $37,089 $— 
Liabilities
Deferred compensation plan liabilities (2)
$9,100 $— $9,100 $— 
Contingent consideration liability (3)
$921 $— $— $921 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 16. Financial Instruments for information on the Company's interest rate swap.
(2)These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.
(3)The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. For the three months ended March 31, 2024, there was no material activity or payments related to the contingent consideration liabilities.
There were no transfers between levels in the fair value hierarchy during the three months ended March 31, 2024.
Assets and Liabilities Not Measured at Fair Value on a Recurring Basis
The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments.
The following is a summary of the Company’s indebtedness at fair value (in thousands):
March 31, 2024December 31, 2023
Term Loan Due 2025$192,099 $190,779 
Term Loan Due 2028$2,339,870 $2,328,130 
Sellers Notes$41,944 $41,033 
The Term Loan Due 2025 and Term Loan Due 2028 are in the Level 2 category within the fair value level hierarchy. The fair values were determined using market data for valuation. The Sellers Notes are in the Level 2 category within the fair value level hierarchy.
Refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for detailed information about its indebtedness, including definitions of terms.
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
There were no non-recurring fair value measurements during the three months ended March 31, 2024 and 2023.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments
3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates.
Interest Rate Risk
Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company’s debt obligations consist of variable-rate and fixed-rate debt instruments. The Company’s primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. To achieve this objective, the Company initially entered into an interest rate swap on the Term Loan Due 2025. On November 14, 2023, in connection with the refinancing of the Term Loan Due 2025, the Company novated its swap agreement to another counterparty and, in connection with such novation, amended the interest rate swap agreement. Refer to the section “Interest Rate Derivative - Cash Flow Hedge” below and in Note 20. Financial Instruments in the Company’s 2023 Annual Report on Form 10-K for additional information and the definition of certain terms.
Interest Rate Derivative – Cash Flow Hedge
The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month London interbank offered rate (“LIBOR”) associated with the Term Loan Due 2025 (the “October 2019 Swap”). On May 31, 2023, the Company executed an amendment to the October 2019 Swap that, among other things, changed the variable reference rate from LIBOR to the one-month secured overnight financing rate (“SOFR”) (the “Amended October 2019 Swap”). On November 14, 2023, in connection with the Company’s refinancing of the Term Loan Due 2025 and the New Credit Facility
(refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for definitions and additional information), the Company novated the Amended October 2019 Swap to another counterparty and subsequently amended the interest rate agreement. Specifically, the amendments modified (i) the fixed rate payable by the counterparty from 1.3660% to a new fixed rate of 2.7877% and (ii) extended the termination date through May 4, 2027 (i.e., one year before the Term Loan Due 2028 matures) (the “November 2023 Swap”). The amendments did not change the notional amount of $1.3 billion. The purpose of the November 2023 Swap is to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month SOFR associated with the Term Loan Due 2028.
The Company used a strategy commonly referred to as “blend and extend,” which allows the existing asset position of the swap agreement to be effectively blended into the new interest rate swap agreement. As a result of this transaction, on November 14, 2023, the Amended October 2019 Swap was de-designated and the unrealized gain of $66.7 million was recorded within accumulated other comprehensive (loss) income and will be amortized as a reduction of interest expense, net, over the original term of the of the Amended October 2019 Swap (until May 2025), as the hedged transactions affect earnings. Additionally, the November 2023 Swap had a fair value of $66.7 million at inception and will be ratably recorded to accumulated other comprehensive (loss) income and reclassified to interest expense, net, over the term of the November 2023 Swap, as the hedged transactions affect earnings.
During the three months ended March 31, 2024, the Company reclassified a gain of $6.5 million from accumulated other comprehensive loss to interest expense, net. Approximately $26.1 million of net gains included in accumulated other comprehensive loss as of March 31, 2024 are expected to be reclassified into earnings within the next 12 months as interest payments are made on the Company’s Term Loan Due 2028 and amortization of the amounts included in accumulated other comprehensive loss occurs.
As of March 31, 2024, the total gain, net of income taxes, related to the Company’s cash flow hedge of $42.8 million, was recognized in accumulated other comprehensive loss.
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
March 31, 2024December 31, 2023
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther Assets$52,632 Other Assets$37,089 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Commitments
Commercial Manufacturing, Collaboration, License, and Distribution Agreements
The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered with third parties. The Company has also licensed certain technologies or IP from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 4. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 19. Related Party Transactions for additional information.
Contingencies
Legal Proceedings
The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies.
For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized.
For the three months ended March 31, 2024, charges related to legal matters, net of $94.4 million were associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. (refer to the section Civil Prescription Opioid Litigation below). For the three months ended March 31, 2023, credit related to legal matters, net of $0.4 million was comprised of a litigation settlement gain, partially offset by charges for legal proceedings.
Liabilities for legal matters were comprised of the following (in thousands):
MatterMarch 31, 2024December 31, 2023
Opana ER® antitrust litigation$— $50,000 
Opana ER® antitrust litigation-accrued interest
— 2,347 
Civil prescription opioid litigation30,130 21,189 
Other
— 3,452 
Current portion of liabilities for legal matters$30,130 $76,988 
Civil prescription opioid litigation (Liabilities for legal matters - long term)$85,479 $316 
Refer to the respective discussions below for additional information about the significant matters in the tables above.
Refer to Note 21. Commitments and Contingencies in our Annual Report on Form 10-K for a general discussion of Medicaid Reimbursement and Price Reporting Matters and Patent Litigation.
Other Litigation Related to the Company’s Business
Opana ER® Antitrust Litigation

From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out
plaintiffs”) of Opana ER® were filed against Endo Pharmaceuticals Inc. and Impax Laboratories, Inc. (“Impax”) and consolidated into multi-district litigation (“MDL”) in the U.S. District Court for the Northern District of Illinois.

Impax subsequently entered into settlement agreements with all of the plaintiffs that were subsequently approved by the court. Pursuant to the settlement agreements, the Company agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all of the plaintiffs’ claims. As of December 31, 2023, the liability for the final settlement payment of $50.0 million, plus 3% stated interest thereon, was included in the current portion of liabilities for legal matters and was paid in January 2024 with cash on hand. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved.
United States Department of Justice Investigations

On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation.

On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.

On May 15, 2023, Amneal received a CID from the Civil Division requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only” after the reference listed drug’s label was converted to over-the-counter. The Company is cooperating with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.
In Re Generic Pharmaceuticals Pricing Antitrust Litigation
Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania (In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa.)) (“MDL No. 2724”).
On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original plaintiff states.
Both the May 10, 2019 and June 10, 2020 lawsuits seek unspecified monetary damages and penalties and equitable relief including disgorgement and restitution, and both were incorporated into MDL No. 2724. The June 10, 2020 lawsuit was selected for bellwether status. The States of Alabama, Hawaii and Arkansas, and the Territory of Guam voluntarily dismissed all of their claims in the two actions against all defendants, including the Company. American Samoa voluntarily dismissed its claims in the May 10, 2019 action and was not named as a plaintiff in the June 10, 2020 action. On February 27, 2023, the Court addressed defendants’ motions to dismiss the June 10, 2020 action, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. On November 1, 2023, the Attorneys
General filed a Motion to Remand their cases to the State of Connecticut. On January 21, 2024, the Joint Panel on Multidistrict Litigation (“JPML”) granted the motion, and these cases were formally remanded in April 2024. See Connecticut, et al. v. Teva Pharmaceuticals USA, Inc., et al., 3:19-cv-00710-MPS and Connecticut, et al. v. Sandoz, Inc. et al., 3:20-cv-00803-MPS.
Fact discovery in MDL No. 2724 is proceeding as to both bellwether and non-bellwether cases, and expert discovery as to bellwether cases is also underway. No trial date has been set. No schedule has yet been issued in the May 10, 2019 and June 10, 2020 actions brought by the State Attorneys General, which have now been remanded to the District of Connecticut.
On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present (Kathryn Eaton v. Teva Canada Limited, et. al., No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, the plaintiff filed a second amended complaint. On May 30, 2023, the plaintiff served materials for their motion to certify the action as a class proceeding, define the class and certify the common questions to be decided, among other things. The certification hearing date is scheduled for December 2024, but subject to court approval, the hearing date may be rescheduled on consent to May 2025. The Company is preparing a response to the motion to certify in advance of that date.
Civil Prescription Opioid Litigation
The Company and certain of its affiliates are named as defendants in over 900 cases filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors, and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act, state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors, and retail pharmacies as defendants, and there have been numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors, and retail pharmacies in which the Company and its affiliates are not named. Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804) (the “Opioid MDL”). The Company is also named in various state court cases pending in seven states. No firm trial dates have been set except in Texas (January 31, 2025, trial-ready date (Dallas County)).
The Company reached a settlement agreement with the New Mexico Attorney General to resolve its claims against the Company, which was finalized on April 24, 2023. A Consent Judgment dismissing the case was entered on May 15, 2023.

The Company reached a settlement agreement to resolve all pending litigation brought by West Virginia political subdivisions, which was signed on May 25, 2023. The two neonatal abstinence syndrome cases in West Virginia state court were dismissed on May 31, 2023 and were subsequently appealed by the plaintiffs. These appeals remain pending. The hospital cases pending in West Virginia state court were dismissed on May 2, 2023.

The Company reached a preliminary settlement with a group of private hospitals in Alabama in June 2023 to resolve the hospitals’ claims against the Company. The Company anticipates a final determination approving the settlement by the end of the second quarter of 2024. On February 7, 2024, the Company was dismissed from the Mobile County Board of Health case. The Company previously reported an August 12, 2024 trial date for that case.

On January 13, 2023, the Company received a subpoena from the New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information. On January 4, 2024, the Company received a CID issued by the Alaska Attorney General seeking information regarding its business concerning opioid-containing products. The Company is evaluating the CID.

In late April 2024, the Company reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. The settlement in principle is subject to the negotiation and execution of a definitive settlement agreement between the parties. The settlement would be payable over ten years. Under the settlement in principle, the Company would agree to pay $92.5 million in cash and provide $180.0 million (valued at $125/ twin pack) in naloxone nasal spray to help treat opioid overdoses. In lieu of receiving product, the settling parties can opt to receive 25% of the naloxone nasal spray’s value (up to $45.0 million) in cash during the last four years of the ten years payment term, which could increase the total amount of cash the Company would agree to pay up to $137.5 million.
As of March 31, 2024, the Company concluded the loss related to the opioid litigation was probable, and the related loss was reasonably estimable considering the settlement in principle. As a result, the Company recorded a charge of $94.4 million associated with the settlement in principle during the three months ended March 31, 2024 to increase the liability as of March 31, 2024, to $115.6 million, of which $85.5 million was classified as long-term. While this liability has been deemed reasonable by the Company’s management, it could significantly change as the definitive settlement agreement is finalized. As of December 31, 2023, the Company had a liability of $21.5 million related to its prescription opioid litigation, of which $0.3 million was classified as long-term. For the remaining cases not covered by the settlement in principle, primarily brought by other hospitals, schools and individuals, the Company has not recorded a liability as of March 31, 2024 or December 31, 2023, because it concluded that a loss was not probable and estimable.
United States Department of Justice / Drug Enforcement Administration Subpoenas

On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered civil and criminal tolling agreements with the USAO through May 15, 2024. It is not possible to determine the exact outcome of these investigations.

On March 14, 2019, Amneal received a subpoena from an Assistant U.S. Attorney for the Southern District of Florida (the “AUSA”). The subpoena requested information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation.

On October 7, 2019, Amneal received a subpoena from the New York State Department of Financial Services seeking documents and information related to sales of opioid products in the state of New York. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact outcome of this investigation.

Ranitidine Litigation

The Company and its affiliates were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers, including the Company, without leave to file further amended complaints, holding all claims were preempted. Plaintiffs appealed the MDL Court’s dismissals to the 11th Circuit Court of Appeals. On November 7, 2022, the 11th Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The 11th Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Plaintiffs filed their merits brief on April 10, 2024.

The Company and its affiliates have also been named as defendants in various state lawsuits in five states in which the Company has filed motions to dismiss or plans to file motions to dismiss in the future. On August 17, 2023, the judge in the consolidated Illinois state court cases granted a motion to dismiss all such cases in which the Company and affiliates had been named, holding all claims preempted. There are no trial dates involving the Company in any of the state court cases.
Metformin Litigation

Amneal and AvKARE, LLC (improperly named as AvKARE, Inc.) were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey, consolidated as In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH) (“In re Metformin”). The lawsuits allege economic loss in connection with their purchase or reimbursements due to the alleged contamination of generic metformin products with NDMA. Plaintiffs have voluntarily dismissed their claims seeking medical monitoring or evaluation due to their consummation of allegedly contaminated metformin. The parties are currently engaged in discovery. On October 17, 2023, co-defendant Rite-Aid filed a suggestion of bankruptcy and automatic stay of proceeding. AvKARE, LLC has been dismissed from this action. Three additional similar putative class action lawsuits filed against Amneal and AvKARE, LLC have been consolidated for discovery and pretrial purposes only, Marcia E. Brice v. Amneal Pharmaceuticals, Inc., No. 2:20-cv-13728 (D.N.J.), Michael Hann v. Amneal
Pharmaceuticals of New York, LLC et al., No. 2:23-cv-22902 (D.N.J.), and In re Metformin: County of Monmouth, et al. v. Apotex Inc., et al., No. 2:23-cv-21001-MAC-MAH (D.N.J.) (“County of Monmouth”).

Pursuant to a Stipulation and Order entered on the docket on May 2, 2024, plaintiffs will file a third amended complaint in In re Metformin which includes the claims and parties in County of Monmouth. The third amended complaint must be filed within three days of entry of the Stipulation and Order. Immediately preceding the filing of the third amended complaint, the County of Monmouth First Amended Complaint will be voluntarily dismissed without prejudice. Defendants may file a motion to dismiss the third amended complaint within thirty days of the filing of the third amended complaint.

On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of valsartan, losartan, and metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern metformin (Davis v. Camber Pharmaceuticals, Inc., et al., C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation transferred the Davis Action into the In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation multi-district litigation for pretrial proceedings.

Xyrem® (Sodium Oxybate) Antitrust Litigation

Amneal was named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with the settlement of patent litigation related to Xyrem®. The actions were consolidated in the United States District Court for the Northern District of California for pretrial proceedings (In re Xyrem (Sodium Oxybate) Antitrust Litigation, No. 5:20-md-02966-LHK (N.D. Cal.)).

Amneal was also named as a defendant in a similar action filed by Aetna Inc. (“Aetna”) in California state court (Aetna Inc. v. Jazz Pharms., Inc. et. al, No. 22CV010951 (Cal. Super. Ct.). The California state court held that it lacks jurisdiction over several defendants, including Amneal, on December 27, 2022, and later issued an order dismissing Amneal without prejudice. On August 25, 2023, Aetna filed a motion seeking leave to file a second amended complaint adding Amneal as a defendant, which the Court tentatively granted on October 20, 2023. Aetna filed a second amended complaint naming Amneal on November 17, 2023.

On February 28, 2023, Amneal executed a $1.9 million settlement agreement with class plaintiffs in the federal litigation. Class plaintiffs filed a motion for final approval of the settlement on November 10, 2023, and entered an order granting final approval, certifying settlement class, and dismissing class plaintiffs’ against Amneal with prejudice on April 17, 2024. On December 18, 2023, Amneal executed a $4.0 million settlement with Aetna, United Healthcare Services, Inc. (“United”), Humana Inc. (“Humana”), Molina Healthcare Inc. (“Molina”), and Health Care Service Corporation (“HCSC”). Pursuant to that settlement, the federal court dismissed United, Humana, Molina and HCSC’s claims against Amneal, with prejudice, on February 26, 2024, and the California state court dismissed Aetna’s claims against Amneal, with prejudice, on February 29, 2024. Thus, all claims against Amneal in the federal and state court have been voluntarily dismissed with prejudice pursuant to settlements. In December 2023, the Company recorded $3.0 million for the settlement of claims associated with Xyrem® antitrust litigation. As of December 31, 2023, the Company had a liability of $2.0 million associated with this settlement, which was paid in January 2024.

UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.

On November 14, 2023, UFCW Local 1500 Welfare Fund and other health plans filed a purported class action lawsuit in the United States District Court for the Southern District of New York against Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) and other manufacturers of generic versions of Takeda’s Colcrys® (colchicine), including Amneal (UFCW Local 1500 Welfare Fund et al. v. Takeda Pharma. U.S.A., Inc. et al, No. 1:23-cv-10030 (S.D.N.Y.). The plaintiff health plans seek to represent a class of third party payers and alleging that the generic manufacturers conspired with Takeda to restrict output of generic Colcrys® to maintain higher prices, in violation of the antitrust laws. On February 28, 2024, Takeda filed a motion to transfer the case to the United States District Court for the Eastern District of Pennsylvania. On March 13, 2024 and March 27, 2024, Amneal submitted a letter and brief, respectively, informing the Court of its position that the Eastern District of Pennsylvania lacks personal jurisdiction over Amneal. The deadline for defendants to respond to the complaint is 45 days after the date on which the motion to transfer is resolved.
Indian Tax Authority Matters
Amneal Pharmaceuticals Pvt. Ltd., RAKS Pharmaceuticals Pvt. Ltd., and Puniska Healthcare Pvt. Ltd., which are subsidiaries of the Company, are currently involved in litigations with Indian tax authorities concerning Central Excise Tax, Service Tax, Goods & Services Tax, and Value Added Tax for various periods of time between 2014 and 2017. These subsidiaries have contested certain of these assessments, which are at various stages of the administrative process. The Company strongly believes its Indian subsidiaries have meritorious defenses in the matter.
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders’ Equity and Redeemable Non-Controlling Interests
3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Stockholders’ Equity and Redeemable Non-Controlling Interests Stockholders’ Equity and Redeemable Non-Controlling Interests
Effective with the Reorganization on November 7, 2023, the Company holds 100% of the Amneal Common Units.
In connection with the Reorganization, the Company amended and restated its certificate of incorporation. The voting rights, dividend rights and participation rights of holders of Class A common stock of the Company did not materially change as a result of the amendment. There were no shares of Class B common stock of the Company outstanding as of December 31, 2023.
Non-Controlling Interests
The consolidated financial statements of the Company include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold. Prior to the Reorganization, non-controlling interests were adjusted for capital transactions that impact the non-publicly held economic interests in Amneal.
Prior to the Reorganization, Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”). During the three months ended March 31, 2023, the Company recorded net tax distributions to the Members of $26.8 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members.
The Company acquired a 98% interest in KSP on April 2, 2021. The sellers of KSP, a related party, hold the remaining interests. The Company attributes 2% of the net income or loss of KSP to non-controlling interests.
Redeemable Non-Controlling Interests
The Company acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”), in 2020.  The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest (“Rondo Class B Units”) in the holding company that directly owns the acquired companies (“Rondo”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. Because the redemption of the Rondo Class B Units is outside of the Company’s control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests.

The Company attributes 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption probable. For the three months ended March 31, 2024 and 2023, the Company recorded tax distributions of $4.4 million and $3.0 million, respectively, as a reduction of redeemable non-controlling interests, respectively.
Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands):
Foreign
currency
translation
adjustments
Unrealized gain (loss) on cash
flow hedge, net
of tax
Accumulated
other
comprehensive (loss) income
Balance December 31, 2023$(66,072)$33,723 $(32,349)
Other comprehensive loss before reclassification(390)15,543 15,153 
Reclassification of cash flow hedge to earnings, net of tax of $0
— (6,515)(6,515)
Balance March 31, 2024$(66,462)$42,751 $(23,711)
Balance December 31, 2022$(32,382)$42,321 $9,939 
Other comprehensive loss before reclassification898 (7,135)(6,237)
Reallocation of ownership interests
(195)257 62 
Balance March 31, 2023$(31,679)$35,443 $3,764 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The Company has various business agreements with certain parties in which there is some common ownership. However, the Company does not directly own or manage any of such related parties. Except as disclosed below, as of and for the three months ended March 31, 2024, there were no material changes to our related party agreements or relationships as described in Note 24. Related Party Transactions and Note 22. Stockholders’ Equity in our 2023 Annual Report on Form 10-K.
The following table summarizes the Company’s related party transactions (in thousands):
Three Months Ended March 31,
Related Party and Nature of TransactionCaption in Balance Sheet and Statement of Operations20242023
Kashiv Biosciences LLC
Parking space leaseResearch and development$25 $17 
Development and commercialization agreement - Ganirelix Acetate and Cetrorelix AcetateResearch and development$— $50 
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)Cost of goods sold$4,526 $144 
Storage agreementResearch and development$(77)$(48)
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)Inventory and cost of goods sold$1,216 $— 
Generic development supply agreement - research and development materialResearch and development$(48)$— 
Generic development supply agreement - development activity deferred incomeDeferred revenue and net revenue$(422)$— 
Development and commercialization agreement - Long-acting injectableResearch and development$500 $— 
Other Related Parties
Kanan, LLC - operating leaseInventory and cost of goods sold$592 $566 
Sutaria Family Realty, LLC - operating leaseInventory and cost of goods sold$314 $305 
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreementInventory and cost of goods sold$5,001 $1,836 
Tracy Properties LLC - operating leaseSelling, general and administrative$143 $169 
AzaTech Pharma LLC - supply agreementInventory and cost of goods sold$2,312 $575 
AvPROP, LLC - operating leaseSelling, general and administrative$44 $47 
Avtar Investments, LLC - consulting servicesResearch and development$69 $188 
AlkermesInventory and cost of goods sold$12 $
R&S Solutions - logistics servicesSelling, general and administrative$— $20 
Members - tax receivable agreement (TRA liability)Other expense$1,948 $826 
The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):
March 31, 2024December 31, 2023
Kashiv - various agreements$1,434 $954 
Apace Packaging, LLC - packaging agreement— 
Alkermes— 
AzaTech Pharma LLC78 — 
Related party receivables - short term $1,521 $955 
Kashiv - various agreements$5,773 $3,179 
Apace Packaging, LLC - packaging agreement1,863 1,091 
AzaTech Pharma LLC - supply agreement1,650 1,958 
Avtar Investments LLC - consulting services22 100 
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
442 442 
Members - tax receivable agreement3,532 549 
Rondo Class B unit holders - tax distributions3,777 — 
Alkermes Plc16 
Related party payables - short term $17,075 $7,321 
Kashiv - contingent consideration
$530 $430 
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
8,691 8,139 
Members - tax receivable agreement2,173 3,207 
Related party payables - long term $11,394 $11,776 
Kashiv Biosciences
Amendment to Biosimilar License Agreement
In March 2024, the Company amended the Kashiv Biosimilar Agreement (as defined in Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K) to include two additional in-development products, a pre-filled auto-injector delivery system for peg-filgrastim and a pre-filled on-body injector (OBI) delivery system for peg-filgrastim. Consistent with the existing terms, Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling, and pricing activities of these product candidates. The amendment did not change the contractual terms related to existing commercialized biosimilar products.
The amendment provides an incremental $14.5 million in potential future milestone payments specific to these in-development products, including $7.0 million for clinical and developmental milestones and $7.5 million for regulatory approval and first commercial-sales milestones. In addition, the amendment clarifies that future net sales milestones payments of up to $37.5 million, which did not change, shall be contingent upon reaching certain commercial sales volume objectives for the aggregate of all products under the amended agreement. The agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.
No amounts were paid or recognized during the three months ended March 31, 2024 pursuant to this amendment.

Long-Acting Injectable License and Supply Agreement
In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal is responsible for manufacturing batch products and performing certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, is responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services.

Pursuant to the development supply agreement, Amneal maintained a right of first offer and negotiation to the licensing of each generic product candidate. In March 2024, Amneal and Kashiv entered into a license and supply agreement for the development and commercialization of a long-acting injectable (the “Injectable License and Supply Agreement"). The existing development supply agreement remains effective for the remaining three generic product candidates.
Subject to the terms of the Injectable License and Supply Agreement, Amneal is responsible for development, regulatory approval, and commercialization of the product candidate in the U.S., whereas Kashiv is responsible for development and regulatory approval of the product candidate for all other territories outside the U.S. Contingent upon Kashiv obtaining regulatory approval outside the U.S., Amneal shall manufacture the commercial supply for Kashiv at a stated price. The term of the agreement is 10 years from the respective product’s launch date in the U.S.

During the three months ended March 31, 2024, the Company recorded R&D expense for a $0.5 million payment made upon execution of the license and supply agreement. The agreement provides for potential future milestone payments to Kashiv of up to $35.0 million as follows: (i) up to $10.0 million relating to developmental milestones; (ii) up to $20.0 million for U.S. regulatory approval and initial commercial launch milestones; and (iii) up to $5.0 million for the achievement of annual commercial milestones. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.
Refer to Note 3. Acquisitions and Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K for information on the Company’s agreements with Kashiv.
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has three reportable segments: Generics, Specialty, and AvKARE.
Generics
The Company’s Generics segment includes a retail and institutional portfolio of over 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals.
Specialty
The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders.
AvKARE
The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.
Chief Operating Decision Makers
The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, because they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment because it is not reviewed by the Company’s chief operating decision makers.
The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Three Months Ended March 31, 2024
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$391,294 $105,234 $162,663 $— $659,191 
Cost of goods sold239,922 44,800 136,409 — 421,131 
Gross profit151,372 60,434 26,254 — 238,060 
Selling, general and administrative33,085 25,196 14,907 39,407 112,595 
Research and development34,371 4,927 — — 39,298 
Intellectual property legal development expenses960 24 — — 984 
Restructuring and other charges— 946 — 524 1,470 
Change in fair value of contingent consideration— 100 — — 100 
Charges related to legal matters, net94,359 — — — 94,359 
Operating (loss) income$(11,403)$29,241 $11,347 $(39,931)$(10,746)

Three Months Ended March 31, 2023
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$343,806 $91,678 $122,056 $— $557,540 
Cost of goods sold230,551 43,191 105,612 — 379,354 
Gross profit113,255 48,487 16,444 — 178,186 
Selling, general and administrative27,600 22,379 12,940 39,177 102,096 
Research and development32,359 6,331 — — 38,690 
Intellectual property legal development expenses1,624 20 — — 1,644 
Restructuring and other charges99 — — 411 510 
Change in fair value of contingent consideration— 2,457 — — 2,457 
(Credit) charges related to legal matters, net(2,444)— — 2,008 (436)
Other operating income(1,224)— — — (1,224)
Operating income (loss)
$55,241 $17,300 $3,504 $(41,596)$34,449 
(1)Operating results for the sale of Amneal products by AvKARE are included in Generics.
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventOn April 30, 2024, Amneal closed on the sale of a wholly owned subsidiary in India to Kashiv for total consideration of ₹1 billion, or approximately $12 million. Total consideration consisted of a ₹416 million, or approximately $5 million, cash payment at closing and the assumption of a loan payable of approximately ₹600 million, or approximately $7 million, payable to another subsidiary of Amneal in India. The loan payable bears interest of 11% on the unpaid principal and is due on or before December 31, 2024. The Company is permitted to offset royalties or other amounts payable to Kashiv with any overdue principal on the loan payable. The subsidiary’s assets and liabilities were primarily comprised of a building under construction and a note payable, respectively. The subsidiary had no business activity, other than the construction of the building.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.
Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2023 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Reclassifications
Reclassification
The prior period balance related to the TRA (as defined in Note 5. Income Taxes) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss.
The prior period balance related to long-term liabilities for legal matters of $0.3 million, formerly included in other long-term liabilities as of December 31, 2023, has been reclassified to the balance sheet caption “liabilities for legal matters - long term” to conform to the current period presentation in the consolidated balance sheets. This reclassification did not impact total long-term liabilities or total liabilities
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
Performance Obligations
The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Major Customers by Reporting Segments
The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue:
Three Months Ended March 31,
20242023
Customer A21 %22 %
Customer B15 %14 %
Customer C23 %20 %
Customer D10 %%
Schedule of Disaggregated Revenue
The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands):
Three Months Ended March 31,
20242023
Generics
Anti-infective$6,110 $5,174 
Hormonal / allergy107,714 104,851 
Antiviral3,866 25,474 
Central nervous system109,456 84,582 
Cardiovascular system45,878 32,503 
Gastroenterology18,197 14,364 
Oncology38,533 10,578 
Metabolic disease / endocrine
11,185 9,265 
Respiratory11,136 12,815 
Dermatology18,975 18,004 
Other therapeutic classes18,523 25,895 
International and other1,721 301 
Total Generics net revenue391,294 343,806 
Specialty
Hormonal / allergy29,375 24,763 
Central nervous system66,276 60,139 
License agreement (1)
4,479 — 
Other therapeutic classes5,104 6,776 
Total Specialty net revenue105,234 91,678 
AvKARE
Distribution109,713 83,230 
Government label34,952 24,516 
Institutional10,858 8,862 
Other7,140 5,448 
Total AvKARE net revenue162,663 122,056 
Total net revenue$659,191 $557,540 
(1)Refer to Note 4. Alliance and Collaboration for information on revenue recognized under a license agreement.
Schedule of Major Categories of Sales-Related Deductions
A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2023$559,334 $23,892 $136,486 $90,690 
Provision related to sales recorded in the period885,322 30,073 16,220 61,271 
Credits/payments issued during the period(987,202)(26,550)(15,598)(55,250)
Balance at March 31, 2024$457,454 $27,415 $137,108 $96,711 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss per Share (Tables)
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Loss per Share, Basic and Diluted
The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts):
Three Months Ended
March 31,
20242023
Numerator:
Net loss attributable to Amneal Pharmaceuticals, Inc.
$(91,643)$(6,943)
Denominator:
Weighted-average shares outstanding - basic and diluted
307,279 152,109 
Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic and diluted
$(0.30)$(0.05)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share
The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands):
Three Months Ended
March 31,
20242023
Stock options
2,406 (1)2,632 (1)
Restricted stock units
10,837 (1)11,576 (1)
Performance stock units
7,827 (1)7,018 (1)
Shares of Old PubCo Class B common stock
— 152,117 (2)
(1)Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.
(2)Shares of Old PubCo Class B common stock were considered potentially dilutive shares of Old PubCo Class A common stock. Shares of Old PubCo Class B common stock were excluded from the computations of diluted loss per share of Class A common stock for the three months ended March 31, 2023 because the effect of their inclusion would have been anti-dilutive under the if-converted method.
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Trade Accounts Receivable, Net (Tables)
3 Months Ended
Mar. 31, 2024
Receivables [Abstract]  
Schedule of Trade Accounts Receivable, Net
Trade accounts receivable, net was comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Gross accounts receivable$1,156,861 $1,199,980 
Allowance for credit losses(3,037)(3,022)
Contract charge-backs and sales volume allowances(457,454)(559,334)
Cash discount allowances(27,415)(23,892)
Subtotal(487,906)(586,248)
Trade accounts receivable, net$668,955 $613,732 
Schedules of Percent of Gross Trade Receivables
Concentration of Receivables
Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows:
March 31,
2024
December 31,
2023
Customer A32 %40 %
Customer B29 %24 %
Customer C23 %22 %
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories (Tables)
3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
Inventories were comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Raw materials
$196,737 $217,744 
Work in process
57,924 59,563 
Finished goods
315,992 304,077 
Total inventories$570,653 $581,384 
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses and Other Current Assets (Tables)
3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets were comprised of the following (in thousands):
March 31,
2024
December 31,
2023
Deposits and advances$1,935 $2,200 
Prepaid insurance4,780 8,334 
Prepaid regulatory fees4,219 6,331 
Income and other tax receivables12,198 13,168 
Prepaid taxes9,205 11,899 
Other current receivables
12,802 9,929 
Chargebacks receivable (1)
8,575 7,876 
Other prepaid assets33,584 22,948 
Total prepaid expenses and other current assets$87,298 $82,685 
(1)When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands):
March 31,
2024
December 31,
2023
Balance, beginning of period$598,629 $598,853 
Currency translation(80)(224)
Balance, end of period$598,549 $598,629 
Schedule of Finite-Lived Intangible Assets
Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights6.2$1,207,469 $(739,351)$468,118 $1,198,971 $(703,297)$495,674 
Other intangible assets3.1111,800 (76,491)35,309 111,800 (72,896)38,904 
Subtotal1,319,269 (815,842)503,427 1,310,771 (776,193)534,578 
In-process research and development355,845 — 355,845 355,845 — 355,845 
Total intangible assets$1,675,114 $(815,842)$859,272 $1,666,616 $(776,193)$890,423 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&D”) intangible assets (in thousands):
Future
Amortization
Remainder of 2024$119,432 
2025121,638 
202673,115 
202752,606 
202833,263 
202926,484 
Thereafter76,889 
   Total$503,427 
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Assets (Tables)
3 Months Ended
Mar. 31, 2024
Other Assets [Abstract]  
Schedule of Other Assets
Other assets were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Interest rate swap (1)
$52,632 $37,089 
Security deposits 3,616 3,602 
Long-term prepaid expenses3,099 3,273 
Deferred revolving credit facility costs4,007 4,427 
Other long term assets10,393 7,126 
Total $73,747 $55,517 
(1)Refer to Note 15. Fair Value Measurements and Note 16. Financial Instruments for information about the Company’s interest rate swap.
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses were comprised of the following (in thousands):
March 31, 2024December 31, 2023
Accounts payable$175,325 $143,572 
Accrued returns allowance (1)
137,108 136,486 
Accrued compensation44,806 71,122 
Accrued Medicaid and commercial rebates (1)
96,711 90,690 
Accrued royalties19,779 23,342 
Commercial chargebacks and rebates10,226 10,226 
Accrued professional fees14,598 11,005 
Accrued other59,965 48,219 
Total accounts payable and accrued expenses$558,518 $534,662 
(1)Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2023 to March 31, 2024.
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt (Tables)
3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
The following is a summary of the Company’s indebtedness under its term loans (in thousands):
March 31, 2024December 31, 2023
Term Loan Due May 2025$191,979 $191,979 
Term Loan Due May 20282,336,949 2,351,647 
Total debt2,528,928 2,543,626 
Less: debt issuance costs(117,561)(123,497)
Total debt, net of debt issuance costs2,411,367 2,420,129 
Less: current portion of long-term debt(33,660)(34,125)
Total long-term debt, net$2,377,707 $2,386,004 
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Long-Term Liabilities (Tables)
3 Months Ended
Mar. 31, 2024
Other Liabilities Disclosure [Abstract]  
Schedule of Other Long-Term Liabilities
Other long-term liabilities were comprised of the following (in thousands):

March 31, 2024December 31, 2023
Uncertain tax positions$504 $497 
Long-term compensation18,073 21,283 
Contingent consideration (1)
433 433 
Other long-term liabilities5,569 7,466 
Total other long-term liabilities$24,579 $29,679 
(1)    Refer to Note 15. Fair Value Measurements for additional information.
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):
Fair Value Measurement Based on
March 31, 2024TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Assets
Interest rate swap (1)
$52,632 $— $52,632 $— 
Liabilities
Deferred compensation plan liabilities (2)
$9,668 $— $9,668 $— 
Contingent consideration liabilities (3)
$1,021 $— $— $1,021 
December 31, 2023
Assets
Interest rate swap (1)
$37,089 $— $37,089 $— 
Liabilities
Deferred compensation plan liabilities (2)
$9,100 $— $9,100 $— 
Contingent consideration liability (3)
$921 $— $— $921 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 16. Financial Instruments for information on the Company's interest rate swap.
(2)These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.
(3)The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. For the three months ended March 31, 2024, there was no material activity or payments related to the contingent consideration liabilities.
Summary of the Company’s Indebtedness at Fair Value
The following is a summary of the Company’s indebtedness at fair value (in thousands):
March 31, 2024December 31, 2023
Term Loan Due 2025$192,099 $190,779 
Term Loan Due 2028$2,339,870 $2,328,130 
Sellers Notes$41,944 $41,033 
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
March 31, 2024December 31, 2023
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther Assets$52,632 Other Assets$37,089 
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Charges and Liabilities Related to Legal Matters
Liabilities for legal matters were comprised of the following (in thousands):
MatterMarch 31, 2024December 31, 2023
Opana ER® antitrust litigation$— $50,000 
Opana ER® antitrust litigation-accrued interest
— 2,347 
Civil prescription opioid litigation30,130 21,189 
Other
— 3,452 
Current portion of liabilities for legal matters$30,130 $76,988 
Civil prescription opioid litigation (Liabilities for legal matters - long term)$85,479 $316 
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders’ Equity and Redeemable Non-Controlling Interests (Tables)
3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive (Loss) Income by Component
Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands):
Foreign
currency
translation
adjustments
Unrealized gain (loss) on cash
flow hedge, net
of tax
Accumulated
other
comprehensive (loss) income
Balance December 31, 2023$(66,072)$33,723 $(32,349)
Other comprehensive loss before reclassification(390)15,543 15,153 
Reclassification of cash flow hedge to earnings, net of tax of $0
— (6,515)(6,515)
Balance March 31, 2024$(66,462)$42,751 $(23,711)
Balance December 31, 2022$(32,382)$42,321 $9,939 
Other comprehensive loss before reclassification898 (7,135)(6,237)
Reallocation of ownership interests
(195)257 62 
Balance March 31, 2023$(31,679)$35,443 $3,764 
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The following table summarizes the Company’s related party transactions (in thousands):
Three Months Ended March 31,
Related Party and Nature of TransactionCaption in Balance Sheet and Statement of Operations20242023
Kashiv Biosciences LLC
Parking space leaseResearch and development$25 $17 
Development and commercialization agreement - Ganirelix Acetate and Cetrorelix AcetateResearch and development$— $50 
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)Cost of goods sold$4,526 $144 
Storage agreementResearch and development$(77)$(48)
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)Inventory and cost of goods sold$1,216 $— 
Generic development supply agreement - research and development materialResearch and development$(48)$— 
Generic development supply agreement - development activity deferred incomeDeferred revenue and net revenue$(422)$— 
Development and commercialization agreement - Long-acting injectableResearch and development$500 $— 
Other Related Parties
Kanan, LLC - operating leaseInventory and cost of goods sold$592 $566 
Sutaria Family Realty, LLC - operating leaseInventory and cost of goods sold$314 $305 
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreementInventory and cost of goods sold$5,001 $1,836 
Tracy Properties LLC - operating leaseSelling, general and administrative$143 $169 
AzaTech Pharma LLC - supply agreementInventory and cost of goods sold$2,312 $575 
AvPROP, LLC - operating leaseSelling, general and administrative$44 $47 
Avtar Investments, LLC - consulting servicesResearch and development$69 $188 
AlkermesInventory and cost of goods sold$12 $
R&S Solutions - logistics servicesSelling, general and administrative$— $20 
Members - tax receivable agreement (TRA liability)Other expense$1,948 $826 
The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):
March 31, 2024December 31, 2023
Kashiv - various agreements$1,434 $954 
Apace Packaging, LLC - packaging agreement— 
Alkermes— 
AzaTech Pharma LLC78 — 
Related party receivables - short term $1,521 $955 
Kashiv - various agreements$5,773 $3,179 
Apace Packaging, LLC - packaging agreement1,863 1,091 
AzaTech Pharma LLC - supply agreement1,650 1,958 
Avtar Investments LLC - consulting services22 100 
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
442 442 
Members - tax receivable agreement3,532 549 
Rondo Class B unit holders - tax distributions3,777 — 
Alkermes Plc16 
Related party payables - short term $17,075 $7,321 
Kashiv - contingent consideration
$530 $430 
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
8,691 8,139 
Members - tax receivable agreement2,173 3,207 
Related party payables - long term $11,394 $11,776 
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Three Months Ended March 31, 2024
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$391,294 $105,234 $162,663 $— $659,191 
Cost of goods sold239,922 44,800 136,409 — 421,131 
Gross profit151,372 60,434 26,254 — 238,060 
Selling, general and administrative33,085 25,196 14,907 39,407 112,595 
Research and development34,371 4,927 — — 39,298 
Intellectual property legal development expenses960 24 — — 984 
Restructuring and other charges— 946 — 524 1,470 
Change in fair value of contingent consideration— 100 — — 100 
Charges related to legal matters, net94,359 — — — 94,359 
Operating (loss) income$(11,403)$29,241 $11,347 $(39,931)$(10,746)

Three Months Ended March 31, 2023
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$343,806 $91,678 $122,056 $— $557,540 
Cost of goods sold230,551 43,191 105,612 — 379,354 
Gross profit113,255 48,487 16,444 — 178,186 
Selling, general and administrative27,600 22,379 12,940 39,177 102,096 
Research and development32,359 6,331 — — 38,690 
Intellectual property legal development expenses1,624 20 — — 1,644 
Restructuring and other charges99 — — 411 510 
Change in fair value of contingent consideration— 2,457 — — 2,457 
(Credit) charges related to legal matters, net(2,444)— — 2,008 (436)
Other operating income(1,224)— — — (1,224)
Operating income (loss)
$55,241 $17,300 $3,504 $(41,596)$34,449 
(1)Operating results for the sale of Amneal products by AvKARE are included in Generics.
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Operations - Additional Information (Details)
Mar. 31, 2024
Nov. 07, 2023
Amneal Pharmaceuticals, LLC    
Noncontrolling Interest [Line Items]    
Ownership by parent (percent) 100.00% 100.00%
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Accounting Policies [Abstract]      
Increase in tax receivable agreement liability $ (1,948) $ (826)  
Liabilities for legal matters - long term $ 85,479   $ 316
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition - Concentration of Revenue (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Customer A    
Concentration Risk [Line Items]    
Concentration risk (percent) 21.00% 22.00%
Customer B    
Concentration Risk [Line Items]    
Concentration risk (percent) 15.00% 14.00%
Customer C    
Concentration Risk [Line Items]    
Concentration risk (percent) 23.00% 20.00%
Customer D    
Concentration Risk [Line Items]    
Concentration risk (percent) 10.00% 9.00%
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Net revenue $ 659,191 $ 557,540
Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 391,294 343,806
Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 105,234 91,678
AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 162,663 122,056
International and other | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 1,721 301
Anti-infective | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 6,110 5,174
Hormonal / allergy | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 107,714 104,851
Hormonal / allergy | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 29,375 24,763
Antiviral | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 3,866 25,474
Central nervous system | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 109,456 84,582
Central nervous system | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 66,276 60,139
License agreement | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 4,479 0
Cardiovascular system | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 45,878 32,503
Gastroenterology | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 18,197 14,364
Oncology | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 38,533 10,578
Metabolic disease / endocrine | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 11,185 9,265
Respiratory | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 11,136 12,815
Dermatology | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 18,975 18,004
Other therapeutic classes | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 18,523 25,895
Other therapeutic classes | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 5,104 6,776
Distribution | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 109,713 83,230
Government label | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 34,952 24,516
Institutional | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 10,858 8,862
Other | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue $ 7,140 $ 5,448
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Contract Charge - Backs and Sales Volume Allowances  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period $ 559,334
Provision related to sales recorded in the period 885,322
Credits/payments issued during the period (987,202)
Balance, end of period 457,454
Cash Discount Allowances  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 23,892
Provision related to sales recorded in the period 30,073
Credits/payments issued during the period (26,550)
Balance, end of period 27,415
Accrued Returns Allowance  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 136,486
Provision related to sales recorded in the period 16,220
Credits/payments issued during the period (15,598)
Balance, end of period 137,108
Accrued Medicaid and Commercial Rebates  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 90,690
Provision related to sales recorded in the period 61,271
Credits/payments issued during the period (55,250)
Balance, end of period $ 96,711
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Alliance and Collaboration - Additional Information (Details)
€ in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 26, 2024
USD ($)
Feb. 23, 2024
USD ($)
Feb. 23, 2024
EUR (€)
Jan. 24, 2024
Oct. 12, 2023
product
Dec. 28, 2022
May 07, 2018
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2024
EUR (€)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Feb. 23, 2024
EUR (€)
Dec. 05, 2023
USD ($)
License Agreement with Orion Corporation                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Collaborative arrangement term           8 years                  
Collaborative arrangement renew for successive term           2 years                  
Collaborative arrangement license revenue agreement                 $ 0.6   $ 0.6        
License Agreement with Orion Corporation | Accounts Payable and Accrued Liabilities                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred income               $ 7.8 10.7     $ 7.8      
License Agreement with Orion Corporation | Other long-term liabilities                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred income               4.7 1.2     4.7      
ONGENTYS® License Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Collaborative arrangement, medical and marketing activities                             $ 6.0
Collaborative arrangement non-refundable license fee               $ 12.5              
Collaborative arrangement non-refundable license fee, amortization period               8 years              
License supply agreement, potential future milestone payments               $ 22.5              
License Agreement with Zambon Biotech                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Collaborative arrangement term   15 years 15 years                        
Collaborative arrangement renew for successive term   2 years 2 years                        
License supply agreement, potential future milestone payments   $ 77.2 € 71.5                        
Notice period   1 year 1 year                        
Nonrefundable license fee received, amount   $ 5.4                       € 5.0  
Collaborative arrangement net revenue agreement                 3.5 € 3.2          
Biosimilar Licensing and Supply Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License supply agreement, potential future milestone payments                       66.0      
Other long term liabilities             $ 78.3                
Collaborative arrangement maximum milestone paid                       2.5 $ 26.5    
Estimated useful life (in years)                         7 years    
Collaborative arrangement aggregate sales-based milestone payment                 9.5            
Collaborative arrangement, number of products | product         2                    
Collaborative arrangement upfront payment                 $ 3.0     2.5      
Biosimilar Licensing and Supply Agreement | Development Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License supply agreement, potential future milestone payments                       3.5      
Biosimilar Licensing and Supply Agreement | Regulatory Approval                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License supply agreement, potential future milestone payments                       $ 15.0      
Biosimilar Licensing and Supply Agreement | Achievement of Cumulative Net Sales                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License supply agreement, potential future milestone payments                     $ 47.5        
Knight Therapeutics International S.A. License Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Collaborative arrangement term       15 years                      
Collaborative arrangement renew for successive term       2 years                      
License supply agreement, potential future milestone payments $ 10.5                            
Notice period       1 year                      
Nonrefundable license fee received, amount $ 1.0                            
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes - Additional Information (Details)
$ in Thousands
3 Months Ended 10 Months Ended 12 Months Ended
Nov. 07, 2023
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Nov. 06, 2023
Dec. 31, 2019
USD ($)
Dec. 31, 2018
Dec. 31, 2023
USD ($)
Income Tax Disclosure [Abstract]              
Income tax expense (benefit)   $ 6,156 $ 668        
Effective tax rate (percent)   (8.20%) (7.10%)        
Valuation allowance   $ 566,000         $ 566,500
Tax receivable agreement, payment ratio           0.01  
Percentage of tax receivable agreement paid to other holders of Amneal common units (percent) 75.00%     85.00%   85.00%  
Reversal of accrued tax receivable agreement liability         $ 192,800    
Liabilities recorded under tax receivable agreement   185,000         185,000
Tax receivable agreement liability   5,700         $ 3,800
Increase in tax receivable agreement liability   $ 1,948 $ 826        
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss per Share - Computation of Basic and Diluted Loss per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator:    
Net loss attributable to Amneal Pharmaceuticals, Inc. $ (91,643) $ (6,943)
Denominator:    
Weighted-average shares outstanding - basic (in shares) 307,279 152,109
Weighted-average shares outstanding - diluted (in shares) 307,279 152,109
Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:    
Basic (in dollars per share) $ (0.30) $ (0.05)
Diluted (in dollars per share) $ (0.30) $ (0.05)
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Shares of Old PubCo Class B common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 0 152,117
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 2,406 2,632
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 10,837 11,576
Performance stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 7,827 7,018
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Related Party Transaction [Line Items]    
Gross accounts receivable $ 1,156,861 $ 1,199,980
Allowance for credit losses (3,037) (3,022)
Contract charge-backs and sales volume allowances (457,454) (559,334)
Cash discount allowances (27,415) (23,892)
Subtotal (487,906) (586,248)
Nonrelated Party    
Related Party Transaction [Line Items]    
Trade accounts receivable, net $ 668,955 $ 613,732
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Trade Accounts Receivable, Net - Concentration of Receivables (Details) - Customer Concentration Risk - Accounts Receivable
3 Months Ended 6 Months Ended
Mar. 31, 2024
Jun. 30, 2023
Customer A    
Concentration Risk [Line Items]    
Concentration risk (percent) 32.00% 40.00%
Customer B    
Concentration Risk [Line Items]    
Concentration risk (percent) 29.00% 24.00%
Customer C    
Concentration Risk [Line Items]    
Concentration risk (percent) 23.00% 22.00%
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories - Components of Inventories, Net of Reserves (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 196,737 $ 217,744
Work in process 57,924 59,563
Finished goods 315,992 304,077
Total inventories $ 570,653 $ 581,384
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Deposits and advances $ 1,935 $ 2,200
Prepaid insurance 4,780 8,334
Prepaid regulatory fees 4,219 6,331
Income and other tax receivables 12,198 13,168
Prepaid taxes 9,205 11,899
Prepaid taxes 12,802 9,929
Chargebacks receivable 8,575 7,876
Other prepaid assets 33,584 22,948
Total prepaid expenses and other current assets $ 87,298 $ 82,685
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2024
Jun. 30, 2023
Goodwill [Roll Forward]    
Balance, beginning of period $ 598,629 $ 598,853
Currency translation (80) $ (224)
Balance, end of period $ 598,549  
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Goodwill [Line Items]        
Goodwill $ 598,549,000   $ 598,629,000 $ 598,853,000
Amortization of intangible assets 39,900,000 $ 41,100,000    
Intangible asset impairment charges, indefinite-lived 0 $ 0    
Specialty        
Goodwill [Line Items]        
Goodwill 366,300,000   366,300,000  
Generics        
Goodwill [Line Items]        
Goodwill 162,700,000   162,800,000  
AvKARE        
Goodwill [Line Items]        
Goodwill $ 69,500,000   $ 69,500,000  
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,319,269 $ 1,310,771
Accumulated Amortization (815,842) (776,193)
Net 503,427 534,578
In-process research and development 355,845 355,845
Intangible assets, cost 1,675,114 1,666,616
Intangible assets, net $ 859,272 890,423
Product rights    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period (in years) 6 years 2 months 12 days  
Cost $ 1,207,469 1,198,971
Accumulated Amortization (739,351) (703,297)
Net $ 468,118 495,674
Other intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period (in years) 3 years 1 month 6 days  
Cost $ 111,800 111,800
Accumulated Amortization (76,491) (72,896)
Net $ 35,309 $ 38,904
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]    
Remainder of 2023 $ 119,432  
2025 121,638  
2026 73,115  
2027 52,606  
2028 33,263  
2029 26,484  
Thereafter 76,889  
Net $ 503,427 $ 534,578
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Assets - Schedule of Other Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Other Assets [Line Items]    
Other assets $ 73,747 $ 55,517
Interest rate swap    
Other Assets [Line Items]    
Other assets 52,632 37,089
Security deposits    
Other Assets [Line Items]    
Other assets 3,616 3,602
Long-term prepaid expenses    
Other Assets [Line Items]    
Other assets 3,099 3,273
Deferred revolving credit facility costs    
Other Assets [Line Items]    
Other assets 4,007 4,427
Other long term assets    
Other Assets [Line Items]    
Other assets $ 10,393 $ 7,126
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Related Party Transaction [Line Items]    
Accounts payable $ 175,325 $ 143,572
Accrued returns allowance 137,108 136,486
Accrued compensation 44,806 71,122
Accrued Medicaid and commercial rebates 96,711 90,690
Accrued royalties 19,779 23,342
Commercial chargebacks and rebates 10,226 10,226
Accrued professional fees 14,598 11,005
Accrued other 59,965 48,219
Nonrelated Party    
Related Party Transaction [Line Items]    
Accounts payable and accrued expenses $ 558,518 $ 534,662
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Summary of Long-term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Total debt $ 2,528,928 $ 2,543,626
Less: debt issuance costs (117,561) (123,497)
Total debt, net of debt issuance costs 2,411,367 2,420,129
Less: current portion of long-term debt (33,660) (34,125)
Total long-term debt, net 2,377,707 2,386,004
Term Loan Due May 2025    
Debt Instrument [Line Items]    
Total debt 191,979 191,979
Term Loan Due May 2028    
Debt Instrument [Line Items]    
Total debt $ 2,336,949 $ 2,351,647
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Debt Instrument [Line Items]      
Borrowings on revolving credit facilities $ 48,000 $ 80,000  
Amended New Revolving Credit Facility      
Debt Instrument [Line Items]      
Borrowings on revolving credit facilities 20,000    
Repayment of outstanding principal 20,000    
Revolving credit facility     $ 179,000
Amended Rondo Credit Facility      
Debt Instrument [Line Items]      
Borrowings on revolving credit facilities 28,000    
Repayment of outstanding principal 28,000    
Revolving credit facility $ 179,000    
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Nonrelated Party    
Other Liabilities [Line Items]    
Other long-term liabilities $ 24,579 $ 29,679
Uncertain tax positions    
Other Liabilities [Line Items]    
Other long-term liabilities 504 497
Long-term compensation    
Other Liabilities [Line Items]    
Other long-term liabilities 18,073 21,283
Contingent Consideration    
Other Liabilities [Line Items]    
Other long-term liabilities 433 433
Other long-term liabilities    
Other Liabilities [Line Items]    
Other long-term liabilities $ 5,569 $ 7,466
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Interest rate swap $ 52,632 $ 37,089
Liabilities    
Deferred compensation plan liabilities 9,668 9,100
Contingent consideration liabilities 1,021 921
Quoted Prices in Active Markets (Level 1)    
Assets    
Interest rate swap 0 0
Liabilities    
Deferred compensation plan liabilities 0 0
Contingent consideration liabilities 0 0
Significant Other Observable Inputs (Level 2)    
Assets    
Interest rate swap 52,632 37,089
Liabilities    
Deferred compensation plan liabilities 9,668 9,100
Contingent consideration liabilities 0 0
Significant Unobservable Inputs (Level 3)    
Assets    
Interest rate swap 0 0
Liabilities    
Deferred compensation plan liabilities 0 0
Contingent consideration liabilities $ 1,021 $ 921
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Summary of the Company’s Indebtedness at Fair Value (Details) - Significant Other Observable Inputs (Level 2) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Senior Secured Credit Facility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt fair value   $ 2,328,130
Sellers Notes    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt fair value $ 41,944 41,033
Term Loan Due 2025 | Senior Secured Credit Facility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt fair value 192,099 $ 190,779
Term Loan Due 2028 | Senior Secured Credit Facility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt fair value $ 2,339,870  
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Additional Information (Details) - USD ($)
3 Months Ended
Nov. 14, 2023
Mar. 31, 2024
Dec. 31, 2023
Oct. 31, 2019
Derivative [Line Items]        
Interest rate swap   $ 52,632,000 $ 37,089,000  
Derivative gain reclassified from accumulated OCI into income (loss)   6,500,000    
Cash flow hedge gain (loss) to be reclassified within 12 months   26,100,000    
Net of income taxes, recognized in accumulated other comprehensive income   $ 42,800,000    
Interest Rate Lock Agreement        
Derivative [Line Items]        
Notional amount       $ 1,300,000,000
November 2023 Swap        
Derivative [Line Items]        
Notional amount $ 1,300,000,000      
Derivative, fixed interest rate 2.7877%      
Interest rate swap $ 66,700,000      
Amended October 2019 Swap        
Derivative [Line Items]        
Derivative, fixed interest rate 1.366%      
Unrealized gain recorded within accumulated other comprehensive income (loss) $ 66,700,000      
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Variable to Fixed Interest Rate Swap | Designated as Hedging Instrument | Other Assets    
Derivative [Line Items]    
Fair Value $ 52,632 $ 37,089
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended
May 02, 2024
Apr. 30, 2024
USD ($)
$ / twinPack
Feb. 28, 2024
Dec. 18, 2023
USD ($)
May 31, 2023
case
Feb. 28, 2023
USD ($)
Jun. 10, 2020
state
action
Mar. 13, 2015
medication
Nov. 06, 2014
representative
Dec. 31, 2023
USD ($)
case
state
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
May 15, 2023
Nov. 01, 2019
state
May 10, 2019
state
Loss Contingencies [Line Items]                              
(Credit) charges related to legal matters, net                     $ (94,359) $ 436      
Liabilities for legal matters - long term                   $ 316 85,479        
Opana ER® antitrust litigation                              
Loss Contingencies [Line Items]                              
(Credit) charges related to legal matters, net                       $ 436      
Loss contingency accrual                   $ 50,000 $ 265,000        
Litigation settlement, interest rate                     3.00%        
United States Department of Justice Investigations                              
Loss Contingencies [Line Items]                              
Number of sales representatives | representative                 1            
Number of generic prescription medications | medication               4              
Percentage Of Prescribed Label                         1.00%    
Generic Digoxin and Doxycycline Antitrust Litigation                              
Loss Contingencies [Line Items]                              
Number of states, filed civil lawsuit | state             46               43
Loss contingency civil lawsuit filed number of additional states | state                           9  
Number of actions | action             2                
Civil prescription opioid litigation                              
Loss Contingencies [Line Items]                              
(Credit) charges related to legal matters, net                     $ (94,400)        
Number of cases filed | case                   900          
Number of states with cases | state                   7          
Number of claims dismissed | case         2                    
Liabilities for legal matters - long term                   $ 300 85,500        
Estimated litigation liability                   $ 21,500 $ 115,600        
Civil prescription opioid litigation | Subsequent Event                              
Loss Contingencies [Line Items]                              
Litigation settlement agreement terms   10 years                          
Civil prescription opioid litigation | Litigation Settlement, Option One | Subsequent Event                              
Loss Contingencies [Line Items]                              
Litigation settlement amount   $ 92,500                          
Litigation settlement, product supply amount   $ 180,000                          
Litigation settlement, product supply price (in USD per twin pack) | $ / twinPack   125                          
Civil prescription opioid litigation | Litigation Settlement, Option One | Subsequent Event | Maximum                              
Loss Contingencies [Line Items]                              
Litigation settlement amount   $ 137,500                          
Civil prescription opioid litigation | Litigation Settlement, Option Two | Subsequent Event                              
Loss Contingencies [Line Items]                              
Litigation settlement agreement terms   4 years                          
Litigation settlement amount   $ 45,000                          
Litigation settlement, percentage of product value   25.00%                          
Ranitidine Litigation                              
Loss Contingencies [Line Items]                              
Number of states with cases | state                   5          
Metformin Litigation | Litigation Settlement, Option One | Subsequent Event                              
Loss Contingencies [Line Items]                              
Deadline period for defendants 3 days                            
Metformin Litigation | Litigation Settlement, Option Two | Subsequent Event                              
Loss Contingencies [Line Items]                              
Deadline period for defendants 30 days                            
Xyrem® (Sodium Oxybate) Antitrust Litigation                              
Loss Contingencies [Line Items]                              
Litigation settlement amount       $ 4,000   $ 1,900                  
Litigation settlement expense                   $ 3,000          
Estimated litigation liability                   $ 2,000          
UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.                              
Loss Contingencies [Line Items]                              
Deadline period for defendants     45 days                        
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters $ 30,130 $ 76,988
Opana ER® antitrust litigation    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 0 50,000
Opana ER® antitrust litigation-accrued interest    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 0 2,347
Civil prescription opioid litigation    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 30,130 21,189
Civil prescription opioid litigation (Liabilities for legal matters - long term) 85,479 316
Other    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters $ 0 $ 3,452
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Nov. 07, 2023
Dec. 31, 2021
Apr. 02, 2021
Jan. 31, 2020
Class of Stock [Line Items]            
Tax distribution   $ 26.8        
Common Class B            
Class of Stock [Line Items]            
Common stock, shares outstanding (in shares)     0      
Amneal Pharmaceuticals, LLC            
Class of Stock [Line Items]            
Ownership by parent (percent) 100.00%   100.00%      
Kashiv Specialty Pharmaceuticals, LLC            
Class of Stock [Line Items]            
Voting interest acquired (percent)         98.00%  
Kashiv Specialty Pharmaceuticals, LLC | Sellers of KSP            
Class of Stock [Line Items]            
Ownership percentage by noncontrolling owners (percent)         2.00%  
Av Kare Incorporation And R And S Northeast L L C            
Class of Stock [Line Items]            
Voting interest acquired (percent)       65.10%    
Tax distribution recorded as a reduction to redeemable non-controlling interest $ 4.4 $ 3.0        
Av Kare Incorporation And R And S Northeast L L C | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes            
Class of Stock [Line Items]            
Ownership percentage by noncontrolling owners (percent) 34.90%         34.90%
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance $ 20,011 $ 183,979
Stockholders' equity ending balance (63,629) 134,668
Reclassification of cash flow hedge to earnings, net of tax 0 0
Foreign currency translation adjustments    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance (66,072) (32,382)
Other comprehensive loss before reclassification (390) 898
Reallocation of ownership interests   (195)
Reclassification of cash flow hedge to earnings, net of tax of $0 0  
Stockholders' equity ending balance (66,462) (31,679)
Unrealized gain (loss) on cash flow hedge, net of tax    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance 33,723 42,321
Other comprehensive loss before reclassification 15,543 (7,135)
Reallocation of ownership interests   257
Reclassification of cash flow hedge to earnings, net of tax of $0 (6,515)  
Stockholders' equity ending balance 42,751 35,443
Accumulated other comprehensive (loss) income    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance (32,349) 9,939
Other comprehensive loss before reclassification 15,153 (6,237)
Reallocation of ownership interests   62
Reclassification of cash flow hedge to earnings, net of tax of $0 (6,515)  
Stockholders' equity ending balance $ (23,711) $ 3,764
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions - Related Party Agreements (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
AzaTech Pharma LLC - supply agreement      
Related Party Transaction [Line Items]      
Trade accounts receivable, net $ 78   $ 0
Rondo Class B unit holders - tax distributions      
Related Party Transaction [Line Items]      
Accounts payable and accrued expenses 3,777   0
Research and development - Parking Space Lease | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 25 $ 17  
Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 0 50  
Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 4,526 144  
Research and Development Storage Income | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party (77) (48)  
Inventory and Cost of Goods Sold | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 1,216 0  
Inventory and Cost of Goods Sold | Kanan, LLC - operating lease      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 592 566  
Inventory and Cost of Goods Sold | Sutaria Family Realty, LLC - operating lease      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 314 305  
Inventory and Cost of Goods Sold | Apace Packaging, LLC - packaging agreement      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 5,001 1,836  
Inventory and Cost of Goods Sold | AzaTech Pharma LLC - supply agreement      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 2,312 575  
Inventory and Cost of Goods Sold | Alkermes      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 12 2  
Research and Development - Generic Development Supply Agreement - Research and Development Material | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party (48) 0  
Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Amounts of transaction with related party (422) 0  
Research and Development      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 500 0  
Research and Development | Avtar Investments LLC - consulting services      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 69 188  
Selling, General and Administrative - Operating Lease | Tracy Properties LLC - operating lease      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 143 169  
Selling, General and Administrative - Operating Lease | AvPROP, LLC - operating lease      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 44 47  
Selling, General and Administrative - Logistics Services | R&S Solutions - logistics services      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 0 20  
Other Expense | Members - tax receivable agreement      
Related Party Transaction [Line Items]      
Amounts of transaction with related party 1,948 $ 826  
Related Party      
Related Party Transaction [Line Items]      
Trade accounts receivable, net 1,521   955
Accounts payable and accrued expenses 17,075   7,321
Other long-term liabilities 11,394   11,776
Related Party | Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Trade accounts receivable, net 1,434   954
Accounts payable and accrued expenses 5,773   3,179
Other long-term liabilities 530   430
Related Party | Apace Packaging, LLC - packaging agreement      
Related Party Transaction [Line Items]      
Trade accounts receivable, net 9   0
Accounts payable and accrued expenses 1,863   1,091
Related Party | AzaTech Pharma LLC - supply agreement      
Related Party Transaction [Line Items]      
Accounts payable and accrued expenses 1,650   1,958
Related Party | Avtar Investments LLC - consulting services      
Related Party Transaction [Line Items]      
Accounts payable and accrued expenses 22   100
Related Party | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes      
Related Party Transaction [Line Items]      
Accounts payable and accrued expenses 442   442
Related Party | Alkermes Plc      
Related Party Transaction [Line Items]      
Accounts payable and accrued expenses 16   2
Related Party | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes      
Related Party Transaction [Line Items]      
Other long-term liabilities 8,691   8,139
Related Party | Alkermes      
Related Party Transaction [Line Items]      
Trade accounts receivable, net 0   1
Related Party | Members - tax receivable agreement      
Related Party Transaction [Line Items]      
Accounts payable and accrued expenses 3,532   549
Other long-term liabilities $ 2,173   $ 3,207
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended
Mar. 31, 2024
Dec. 31, 2022
Mar. 31, 2024
Kashiv Bio Sciences License and Commercialization Agreement      
Related Party Transaction [Line Items]      
Collaborative arrangement upfront payment     $ 0.5
Collaborative arrangement aggregate sales-based milestone payment $ 37.5    
Collaborative arrangement, profit share (percent) 50.00%    
Collaborative arrangement term     10 years
Kashiv Bio Sciences License and Commercialization Agreement | Development Milestones      
Related Party Transaction [Line Items]      
License supply agreement, potential future milestone payments $ 7.0    
Kashiv Bio Sciences License and Commercialization Agreement | Regulatory Approval      
Related Party Transaction [Line Items]      
License supply agreement, potential future milestone payments $ 7.5    
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement      
Related Party Transaction [Line Items]      
Amounts of transaction with related party   $ 2.4  
Ownership interest (percent) 50.00%   50.00%
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Development Milestones      
Related Party Transaction [Line Items]      
Collaborative arrangement maximum contingent payments amount     $ 10.0
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Regulatory Approval      
Related Party Transaction [Line Items]      
Collaborative arrangement maximum contingent payments amount     20.0
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Achievement Of Annual Commercial Milestone      
Related Party Transaction [Line Items]      
Collaborative arrangement maximum contingent payments amount     5.0
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Initial Commercial Launch Milestones      
Related Party Transaction [Line Items]      
Collaborative arrangement maximum contingent payments amount     20.0
Kashiv Biosciences LLC      
Related Party Transaction [Line Items]      
Collaborative arrangement upfront payment $ 14.5    
Kashiv Biosciences LLC | R&D Reimbursement | Related Party | Maximum      
Related Party Transaction [Line Items]      
License supply agreement, potential future milestone payments     $ 35.0
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information - Additional Information (Details)
3 Months Ended
Mar. 31, 2024
segment
product
Segment Reporting [Abstract]  
Number of reportable segments | segment 3
Number of products families | product 270
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information - Schedules of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Net revenue $ 659,191 $ 557,540
Cost of goods sold 421,131 379,354
Gross profit 238,060 178,186
Selling, general and administrative 112,595 102,096
Research and development 39,298 38,690
Intellectual property legal development expenses 984 1,644
Restructuring and other charges 1,470 510
Change in fair value during the period 100 2,457
(Credit) charges related to legal matters, net 94,359 (436)
Other operating income 0 (1,224)
Operating (loss) income (10,746) 34,449
Generics    
Segment Reporting Information [Line Items]    
Net revenue 391,294 343,806
AvKARE    
Segment Reporting Information [Line Items]    
Net revenue 162,663 122,056
Operating Segments | Generics    
Segment Reporting Information [Line Items]    
Net revenue 391,294 343,806
Cost of goods sold 239,922 230,551
Gross profit 151,372 113,255
Selling, general and administrative 33,085 27,600
Research and development 34,371 32,359
Intellectual property legal development expenses 960 1,624
Restructuring and other charges 0 99
Change in fair value during the period 0 0
(Credit) charges related to legal matters, net 94,359 (2,444)
Other operating income   (1,224)
Operating (loss) income (11,403) 55,241
Operating Segments | Specialty    
Segment Reporting Information [Line Items]    
Net revenue 105,234 91,678
Cost of goods sold 44,800 43,191
Gross profit 60,434 48,487
Selling, general and administrative 25,196 22,379
Research and development 4,927 6,331
Intellectual property legal development expenses 24 20
Restructuring and other charges 946 0
Change in fair value during the period 100 2,457
(Credit) charges related to legal matters, net 0 0
Other operating income   0
Operating (loss) income 29,241 17,300
Operating Segments | AvKARE    
Segment Reporting Information [Line Items]    
Net revenue 162,663 122,056
Cost of goods sold 136,409 105,612
Gross profit 26,254 16,444
Selling, general and administrative 14,907 12,940
Research and development 0 0
Intellectual property legal development expenses 0 0
Restructuring and other charges 0 0
Change in fair value during the period 0 0
(Credit) charges related to legal matters, net 0 0
Other operating income   0
Operating (loss) income 11,347 3,504
Corporate and Other    
Segment Reporting Information [Line Items]    
Net revenue 0 0
Cost of goods sold 0 0
Gross profit 0 0
Selling, general and administrative 39,407 39,177
Research and development 0 0
Intellectual property legal development expenses 0 0
Restructuring and other charges 524 411
Change in fair value during the period 0 0
(Credit) charges related to legal matters, net 0 2,008
Other operating income   0
Operating (loss) income $ (39,931) $ (41,596)
XML 95 R82.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events (Details) - Apr. 30, 2024 - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Subsidiary In India - Subsequent Event
₨ in Millions, $ in Millions
INR (₨)
USD ($)
USD ($)
Subsequent Event [Line Items]      
Consideration on sale of subsidiary ₨ 1,000   $ 12
Proceeds from divestiture of businesses 416 $ 5  
Assumption of loan payable ₨ 600 $ 7  
Loan payable, interest rate 11.00%   11.00%
EXCEL 96 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,*%J%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #"A:A8$)B[T>\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O33K1$+7%\4G!<&!XEM(;EM8TX3DI-VWMXU;A^@'\#%W__SN M=W"-#E+[B"_1!XQD,=V,KNN3U&'##D1! B1]0*=2.27ZJ;GST2F:GG$/0>FC MVB,(SF_!(2FC2,$,+,)"9&UCM-01%?EXQAN]X,-G[#+,:, .'?:4H"HK8.T\ M,9S&KH$K8(811I>^"V@68J[^BM[!] M(M5KG'XE*^D4<,,ND]]6]P_;1]8*+NJ"KPM^MQ5&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #"A:A8XINAO^8% #M'@ & 'AL+W=OK9?"&^G1<].KJ\DL8;(;]D*\X5>8JC)#OOK)1*WUM6YJ]XS+)3 MD?($WBR$C)F"6[FTLE1R%A1!<611VQY8,0N3SF1<+'HG->13BB[ZY"!1I)2C'/UO1 M3O4_=>#+ZYWZ=0$/,(\LXYZ(?@\#M3KOC#HDX N61^I>;'[B6Z"^UO-%E!5_ MR:;\MD\[Q,\S)>)M,)0@#I/RESUM*^)%0&_4$$"W ?1-@--K"'"W 6X!6I:L MP+IDBDW&4FR(U%^#FKXHZJ:(!IHPT6F<*PEO0XA3$T^LN21=DJV8Y-G84J"I MWUC^-OZBC*<-\2ZY%8E:9>0J"7CP.MZ"LE0%HKL"75!4\);)4^(Z)X3:M&'3U,=;IO"7Q7'K>K'+?3^O#_ -N5$\SOXV55@I MV#,+ZF[Y/DN9S\\[T.\R+M>\,_GN&V=@_V"B_4IBK]A[%7L/4Y]<"C^''JO( MPW/*3:1XN&-W/YF0T*B62/T*J7\8TJ><2<5E]$SN>2JD,N'A4DKFIDKQT*B6 M>(,*;W 8WHS+4 2Z4Q(8%HS)PY6J;MC8#]'XEIS#BG-X8,N4#&:4HELVYQ'7 M6K H,R82#6L).*H 1VBAML/.=1AQN)UCZ$&@HG)+348BXY(7,%W9,(23R1)TH^PV]@K(H]ZI=7)F(\J"WR"V_A M'(+\P)[(30#=-5Q AHK.VMRF]TB>N=T>I7TZ&!AYT>"VO+3FI8?P3H, U*$A M;B](81@^)N:\XI(]VR:>%%D6)DMR(?*(KYD,3HSPJ%);^-HH.:@7^0^\I^^@ M83^(36($Q^4N9!@L^09ZAZF9>'AT6]C:&3FXMWD+6W7CF13K,/'-J<8U[WXV M@A[#+CFU7W)PE_,6="8R!6/NGV':/%+ABO9H9 ^-I,=P3DYMG1S<\13M=0I+ MX68P7.#,'AFQCF&4G-HI.;B]^2#\8HX4">8D]HB<]89=UZ&VD>\8/LFIC9*# MNYR'4(%'$@OBT'>/WY,Y]W,)F31"XDI>Q&"LGD+ZXQBFJ+D2_I<3DC))UBS* M.?G6/K4=DL)RN5@L&^OB&+;*J7V5@QLB<,.!GB?FS_&CB(Q5L,=1W=[_8>0Z MAG6BM76BN+G9)95V4Z$%.R;MWIA2G;$1LY<<4FSF.X(%J[ M('J0"](+-_#T8 J60AH'HSTZ4]_G( $"02EF9#V&":*U":('F:!YS**(7.1@ M4<$B&%EQG<85.![7EJ_V/O0@[W,5<[G4P^J/H*!6>GY(66).*B[8#'H,ZT-K MZT-QY[)+Y(I#(C$\7*89[Q@6B-86B.+N93>XOIK7Y\6&-_F8*S"T23%MO@N3 M[3[X]T;ZKV1TMG52JO4+-7W8LIZX]FC0=]RA.[;6)N#:$]&#=H\\&%@EF+^; M).!/Y!=NSNF^323;&5+P?D9OBP>W36SM=RAN5W;3Y768:9/[F8-7P[8\]\AU MNPX%FVL$/88!UI:QMD N[EO>,FZW ML)LI<;E/QCSB06T9:Q?DXIYE"H!!"1DQH[G;(] XQ.)Q_Q?,>G&@J&>_XIPU M([[>HRS/%JNGU5GNM#C!M.K/RX/@6Z8GSXQ$? &A]ND01CQ9GJV6-TJDQ?'D MHU!*Q,7EBK. 2_T!O%\(H78W^A]4)]R3?P%02P,$% @ PH6H6";21=MY M!@ >1D !@ !X;"]W;W)KN#BN]PPIM!CD9?R>K)1:GLYF\EDPPHJ+_B6E?"?%1<%57 I MUC.Y%8RFU:(BGQ''"68%SH(G MAP\^9^N-TA_,YE=;NF;W3'W=W@FXFK5>TJQ@IO4P*._QJGD_8[]<+C]P?O MOU?!0S!+*MF"Y]^R5&VN)]$$I6Q%=[GZS!_^9$U OO:7\%Q6?]%#8^M,4+*3 MBA?-8B HLK)^I8]-(HX6@!_S M(L(/T%WL@"MUG@5H'69%58[ZBB\RO!'Y#0 MUN!-OZER4ZV&:+)2W\9[)>"_&:Q3\P4O)<^SE"J6HGL%+W"/E$1\A3YMF: Z MUQ)-T=?[=^CLS3F2&RJ81%F)OFSX3M(RE6_1FY/KJYD",.U^EC00MS4$&8%P MT4=>JHU$OY4I2T_7SR"@-BIRB.J66!U^I.("N?@M(@[Q##R+'U_N6G#<-LEN MY<\=\?>^3'C!NO2B?VZ64@DHX7]-R:J=>69G>E]?RBU-V/4$-JYD8L\F\Y]_ MPH'SJRG25W)V$K?7QNW9O,__@C8DV)Z5.V:*LUX<5(MUN]G/ S_&,;Z:[8\C M&)KY?NA[3FMVPN:W;+Z5;<&ETE6^YCR5"/9 :D*L??A'W^T1C-T^XM#,#6/7 M]\R(08L86!'_$%Q*M!5\E2D37##X5N)&3N#TX(9F.(QP%)CAPA8NM,+=0^?- MRO5;M&8E](DG2ULW9Q!P.83#Q8[_';#!SB!./,$*3UX(#PA\<)^'1NL?#R2:GRD?]C>!S:T7#,M8"N:";2G^8[I MOI" (D$ .L_P5F9I(X9&?FPHUP'^T(AX?CC"3SI^\AR_3BLZ2P1+,W4.#3>O MQ%SQIF1@UE%,@$R7S%CIS1>R3RW>60X]^=Q&Z1D0G- +^JA#.]?S MO'@$M9,U[%MGC3J?9TUO.)!>&E&M"OG20>.UO)W&W6DEMHNE;IK@M^V*X^4^ MU,-IX(>.V[]!!CLO=K$_+G.&Z%JP>JC-,[K,\DP] M&?F'2CG%L=?74Y-91,::3">HV*ZH]::HM\)XBH=ZZ#DAZ1,:K-Q@I"A(IYK$ MKII?N()672OE9Q*Z9'_1C2#RB@*130&)7P ],RDND$<_J')Y7 MK AF"Y$M=ZKJ!3!RE+RQ'!3E PVXQU,5@4(UDYE"&$,PQ^<4*3[!H[$,#8:)P=B MU>*73@ZOY>TT?9T>$[L>WU*9);JL40I%2\51'L^-P=?NPN/;Z%P,;K;1RAGK MO9T4$[L4O\ORG1[O7\ ;_1"OT6J4MY->$EN+\UOU()6E4[J'&1JFG4.-U0\2 M^4Y)!8=$Z!7F2K,*^XLK[96\G3X%[$3>M8M\5VEU],;;Y0Y5VX4Q).R?QPQV MV"?8&3E!N)VZNW9U/ZXP&^=0L,VCOP*5S$0*4J)_SUQ>*;ZM' MY4NN%"^JMQM&H0UJ _C_BG-UN-!?T/[:,O\?4$L#!!0 ( ,*%J%A(UE2T M!@0 % - 8 >&PO=V]R:W-H965T&ULK5?;;N,V$/T5 M0@V*#1!'-UNV4EM XFW1!7;;(&G:AZ(/M#2VU*5(EZ3M;+^^0TE6;)G6IMB\ MF!(]KI9"ZX$JS(J(:,/&I<,$9:$;$D'M^3 M=Q>7Y((4G/R6BXVB/%-35Z,M!M%-FW/OZG.#,^>&Y)/@.E?D1YY!=JSO(H>6 M2+ GO6PQYRP]6M8X85G\%I7&D_^JG.0'7]^ MX*DH@?QYNU!:8C+_9?-A?<;0?H:I\!NUIBG,' 16(+?@)-]_YT?>#S8'O!'8 MD3N&K3N&?>C)+]B0WC%,H4O,&T/\K"(^9X7 M#UNQ(PM'K86C7@L_@E(WI+*SMO"2&'L)U5H6BXVF"P9$"\(%'Z28NE(PA%@A M'0WH+VVM@?K(T:&I<1R-.H1.I4)_Y-OI1"V=Z*L.M]I_6W*@C-SG%)M@"AM= MI)2I*Y./US8*D86"'PW##@>+6!0?2!V1&+E0W1UET8[-X_)9% M\T9@1_0G+?U);PSQGL);B.,U("7P] O!1L$5H_7]E_V-MT/=K*DLE,G%;"/- M@EXC:Y"%R&SNF9Q&*HR]3CA/A?QQ/+9',V[IQ+UTGCC.&:SX%R^:%@D+T^E!OXP&'MV*K[W(&54J6*)Y5/% ^WLT##5!E1R#(EZ':7FS.,J&OG=?F$1.\?G8 SP7]'^ M; 7W[5VP.=IN;T/I5"0*PN@,J^"%5=#+RL:G[AS[[/O6]M@8<&CX) J[5Y9% M:H#\SA24_S)D^+V7=C+_>J3^-Z'0<@N'GG>2A!8Y/_0GW4QT#V;3$N2J&MD5 MQF3#=3W=M;OM9\%M-0QW]N_,YT(U\[[ U-\:.+NM"JX(@R5">M=C]+.LQ_?Z M18MU-0$OA,9YNGK,\9,'I!' _Y="Z/V+.:#]B$K^ U!+ P04 " #"A:A8 M[]-C6CAH1'2C(/:VN5%&)J\QH:94[5$23NET@VS--55 M:)8:6>&3&A'&4706-HS+($O]VDQGJ5I9P27.-)A5TS#]Y2"-R@-5Q(TEN/@ZLVG[#3XPGF2AC_A$T;>YX$D*^,54V73 P:+MLW>^CZL)- M./L3XBXA?IHP?"8AZ1(2+[1EYF5=,^.S20V7[BO.K:9= M3GDVFRIIE. %LUC W-*+/I$UH$J8JH8.1NV^V!KALS(&CF9,TW:-EN=,F&-X M"W?S*SAZ?9R&EM@XS##O*D_:RO$SE1.X401EX(,LL'B<'Y**7DJ\E3*)#P+> M,'T*R> $XB@>[N$S_??TY "=I.]LXO&29_#Z9O[=RVN9JP;AV^7"6$T'^?N^ M[K7HP_WH[G)?F"7+<1P0L$&]QB![\VIP%KW?)_T_@3UJQ+!OQ/ 0>G8GR5X$ M_T4'K");@2-!1^D8Z [GS-10DI% C46%)R#1=\NRAWT=:YWV(NF#&\I//N;8?8/6$-5@$R+;FLS$L*1B\J.!31*@AW M+GN#NO(>:"!7*VG;R]*O]C9[Z=WER?J$[+=URS\PK7?35:BX-""P),CH])Q8 MZ=8/VXE52V\I"V7)H/RPIE\(:A= ^Z52=CMQ!?J?4O8;4$L#!!0 ( ,*% MJ%A;E+_E$@D -DO 8 >&PO=V]R:W-H965T&ULM5IM M<]NX$?XKI)C.V1;SQ)6=[)G'NVLQ<[CQ)KOU,4Y#%"4GH2$J.^^L+4+) M$@M(2GE?$LE:+)]= /L\"_#Z2=;?FI40+?I>%E5S,UNU[?KM?-YD*U&FS95< MBTK]LI1UF;;J:_TX;]:U2!?=H+*8DR (YV6:5[/;Z^YO]_7MM=RT15Z)^QHU MF[),Z^?WHI!/-S,\>_G#Y_QQU>H_S&^OU^FC^"+:/];WM?HV/WA9Y*6HFEQ6 MJ!;+F]D[_/:.)WI 9_'O7#PUO<](A_(@Y3?]Y>/B9A9H1*(06:M=I.J_K;@3 M1:$]*1Q_[IW.#L_4 _N?7[S_T@6O@GE(&W$GB__DBW9U,XMG:"&6Z:9H/\NG M?XE]0%S[RV31=/^BI[UM,$/9IFEEN1^L$)1YM?L__;Y/1&\ 9HX!9#^ G#J M[@?0+M =LBZL#VF;WE[7\@G5VEIYTQ^ZW'2C531YI:?Q2UNK7W,UKKV]DU4C MBWR1MF*!WJ=%6F4"?='N&G2)_OCR ;U^]0:]0GF%OJ[DIDFK17,];]63]?AY MMG_*^]U3B.,IG]+Z"E%\@4A &##\SC_\@\@.P^EP^%S%>PB:'((FG3_J"GI3 MUZ)J4=HT*LZW4#P[!PQVH/?6VV:=9N)FIC9/(^JMF-W^_6\X#'Z"HIO(V2!6 M>HB5^KS?WJ7-"JE90YG^(/[7%_E6U:G QLAZN1&M%9>T%JD0+@8XM,(PF,>8C MS( 9BWCD6!') 7+BA?Q/*1=/>5% P!)[#28Q9\D(&&@6D@0&A@-#-L&1C=2F MU6/^4(C]C#LSN' &><<1PYXAL&PES3VV\<#CUC/I8R'U*J7H&%$>.B:;$,\F)[$LD6>/N1% MWJKJ"5(M]A+8N5P[E;=AT(;%L)_&7H)>R[J3J7+9CQ\IW8T*\:BF3BG05M3P MW-D<1@-,QS0,F$5A$L>.>3-DA_UL]UEL9;'-JT>4U6*1MVB99AK_,XC59C4< M)4%@@3UJ-T1KZ _[^0]*N*P>+U5R2Z7G']Q%&MN\1FD86L@!,X:)@_ZPX3]\ M#@'V%@F(U::WF#(:CZD:LE,2+G&A-32(_3SXZXDYM2F-*!J. JOL0(9QJ(C= M@=2P'_;3WV^R%6B=/J>:92Y5JUETO%GL1"B['9'):M+G8-:%H6N]WFE)E+U8?#\ M47L#1 $9"S+(#)/$H<>((5;"O&KB2RNS;RM9+-2V^ =Z_4$L.0N%G#XX"<*3H4M ,9,ZS49)LW( ^*7!^\62L$H7: JE6Z3+_,* M9>DZ5Y4+!&ES/:>J);:00G8)82ZX1A00OR@8KO(TRS;E9L=?BV[!@Z1+;-*_ MY#&.L<4#@"%+ ARYN,#( ^*7!^]Z2/>'#[)4NV"E#WRW0K%$ Q<56P9<*L& M\1@Y8$<)98XFA1BU0/QJ84=B[\I*J/_NUM'F6%JHY_5AE5[O=9BK/ MHE=YA+ORV'+A,J01&1]; '8XB6(,QT6-K*!^6?';.:6=VOH@&9]5 #:$.M8[ M-1J"GJ(A?BC#U)8)*L/]0XH]<$!.! %V9=B("7I*!]YO[G1!_+%03FW604-/ MLTY[I\3'5,%N\]Z[9+)__+E4.I6W8;1&3%"_F#CA H!.*AVF\C:,UT@'ZI<. M7^MT(32=R(W6OK5B[7RK):"SD:- O\[)N"P#5@EW])K4<#;U<_;O:U&G6IBK M9BAM!*KU5=RE7%YN&N$Y\J(V*6/"PG&+#)HEW-%W4D/=-)KDN(MZ%<#9"VLB M;\.@#>_3H[R_6U(O#;>N@6J=U5H\OEQ)@%FP"1U'062QCFT64>*JW8;UJ9_U M@4,C.5IT_<)^PBD"M7FPS#N$]\^,, .4U6_ M'&O2T#GST_D/$B2SV9J2)!HWMY!90%V7?\S0.O/3^B]YE5;9^:B!7COA=%Q: M03,2.SH49FB=34/K;%):G\K;,&A#Z^POHG5F\S7G,<=C$0;941:&KJUAF)U- MR>Q@"#9')SRP @"L2.#@1FZ8G/N9'("_'&V;(_ Y<-9/@W%I JR45';!-]3. MCU#[>:GFT)5 %(\O!" S%KCNM+BA=NZG]G%!.H;6;KYY' =CV02:\= A1+CA M9>[OT,^43=P^AR>,6U=#D%D21HYBSPVK\B/WX+(LU?J]*U1A1^] @),VV%-Y M&X;;>T&,3W\[P;TL?W8&)O(VS(!A=W[D'GXWX=WY%Q@L<(T>V%L=LG+N'4/B MW'^L/EB-[T%XD]+W5-Z&X1KZYO%?L!J]DN#L#$SD;9@!(P/X$1EP;#7NAO?? M81W+8*_)#M:\]]ZU?NG]4UH_YE6CZ&2IQ@17D5K']>X]\MV75JZ[5[$?9-O* MLONX$JK]J+6!^GTI9?OR1;_=?7B;__9_4$L#!!0 ( ,*%J%C/%>;A\ ( M -(+ 8 >&PO=V]R:W-H965T&ULM59=;YLP%/TK%INF M3NK"5T+2CB U5-/V,"EJM>W9A9M@U6!FFZ3;KY\-E(:&$-*U>0C8W'-\#G#P M];>,WXL$0**'E&9B;B12YI>F*:($4BQ&+(=,75DQGF*IAGQMBIP#CDM02DW' MLCPSQ20S K^<6_+ 9X6D)(,E1Z)(4\S_+("R[=RPC<>)&[).I)XP S_':[@% M^2-??(OGAJ45 M 85(:@JL#AL(@5+-I'3\KDF-9DT-W#U_9/]2FE=F[K" D-%?));)W)@9*(85 M+JB\8=NO4!N::+Z(45'^HVU5.YD:*"J$9&D-5@I2DE5'_%#?B!V /3X <&J M,Q3@U@"W-%HI*VU=8XD#G[,MXKI:L>F3\MZ4:.6&9/HQWDJNKA*%DT'(,L$H MB;&$&"TPQ5D$Z%;3"72VQ!PRF8 D$:8?T2?T'IE()&I6^*94JVL.,ZI76E0K M.0=6^H[Y"+GV.7(L9]P!#_OAUQ U<+<--Y7GQKC3&'=*OO$!OJ5Z78!SY5K= MX^C^'.68HPVF!: SDJ%"Q"@'7KG]V.6VHI^6]#HLF\ :6;9O;G8]'2EJ*7<; MY>YIRJLG@G A$\;)7W5!.ZAF.Z57_),=52KU^O=,_?&ZEH%Q8V#\(@-$B.*X M^/&>J.>R^RI:@B>-X$FOX)"EJ?KDA!0+@:ZZ1/7B]:?X4N0X@KFAOK4"^ :, MX,,[V[,^=P7AEV,N+*LS M$D,J6PYFC8/9Z0Z&)6*VI\FU9I[C[JOOJO0FWN2@^HM&_<7PA"RZ1/;B3TW( M*Y&UK-K6TY9IO6%&:O(C(3E6U9:^L]O;;YF3FKW] G4'95!IV\73UFWW[]W_ MD96:N6_[Z"VI%)L[#9?N=E5OLR:90!16"F.-I@K,JP:R&DB6ESW8'9.JHRM/ M$]5T ]<%ZOJ*,?DXT&U=T\8'_P!02P,$% @ PH6H6*NN-V"R" _B4 M !@ !X;"]W;W)K@+%($B-BM7VR).@"_<_W. M 7GY).0/M6),H^=UW:BKR4KKS<5LILH56U/U46Q8 [\LA5Q3#5_EXTQM)*.5 M7;2N9R2*LMF:\F:RN+37[N3B4FQUS1MV)Y':KM=4[F]8+9ZN)GCR_?$"_(-Z@;RNQ5;2IU.5, P:STZP\W.^FO1\9N5^,OHA&KQ3ZW%2L M.ET_ ^Q'!/V=,8;6F- MMI1BC2#?)-6\>6P#EFO.U(7/;.VVB7];D\P7:D-+=C6!;%5,[MAD\?>_X2SZ MAT_G=]KLQ +)T0)):/?%'U![SFJAU <(E5*LF4_;=HO,;F$JS6XQG>,LGU_. M=GT]/&(XBHKD*':",#TB3(,^NJ[^ XG5QKD64(Q*T92\9J@!Z :YN6H^E\:9 M9UL%J<&;#V@CQ8Y#U**'_>O]FKZG7]]ILQ.K94>K94&_?F*P:EO(%: M*B5KRGWKX+-'8+@//M2Y@P>G& ] NT)37,QS/^CY$?0\"/JZ9T]3?ROVH!%7 M:DN;DJ%2* A78_>*JU)L&^U#/W> D?G0XAZ9*)W[L1='[$40^^^-ILTC?X D MHDI!ZO#UAG)I<@R5*RH?F9%$1[NP*PS##9$D"B M':VWS%@!%R78Y&]^$6)X$2#;%[A$B2CL0)[G$V#N*_UZ+\,37= M2P5 U]#2J7&5ID(T!)!Y3\)"QV8$PA]VWM5&,8B6LF4A@^ M/@7I$4M)-,(&N*-L'.3#Q3_UBLE>13\$K$VV4K**:W5N^, +/7;#@*1.'+A2 M@'LL#CJFQ4FXV;!QK$P@VZQK(=>Y$FRN'B[3(QZI/QZ,X3*0O2<']-1&[ MC#C%A+BUQ2-'(/1&*CGNN!.'R?-.,JC=%6+/IK PB'UA$Z1E4-T/M?:']H)7 M%Q]1XCP:4I)'CA00(R.J=(R*PY3ZE=5VL-E0J?>]X/"#=8EQFF9.I72EDM&8 MZ.@3A_GS^B6 -W3?1B^$M-RRS@L]>_<2W*N'RY@9P7DR5,05FT+CE7.J=)@H?I MZA'#<9'C,34ZCB7D31,GA_*B7C.9D"!WOY4'WFNW4RMT'$["''ZWE4#;)D^@ MCP,W@O/T_AQM:FHJ%J0.^W/+-Z8?]9K"Y>=I 1W]T(<^L6P^4G%)Q^,D/#)? MEP!.\9?&GP^::7_8)1XLN<,2/K$X'D/H>56;Z4AX1,M MWNX$#S'/G?KKD\)Y;T([U:AC91)FY6,U.!0#;QYY8?OXNL@SQQ,^.6@[1KI MTO$UR=]4 ):\@8GQ-04@V >\N0"\TVZG5NBHGH2I_H[NCR>7&\G! !M:(PA% M,T:? _?O1+VSW;WMZ&'R*P\<>MZS6,WH"==ZS>;I$[(XSO.APSUR.F2RYLL.W,D,ML*ZI'U[DL6>8'E9HC\P8Y*Y/B,-]PN?UIA9[QDPG(T5= M(TV?T1/7JY6H*V-WZP2E)2]-U]/JL6W $X<"XE7&TS7D! ^KG4^,1&2D:8B[ MIB$.#^;?0(6*&\P/6VMP>^0IFJDY C%*&KV AYA1S.\-=QB?IL6PR?1)X3G! M(SD0]X[9PWSOE&M?U?/B]G XB7$Z;#I]/,0>Y*Y=D(R\0=X\=AQK?'^A6#&@,5TA[MVT_& M] ;N>>L-0_ [6IM"?&ZK:"\Q1K7R,'J2)\6P)'GD,$[GR5@R=-0?AZG_]O7X MT10]L$?>-#;O@6F8Y*+R:N72?5'@:$@2'K$X)63,75U3$(>'^+?IQ S?!;5Q M!_049]C1QGMZ'F5CZ=ZQ>QQF=]OCV/.X@4:O N\9V;/4.6CVB.$DR?*1\\6X MX^LXS-=?_P=[N_2;1H5C;L^D'_?&Y]/G=QU')S\Y'G_?V$D\0[XG=CQBH=A) M.OY.<+ _OM]N-K5]K T-H7EX4@MEYA5SX/_2.D,9:U^) "[T]LI)L$=X:Z_\ M7KN=6J1C_R3,_C:;[!F?&=]>:-ZKMLO?69+B(FS1K)A_M"T8*V M[.P%+<$6-Q2IDK2=]-7DW5=;]_.9M5RS39)]:;8LIQ_713W=9;F[$.I5?>;35)^>\^RXO%R8DR^OW&=WJWKYHW9 MU<4VN6,?6?UY^Z'D1[,#995N6%ZE1:Z5[/9R\LYX&U.WR="F^"UEC]71:ZTY ME9NB^-((A/][8'.690V)E^.//71RB-ED/'[]G1ZT)\]/ MYB:IV+S(?D]7]?IRXDZT%;M-[K/ZNGB,V/Z$K(:W++*J_:L][M/J$VUY7]7% M9I^9EV"3YKO_R=?]A3C*8- 3&<@^ Q$R$/=$!KK/0(4,U#N1P=QG,,_-8.TS M6&*1G!,9['T&6XQ@GLC@[#,XYQ;)W6=PSRV2M\_@M7+8U5];^8ND3JXNRN)1 M*YO4G-:\:!74YN9UGN:-V#_6)?\TY?GJJWF15T66KI*:K;2/-?_'E5Q76G&K MS==)?L6+5UJU3LI=WD_KXKY*\E7U6GO1.[Z8U?P$FF+,EOO"OM\5EIPH[*>B M3C))MKDZV[S8;(K]26C[@WF65)7V3@);C(#]FJVT#_J)X M1Y!?ZS4KFQ/FS?:Z:4\?F!;GRV+#)-Q8S?VER*<D8N4#FUS]^(-AZS_+;@(D;+>VL>6 ^ M7!F687KZQ>SA6-.R9,0PG'ZR %FT$ F+D+ 8!.MIDAXT2=6:[-V;;-SC2G6IYWC]2ITKRS-6;Y*87&^"VF2)FE/H:6V8R/8,FPBE#X?)IJ9N M\Q/MIXN&Z3R/"K!8 C,,TS2[LO7JU#S4J=EFI"?JE#=^O -;L>8ANWOU2GP: M__3].?S/:][0:;P#^)B4JW_)JM5$-C9(V ()\Y&P D+D; ("8M!L)[(K8/( M+67#]0L?T;W,BJIJM'WB8?_>&CQGIH9E4T-HDI21QJH2"?.1L )"R67UO9, ML1E$AHPE(5W;=>6-I7W0D:W4$6_Z^,@VYX.FLFQ&(UI=)GG%>Y;MF'KU;SZ6 M:H4IM\:X:]6IU\Y9\?#4IEDE669&RW$ E;N,-6V14?^3XR8H"$ MA4A8A(3%(%A/VMY!VM[?)FV9G#U)3]'S+*$)5I9QK$X]R7A94"DR7C \1<,4 M>RLA,F(TC&@+P^Y8?CWBS]D\OE+N$-V7ZDP+MT MRZ1::[<9!Z[9ZHX=I,.5(9U9UB7",(DCS&C-U>49*PTHS8?2 B@MA-(B66TY M!A5NX_C)9'W5'9DBAE)UGY*OVBIM&JJ;^Z:K5[7JDLK*&): V*[NBK)2!APM M*R3-A]("*"V$TB(H+7ZZ[OORZ^P%0^TO7+-E8_>DM^ER-WSES9K0W#5/1):4 MS=QN==ST-?]>Z%*E#N?J!VT?U$* TGPH+8#20B@M@M)B%*TOY&;1T(90606DQBM:7 M9F>N&,II;;EC)@CU+'&:PXJEIFT/N@!0SV1/ZYMAE(BBDZ4:6&:2,W!TW1'3 MA9)T4].@!A%F=2))0NK8IMA[D^ ,RW-,^\0#M+,4#+6G<,U6C&V2FXQIS4( MZ3J U\]T1XWA[#4Q/5-T1]4E'%W;4#,"2@N@M!!*BZ"T&$7KJ[HS. S[.7;P M)[;9%F52?CO?"C:0\_)S*&T!I?E06@"EA5!:!*7%*%I?ZIWE8J@]E[-,86/H M,%@6%6T[=:31ZH3Z+5!: *6%4%H$I<4H6E^=G3MCJ.V9$=-#0P]C2CQKT%F M^B90F@^E!5!:"*5%4%J,HO4UVMDLQE,^RSE=X.<,=X8S_<2QR*#9A5HL4)H/ MI0506@BE15!:C*+U%UUW7A!1>T'/678ME; ZSNAUUT,3@NJV90MFQ0(:U8?2 M B@MA-(B*"U&T?H:[IPEHG:6GK=,6Z[BH?U =-T0UT3ND]E]>=JB.*&.$I06 M2$[4HAXQ!?LBE*2;FIYN..+TE"PA)52?%_\K*9C0WB&#_B#4W('2?"@M M..-JA-"($906HVA]Y766#?G_V5&C+LKHQG5H(1'==,7F%>KY0&D!E!9":1&4 M%J-H?9%WG@_YW^ZM(9)-'@ZQ!J.GX888,N@.0 T=*"V0GZ:X4R2$!HV@M!A% MZW\52>?4T+]IUPX=>BN&98G3%G-U<<9V Z T'TH+H+002HO.JZP8%;2OSNTLXGH65\R M=O[."5,J3*@]1(=[B*CNVD2XQ1?0J#Z4%D!I(90606DQBM87\-$7DCWC&\G4 M"X[D$I:X"#8=?*/7G Z_A:L1IRA-J.<#I062,["HZXB=YU"2;FJYAFL(ER22 M)234$=<(Q))TW@F;AG8V#57;-*!-&-*U#W1H#9@&\0;]0JB/ Z7Y4%H I850 M6@2EQ2A:7]6=WT.MYZS>>,8F#(IT(N90V@)*\Z&T $H+H;0(2HM1M+[4.W>) MJMVELU9N4)GW8^CBG) ZU&AY0LTD*"V TD(H+8+28A2M+\_.3*)J,^G\71AT MZ)U,3=X-$C4*-9.@-!]*"Z"T$$J+H+081>MKM+.=Z%.VTU_?A2$?%+F#'KOI MZ(.U).KBC98TU&2"T@(H+832(B@M1M%VDIX=_79$\_,F7'E\0%9I&;OE>/V- MPUO-+(;N#NMBV/R=Q4]1UL6E?KEG"!_E- O[Y;5'4WP^:7Z@X_&[+U7\ M4$L#!!0 ( ,*%J%@,/MM2B ( *0% 8 >&PO=V]R:W-H965T&ULA51=3]LP%/TK5V%BK81(FK: ((U$"]/V@%11L3U,>W"3F\3" ML8OMMK!?OVLGS;JIE)?X\YQ[[HW/3;9*/YL*T<)K+:29!)6UJ^LP-%F%-3/G M:H623@JE:V9IJ7*>)6EO!)>5E9MQ&FR8J5N$#[M)IK6H4=2\YKE(8K"1J+27 [N)Z.W7U_ MX3O'K=F;@\MDJ=2S6WS+)T'D!*' S#H&1L,&9RB$(R(9+RUGT(5TP/WYCOV+ MSYUR63*#,R5^\-Q6D^ J@!P+MA;V46V_8IN/%Y@I8?P7MNW=*(!L;:RJ6S I MJ+EL1O;:UF$/$,?O .(6$'O=32"O\HY9EB9:;4&[V\3F)CY5CR9Q7+J?LK": M3CGA;#I3TBC!#R!NY? MUMR^0>\."YYQE-E;'WISI@E>H>49$_TDM"31!0JS5LZTD1._(V<(#XKP!NYE MCOF_^)!2Z_*+=_E-XZ.$#TR?PW!P!G$4C^!I<0>]3_TCO,.N;D//.WR'MRN5 MJ]1^>3[O"O/S=FFLIE?WZU 9&O;187;GQ&NS8AE. K*:0;W!(#T]&5Q$-T>T MCSKMHV/LZ9,D^PK^F_YX2;:%GE#&]($\DC%304%&A0KS$L] HD_0LM=#231A M+GP8Y_Y-&B7AYH"R<:=L?%39(V:"&<&G7I^X.!3*VE;4S4[78MZ+9QWM_K3?^BEU9R:4!@0=#H_)*BZZ8G- NK M5MZ'2V7)U7Y:41M%[2[0>:&4W2U<@*XQIW\ 4$L#!!0 ( ,*%J%@A@#3: M>P, (\' 9 >&PO=V]R:W-H965T)"D1IYBIO]^MU1LI,,2=!^ MD7CDW&AN624/4':=I*!ML59BX#BVO;)UO%;'IZS1T M'E45@UJ3YEGV*FV5MLEJ$>,A]&VK_,T9&K=;)M-D/_%9UPW) M1+I:=*K&"Z3+;N/92@\HE6[1!NTL>-PND]/I\=E<_*/#7QIWX,:C1$@IO'/B)DJ-_39[=[AF,]+P2N="?$+N]$W2Z#L [EV#&8&K;;#7WT?=?B1@'P, MR"/O8:/(\C=%:K7P;@=>O!E-!C'5&,WDM)6B7)#G5O-#>O.GT'^XBC^/ J>M199ATRB^ R7VI$MEPA&/[L39YG M)VO7=LK>1&MZ\BOH IJXPJ.[NY%0SFX C6*^ I=!-=[^&/TAH"UG('H%SJ4DT$W4'@E MY_U_Z84)_,FRC'J BUHR[\XS&]TI8VX$7Z2[M)HX/IZQ "]&)2\G%Y.]C")T MI=7 \-RCX?]@<&:VK_K9RT1GWY6:B M4K2]#*"X8GRM%)^Y:9;](D444=B]Y5O8LS9!YAX[@>_?KP^2#3Y[T28/7:GT M3I-LT=?Q*0B\6V]IZ)>'V<-K;S"B2+#N;E^T9.8\VTTGKB>/V0Z+Y<^+U4M_<(VRN#-UKI: M!CRZW=(W3LF"A>IJN5ZM?EG64IO9^2E_=^G.3VT;*FW4I1.^K6OI]A>JLK=G MLZ-9]\5[O2L#?;$\/VWD3EVI<-U<.CPM>RV%KI7QVAKAU/9LMCEZ?G%"ZWG! M/[6Z]:/_!4626?N1'MX69[,5.:0JE0?2(/%QHUZJJB)%<.-3TCGK39+@^/]. M^QN.';%DTJN7MOJ7+D)Y-GLZ$X7:RK8*[^WM7U6*YS'IRVWE^:^XC6M/CFI3R,!)ZNOB*P3@)K]CL:8B]?R2#/3YV]%8Y60QO]PZ&R M-)S3AHIR%1S>:LB%\ZM8#&&WXDKOC-[J7)H@-GEN6Q.TV8E+6^E<*W^Z#+!' M4LL\Z;Z(NM=?T7TLWED32B]>FT(54_DE_.R=77?.7JSO5?A.NH4X/IJ+]6I] MB7U8M[O#WIO3VY3_L/ENJ/TBTNI->>%EY2B"9(GJX/I<*$Y;9NI-G3 M^M;(MM!!%2*WQD.XD/2PU4::7,M*>$@JC'?PJ(75R<+!Q&HJ;"BY"-L"?:\/VK\@0>[RIE4-@XL'/ M/SU=KU:2GX]>/)P+7]JV*D2F!$$<:8+[O[8F8@B[0:I?QD!) M[NC)"R^D,2UBZD(^%*4 @K+L7DDG%(V$>*5R56?*=4U]#(-YU18Q_D.&>-$F M6GNO&NN"@%\$4.)H]>AO"_%2N0 LAGQ$;(8^ Y>L#<8&)0KM\\KZ%M43AI90 M0L=F4RP'8RCEC4)RE!&VUH%#=;9F3W]O]1?B;0S5-MJ0MRA4+0UV!'H]_R'= MM(*S@2"%+'X%GJ:.(U'MN7%@SQKD("8#=<];Y^C%1,"@5-[3C% =I=A*[09+ MI.10N0:G&NMU+ :W(J ,'=]A&?R1OA1;;)%#GX32*27J"*&Q7Z927%=N"/J' M1%!3[$9L0--'@WDAH_!?#IZ+K(4=R\T?NK[G_A@/AJ. "8:RO>A18B%>WQ'N])&W3<'0,AU: MS:K5T+D=0'4(.NT5ACVO6"O0!2K^3F.Z7HC? ,JISW\ -ZZ](D.O,1,U!T6E MBF@<000O#XY82I4?F_VS'XVP"!9/'Y50O6YJ".E!!!ON3HBBZ'*[!55+?4P> M3H9ZF)^XA#+?9?*@7\-,)%VCX1@&0Q0MS_JPDDN%3K,%50!M_'6W#WDL:RH. M6\%211U7:9GI"MXK/#AUHTR;E*D[D&M/7]/3T( D326%+Y3 J(C7C'1UI?XV M"K+?8PBE_O1Q&K>V NHPW%$?VEK%$:'IP%3,R14_2,$'A$RTZ21U5SI&PFU<_K2M:J8EF"<0Y*LU [Y0FR(*&X-7>(G M8MB= B66?/5MYM'WM&82TDB6=Y@B]1DY93'"_[TW(D;>1W3(*!BKT1O\ZHN\ MH86"!3(D]/3SPR5IO=JV%:*X29$VSA8M.M;16648$ 0 -Q34A_<;\8!WC6T'C RL MCXEP(+M8(>^0EX<4\Y]6BZ5H00JELT.\ MAI:FO#5C_GX(2T8(,L%, @[M1Z&DRA2ZB)LJ"DZP: -*'=.6@"[F#6FC#^(? MB^\J)_<5]?;]HYL*>?Q=A3RL,Y*S+^C'-PHX)3&?5>]^EQ^Q(X(<^>,*-_'G MMY7K<%JHT>/KX4L>3;B![+[%G@BS8V+BK,'_>6J?MS1[-S&G,9_D\YM^KQI) MXK1F"ND*'#0M/L0#6IE2^69S==$=U83^PF@G*JZ9E_7'O,W5=2]%UA^MGLS% ME=KQW+SO-_T''W "R<7ZZ>KA<_$63)D\9O=1AKB,9ZZ3?#7BBR-3G8GA3!E/ MMZ0/^X&G?$]4NT&U3ZI'3"#1JT1>,2F@A!HY!^C8=H=MV914ZV)"7V5FL87[ M$6GL-'>, U \N#IPN+$2N-;18T8Y'=)&W5.Q1+_R4JL>'Y#(0N6:+^V(];D^ M-R__\>K=Z*!]CW.)#W+TN[:2-,$I??W,D3;L[S#F;SI\XW)U"G 9J3QS^ MRQQ'RL7\NR@X')I*P"S'3NRM6]ES:+BPU0Q??'3B/3';]]Z@SL '"KZ@+)3V MEGPEEI)3-T*M;5W^>>IEY>V0?SZG1I8^+D4"@&H_.9CT_4IV,C4!.7 K@$6= M(.,SFT #Q=25CH&$25O8@DFZF2"8VVECF!%NH61 PZ/''1KRJ7%J@>]&8/@W MJ<+!EZ]4%)=8%C;6L2$:$^))KAB2 SKIK&^2W[)IJ@[*8IXG^XCO8'(X$QV^ M??@P.HKI<:I'7(=WZ023A*6[5G?W4C#+ER($Q?'"X3NN._H\C, 0V-9C6E^K M9_,I64D8]>3D$$8-*[^!3<\^QZ8$(O$,%YPTGB[A<,KG D0:R7R5V2=;(2(R M:M%Q@ST;GPDQR$V;H5(#Z86_:5NARZ:NWS.^5TPJ,::H,^&#H.'963Z/$MZ+X6B1G!@#VO:MZ7XU$IR37)_$:OS= TR#>W' M9N>;#<\GF7LNX-A=;CC:NO=PFUE):AP(UY(R<"-UQ6C'!!POJ;S__UX_=.N] M'/U8 7*VXY]D^"A@0OS=HO^V_]5G$W_L&);'GXS LI%N#TJUA>AJ\>3Q+!YM MNH=@&_[I([,AV)K_+142Y&@!WM.E:/= !OK?PL[_!U!+ P04 " #"A:A8 MXW>%O<8& 5#P &0 'AL+W=ONF;T\;.T#1$(2-A3!!4 IVJ_/ 4AQ M.(X\FSR( D%TX_3I&W![5/H7LQ/"TJ_[NC%WLYVU[?OYW)0[L>?F6K6BP9>- MTGMN\:JW<]-JP2LOM*_G41!D\SV7S>S^UL]]TO>WJK.U;,0G3:;;[[D^/8A: M'>]FX>P\\2BW.^LFYO>W+=^*)V'_WG[2>)N/6BJY%XV1JB$M-G>S9?C^(7'K M_8)_2'$TDS$Y2]9*_>)>?JCN9H$#)&I16J>!X^\@5J*NG2+ ^.^@-OT__W7@82)0!%\0B :!R./N-_(H/W#+[V^U.I)VJZ'-#;RI M7AK@9..<\F0UODK(V?M'<1!-)^A1E&K;2,?4[=Q"L?L\+PJE_!R 1E31&=5#]*K"CUQ?4QPRBH(H>45?/%H9>WWQ_[%RH]6> M5L"J$0U@VNYHY3D6FOZU7!L__^]+!/3ZD\OZ7>:\-RTOQ=T,J6&$/HC9_3=? MA5EP\PKZ9$2?O*;]C_KH5267(5[03'_;"5"T;WES0M;Y^?\)@V&_5+I,*I6N M>%.*GL(EWKO&RF9+3Y8W%=>5@8I*;F3)>YVJE25E0<;HHBO,2U\8NOKFJR** M@IOET\J)^;?PYNWU*"[-,[B*CCO1D)T A];&;)RFTFV!M%(;DMBGU:KJW(96 M>8%RV))!ARQW9$] RNOZ1*HL.\AS2YQ:)1O[3C;O+ H2(P&PB)BNA6EF)UL4 M*4M*HQK4*#'Z=$U/'8*)@Q.O"@^W_P2@,RC,;PPUJ+L#MU1< MB]$D#7L_ W\!Y#7]*$O43D'+K1;"(30@#_).^">%;9)K6M:U]'Z$UP"MKOE: MZ=YEJ/>TZ;0W5#9]]>\+L)?6 PH^HKAV7L>D'38" M,6>GNM#; (4ZNEBR?%V+H5M,0]#TL2,XB/D"J^482#U_LJGD059=[XT^7('0 MV1@&7SO7[14H'F+$*LOKJ6?> QG@OZARA!H%S>(R3 M#Q2F> ^3Z>2*((>5P73R V#A?8'?!VGX%N1M/:=3ICXWVD@XP:4<@M&YC;>B MLTB[LH93'&LPTYGWG6B$EJ7Q3G]J!=Q5VQ,9L>VCQ$T;7D.BW/&F$?6SZ/+P MU^7CM^>E#-Y&S%NAT9@ SG7'BN#2"75>U+G(>@;W/8/B$H-N7\;M'_;(:.P2R8CDV A_#* WE+$0)+^AE(5Y0M\CP%4# MM\]=M@J]/<$%.3*A[*+%WT /#(G8\4> M4@N6I!D5"4N+B%8HBE(=N"F[FNOSHB1E15Y0'+$T %:.!J2@3J!@*8>@8.$B M1\"P.$OHYZ;LI^."I7&,'5@*X8\"B:*09U1)(^ "F !^5:GA% I#%A8I+5B4 MI8@>T\( J_3)?X@S"B-6("H_")??XZZ+/'5_08!=?06X%$]8D()AT% L4OK! MP6Y\2H,,YTOE)4.6(Q7B($03<&DU.F0:)/$B9-$BH3@!M4$VB,101 B(RED-A;\0S MOJD589"R*$X(QF1PS) L2&"KY;KSQ@4B*V&+ M-'*VI6$&3HV5MALXA;^+M* "P1<-:',6)@'P)4DQ(!LV?0$KBU@&IL(H8D%Z M-F&Z LF0+A!JH4N'-&] ?7J#LD*MK5[]L"=!.BWETS MCDB5F!FZ'5F-^5EO& MN.)FY_SG^X4[YN@.NL[_#[SNN;!(GU+LU[!LV"'V1").$0UO4."1(1$&2#B6 M%!E&BX!EBX ^:760YK.VVM=>1YIVT&5_LFF1-:JBHDA9C+82!RS(X5.$.5I' MAO3)0UKA;( R/6_YJ2_ETAB'M.JT;ZC/:JX613HCW5_"^A>K6G_Q62N+MNJ' M.]Q;A78+\'VC$-;#B]M@O G?_P902P,$% @ PH6H6 P@:%FV#0 QBH M !D !X;"]W;W)K&UL[5IM<]LV$OXK&-?326VES2Q)>DO5YO[@-$0A(:$F !THKZZ^_9!?@F2[+3WMW0+IV3*@_+L:')\?':42VT.+I[PO6MW\<169::-NG;"5WDNW?I*97;U M]&!\4-]XKQ?+DFX<73PIY$)]4.6/Q;7#KZ-&2JIS9;RV1C@U?WIP.7YT=4+O M\PL_:;7RG6M!ELRL_40_7J5/#XY)(96II"0)$G]NU#.5920(:OP691XT4]+ M[G4M_27;#EMFTJMG-ON;3LOETX.'!R)5TY)7F(SS_^+57SW M^$ DE2]M'@=#@UR;\%=^CGZXSX!)'#!AO<-$K.5S6 M#>6TH47Y4#H\U1A77EQFF98F44*:5,"T3,ZLD^2P)TC#BZ^_FI\=OQXCWDGC7DG^Z1_ MX5K^45GBXU+A3EY(LQ9+Z06\HIQ*A3:E%5[=* >'R3A^()+NX('(=(*4QOU4 MPXUZ5C7>]SK7F71"+IR*OE[INNE1^Q*4D3!K#!M^N,.0!]06T/XY*L M2A64N5&FHK^)72"6,*9"M/>T+O7ZI MDZ58*$.KB4GL+-,+^*9G'%3 $MQH^.7]US(O'C]O5\%"*9$#&W61*0%':IM& MC\?A7W_U<#(^?^RQ\-!HCK4A%9R39A&5D$Z13P"#'OK.J(*,Q#M'WGEF75$' MY)L04N*R5E^\,^*Y2E0^@PZ3AXP?DX&XS(W"^M-T$"=%9LUBB*7)ZZ!L'1#\ M?7NJ!Z3TY/@Q/^'K\>-O!I"UR.PL."K$#!85Z&&T7VX/O_6 X]GFN7*$,%@1 M2#$5JQS#F][,U.>P"CIIPQT9D%M?'B(KU$#)OH-['7RQXM&^2J"!1TT7Y'(E=,A!4LDDH13K5&L$SV4Z0V!V$@\ MKQR]-+,,+90%T!&+P.5.4;D3*%:07%3YL8*.I+Z+N51(%2)K0Q#TEK.LE J<--5>!ZU#DMO M>2&ZZ29G.H/?E1_4\(YUS-:ULDWR1GW)B]L4/A\][.M[TC'@OZCOIG.-;6-_ M*1&A,Z4,0J\H,DU(MJZQ:,^RO2=[:;7?6L#N*:;:79*I)%8N>.K2F J2WRN M%D6S(/8JQL?#UYPV,DTUC>'H#Z0>OP"K;[][\?;CWS^ C9R?/+X#4T_#JO1# MNU?FY"Y,O7IU^69X#=40SH)#7#R3HX'X,+H<-?!*+]6PQ%K3/.HS2C#GN[-K MF97KX9R2T#&*8,I03MD[32%5FW8]L 60!*BEOB&OD=P?1Q]&5/@=XX#MF#E^ M&*./9"++(TXPA)38FJ!*8EEK>&XD"R\!0 @4B?=JR@*^ERJ*)DW%A_##+VV6 M^AXRD]VW7=\"](8QVHO:4UQ($7.%TPJFH+Q8A,HPE3K#-97?8AE*^9 V0F8Q M$$LX#C_C#@EN322Q!YL-WPUS52[7&6J)\8A"['K@K*6>Z9(BJ*"B'\*8='_Y M_))<"4<=,XP1;*9# C%XH.25IU(GW4RGMI!'X"N6+FA0@>AKF=XU5E"#C9G& M(BRDHMDI/6$9R#B6H"YC\WGTC%"%]C8E1O=CDU#LR\:'_5#5GM,8Y$H3$%"$ M=4MQNR-H*1JR?-/[G?"A=WG"+9)S::HYG!Y*"%-5 H)UJ'E]-<&;O86$WRH- M,9MD"\!#D$7[0)U77)X/ST;'#>(1+U ILXR^\KSW9?R"1X&))5?2II[T#>N1 MM*;6IWUV>ML=:;#O7M6Q*:@M2[L%)X749*NQ!OMTX"1#=@TJ"?^1D+ID=I7&V 0Z@6#RXDC0RK+E)C/O"*B-C%6 @7!2S42?HG@^,27U" MQ"_(9Q8F!0R+>=)GX:^N?YX<3RF7GDDCTT"EWQ"E1]$FH)<]R(X3[P%MBHU= M;WTYQ8T[J:TDMPDU8R%,1=)+[NFQWGU4EV*(5K<[H(FB.DTV$8ZY?J"BC0R\ M63/8%GT&V]9@*H'-&]B,1M9&'%9[RS)PH6LMG.N QOBP'> MBU"MCIP-5:3@AN%2JQN:?M>@FN,U6\M=#MI5 NA70Q2A9/#SB)+OI9JYD'UG MV[(/(*[TC;H'0G;JP]S9/,[1!G M>J'+FH*V.E-K."5D[L%Q )-M^,K@]XO,9QARI2TQK_ZR3^\!NE\*MAOS]9 U M/+N-K'',OQ590[^BAZ-QFCMPE+=C=5SN&D(D;'P:2G/-7\@2#O^26W[[&Q9U MG[8PCJV=$X>GHY/V1@_+0UT@NH+-8!8!^EU0JB.\KQ9B MPB:\'X@33MO.3YAPVD5B:F0O*8@S3 ;74U0!T$T2.5L#3'=7F2_;-[PR30?C MUI8.R@1B7]K:#_=T< MD*%GL[4\U7'W<1_B]:N5AVH9-O]",/UN]4"_JPYDP=9TI'T*5:?6X4C7L,W4 %,K6F[9L-;?;;CQE-?7/ M9ZW:0/*4CWCXX>4-$%:;NB4T:Y6.9>:V!I(ZQS./C3E^TJ,\Q*5\)0-"[@.0B&/]@AR/A7I-B4Y## N-0!TBADE< M[\R'#X>:Z-V2*%!ZI6B7XKN%<\N+G <4X8R<:L@&I!L1'16,NE';KE[ 32D M&X?G#T?3.N^8"P<@&T_K@YRZZ]1THCK^:5I'6/W,+F@[V70BJ?V:A.8.A4%G MW8>YI#Z9[,:,HP9LI Z]B-E1 [CULYT'2>\MO$;P&LOE>DNSHW$I)]_AY*S3 MV^B@)+."$$2;??)) [C0?+/Y$8&HYFZ;C9! ENG(;:8X;._HA4 5#3W@EIP- MJSQJ&"'_3="?3H)-W1]Y_@4@O[4-Q!,/ TRUH4=N^K8+V[L[/W>9S]9C">\R M'K8H8WV-<.^2TG*K>'+OEOA]82X0I7Z:_'391W2K56:O(7UL4G&M9SV 3.;KD7J*EI"4-38#(:W:!60 M]#-O71$.$EXQ_]:&^I 4%[66N?R5VJRXMPC,,-1')XOUHR G5R6R3'H,YV)[ M(T&G*Z:5.;^>$(-U ="8/M1\:Q9P2(>]S]PQG2-*&THB]\Q\J6QA'1SDAW7O M4YM?*\=? K1NW]+!Y3T#L?6ZL[J+=')\KVS_X+/S,FB7;P#<+Z5KN^BTJ*Q) MX+<=$M&EOX..HKL(;1U7)MU:-^YL?/>R=0_83&^?;#*_VSRXY%,GP%D'S6+) M0$RD*A"HW?0YP)+I'ESU9 7QG9+6+4Y_!GGN,FC:Z:ST# K/FX#I*--O,?R! MODAG^>&G6"_/NF< DL2!S*_\(_% ?U._TV'O\KU#<-.NYN&PO=V]R:W-H965TJF+*KP8K2*L7YV?!RRE2EUF+C: M5'BR<+[4$5_]\CC4WNB<-Y7%\>SDY,EQJ6TUNKKDWS[XJTO7Q,)6YH-7H2E+ M[6]?FL)M7HRFH_:'CW:YBO3#\=5EK9?FDXE?Z@\>WXX[*;DM316LJY0WBQ>C MZ^FSEX]I/2_XIS6;T/NLR)*Y<]_HR]O\Q>B$%#*%R2))T/BS-J],49 @J/%' MDCGJCJ2-_<^M]+^Q[;!EKH-YY8I_V3RN7HPN1BHW"]T4\:/;_&J2/6GHY4UH3HRK09&I2VDK_Z)OFAM^'BY)X-L[1AQGK+0:SE:QWUU:5W M&^5I-:31!S:5=T,Y6U%0/D6/IQ;[XM7;*G.E49_UC0F7QQ$2Z??C+.U^*;MG M]^P^5>]<%5=!O:ERDP_W'T.33IU9J\[+V8,"WVD_4:?3L9J=S!X_(.^T,^^4 MY9U^USSUVH:L<*'Q1OW[>AZB!R#^L\]DD?AXOT1*DF>AUIEY,4(6!./79G3U MRT_3)R?/']#W<:?OXX>D?S<<#^[>KUM?I *255P9_//&J%*"9RAX"J[/5IWO MQ[SLE2MK7=W^\M/%;'K^/*C:N[7E? 0=*"N2(TO65:[,8F$XR^@WY74T:F/@ M[T=/)C. MR@X#['PX&(R._QYC*P.M>PH;L=*!Y71@1[:1*<>G4S.A[O.)].[ MNQ9_T:33R8]:7QMO77[DUL8?R6>5K72U-+!<%MSOCHTF;UD0G2UNH7$!9[!5 M(B&T(KXVWH;<,D7I N;>*+=(HB;J\S8&D)$Y3ZJ"460?&FREAK>FZKM0D1Q!KIE^NR,C@8-KS3M^HQV3^]&$,8 MI)&"%0H#2@""::NE0@(%4O M=+I1O^FYPP/GK0EC!:!-QFJSLG DF:^S/QI+ M>LYO^V"B0^6,A7>E^KNN&E0#-963*3:N6:[N: -U,N,CRHQ:F!SZ%(R)$ EE M&8Z!:6.!B5W#$56$U2&J3'M_"_=LM,][JL>5C@).':.W\R;J>6$H0#U5]P4@ ML _7NFBTE)4"=4W#O3!X">UP)"W8%Z0#RJ/9R?/7GZ\#?YP^/X2_#(5%(52E M@SJ%_098DWZ5JEP417&(0H2UJIWG4V&'5I"#:H%'M&YNH* N[)\FWU$;> !/ M0*81K:$IV2BK]=P6-MXRZ* BJ4;Q(HU#H(C34M;)KAP2@-7I5O+I?')&64*Q M1H7,E?A%Z;6V!?NU=L$R,5" *K/4_,6L@5.X;DR +YJ4:1-D!]'%5^*M^T0. M.!=46%$:>P'D M".%BBS)&2E/?P8J;?TU5A#0 !NS"\H,M7.8X?C^F^@;W?%; -@$2"N,1P2%% M\8 8[5 $DB;L=E?8G/E:*)3D43-A8'[X/P4$^)1NV;G&B;/B\,#F?*VH_MB?IDR>4+ MZT%)76AHT=[8#,&W G\O347!AY)94S;)OH%[N(X>W1KM.W7)G4PP+8OWR^I$ M(>XZ 9AL97)Y:,=0J]R U-$$FXZ''J9-/._X,9$CRYO#LH65G*<_0'Q(J.18 M4U8O2"I--912./ >UF>3(&:H-HMY;3)3SHWO&A RQNZ5PO7RT=F3)Y.30FGEX@VMPUM(?O\\;JK8]2!2.TGKW?P*;C[28T I-9:FH&5*YC;H&3J M0 !S, N(E -#J>@J8,H=X4^;:1=G/[>PT75=(+7;# AZ#:@53)=WH*=0!'F1MI M \G5XF@V!,7.'"8(4M7WW-EPJNTH"ZK0X,\;=O%;@]59R MVD9E)R!P #82<.=NO:>X]*A\R^)'PN)'Q.)'=&Y+X',*> L$M+.S J=?6_%AI^]-Q+O('W0H;MI0&+\C>Z*^L,9M\8$S,.A*9\^AY+J0;B6H2 &ZF_B9LZ[U&QRM?2R2^&=#,WY*_M!/JA MW2.R,<4Y.H \86"C'%*-(!QVF[B5SE,.TT@V)T5_ MX***3[NK<9=C-(!4U%[OCAQM"G =FSP=:G^RU7ZH+A?:=D#A&[&=RLE)+@S9 M,%FW=PYTS\& I%5)P@!;.SY@13(T\PAA.Q[E]"-W>,%1]]L]Z!6BCF92V098 MM@WH>Z"S6@3H-=.ZH3C5.2XR4K:TYQ%#2Z72\ Z."J) MMS0'RR18N41[,*+-Z%K;?(?U[N3@$+ZIW=F;+!@J5RQY[U36YH?<2P%D^R\! M1/LV*;D!1@4/&!(H?@*K<;JBDCJZ=V+JPI1ZM18;;9M,?-1#F/3X.^30HFW, M@[\GJ#NI \,8]AN7ZMTU(T!#%E@H37?OLRA MF%P 0;/!C7JZ=.FW)_)-VH,A@'"\='_]]!988!>1!G2$)W9N99P)Z0JZL&9M MI/=6?'%&[!3IMHPF\%Q:%WQ$69(W<7-#=YRA9_A$[7N-=MQ[PUD:T#"]Q^7F MHHKRLK/[M7M5?"UO2+?+Y3WS.[G(1%P7V'HR.3\;*2_O;N5+=#6_+YV[&%W) M'U<&,Z>G!7B^<# I?:$#NA?H5_\%4$L#!!0 ( ,*%J%@>FUI) @4 $<. M 9 >&PO=V]R:W-H965TJ_DG;/GL.WNY$L;_PCS(]I((\L985;7*A*#B,ORS^S8.:PJ' MSREDK4+F<0=''N4'9MGH1*LY:"=-UMS 4_7:!(Y+MRDW5M-73GIV]*LR!FK4 M<%,RC2==2S;=EV[>ZI\'_>P9_1Y\4=*6!BYE@<5C_2YA60+*%H#.LZT&OS#= M@5X:0Y9D_2WV>DN"/6^O]XR]2Z8EES,#XP5)^.ML8JRF?/A[$]]@KK_9G*N1 MH:E9CJ<1%8%!?8?1Z/V[]" YW@*VOP3;WV;]%;OQ%GWXJ 05';$'6R+PJA9( M]629KPZPFI"1@=^$7@Q,"*""-I;)PEDSSKIQ%GX3 M!8R;R86""\'(]QGDJJK(""5N?@LD_YW(^6.1.1)0O,]+)F=8 +49T@+\UO [ M)@@LR,:#(6OJ1>Z<=9 M<)[GOD]@LP._M1TH&KW85N+&5=&!#UQXI-\3_I^1HWPK_J'.1\#( M[8R:-N!T2EW<36ME*2DX9:3#3(S=9X,YQ<-R-!WX_:=@^/2C; ]!I3C2GW9^ M-Y0*E[EH"C+VVG((X*:KHO2A-6B-\VM+.N1R)7,NN'=@%LE*Z(F&5=KX@BI0 M*CH)PD)C0IC:O70G%"6]%WM;/NQP2 5<+K$.X^J%,^@5VCM+XH-_;=<.#^,B-/JPH#^'KT]U=Q'^M/O8V M!**7#.)L< 3I?A:GR=$*WQK)-R#=VCM*)0K49M@VH748Q"KI])+=,$CV=V'\ M?)+%6Y+K22,M> %2V9:)WTWT_- \Z7H.3NP6Z *D-,:A!SO=FFFBR&OR[=K\ M6EF=49HW>4EXD(0899H__M8.D]=DW@L4&DHF[9':N=K+O4B%E)4%S)D)"(-7 MI(9WZ9N"J_\YI^+9%+S7'UR;3B73:(T.$G%QO'(F<[I.%IOKN$5F7FI1KK1< MWZ"S3JO*PP[%NRKZGRG=EPKT)K3;.CC+XGYR #OI+HT.>ID?72/=CGCN "RV MA1.M-(D/>P,OD:;Q_B"HT:W*OPPH,H^D!_%A%H0'<9(>^M'-:Z/O2RL[#I6: MDIELUQNXW!:Y'PCGCX84DO/=1.@+Y/%>5V M.W$.EF_'T7]02P,$% @ PH6H6'QM+&(J P /P< !D !X;"]W;W)K M&ULI57);MLP$/V5@;J@ =1(HB1;3FT#MKL>6@1) MET/1 RV-+2(2Z9)TW/Y]AY2M.$"< NU%XFQOWG#(X7BG](VI$2W\:AMI)D%M M[>8BBDQ98\O-N=J@),M*Z99;$O4Z,AN-O/)!;1.Q.!Y$+1X4,TW4=EZ$A0!5+CBV\9>J=U[W->3.[Q2-<9_ M8=?YII2QW!JKVGTPR:V0W9__VN_#44 1GPA@^P#F>7>)/,O7W/+I6*L=:.=- M:&[A2_711$Y(UY1KJ\DJ*,Y./VM>(>@+OKD(#WV=+8S4=C!\/%=KA9 _CN,MR83:\Q$E M\&@OL5@^OQ),HA? M/<(RZUEFCZ'_0UO^!P\Z,S^8]9%9DGG'#92JW6AAL *U ELCK%1#-UK(-;P0 MDC1J:[BLS-D%4,O*VO?L-0&U2]1>>*>5,0\E@:>0A$D^"(M!TJU'HW!4Q#!S M&;@L73(-I<9*6&@(A7KW(@WC='CF_XR=P8*.G6LEE#77:WRYY.4-99,5&.YZ M?:N:;4LU'B )($$XQ#$?QP.$4@Y!EQ=G?-O0I# 9%.,ISMTK2<)@R5T")K@8_K6B3CT_J M23Q8:=7N!P5J9_&G45K7F"1^!K1QK=)XZ-J"VLCE[^=/"I8,7QGH2K GX7=( ML=3^KMOF9',7>P8P ZKE&60Q?7KE'-B(9)8=*Q? 4JW M.X=$L9MOO;9_'6;=4+QS[YX6XKP6TD"#*PJ-SX=Y +H;UYU@U<:/R*6RQ,TO M:WKA4#L'LJ^4L@?!)>C?S.D?4$L#!!0 ( ,*%J%B?MT# A@( 'P% 9 M >&PO=V]R:W-H965TLFC8I:D(2 M"#! *NVF]:%2U6[KP[0'DQS$JF-GMFG:?[^S RF3*'U)[NS[/G]G^_.L5?K1 M5(@6GFLAS3RHK&VF462*"FMFSE6#DF;62M?,4JHWD6DTLM*#:A$E<3R*:L9E ML)CYL5N]F*FM%5SBK0:SK6NF7Y8H5#L/!L%^X(YO*NL&HL6L81N\1_NSN=64 M13U+R6N4ABL)&M?SX&(P76:NWA?\XMB:@QA<)RNE'EUR7=[>05WG% M+%O,M&I!NVIB]T M]P)7W!1"F:U&^'VQ,E;3=?ASK...,#M.Z"PR-0TK9;! WD2 MB*S1JD!C8)B'DR2#X20]X8ZWDK;F:,?[9^6B\Y1K^7=NT2M M;[@T('!-T/@\'P:@.Z]WB56-]]=*67*K#RMZ'E&[ II?*V7WB5N@?W 7_P!0 M2P,$% @ PH6H6,![X&ULK59;;]LV%/XK!VI1M(!@61?;:.E( M(B*1&DG9R7[]#BE9T[8D>]A>+%Z^\YW[H3=GJ1YTA6C@L:F%WGJ5,>U5$.BL MPH;IF6Q1T$TA5<,,;549Z%8ARYU04P?1?+X,&L:%M]NXLSNUV\C.U%S@G0+= M-0U33]=8R_/6"[W+P3TO*V,/@MVF925^0?-3>Z=H%XPL.6]0:"X%*"RVWCZ\ MNDXLW@%^YGC6DS583XY2/MC-IWSKS:U!6&-F+ .CSPD/6->6B,SX;>#T1I56 M<+J^L'_G?"=?CDSC0=;?>&ZJK9=ZD&/!NMKP^TCI5FC!B9R^-%4J.#0*87"P%YK-'H3&%)G MA8)LH+[NJ:,7J&/X+(6I--R*'/._R@=DYFAK=+'U.GJ5\#-3,XA#'Z)YE+S" M%X^^QXXO?H'O!@LD%W,X2&VT#P?6NW)\]IMMUWIEF6X]:B=-*H3>KMW;\+E_.,KOB6C;\EK[/\M MK_\3]26&@%.D=,AL0+(>>4:*9B:;5G%-"9$%$ H*6=/0X**$]US0B>PT,>@/ M5T"ED%6N%FXPP^9(C/VFE9J;7A'+3TQDI/4MA/XZ7M W\FE8C69Q04FT$$C\ M53J'U(_C9+Q56'8U,U(]08'$DOA1N(8E84+X),A6G+ACV",)9,A/[%@3.(S\ M<)U"&/OA,ATI"45W:S)B 6'HI^OU$+=+-/Y&DPOT@2BR%\G*7R55.(CY-\S\Q;2E1^1+[2( M_&6Z<$J_54@3%30C(V1&(AKLB*44"M

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

L10LY06X'EY0U<-8;\ M=7HYS0X:ETTPAK4UT'-# 9!2 89X BK?"6Y]$W 9AXU']Y?=$9$,W]'=0W2S M6'*JY2R#0+!F<*!B=!@)$.R:2)XD]935"M!_N?,Z ['M><,I+4IPD$D><0;% MFI,0@-6N*,_C<) =L 60-R"VMX^^HT4S(DKU-GNN<[U9TN>.&\110B39BP]_ M^=/\]/C[#!&H:_JVBU?W,&/ON?B>_CJ936:SV7U>.Q3X6'B#]J,L)D?'IU:\ MVUB\-BV)ICZ:3>9'LVPQG\R?/LO>,9ISPQQ-CD\6V;FXQC@S*N_DY$,WZ,/L M],GDV=.G]Z/DX&[Y'!+0(#' ,!_1R$]/)L>GSS#7_$G(E<7_M%LMV+XP;=ZW M+3M&25_N2)0IG>_%"N.,TTUO_1^G)BV>O=ZK$2SFTZ1 NE\^11F@;\CM5@1O MZ6VP%#X(.PK9?';X5^MQ; $IHA]K%_; :&L M%Y9J_DXAM8A,>FK%'!GYAV"J8R']9PM)AEIYYK4R&HL#WNN^(H;,YL<8\HQL MJL2_3B9PIST;"(I&@,PH$U"2W^W8%[8V958!2RWU6I4KJ>(V0 O;GDR.W&WC MOX755%G[Y."0IN]JO(IT_V*9/$Y M>R/5)LK=X?KYRP,[/3_@9[1X@.*4*5BF1%)-L8-PY&%A!*8F9F='N7C^QH]A ME9U#QW/WSCFI+E=8^+NW-5?9JO ]+?45N?*J-N1KA>@D@7&%8J8G\N=1X52B M-:$&ZWT#0R6 ,N^201EJ72.[D70P!Y'3['U:XQR?;I"+XW-?4E3T1Z>8D(>+ M)R?3F8]3E G?('B3"H:)&&-[#< R=-0E- 6@L+'M0')"JJ$J#04&^/]8& "3A*AB9':NR59,">;N!3"X9])'T 6^<&%^3@X5[?Y7FAH0_GO?("=?;FM- MOLNG>L'?/R?/Z>3!KN(>],0IH M-AR=;1E&R,]K26.#-27IN!T;=.J8) EJ@6!3,::A@;7W9Y8%K?# !5KZ[Y-I M]DM](]DEJGJM2^^0'5 R9I-F7^=U&R1-7%O=(Y5E)&&3HBH_-7SZ.R M &.^H9Y 4K$>I$\%E>#5N!N'0MAM M2:73RSZM_T<["DU,P,U:W_\U75VI*U$6T4#XE#J/E87LZ'!E/O-ZHD FSK84 M3]QHRA2UVWUG/*!Z.(,5+<[[)ZD+D"(17HV@WTH7C)*ND,-7&-YI\YH3-*_1 M=K]W*&C/U('^_+N4\H*"-1R&Q,BS3:69 _?2RQ*T.HE-KL]U: M]T NH*Q79)AYUM:%Z0G5_YED7U(DH/Q# *[5_#0;JLJ=5?Y,K3I;=N2DG7=8 M2P)9\!%-?^49S$/:M)G8TE@B(;=#>ON0"P>ZV=LP=S)D]?Q_0(BOD'YD_VD- M9 B#WUOK'4TU+@WFE]@!WS<1G(O*SK;O;#^#?S'.+&+$/RS(W)US3.Z3<$S2 MS 3!EHP3+T(4-=R#%]/GQ#.53;-'C^)$TS\SP(#DR@5=/"-7 MWE&R6^E=*V0(2C\^'R&:%M*3R=39!Y/7+LL.:OE5;(K9N I][+BO5!R:R/YZ4;:$;00P$4CT8#%[#8->&+%-OF2^,7L/WNUF81BR-],0T(+SSLM3'6E[#=+,B.G M?I6^B53PWZ\^WZP;D93VM>-2;SM1CVF]A^!(4A M'A<[0?'UHU0SO).F=>!WDA%AOO)&<@IPHK?;Q-:5$4//"!?2>B;9+^I&&<.4 MG#6?T"P6*>R>DF?7I+;D\T;%==JDVM;ID:,DMG3"6=>[ .)J%05*F-0&P5Z8M]-V6OO,QZ_5(O M&RE0G<:5-HD%I(\D5E 35N4*=IO:[KC6CNA;)\*6;VG98+M@K!O$IB]WPJ%@ MJ4,;I44HKA5)!!?VA M=[3@"<[[CX?KOM:FZ@0^Q=$9DCCA[M^I;[3B[\*-\ MT!NK1:9QVYYUY O2<"F.W=4 _?8NT(C).K^D8F]!*W^GD+H@O8X\A!CV1C MP._!2',!."&>!@$K))KCZ:4U(+OHE]:NQ;MP^*M4P:'O8XU>=4(M[]@5UMZG M5DA%XJ3FKAK2)(VN>^1QWBOSQ\,GL]' Q>S3('VWZV J4 MR:3B-4&;(2H*HIIVOP2%R?X*28I#LLWH71"FK@( M(_&0^^9#2IO.% M$>3 D9W"=R^U+D4@_Q><*URW68F6NMB$2"1\#Y8Z02@!)K9[!:UMX8E>SQFS M9E*?FP(LC-F ;LTK"P)D#%N%1G\CUZC81,F$G5$*CO ;3.*/EY38 M1!W\J MHV?!;57WZEWY.##C//3B UVH%:F&D70$>TT./H18SSOVU\"\LYEUAMZ>7>6@ M\-&:N68KAASL:[^IP"WC(_T/6\75?>[5:M("@]A?J[TK=*W-7-C;I36?J%[; M FU01M!Q_C#>(,3]T%P#7?4V\3$-JEH*")P*\=H&$,O MV=G 1=@4B,O3_(2#2P$W5OJJ-.B?H 1XVR]+8/ M^]89NB/'E*#JFKJ$DMC]033[ L]'+&'HSFG,&3HX)8DU) 8TVTB0X$2F33"Y14F-CJI*/L;4<=CW!#'/[+)C[?ZR1OLH]LW4 M^U;#84P>LV"7!! *(6]E-V5E-:3PA53ZO:@\V+2&>TN5;<7GZ?2A()ZXU_/; MZF^CK1/OUA3R#[CN]AT;+:?A0_\&98MK;>>T- ZD\]/#35$>+I[.CA\EI5_K M%*/NCCV/G"(:9Y2BV1((]CB(7IK*I^)O479 -[.'A#$OT9RG/^=ZR^6WC_HS MZ>.!RPAL>\/)1%X^Q$GRG828@^<2RX@:P9N))#X.N^N&)* M;-+E[!JLY'%<.TR=[F%]U2JC!4#1G8"B-H,(/O^&7@\I8!D<.,%3P(_DI0J[ M[]/&"T477*!OD="'W+_2I*+HD5%+[*'Q/E6[JXH&6SW.@PQFC96*T71(]^T\ MOF^2$_NQ?A]*>$._3]C1< <7Y8F6P3]Z?84G0K:+B_L*_;5D+NZ6UA8.$&<\ MFUTL.=N-?$5"V0HB$&SMXS7GIE+ X=X9Z:(C;D22[J*%#+J'QG1W.D!!'0,& M]IBVX:70[D J@U8&?;XA(A!O.1X=W;& ^A]DR9UT]$E&'5=53N.,WU%Q(]TT MEJ5^>_:B7N(0D!A\]G.M&I[J%RG>0F;I8HC+UT;Z\QMN?;051TD'Y@O;DQME MJN*"56<'BTH3TGH2JC].HIG?2=YO.X%O^7O=?-KS+!/&1\-]Y= 5P*WXKJ>2 M>$BXM.*]4G;6AX 0)$<^TN /]]UG%]=N:+O&$@)N^-JB;,.'EJ*3J='JC\>D M--A%M^F[50/2TO:3VO>I__:%4TY9]LKW^1!EO(5<*U9]Q2L8=4I)4 MU_"\HP',-5,R[^,#_K'3=,?;*2^1 Y5(R#IZ:T<8C\^\N7-:M] ]<#X\'M/@ MNCT?/EM,3WR')^Y(0(MBL"*=/9P_C7HILP,H(032T3>+D\<4$#$A)1# MM?Z,KKM*M;");:-X9P20L3ZYS M8%9QYT6]M3B C97B])^=>QZCPI>*>0'9 <4A>OGA<=3A^L@SH) FEXYWHMM. MFM^8Z6X*+P7?=@I[<2C"G\C%L4T)7-)5:\^:HL$!\WQ!.I;&^=%I$)+KDQT> M&XJ'@G^17E9>0=WN-?/L'T+@SE5[FBGLEKC7> P\,G9E "<-!B?)]V-GK(U, MNK*'W<:.S,J>-9]EV3_@-#S;=,=$L?R^>.(*+$DD%;ILU3BG(9+YR?1):#"& M2V3!/WQZ$MG3C>OJETH!_0LG.0ZA*>'<+[F6,*,O*'_3L5_36V"#RWY[F3TCL\C1D3:)[?8W'4>)F;G;'IT/VZZ0UH" M?B%\"39(C+G&'P+XK;Y28B#VXJ+D0=+WJ*[4YNNZ+D"2"V/.HHL! MT&[FNVYYPZ"TZ'9^ZAL/AWM%-+P#B9/LS9OS"%-5PVL'/+Y,@=8;U'JEX6"2 MO?U[*!J\PVE=WU3W)=J3YNL79WX?[98>R$A5N4XN-Y](^[XMHHI0/VF]=9V0 MC3]_9&]HL3?*$+> COA\E4 TP>9VXX?SJ:=QS\D> AWI_FX##F?BT M6S_M'HYOIQKT$?LC!M@?F-@3^-'E:#@%_WFWJ9OMFD#<0.KAD+IOR0Z" "RYVXC6%/]KN\J^' 3^\KL"29EBW>U$>_]/G8I6ZNT=WD M$\W;STU$')=C+WRO@!2I!]?UM*YSP5'Q[\BWO]$HS%X;]@<%Y%+@G3LVNP;U M<:YCC6QQH9>L=HL:[ ,L&[F#I[CGWO/-NB8^8[LKK>RG57V&8J;R%7^D303> M)*MH_-K&J@%\T9XTI_X?(E[ECR->O'U^<9;TC?AVB6>+XT<3)^N[3#_9X[(M MS++I&+8$5XIS<>FGX6-6T>U,N50G>1/8;C2Y^S;L3KF$[+>';PVY=QP2V.AN MO2L5JP#:R*WCP6KB YDLBT/>"9*EV_.D=3A<$GCG,Q='1)0V-*;])*D7XM?4 M8YFG<5L?6">[%FDOF*TS+F5G)3J?&9:52=]$GPK#RT/&\!^ MX\1V^QP/:]1[SDONC\$^E6Q7CN_4IUM7\>'+%0-L0?^C&XIKY>@=:>O#_A_A M[];KY<@SEN]RPV#RN)CM\X_O5]FX>MT,P7,LTN] =8B(]%[EJ"Q"X M5_7ZKV)H<7QX<7YV>''V2SB78>-J&#V%O7Z!-BQB[Z?>D)?G!%SNE:UT=*VL&+[K M+H,1-?&]%22LWC?^N##%(=]O146GD#:>*@_=>!)$R<3IL*<8;RCNXB9F!Q_E MV&X99V=\,9ML,A 1@4KC[E_<>/(LW>4NHAP^Q%$KK'/E6KY(TU\T%9WV]!V8 M"7P.GB.O#[UF9Q](H0[/",3ZOK;^ZDK)I=O!\^G;Z>DIP\8+< MJ-)E]HNJJMM'VB_QN)9>._81QEXLGLT6T=C<4YJ:VW=NWQ-%L;K: *7&;<-G MN"+R<])XG TFF<]F<[+I<]BUG\S;]_[PP<#C^S(4.2NSC2X>S=YQ_2)J6. " M:HUNJ70__'@20T*^_XOCI1(PLX_C IP/;L=>+"9EOM:U2;HK%9PMT8/["[+- M";?,M4$X7KK+5_Q%EU#H0NU8DK3&Q@>O43;@-#1\AKL*DE):CV818>4<<'<[ M&?YXP8!VRG$;-HWA<1EWC=JX4W/ F2@A;$%*/Z74V8,BM&E:">Q#ASN(#-PQ M@)^./?=>9%2V6?CC0FJD)_?;CN9=F*(HT[#INB9PWZ?4( YF(6#=ZL'>-5Q3TD$WMHMKBXG1W ?9 M4 ^,()C%GFK:%R=AG[*6= M&PBG,$_B5#"5R&LH&5SOE\]M=+BA>J6;QB9 \9QR"@J?VI:WOP5IO$FD\:I9 M:ODW+JV6T/_&;R)$T]U^Q9%MX-OKWYMF_[5K],8FT@>7?=DI;Z:/S( MN8T"O.$0CAOYZ)S SM?JCS]ND9H_TT*/)%( YNTHCNFN*>)[(S M0LK#7S@(8AH'L/$N&:"37*46J5948XP8;W\1P-T>(C<+IN>V_V7LO4VY_2EN MINN>VBV X@2(:%-0HO#LR9/#-[_\E?('N!&:=0HO$=E U#N:&H(+ T>+\;[/Y[-G) M/#L _=EEOT44/^^FKJ-T?)ZU+NT>HR&)J_P3JB&-:0MC;Z!!%XJSI?$SC\(G M/I(3CEOX:I%<$(7&.;OAAV8.1EI1RZAC]7Z4C\Z]A.M/F#4NMMJ([S*=M+1V M^W$81O=AZJ%_B\L+X%/GKI&B*.<*%75(8A8SWQN;$'?K[)7:1+/7\4G%4S=4 M#R%VE!XDD>SJ?/_,;Y[7W"]HC.\.B%[Q,/]DYZ,WQVP&V8H[15#F\7 MBUU)O"I_Z(CWK*WC\KK +.5?!4@&G;@3,O@J&IF7XC>3G!8-%^BZ1@?Y&#/# MJUA4ICMU9;IWD2;/[V+\<=0L-6R 9468..\GW9TY0SX+SUR0KZ5GHL&3Q^7K\#CX9=M,SR-*DLF(?$TSBB;-KG60/*=_ MKG%_CL#Q%"L0:+N3J='1]'@YTW09_)3 G[FM#RK/:;-=AAQOL,+KNVW?Q],1I>S!-OL)I!#N00ELZ!L$X>U5=580@[?52?"1T39F[@4NUMV&,_ MMO@X^JU,2KRO^!=!6^FDEY_-])_Z'QT]D]_:#(_++Y:2S,@ \ -:*WIU-CT] M>8 ;>-;^'UV]Y5_>7-9=5V_X3S([BH)X@+Y?U77G_H$)_$^Q_O0_4$L#!!0 M ( ,*%J%A:V'H#0@@ +\5 9 >&PO=V]R:W-H965TU 7:VV>;"I$R;[EF;*7K;0LB_?=KHU3 MD7/;T850>+/0)N.(VY5DWZO7&W9Q+U;JZ<,_NS=6%KLI,*G%O MF*WRG)OG:Y'I]66KWZH?/,AE6M*#[M5%P9?B492_%?<&=]T&)9&Y4%9JQ8Q8 M7+9F_??70UKO%OPNQ=IN73.R9*[U$]U\2"Y;/5)(9"(N"8'C9R5N1)81$-3X M&C!;C4C:N'U=H__B;(]_IL(]HP(+]:9 M=7_9VJ\=1RT65[;4>=@,#7*I_"__%ORPM>&L=V!#%#9$3F\OR&EYRTM^=6'T MFAE:#32Z<*:ZW5!.*@K*8VGP5F)?>?58ZO@IU5DBC'WWTUG4GYRSNZ^5+)\9 M5PE[$(D "^:98+]J]?.-5J71&4"6[(,JA1&VM!?=$HH07#<.0J^]T.B T '[ M#*#4LCN5B&1W?Q<&-%9$M177T5' S]QTV*#?9E$O&A[!&S1>&3B\P0&\X(%_ MS>:V-"#.O_?9Z"&&^R$HF=[;@L?BLH5LL<*L1.OJW4_]<>_\B(+#1L'A,?3_ M5]B."MUOTO] $W:W6 B7G2!_F;(R%=B'0L.5_).[Y,6_7_5*Y'-AV,2%>=!V MZVYT7G#US$@#R_J]WENF%^[-+%>"9[0@Q^[?E$3Q@DP6:Z5"23@@;1>9HP2! MI7N $8BX4IY4+&>$ RI8JU*;1Q$!WV!1 K79*AABJ#;;-$KF0B",8] M<(@%!T@L"V]F> &TX%&ZO,FXM6P&Q9TEEAQ>&UDKF#/B6%=A#2QF6"]+ M"?WC( ^8\^?M[>VPGQ0)]* 84#!M-;%+4IV*D-.*O@H7C+0[+Q$%JNTP"D\DFP M>*5JG7' 4CJ7\=;N,N4EUK-$"^NX093JL'LC"5;OY?UA71Q%>/('.A*%"A Q M+V0)#Z) *LM=0M5"82"\0@((L*CFF8S!R%1DR3Y-I0K1^(YV(61K(AL@EXXU M6)OS)S""?T-H4*[EO JZ>)0E0ED@I'HI<&N:I)>&\<5"9A(P/A"7$"SW3="7%[2P.&T29[<$>:I@D<*4=M#0()!H\B8:=\XP+B"*-/GX M$I!4<4VC@W'NL$>P2WRMD$R'PK"3CT0MEFE4&O-7@A)TWM2O?2(I$^EJ"887E FUUEOA'-/>T MH<4>QX?"VGLQ-7*[Y=T?<%;C#UI@,4BQ%<\JX=O'EF8>M@F3I_0^0+*!9Y:B MUY2+,+34]*@*Y_\PSTE5UP6B6,PK&PB"_7E1%_A#^B.D-+9A#'TQ637!#.#> M3]6&A'.!QN?&?D5IO85B]YP 1#@!V&V[CA3+ U78I_/A0@S3-%$+"KFV[DTN M]7\A=8UFZ2.!N=*(]N6#HB'9D0'C=<&D:&':&FV$ &\&G5[]H$V'@\(?ORA[7@\+/^*#790. MNW%D]:-='%>H'2Y(_W I3%H;D=*7'1#KY!,B>4J-C"(+[M-KK9@X"Z,;JE(EFA91!KB#_RRK4A= M2W84\2B!8M<\0PT2K\\T[ T[&8_;O4ETBLO!H#WQSP91>S"N.&S6%KDX$G_2EV1*,)&T?[+?0AZK?' MDZD+VZ@]'-(SV#<>LGU?9+I;']5R@39$GPZI/N+,Z;^O-4^;KY,S_U%NL]Q_ MVH0F:$F696*!K;W.9-3R+:>^*77A/M%ALBMU[BXQ5:&@T@*\7VA=UC_4?4$L#!!0 ( ,*%J%A"D\*]A L $DB 9 >&PO=V]R:W-H965T MUAF MN7G;6EA;O#HY,#)3>LDM+O7\Q!1:\-1M6F8G<;=[>K+D,F^= MOW'WKO3Y&U7:3.;B2C-3+I=#X=R[^VC\5)::Q:ALV08"ES_Y\_!!P:&\;='1OB ML"%V%IQ3MH]=D7E=N%8>_S5*2;^T\@5RU<7 EW M$>\E^(7K#NOW(A9WX\$>>OU:V;ZCUW^VLNP?DZFQ&E?_W*:W)SO83I;BYI4I M>"+>MA 81N@[T3I_^4OOM/MZC]"#6NC!/NK/M-!_2HM]6PAVJ98%SU=LP0V[ MXUJJTK!I:4#$&,;G6@B$HS5P4;M@B= 60<\*T)+",'R]7\ADP>Q":,&D848M M!4O4YT&8ABP[[3=V+.Z$C6EBS3!5(Y,JR5&H$;+:B'4QI^'J.Y,!H MC9HA=X"!#EH$SAWV_B$1A660.I4FR93!PRGEFXCN81O/4X8$YCC:!?1@2^^I M@CR5P<] MG*T*&AP3Q^Y@@16:,DSEBQX/H>85C%5Z@TQ5DUX5'A&N$)CXP03 M)M%RBN7 Z7=E!8L'';;''B2R7Q=WV(U5R>U"92DP?/G+..Z-7K/WWTN)32!' MPD#P/IOD>0DYKT6AM&5 G1(7ZW7;GSK.OC.5 129SYGETTR$3"Q_D$YK6P0& MYI&"MBG=$=C:!?P#8IKC5Z!.H#;#OP'JII9.,6Y+@ O+-'1FE[QP_T'[@F<\ M3P2[<86)MMQ8T"!\:=?70FB/K[.8U_X3!]IW[$(JDTB!W89]_GQ)7&])91>A M+!-(X9#(""<>44[AC9DJ'.T7+![BHS=B[QIW:17YL= )_$#^X+Z@5!9G;?8K MS^&WF7Q@DT20I&[/I;!:;=[>P]GA'K_&MV'WF>P_R&RNN;%RZ19?B?EL?:?- MKM6*9X!>/*"60_TC6$24M\HM_K#*P15C+_%_*U2R=[M!UV MNPUN7RG!;J0%*B"?D.GSR,5LFRD?X6#@(_8 *P[/8OH\/64WI45:X^P#7TH M>"W(^_\$Y7YO0)_=(9NX)/+I[YY8>C(]X>'>%4]N^9S(>C9%?;U&[A EHFZW MYUQRW#^E[)BLV)4FF1U&VU6X05.+JXC-R8O@=T2>IV@7)34UU/>Z".[3Y^D9 MF_S@WP3L=+7@:&P#T2?>=H"T<=3O.=!'@.;NZOKKU2Z4#Q-Q0#@/1J % SH! MC'4UM2*;(.6CWW;Y''V6I"2_Q^V@*S0>C]DDNQ5ZB<6'9 /2*&;7+_FR>'W# M;E16^E+39IF:0UR9F#7WPQ1;Y_:XR[Z(Y12%'/0L?T!0)D+>N0!:8W_T[7K" M,LFG,D.$'X>(J?(WNYH M?,%G.RK^9L^$!)(XK:H[=3ENUYUDHT,B!09],O;9SH(8)27OI1!O&/2?:\"=*#*/1B&*J'_5&9\]1 ]%] MVL=G]VRKU%N"L1>=HBN V8?CI]&Q)SCB&/U?UWDIN1Q\?7+W:7+]WFTA5ZW< MO(UZDNC251$ (8QK(*M]U(D:A&?L_@YPX'XT[,=L.#A#\Y&GBEUF'#/$!:J^ MM"QTLF%_2H$BIR'(^L!T]-3*5UF"U$5AN6'&@J^VVW 4=4?4R8VB/HQ9FQ$0 M$3XD(:$ET]!'DC'[5*(&_?\66./H%-8=1[W^V2& Q?"A/K2/NZ/=.F:*(CRH MV(OZ9P/_930ZW=;^3D Y==01]/1 HA["=3[#-2B/3!JY/@1T/0#5B8$O_9!$ M]QH\ JDUB2,WYGFTVFQL4 M5-Z>JG3%:B)'7R\^'A] J@-MX7=X"O'<'$T(B 9 MJ8U^.<+#>0EPJ9J! _9CJYK25$ZT/KR;,%X @CN>14X%S-+E#."7VN4GNC59 MYH)P>\H)]>-66+?05#6.=A1H4UTV\^TG=24(%&@!APIXLP0+90JS&S]X\MH1 M<=N-^7Z6=LI33-+)"YG;Z5_7(=BY1J;9D=)XOW;!RLB/69'F"' :I7)PEDV'"2M=0C,[]!Y89Q14XHQQ)6ISW#X'&EG3O,T'>Z M?H5^F"IK)2G8JPP5_*-.6+5_$-40!] *>KI85S-4*D@//,3WTC\;=O]"' D? MOX RRPQ.6U<34F@CS$+@A5AR'2=,\KNJ>S)WS%1PP.:LG*AY[CP\]=L/.K*B ML=J4W"=ZNT TKTW<\>/:Q(]K']?C6E4%W.F*[SJ0GH2K M?:X&0IW]HVLS?F9T8#4/ ^^VE+$O*36AG7(+$&K;N^PD-+VI:/K59IPUTU8. MOX1[SLBF7J=.^.\/#NG,,B0W]A&CS1:!GI."#\^H'7:U85 1$F.091_240,] M5*.YDY02*==Y%;=Q9U#GED:N=5$#I1P=/,/=JH]\*M!!,M!;(<*"PI!I>D%" M*OB4I68SH.N/)N8*Z=?U88%ZYGR30,%Z2A2[_:7SN'GYJ:-F#<=_XJA5BOGY MP12E'M>1;3D*.2(2U-#$W=<'AESKV">HNN+MC2<8";C"Q$#1)<=:N Z!Z7;9"0C#K8P""+CA2@*)N MQS->YE38'QF O7M&@=H<*:C*:5KDYZEW]<&&PYR]Z#9ZG]!V ]@Y= 5#R(I MFWZR+Y[W%OU#&C^$1F7.==\S;/1UW(33%_.*'O4T']L M>V%\TGB]#RO,W8\8#)1%_^C?]-=WZ]])3/S/ ];+_8\L$)5S*AN9F&%KMS,: MMGQ=KBZL*MR/!:;*6K5T7Q<"H:=I 9[/%) +%\2@_O7(^;\!4$L#!!0 ( M ,*%J%CEO^7W?@@ .\4 9 >&PO=V]R:W-H965T"7NA/V]N]7X-ANUE+(1K9&J95JL+R?7 MT=G;E,Z[ W](<6\.UHPL62GUF;Z\+R\G(0$2M2@L:>#XV(D;4=>D"#"^]#HG MXY4D>+@>M/_+V0Y;5MR(&U7_*4N[N9PL)JP4:[ZM[2=U_V_1VY.1OD+5QOUG M]_YLO)RP8FNL:GIA(&ADZS_YU]X/!P*+\ 6!N!>('6Y_D4/YCEM^=:'5/=-T M&MIHX4QUT@ G6PK*G=78E9"S5W>B@HLM>]_Z ,-3%S,+Q;0]*WHE;[V2^ 4E M"?N@6KLQ[.>V%.5C^1D C:CB =7;^%6%'[B>LB0*6!S&Z2OZDM'*Q.E+OF'E M)]$I;65;L;^N5\9J<.*_Q\SUVM+CVBA/SDS'"W$Y02(8H7=BGK^" M-1VQIJ]I_[L1^6XE[+>-8#>JZ7C[P#;<,+O10B"QR"5\50MFO) Y8[^(5FA9 MF(#==:*0O+8/ >-MR:YWOUY_^GDZ'CA4^M,/BSB:GYO]9J^0R;:HMZ4PC.,Z MRV7M=,G66&FWA(W7C%"L52T54VNF=D*S>!ZR3JMR6UBVYHVL)304M$4!Y"T3 M7RU5AQV,X&TE2+!4!J6$D='&75**&@?T S,/QHH&%GDPI&*E[(;)IA&EY%:X MXTXE./Q&HVX@V9G2P&: JX1HI^Y+H;&HY9>M>P*=6L)ULOT?R@QY$0];;DBH MT_S!W;?AM8\ W0#"=%)SJX"IMPZ'5E(9"1.Y/GBHNHV%;.,"L98UH0=G6P,0 M#;F,6]1H;Z=5G2QX;:;[B!V-S7YW#(YAHJW@-8H(2"'@LQV*=4>[ <%I%*&' ML;SV7BHEN7.C(ZSC3:8G(PJ85 ,*!K-MP@"P$#A6$=;3J7L+K'"%"=6.0 M'W88+TLXQU!D"EQ-C@>/=@K'?/#H7J5]!/91O.7Z,ZBDVM%&'*/8><8BG*H M8\1>>MK3^*B#^JW!.T"WDT3=Q_8 =&&+*-+S%97C\ST3X%>%B2K)3J>K!\0 M)E81@UM23L*5: M)I$$E*14*/&\MSCGOP(O*1^3WZ=V4O1,=U]:A@L_?B37( M[^/QPI$_!-@)NK#K]9K+ [NES\0WJ&&?@4#3822#[<.[;:6E3!)/C<8._.>N MTZ*21'Y@;'D#&Z&BU^[KQ.WUKX_NJXW"I?<;A10A'HT<4N[Z9^YU)8!N*M2V MQ46LU-O*^W7PO-EVG2L*\*J$SU^L+;Z/(O)0R"WC6K!:%*#D*NAF M@@?-!71-V><#_TQXCS&T<#)JE"D'F<;+B!VOMU30 MR* U,8HRGN&\ZP5MX2JE/:)Y: !NS@$/.B@=$F%_'U(/SF0GM3+F=,K>4UEE M*QKO7CKD/-XJVS<;J%Z-]0>U3Q0<_B9$#^ZD^.K:18UK_B89:_[#$0M2^G)4J/35=3 ^M3F)9*2N,II? 2VCM(. M!"T$VJ8D!]4UJ7R^ V2R\I7?",HNYUQ?EEK5OGGF+=^!O!KGB;YQNLI,ML3A M^8W2\.'0KS["6#UU6]'YHPY?*NC8^QPAK5WH_:@O#^:"?2S&4$C7%KST/W$L M2@YA\HVQYX@;F7#7?CC80]$"&5.@H5)#PQ^5R,&@/9.A #/WT$I>)"@*"['O ML%=4&@]ZZC! HEZ!.^V1(!)*KHM-/T6,'?'@".TH"L#!W6/X"/]&^($"^JGM MKJEJH9J@,J!HN.IQX/L3UWW1[:#6G)[!<32>'0[6* H$:)B+]W/6271ZT-C[ MHDL/CY"%_?;(J_\1+L:BW0KV(TN641 O4ZRB, OBQ*WR.,CS!"L7]/@Z,\R#.TE$D3A9!F(?LSL?HU?1,DB!<9"S. "]G41HLPSFL H0Y MBZ(XR)89?@2\$-DD!8J(02B>C[+B\%A6^'F,) M6P)YG#Y3MURD!,1JM(QM/] .;"K0"RN(CF?3?%QGT!4%*4;CFXT;>L$::NZ, MBKXKD,@@8B*!<.VG=-14[:@B0EB>PJ%G-_VU&'U]:U2]74A.ZX:N%F19PDG9 M\IF"/5:WO>]H?0?H<_)'T!+PP^04RQ@N32.B&,*?SFF3R)-$I^Y<&,S3_/2; M>9!\5QYX]C]A?9J JSE6H'\^7Q"B. ["+']$^BR;!UD:'B=]&&09J).XM*#D MR:-XSYWY$EY)GY ^2D#SC*6+(%V G%&\#0^PK,@3[]-_.5S M?J51Q++H'[ ^#M+L>5;[IR9!@JB#OD$64J$^22/4M_S4,1H(EX[Z>TU] MVZ0?QZXUN3& F%6;MRK]J,']_]^ZCQ MZ?@V[]J_Q-H?]Z\"D=\5)GCX?@W1<#K/)DS[UVO^"W[MNE=:]*-%-6ZY$1PQ MIP/87RMEAR]TP?B.\^K_4$L#!!0 ( ,*%J%CU'*)UC0, # ( 9 M>&PO=V]R:W-H965TS$:6(; M<-(NME@4&S1[>5CL R6-+:*\J"1EQ7^_0U)R[,#-=E\L7F;.G#GD<+SHM?EJ M&T0'3U(HNTP:Y]J;-+55@Y+9B6Y1T!/CKT]&H//I-3ZJY]\JI=)Y@FAP,IY!$:? M'=ZC$!Z(:'P;,)-#2.]X/![1?PZY4RXELWBOQ5^\=LTRN4Z@Q@WKA/NB^U]P MR.?2XU5:V/ +?;0MWB=0==9I.3@3 \E5_+*G08!-Y+CRA_+H#.UR\G.KQZZT^*U#Y>#CCG[M(G4$ZS?3 M:H"XBQ#%=R"F\%DKUUCXJ&JL3_U3HG/@5(R<[HI7 3\S,X%I?@%%5LQ>P9L> M7$_G M\]L\:E-R(6CC LB!M:W13YQJ"BG,V[R()C*:3.#W,X!A9IVGZRD.X+/\ZL3W M'/SE"XN*F$/+]M(KQ%Q0@:LM,%4''9BE%ZH=LV @-%/>GI6#/B?P Y&K+/M/ M(O,7%B,FJ?R.K- MQE*[,'K/A.-H/5*DSZ3N?'T=93;"#04_H>D?H*)Z4K(FZX'>]*V7%1^Q/NZ($RX28YTPU= M@9 8D/HXQKZ@7F-;#-U"[%\R@8;59$Z8=&?0VMA6N-M?#!*XAL5\3L(0#[\V M,IF<>RG2HU=@R)UAQ^V'HA^H74KB99?>C50C5J[T]GZU4*?W$ M5LK@S<*Z4@8\NN6>KYR2.1.5Q=YL.CW>*Z4VHXLS_N[&79S9.A3:J!LG?%V6 MTJVO5&$?ST?[H^:+6[U/PM-=RR76IC-?6"*<6YZ/+ M_5=7IW2>#_Q#JT??^RS(DKFUG^CA?7X^FI)"JE!9( X2_Q[4M2H*8@0U/B>> MHU8D$?8_-]S?L>VP92Z]NK;%/W4>5N>CTY'(U4+61;BUCW]3R9XCXI?9PO-? M\1C/'AV.1%;[8,M$# U*;>)_^93\T",XG3Y#,$L$,]8["F(MW\@@+\ZFESEF_1[4+G5>];H?37; MRO"#=!-QL#\6L^GL< N_@]8/!\SOX!E^0P;_ZW+N@T/>_'O(X,CO<)@?U=(K M7\E,G8]0+%ZY!S6Z^/FG_>/IZRW:'K;:'F[C?G$EO?84LQOB;8*D#!]2\@?8 MB(\KA6+);%E)LR:'U$;6N0XJ%YDU'M[))3TLM)$FT[(0'I0*E1K\6#RN=+82 MTBD!NRO\SX4VS,_E.*Z0WV$EELHH)XMB36]41>QD%X'*:3"N"L0 M 'ZW!N6 M?T>"6./+4CFDJMCY^:?3V6SZ^GYR-Q&_7%[>\//^ZQ=CX5>V+G(Q5X+0BCA! M_=]K$^& U2#6U]%0HML_>>V%-*:&38W)0U8*@"'3KI5T0E%*BS_RG>=(*] 2.%S'\'-*:,(U+M.7$@SQKX(#H#<<]JY^C%!H%! MJ+PGU*,X2K&0VG62B,E0N#JE*NMU# :G(J (&=]@$?21?B46Z'9=GH254TJ4 M$0)COFQ2<5PY(>@#D2"F:"PL0-._"O5"0J&_9F^4J*\5=4>$$4G@F9)?K:19 MQM)!^\@^K6R1*^>3(4)]KG58BQVT+H(YDZU?_(">$X:)C:C-9<$%'H<)?">% M# -U\0BW02'HW4NYKZHPY<66#!Z+>0TYEI,_-'G/^=$O#$<&$PS-UZ)%B8EX M^T2XTUI>5SE#RV;1:F:MNLQM *II$9NYPK#G%7,%NH#%KU2FLXGXCC:;\OS' M<6-+?SEJ^\O1UL9P[Q6I^A9559);AEK+]W'@=(D=(0(97@Z6>0J7[YO^5]^# M$1$LGCXIH5K>E)328ZZLN$) BL23BP4FOU1+Y*4-8.EJ.!ZAZ#?1'-2KJ\O$ MJU>@77&*O&:\Z4YRNB#;;4Y9@%)Z7NTAC65)"<)2<%11UA=:SG4![14>G'I0 MID[,U!-F=4]?TU-7!$1-:05=R(&1$9_I\6K2[=M(S'KW89QJQ$=$6-@"R,>0 M2[5@2Q7+E"H4E3DF5?R&&UY%_ZN@'.;;-CF 8FZIYC+[!'.\++B20^T,&STG MRK%XD$7=4FC4C5GJ>:%80PNVKK4U2R (^>U1[)ZQM!YDD@N(\4)P")LIVHG MJ9G2#Q)LQ_2EJU6^&8*^#XFR4$OX"[;!HMB>&L=OD*%#!G(LZ>KKN4?>TYD- MDWJTW.7RE&>DE 6,_&>K18S^N[2SY-POD!O\ZBN_(86"!3HE!/?CX9#47BWJ M E8\)$LK9_,:&>MH]>E*A'SN?=-+*2DS;O%=7ZQ]5%PE19 N2VOS1UT4O=@5 MUBQW"^X3*8PD5"/MM"/N$^!GJ+G/QU+,>.#+->K(-:W%^AY2;,/&XQ8;C[7?5;&5"?R6T(17W/(*U&]WEW7U+1=)W MIR=C<:>6G!FW;6_=^8AE(Q.ST^F+5^(]AF+2F-5'AL1CG%4-Y9O>:-@3U8CH MUL>XR!(_P*ZG!-A@[3K6/K'N-=PTQ:0Y%:6-Z4_#YR@K6R_1_N0^F$[\:0I)UMIU58 ')FK3/-5 M&PU7KO7-]6]O/O1VZBW*I;&+K5_6A22P2>YK88&XH8U"F,^DKCUS->M-H@S((R, MS\D+*]0I=*5A(*-L!%M;N^Q+U\O"V\[_O)+&@;P?BH1-Q7IC!VGSE>3,U08> M8X0!CI4)S;Z0"7A2/"'2QDUJ7[KNZ-%-R'$FX3N"]KW5Q!02S??U"7B'<+?^!FH_5##PR! M;2VFM;%Z.=YLQPFC3@Z',*H[^0UL>ODE-B40B:M2<-)XNF_#0L\!B-,:CX4\ MY+$4:K6]%.TGV,O^ZH5"KNHY(M7-EM WSKA\"]7D^YRO$!-+E"GB3/@@J'B6 MUO7V"A?+":[.T-.[VZP$$?V"[E]X4:*W5 AJ! ?6L*1[!BD^UY)4DYQ?-+=X MNO'8-.W/U4GC_ M_[F^97XY;>>7TZU#QHUR'$+2X#?DT?+Y47D[H[[M[=+CF[5WZ&IY<"JYMGEO MVN9J/)X>CS$@1#Z\+%QCVJ7K_HB*XII_?<$.UZO%:R)KZG#2DL?)L=G(N*/T MKX6X-A?$B18Z9XOF5B\M4+Z;9J/(IL+#&IKRK:[-$'9/MQ42G1PHOJO-+K8: MC)]*<_>L*YCF5[J*BY=#3Z/=R:WIWF&.\!I:-RE_B^*Y.TX:8=L;A;A[D&JM MFMWE?F.2ZWI[H_R DH,IM=?[U0ID2_YMCIDX,XC%^R6Q/2/+O4V;-F.[[4.G#Q ) M26A)0@4@N>K7]P"D:*55U/1%)*#=Q=G+V06OGI3^W:R%L/1GVW3F>K*V=O-F M.C756K3<7*J-Z/#/4NF66RSU:FHV6O#:*[7-- J";-IRV4UNKOS>>WUSI;:V MD9UXK\ELVY;K_:UHU-/U))P<-N[E:FW=QO3F:L-7XD'8'S?O-5;3T4HM6]$9 MJ3K28GD]F85O;C,G[P5^DN+)'+V3\V2AU.]N\4U]/0D<(-&(RCH+'(^=F(NF M<88 XX_!YF0\TBD>OQ^L?^E]AR\+;L1<-3_+VJZO)\6$:K'DV\;>JZ>OQ>!/ MZNQ5JC'^EYYZV0PG5EMC53LH8]W*KG_R/X5&K521^IBT>^:(1Y M=36U.,')3:O!VFUO+?J(M9C>J"D!O/SEM MWU'HC=GP2EQ/P!$C]$Y,;C[_+,R"MV?0)R/ZY)SUFP=0LMXV@M22#IXL]O2. M_Z;TB-^XK7NQ4=K*;D4/8@4.67/*E_.G/:X1)]6 MLZ.=34Q<%?^)0P8Z0&8 M/I:"5VL'RT)IKMH-[_:??U9$8?[6#&7LD#VM)<1D5\N=K+>\:?:@9:6VG14U MSM(4!B\)CU9I[Z2TAJRRO*$._6DX\0T]KK40'Y0:8J!A^5 I[B=^SNB,HI!> M4A3A9]R\I3#%.DR.-^<$/4@&QYMW@(5U22_/Y# ==-/IZ(N9%@\U)6O+,N)YIOQ-;*BJJ&&^.2ABB[Z'XE.J%E98AW-3UL M1"5Y8_=DAJKQVX:C&U"UYETGFF?5V>[;V?T7!U%&W* =6J'1I>"-:Y4UH9L< M9?7)!C,[. M.BM?RVXI_$R@%Y2Q$#E^02D+\X2^1K]7':IN2JA1H5=[5$#.NI;ARU3O ([,W5K30*EF29E0D+"TBFG-=2[7CIMHV M7!^$DI05>4%QQ-( 6#F:D((YH56C'(*"A66.>F5QEM /7=5OQP5+XQ@GL!3* M[P1XJAHDNI9&( 5P ?%5E492* Q96*14LBA+46YF P>LTGO_1YQ1&+$"I+@3 M;MR-IY9YZAY!@%-=*9VL)PBDB##"4)0I?>-@=]Q-$P3#Y5)YS9#E8&(7#B6 !G2$J46.CJD M.4MAU 7H7BQ=2!1]KZR@Y))F32-Y5PF?7]R* %IIG_.^173]E=&M_06N-Z_[ MB\9?H.@61-7$J?EG0B[/]-EL[+/9)_?984"BRZZ4ED@B]AY<4WM]+QK?>^\@ MZZ^))^?DV9-.S_P9@;;NTOP$KA\&8^MQ5!_@\,WUM1YPU".._]$KI7&]MQ_5 MYE^]<;SES+E9NP+T\Y9F5:6WL'5XWO*F3Z9%,"K1+I":X8385P*(AG)^@0$) MBD=X0<=@29'AK0Q85@;T7JN='&[KO3NHEGYXN*QK!]V#$[0![55-19&R&&,Y M#EB0HRC!4XS>#/S/0YIK46/.3#=\W\\B:8Q#6F^UOY \F[DHBYP!Z"NZB#*6 MI@%>PI2E98&7%#QT.T<._B-^+]!Z<_1G[QU>T *==^!34#CO0/8PI%,U.3VZ M>..FL/*?%QB5+L+]'7S<';]@9OW%_5F\__P!II5$VANQA&IPF6/FZ_Z3HE]8 MM?'7^(6RN);XUS6^PH1V OA_J<#+8>$.&+_K;OX&4$L#!!0 ( ,*%J%AC M4!O % 0 . ) 9 >&PO=V]R:W-H965T)HD&G8%P&T[$?6^CI6%56<(D+#:8J"J:_S5&H[22(@_W M$]_DU@UTIN.2;7")]M=RH>FKTZ!DO$!IN)*@<3T)9O%HWG?S_83?.&[-D0TN MDY52+^[C4S8)(D<(!:;6(3!ZO>(]"N& B,:?.\R@">D M*_&59S:?!# NO!929L;>)099J?^'2+5,$OV MS.;)1<#/3+>A&X>01$GO EZWR;3K\;KOX#TR+;G<&%@TV?X^6QFK21A_G,NW MANN=AW/-,C(E2W$24#<8U*\83#]^B ?1W06RO89L[Q+Z=$G-EU4"0:WA=(E" MF#/#4V R@P()ZKS4G&/+GS9 M:KJDZ7N,X*B4S @G +6LC*\I0)BOE)IFWX :YNXW#0Z[:< M.0AOG?5P2'D$7WW'8W;-7BG4!FN"5*W*&DOL76FOSQ2B&PW#9'@+<3\)X^CV MP.\HR7_!]..'FR0>WIFSYDW8JGCD"-7TE.:<51>-,=^AEQ'/:'M1L5T1_9,L63VX_%&Z%*:,=Q2/A>DTG M^&X/XAJXI%C^3K!5%='-J?W( >F$I\6]/BPL=ZF3#\79,NI^D.]M!"Z,$R*3 M) Q2@Y,.#1%/KK*VR_)<;W2.3EW:;#;^;F$H$=J?Z@.X&6VN+[/ZU#Y,K^\^ M=-9M.*VZP#6Y1NTAJ5S7]XGZPZK2G^$K9>E&X,VC%3G16- MQ$<-IFM;KK^N4*C#/$B"D^*IV=76*:+%;,]W^(SV]_VCIE4TH%1-B](T2H+& M[3Q8)@^KW-E[@S\:/)@S&5PF&Z5>W.+7:A[$CA *+*U#X/1[Q34*X8"(QC]' MS& (Z1S/Y1/Z3SYWRF7##:Z5^+.I;#T/B@ JW/).V"=U^ 6/^7B"I1+&?^'0 MVV9D7';&JO;H3 S:1O9__N5X#F<.17S%@1T=F.?=!_(L/W++%S.M#J"=-:$Y MP:?JO8E<(UU1GJVFW8;\[.*SYA7"LBQ5)ZV!)RRQ>>4;@2'\1BUQ]]G)9C2+ M+ 5S+E%Y!%[UP.P*< J?E+2U@1]EA=7W_A&1')BR$],5NPGXB>M[2),06,RR M&WCID'GJ\=(K>-]2-?#7+] MFV09]T'X*8@^"R*I(0[<0*G: MO6X,5HZ4K1&V2M!P-W('=XTDC>H,EY49/0 5K:Q]U3X24+M![1<_:V7,I2#P M%I(PR<=A,4YZ>3H-IT4,2Q>!R](%TU!JK!H+@E"H>G=I&*>3D?\S-H(U-9XK M)I0UUSO\8%^$TSYV4 MI.$D97"C;_*A;_+_U3?&U>@1=8F4!(G]R?>[S74+L=WWG2NN9)XG= Q6V5QE-GK:G5N/SZ_DW!DLD' _TQVZOP M!R1?:M&^(\W5!EP?&< 2Z+S?01;39U"N@$UIS;)SY1I8ZI1D?JD^T=D=3.8[ M_]*X62&*_74\:(?';-G?X=_,^Y>0..\::4#@EESC^PE50O>O2[^P:N]O](VR MQ,V+-3W(J)T![6^5LJ>%"S \\8M_ 5!+ P04 " #"A:A8C6 KBYT" "3 M!0 &0 'AL+W=O<' 4O *I>%*@L;UTCL?S2\2%]\%_.38FCT;7"4KI9Z=\1"$<$%+AFC;#W MJOV.VWK&CB]7PG1?:/O8F(+SQEA5;<&DH.*R7]GK]C_L :;A!X!H"X@ZW7VB M3N45LRQ;:-6"=M'$YHRNU Y-XKATE_)@-9URPMGL1KZ@M$IS-'#ZR%8"S9=% M8(G9G0?YEN6B9XD^8(GA5DE;&O@F"RS^Q0>D:) 5[61=1$<);YD^@WCD0Q1& MR1&^>"@S[OCB_Y3Y!E?D"-DH5ABC'_FP601PF?IBF\*@L$X1^UWU"!*$_&)K H6L( M]AJE0KWIQH&ABAMI^YX9=H>)<]XWVGMX/ZZH] V7!@2N"1J>I6,/=#\">L>J MNFN[E;+4Q)U9TM1$[0+H?*V4W3DNP3"'L[]02P,$% @ PH6H6"K56I?? M P 9P@ !D !X;"]W;W)K&ULC5;;;N,V$/V5 M@7:Q2 #!LB1?Y*QMP'%2[*)8-$C2[D/1!UH:240D4B4I.^G7=TC)JMHF:5\L MD+]O',+5XJ*^U^X=3I+I<>I*TVLNZ-R8.:B^[+GOL\C R2 MZ1L&46\0.;\[(N?E#3-LNU;R!,IJ$YI=N%"=-3G'A2W*@U%TRLG.;.\4-HQG MX[KCB-Z@R.& M;U*84L.MR##[NWU _@Y.1V>GKZ-W ;\Q-8$X]"&:1K-W\.(A";'#B]_ N\$< M*=8,]E(;[<.>-=RPBO^!F0]]AOQ19OJ,W'"=5E*W"N'7W4$;15?LM]?2T['/ M7F>W;7>E&Y;BQJ.^TJB.Z&T_?0@7T\_OQ#8;8IN]A[Y]H#;.V@I!YO"_B_U: M$._3G*%Q#"T==-I#LRYK)Z1\I;)N%->4&K(%]Q%(YASV20(C^Z?H P\L-5 M F'LAXMD@"0M.EN1$W,(0S]9K?I$G[/Q#XAD&I'V*EK!OF2JP -+G_1("2[" M2_)ZOIS#TD^6BQZMZ>GZW,:Q/T]F$$7^:I; HZ1+/*C\=V4^0K+T(XJ%%I&_ M2.:.]'N)-#Q!,WN'4C+18*I(@:[MGB#B1",AC^%6[@G3A-)*TSW#@S2X17==8_'7^K=$TRM5E"G0(4YF4XG MR[D'JGO6NHV1C7M*#M)0;MVRI'\"J*P"G>=2FO/&$@S_+;9_ E!+ P04 M" #"A:A8ER(>-*D$ !5"P &0 'AL+W=OB#[0TMH651"])Q4F_ MOD-*5KP;V\A#'Q*3U,R9RQD.YV(MY#>U1-3P4I6UNAPLM5Z=C<2U!-57'Y M>H6E6%\.O,'FX*%8++4Y&$\N5GR!CZC_7-U+VHU[E+RHL%:%J$'B_'(P]^=YB#WJ11 MW%YOT&]M[!3+C"N\%N77(M?+RT$R@!SGO"GU@UC_BET\H<'+1*GL?UBWLC$; M0-8H+:I.F3RHBKK]Y2]='K84$G>/ NL4F/6[-62]O.&:3RZD6(,TTH1F%C94 MJTW.%;4AY5%+^EJ0GI[\(D2^+LH2>)W#'WJ)$NYJS>M%,2L1IDJA5C!\XK13 MHXNQ)I-&<9QU\%NE@L]UCOF/^F-RM?>7;?R]8@9%[?B"&H(\A.(0^>:2;FC?DM)C#)IY=/AY$V>WCTQ(A M6U)24$%1PV*3+>H&0,5"?Q(1JI9C-!P#,90M>XIL7C?2K\AE)W6#&58SJK9. MT(,GK#!V8X:*HZZ)>F#2L4!8B MAR,(T\2)6-JMDM"'ZT9*K+-7(#)K57+;'(:).X(A8\'H#9 3BMA-3% MO\9L\7-,9W O1=YD&J3!5Q"=,N+-B=1 ECN1$7F23M_&6)%*78O$/79>HOR[1_W1='+AM MM.G;79VT]_SS"TTS"G?=I8.&]W?'M^+7YI$$^[6FC,U;\WS;/+;F^X98XXN& M.05@6Z.R[)D*0S[7**D%O61EDQOP(R+H-*$)H"P-$(5??(#]H:&7N>=W]P_' MO%J=W]B]=S[:P?#/=[=+WP.:T2ZGJB>;]A83T52N@<_,-@2/$>]^8C81Q#Y5 M2&C6,83,B=S(K!/PZ29%OEFGP.AZ) $\]7$"E4J2I%WM'?6UOZM>QENC3H5R M80E-_%VX*3F1"^&@A+GI.J>QM1-93O$M1LM5G9P MF@E-8YA=+FGN16D$Z/M<"+W9& /])#WY#U!+ P04 " #"A:A8F5H\:O4" M ?!@ &0 'AL+W=OY-!:.G=E."]]^YR1DG52JO7'\[ M_SFYRVRK]*,I$2T\54*:N5=:6Y\%@:#!-53']O$2AMG,O\EXV;OFZM&XC6,QJ MML8[M-_K&TVK8*#DO$)IN)*@L9A[Y]'97R4JI1[>XRN=> MZ 2AP,PZ J/'!B]0" $=(Z[\Q?Z99L[Y;)B!B^4^,%S6\Z]4P]R M+%@C[*W:?L8^G['C94J8=H1M9QN//<@:8U75.Y."BLONR9[Z>]AQ. U?<8A[ MA[C5W05J57YDEBUF6FU!.VNBN4F;:NM-XKAT+^7.:CKEY&<7WVR)&LZ-06O@ MZ)ZM!)KC66 )[0R"K,"3S#'_US\@28.N^$77,CX(O&;Z M!)+(ASB,1P=XR9!GTO*2_\GSY_G*6$T?Q*]]F7:@T7Z0*Y(S4[,,YQY5@4&] M06_Q[DTT"3\!*VD):2QH9A', MEM5P%!W#6QC'_B2):9*D?G@ZA3O,&LWM,U5*K0PG+8D_B29N#&/XHN3Z/9$J MH+NL&<\!GZC=&'1FX71*8YPF%+] K4FXQHT2&Z,:WA@HD&X1F8:C=2="$F7UAM-R(A+)C-.V"M)'UG3FNS[,H*= MHJU0K]O69"B11MJN?H?=H?N==T7_U[QKG?2ZUEP:$%B0:WB24K/173OJ%E;5 M;0M8*4L-I9V6U,%1.P,Z+Q3)[Q&PO=V]R:W-H965T:&ED$:%$E:3BY-]W2-FR%W6,O8CD M:.;->QQRN-Q)]:(;1 -OK>CTRFN,Z6^"0)<-MDS/9(\=_:FE:IFAI=H&NE?( M*A?4BB .PSQH&>^\]=+9'M5Z*0(>/"O30MDR]WZ&0NY47>0?#$]\VQAJ" M];)G6WQ&\T?_J&@53"@5;['37':@L%YYM]'-76K]G<.?''?Z9 Y6R4;*%[OX MK5IYH26$ DMC$1@-KWB/0E@@HO'O'M.;4MK T_D!_5>GG;1LF,9[*?[BE6E6 MWL*#"FLV"/,D=U]QKR>S>*44VGUA-_IFH0?EH(UL]\'$H.7=.+*W_3Z@K#>AV8F3ZJ*)'.]L49Z-HK^AD8RFDC@W*/?S?BQQ_@)_ @.]-H M^-)56'T?'Q#7B7!\('P77P1\8&H&2>1#',;I!;QDVH#$X24?X.UUZZ-P)C3\ M?;O11M&1^>>0E\_ MT[6L!BJ4K.&'BG=.P.44$VQ_ LOVL'@X$SM4"*5L>\4UV8F.:1!J*>B>\VX+ M5[PCBQPT1>OK&Z#"E>8G<69G:>)G\WA2I] , MJJ.JV72L*Q&NHFN(DKD?A0L:HOPASFD1_%1\ 'K'C) M>.7$DG^+JN1,4*(-,_8*$'R1^_,H@B+T\R(\4I'O3!A./E'AS^<%Q(F?I#'< M'T'*AJDM 94OXSD[@$:A'\?Y83@ ]DK6J&W;H] :K5_J9P7)BOPPS"8_21NN M("O\(L\@7?AQ5, W:2B(_5 %/T&6+?PL6MA9DOIY'CN93U@3KI'PNS0(R8P, MK]@-2&,IMQUWNTCO 3#2+NS+L&-J.@$;)EP]:B7;,U4FV.]/PNS%D;WKCQMI MJ-NZ:4//&RKK0/]K2=NP7]@$TX.Y_@]02P,$% @ PH6H6,X&UL?55MC],P#/XK5D'H M3BK7U[7;V";="PBD0SIQ!WQ ?,A:;XU(DY*DC/OW..E6AC3V9;4=/X\?UXN[ MV"G]PS2(%GZW0IIET%C;S:/(5 VVS%RI#B6=;)1NF257;R/3:62U![4B2N.X MB%K&9;!:^-B#7BU4;P67^*#!]&W+]/,-"K5;!DEP"'SBV\:Z0+1:=&R+CV@_ M=P^:O&ADJ7F+TG E0>-F&5PG\YOZ=>ULS@K1)?>6V;93 -H,8-ZX7] MI';O<=_/Q/%52AC_"[LA-RT#J'IC5;L'DX*6R^')?N_?PQ%@&O\'D.X!J=<] M%/(J[YAEJX56.] NF]BXMG#QQ-8"S>4BLD3I M#J)J#[\9X.E_X!E\5-(V!M[*&NM_\1%)&?6D!STWZ5G"CTQ?09:$D,9I?H8O M&_O+/%]VKK\[;BJA3*\1OEVOC=7T7_A^JMF!*S_-Y>['W'2LPF5 %\"@_H7! MZM6+I(C?G%&:CTKS<^RK1[IO=2\0U ;NE=R^MJA;'HO^F#>5?NC[+,BSC#XOD;_JPCFF26TX3%K@A:'Q53@+0 MPXH;'*LZOU;6RM*2\F9#7P74+H'.-TK9@^,*C-^9U1]02P,$% @ PH6H M6$IJB3;= @ 0 8 !D !X;"]W;W)K&UL?57; M;MLP#/T5PBN&%LABQW:N2P(T[8H-:+>BMST,>U!L)A8F2YXD-]W?CY)3+P-2 M/\0F9?+P'$EDYCNE?YD"T<)+*:19!(6UU2P,359@R4Q?52CIRT;IDEER]38T ME4:6^Z12A'$4C<*2<1DLYW[M5B_GJK:"2[S58.JR9/K/"H7:+8)!\+IPQ[>% M=0OA2X8;6P=VKW&?=ZA@XO4\+X)^R:V#0*(*N-5>4^F1B47#9O]K+?AX.$ MR5L)\3XA]KR;0I[E);-L.==J!]I%$YHSO%2?3>2X=(=R;S5]Y91GE]]L@1JN ME=Q^>$!=PC5G:RZXY6C@](&M!9JS>6BIDHL/LSWJJD&-WT!-X$9)6QCX)'/, M_\\/B6%+,WZEN8H[ 6^8[D,RZ$$TBW[0.PE-YE0IM8(/\[7 MQFJZ+S^/*6^ T^/ KH=FIF(9+@)J$H/Z&8/E^W>#4?2Q@W;:TDZ[T)?WU)-Y M+1#4!CI.[ACM;N &3#@PZ\#$P<[LD/8D4V6EN<'Z M/!57F88 \TT\F/2B<0+QH!=/$KB@2T8,4%J*HCF1HV["3@=GD":)_W5)&_:& MHRF,>^EH! _*,@&J(_H$XK0W'$^=,>V-R'!U[G!#&5;!5V41!L,^7#&NX8F) M&N$&F;M2-,6LH2W3P/+/C02FD[LW. MPMX7.SLSM5=2XQ<+KBY+89\N49G5>6_86V]\EH]\$V\F6N7!X9=1?,O?%>6_2@QP7HE;^JUG] MAJT]@6!FE M_8=7<'4][D-7.F[(5)@:EU,U_\=CZH2,PB=\02%J!)/!N% 66 MU\*+V9DU*[!\F]!X$4P-TD1.:@[*G;=T*DG.SVZ$M/!-J!KA,PI76R2/>P<' M]V*NT!V>#3QIX;N#K$6\;!"3-Q!3^&RT+QS\JG/,M^4'Q&Y#,5E3O$SV GX6 MM@_I,((D3D9[\-*-R6G 2]\W^5JZ3!FVVL'?%W/G+67)/[ML;B!'NR&YH7/X),5< M*NDED6]CEX/PT+&/TQZ^8E9;*_42+H63;I=U^_7?%P@+HZA^&<1S8D!@03W! M%^#I^,J4E=!/'S],DN'XE$ZD%CJ30H%X)JPZA'U!3%=H$F\\ MD?^C-IZ.[^12RX7,! ETUVTP;K4G0YP'*SQY9B4J.!@>PD]PE$3':4*+X)?D M=-=6-XK7N$#+KLC(G=3X1&AM?ZI MM7WZIN5\PK:$ GA.S;*3/Y2.N_)?OG9*IJ@4*'/(P)7T!:7G)WQ !L#R<*6QI"D' 4O:UY"S*H)=%9(R62@%KI.K4EJ66IFRD@Z*:J6]\@P^JR MXFU');L4-LA7POD(0C_4M&"!1>UKN];%8ZNI,=?-NT0$MF@8W?7_S[L\WP\I0S%TN)5([ IJ,,;F3?-AG+;W- $1I:DY MQ"LZ)V:\%;*Q$M;+3))"[Z(03,@*0:G&VEL(!B;G_\O0;CNC\9'7V ]IE0F5 MU:JUI5&;OUT'9J[DLOFFQ%@GQ,*:LAO4UKV4#P+F3SPZD4=TAFQ$\5094D+\ M0SP?R%.-8YM!B=!((EC:,;+/E;+G(3O:/&1'^Q^R9O)[JVAN:6"8$P6-SFT_ M9+O>K+VJ=K_(VP]9*"VWGY)\0:E3HR\?F!8^VA$^&PGA-XK1UQ,UU MFD3Q=!I6<30>3U]?XY:>1&DZC2;CN%DGDVB8QG!'PRQ:%VK&T?KS<1.%B\EE;S"!8G&_3&% MQ#93&94$_'-#R!3I?&"+>?K""S4^1V7]02P,$% @ MPH6H6%4'=1;+ @ 7P8 !D !X;"]W;W)K&UL MC57;;MLP#/T5PAN&%6AKUTDORQ(#2;NB?2A6-%OW,.Q!L>E8J"QYDAQW?S]* M=MQD2(*])+J0A^=0)#UNE'XQ!:*%UU)(,PD*:ZM1&)JTP)*94U6AI)M.++PKJ#,!E7;(ESM-^K1TV[L$?)>(G2<"5!8SX)IF>CV=#9>X-GCHW96(-3 MLE#JQ6WNLTD0.4(H,+4.@='?"J]1" =$-'YWF$$?TCENKM?HMUX[:5DP@]=* M_."9+2;!50 9YJP6]DDU=]CI.7=XJ1+&_T+3V48!I+6QJNR1(Y+]RASJ^F6DY]-;KED,N5, MP+TT5M>4;VO@XS>V$&B.QJ&E&,XR3#N\68L7[\$;P(.2MC#P16:8;?N'Q*TG M&*\)SN*#@ ],G\+@[!CB*!X>P!OT@@<>;[ '[P8U7S%7"EN*F,8L9S)B@ M*D"8NSHRN_0=9+!;WW3=Z8Z(+1!RQVW5<\O>N/%M;LXXW>2WZ/CY.C?0,'HP M [D2-%.H6KV+J@T]HCD: 95,6O0U0SE(L5R@7I\,-K)"+XR&+Z6/0I#K$MA, MUE9R-A*\_^*9:>X:Z,2JDYR_$C27%BDQ%C1% M.P"KZ22@U38YRB]W >'U\, MXG]/!Y?'T=4GV%4DX4;3EZB7?K09RELM;=O__6D_/:?MT'@S;TGD>@&['6;NQJO(C9*$L#22_+.@+@-H9T'VNE%UO7(#^FY+\!5!+ P04 M " #"A:A8C!4VM/\" #2!@ &0 'AL+W=OR5SK9S_Y7$R"R M"@;GS"(P^+SA#(3P0R?BUQ@PZ2I^X/=Z@?VR\DY+]?"-K^P:O<.B#&OK=-RG4QSR57[ M9:_K.FPEC*(W$I)U0M+H;HD:E=?,L>G8Z!48OYO0_*"QVF23.*[\H3PY0ZN< M\MQTIJ7DCJKL+#!5P$PKQ]425<[1PM$7-A=HC\>A(RZ?$>9KW*L6-WD#-X4[ M0BHMW*@"BW_S0]+8"4TV0J^2O8!WS)Q"&O<@B9)L#U[:&4\;O/2_C%]SFPMM M:X/PXW)NG:';\W-7%5J2;#>)?U'GMF(Y3@)Z,A;-"P;3PP_Q(+K88R'K+&3[ MT*=/]$*+6B#H!5E+]MN M+]M4U"% -!RRY8 54OUR+2O#+6D@F:Y$VB>H%5"MX8@KBNC:DFI[?+[61A^3 ME]U9PS7F*.<47T=2N*^88G#S2)4<9A?DV7%GZ*V 5[)DS7,_@,,/HR1.+FC4 MCWI1%+TG[83EN:E)*U>D!&EM@Y+TTFP(,_["!7C_N>%50Z0KKGFQ39U&O3B- M((E[\>@,[LFSZ6#27M9/8%8;0S4K,:%8^P"^R+>9LZ<,]0,9WNI[G6):."QYD+/ MO=*8W640Z+S$FND+N4-!)QNI:F9HJ;:!WBEDA7.J>1"'X2BH626\Q8>-VVI;&KL1+&8[ML4[-%]V-XI608]25#4* M74D!"C=S[SJZ7*;6WAG\5>%>/YN#5;*6\MXN/A1S+[2$D&-N+ *CX0%7R+D% M(AK?.TRO#VD=G\\/Z+\Y[:1ES32N)/^[*DPY]R8>%+AA#3>W:"/KSID8U)5H1_;8Y>'?.,2=0^QXMX$H-)O7DWB:'P%[[\WE7D")@JXQ0+I M+UASA$]2O%U)893D!+*%#\*@0FTT#/ZT!GHX"PPQLKA!WD5?MM'C%Z(G\)$0 M2PWO18'%L7] 2GHY\4'.,CX+^)&I"T@B'^(P3L_@)7UZ$H>7O(#7I>+K]5H; M17_0MU,:6XCT-(2MJDN]8SG./2H;C>H!O<6;5]$HO#I#,.T)IN?0%W=4I45# MUR,WL"J9V**&2L!UGC=UPYG! CZ;$A6L9$WA2UM.#PB#/Z360[K#7-8(ZR=W M+ 4*(A^"J.;XBKGX69<-^/.BB M4LG+OE8Z4>G(B4IC?YQ%=B\F>5$T?#$;\4'YY."8Q-9QZD^3Z7]/Q60Z@<'8 MCY*6<)R,AY0*QKG\F0:Y%]2LRFI'-]6WH&A*'G$VAE%\6F%[19$_&D_=M65^ MFMH]TC=*X50E!L^Z:HUJZ]X.36H:8=H&V^_VS]-UVY5_FK=O&S'95D(#QPVY MAA?CS /5OA?MPLB=Z]%K::CCNVE)3RPJ:T#G&RG-86$#](_VX@=02P,$% M @ PH6H6/T4-TD1!@ LA !D !X;"]W;W)K&ULK5A;<^(V%/XK9]C.SF;&67S%D LS)+O9[F0O#*3M=#I]$+8 -;;E2C() M^^M[C@P&ND#);!]B+%GGZ/O.5LZY@><\*_1U:VY,>=%NZV3.R,IDH^%"!KO*< MJ>4-S^33=,830QH8_BSX+<\R4H0P_E[I;#5; MDN#V^UK[G>6.7"9,\UN9_292,[]N=5N0\BFK,C.23S_S%9^(]"4RT_8)3_7: MH->"I-)&YBMA1)"+HOYESRL[; ETW0,"_DK M[CKC2S*=\RP_I623Z!H-6JC M%TO52B,X49!3QD;A5X%RIC_B&3,\A2%39@D/BA6:67MI>// )AG79U=M@QO1 M\G:R4GI3*_4/* W@LRS,7,/[(N7IKGP; 38H_37*&_^HPL],O87 <\!W_?"( MOJ!A'5A]PIS#!G13$#0Y&P2ESQC6LP M^/E6YB4KEJ]?=7TOOM28HC6FTF(R.Z$D"A21E69%JL\NX&&N.-\)$D 7)W/K MXUUN* %?F*F4Y;W%%&Y9:7]1]PW+6)%P&-LZ1B)C@SJP>!B2^EIRQ6HD%$#T M".">Z;E8P(V0.A$Z?P(_P MX<7P;FN65B4RS[E*!,O$-U;7GQERMM_/X0,K!)I+/,,@X834RMQRH^3N])&= MK=W]2WR+W!=N?R>RF6+:B-PN'O+9=#-S#B.Y9!F:GC]CZ4?Z;] CO'J4=O'= M,BL0)SM#_VMKW9F4J08MLQ2QA$[D=\@D88@^D H+^];61^B\B>,S^@F[9_"Q M6."D5$LH*UR-+M!0892H'9D?Y'F U6;O6O\>CI[C>YTM#WS@!5?&6.^:B_B?0K=BSN%*88*) \W&,G=58X>JBJF,1 MK=&,:7??W][^9>'V21:S<]H>TTH4?V$_MN7D"-O(=;=V^XK51NV4!8$!<<\* M5C@V9\]!UAF.&]09>X(7HYY/STX'QI7!LL;@CN4"#3CB%/T_H#GP0GJZ$0QL M$;G_O5:6MB=MMIH;LN21S4AMO4W9C#>6.X6$X[J>#HRF60Q'7X>'K'P:Q)#L',:H"QUH 6A#6/1:;8(E'X]GMIYC7Q-4 MY(^$'7)%QMTN#+)'KG)BZ5 M 2S:N846^9Z%%OT'B1Y/!]\+#V4I12R&&L#Q;W@]%[*T*AN@[S<^PGB:IL%T%#<$J,HI'[(@TJ M"T/?_IT0P($3!3Y$80\/'T4JX39C6L,-=GUA8(Z)MI%/*5'$9)5D =HT_M[+ MPRS!TD5IN>/&DBWW^S!VW)A.HK93/;7,@']3UTL[R^S6.^8Q!K+.=3%'7?QE$+5'U#K@=&EO96 M.I$&[[CV=I1+.L!K1!\V^*_C]02P,$% @ PH6H6#2L12?1 M! 5PL !D !X;"]W;W)K&ULI59=;]LV%/TK M%^Y0V 1DQ3UU28&DJQKBZ%KD73;P[ 'Q:)MH9*HD732_/L=2K:2UFZZ8B\V MO^[AN?>>2]W3.V,_N8W6GCXW=>O.)AOONQ?SN5MN=%.X$]/I%CLK8YO"8VK7 M<]=9792]45//)>?)O"FJ=K(X[=<^V,6IV?JZ:O4'2V[;-(6]O]"UN3N;B,E^ MX:I:;WQ8F"].NV*MK[7_O?M@,9N/*&75Z-95IB6K5V>3<_'B0H7S_8$_*GWG M'HTI>')CS*

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

&@V2(/RIHO=4TGS&LKW]TKW]>9,3@G8Z@I8T.AZUJA:Z5"+[ 6,@@)A XX MBN@*XN,BI0F>)FG"W]O<4.:YM+_2"9OHA'DZ8?[UP:!C7=ON_G@>Z,P9:H(U M;+/,CU=KIM*W/RN%$F#2,4)C(=PJ%SW24>W:9%-GN=2VBC;8O0_NX'!>I36K MIY7F:Z4%6FGAZ?9MVK3SHM;ZJ>F5NJ=20R^6QSJXN,'P4!V=.3VM-%\K+=!* M"RO:;A?9Y=I[+YP\ MK87Y6FF!5EJHBU8ZU-U9,,J SHO%0R8FQZN('Z?$<*W.S)!O&ULK5;;;MLX$/T50@V*!&BLB^^I M+2"V=[$%VB)HFNTS+8TM(A3I)2F[^_<[I&15=A0U"_C%%LF9PSESX\P.4CWK M#,"0GSD7>NYEQNSN?%\G&>14]^0.!)YLI,JIP:7:^GJG@*9.*>=^% 0C/Z=, M>/',[3VH>"8+PYF !T5TD>=4_;L +@]S+_2.&]_8-C-VPX]G.[J%1S!/NP>% M*[]&25D.0C,IB(+-W+L/[Y9A8!6;>Q",I;&C!S3=Y M^ LJ0D.+ETBNW2\Y5+*!1Y)"&YE7RFA!SD3Y3W]6CF@H($Z[0E0I1.<*@U<4 M^I5"WQ$M+7.T5M30>*;D@2@KC6CVP_G&:2,;)FP8'XW"4X9Z)OXLM28[4.0Q MHPK(+5G*?%<8ZGPL-V1!-4L(%2E9,5X82,F9QO4*#&5[S"G7X>G[_#ZK^!] M+7)0U$AUU^:;4G?0KFL;P)W>T03F'E:X!K4'+W[_+AP%']N(70CLA.:@ICGH M0H^_8K_B-J^H,8JM,?_6'(B1Y#X70#EYP-S)\?+"L(1RS)M/(NFU>:2\9N2N ML1UL']].P]$ 0[%OL5B D5NBKT1I>,EH7 CLA.JJ) MCCJC]\#&-8_Q!7BD5=_[#9/QVYB\%.MB,JF93+K;Q+%^;%]V M1OZO2GK_;A*%XX^:+#E%D'N2R#S'_H^O3_*<29Z"TJTI/;ED2E\([,2!T]J! MT\Y46-3)FDK.J6IXLC7:)=JXV4""WGF7:14*ANVA#H-?+W;0:>NJD9!OL[8" M_(VY[5(O[/4;PP8^3ELW@VE,F4*8\IVM=^LY[]Y--V?["SO_N2'F%TPY/.(K MNF5"$PX;A QZ8ZP75T$]%-T^T05 [!L4-TPB&L'$)+M(S,TKK& M"B]F@N^1,-8:S=Q8;:RW9D.8V<:-$OHIT7YJ\8%+B7(0:)-B >@OM(&X$$01 MD.CM0TR+!!*T%3Q#UX062@_>8L$(VS6]5CS+"X7MOIQ=@\*$RM<:2YJG\O%" M&/J<\D)BELB9JW3P)@0WK@)=EH$&)P(-T4?.5*JC8CJDMK^K2=?,@T?FRZ 7 M\",6YRCT_T2!%T0=\:Q^WCWL"2>L-R*T>-$)O$TI$M^B3S1!Z^)VQ=&*8KT[ M2Q3S+-/2ZF2([[J4ZT4V+X)+F>,8YHZN= GB'IS%JS_\L?>FB_9 8"T1HEJ$ MR**')T2X8HHD)L]T:9_.Q&:Z:;WJA%S7"?GM@P9&[Q5D\GN78-&0@@T$UA)L M5 LVZLV:-5>@-<.4_D"U-]D_M?!'@>]/:K,6KW'-:]Q?#2;5$<_-'G>^+'K=G[N# X&UF$YJII,7 MD?*3(04;"*PEV+06;/I;4W[Z)*&#R!L?97V'T3@,NG/^HB9VT4OL!J02)#;? M6/NF1P4CJC/Y>W&>NY<#@;4H^][A^.&]B/2OPAA(LZ'0VJ(USFS^;RV!:OG6 M2]V;AI.C(N@R\T>3<7<9^,&!7M!/#X3M3U@,_U<)_4C/WM:!T-J\#R= /WP9 MM3#H>7$HM+9HAQ.CWWN^^O6U$#U)\LDT>%(*'5:>/SVJ!+?1IV4@=K9]E?IX M7S!5-B[U;-TB7]G&\&A^:5IGV_\=8,J^6[ MVV[PEBO=6]K;5+?_((R!?K[E6M!J8!:H_U!8_ =02P,$% @ PH6H6%\! M3],\ P H H !D !X;"]W;W)K&ULM59K;],P M%/TK5D!H2-OR?HTVTN@$3 (TK3P^(#ZXR6T3S;&+[;3;O\=.LM!V7@;2^-+$ MR3TGY]Q>7]_)EO$;40)(=%L3*J96*>7ZS+9%7D*-Q2E; U5OEHS76*HE7]EB MS0$7+:@FMNZ>S5Q' ]J(;Q5LQ;+&1'M+]KVL8Z%\D9(5O=@I:"N:'?%MWTB M=@!N\ C ZP'>WP+\'N"W1CMEK:T++'$VX6R+N(Y6;/JFS4V+5FXJJO_&N>3J M;:5P,OO"<0'H/,]90Z5 UY!#M<$+ L?HLRJB$S17A5,T!!!;HB>"CRY XHJ( MUPKV=7Z!CEZ^1B]11=&7DC4"TT),;*DTZR_;>:_O;:?/>T3?)\Q/D>\>(\_Q M @-\-@Z_@'R ^_MP6V5J2)OSQ486B M2PFU^&FRV?$&9EZ]6<_$&N1.[,VN(5-9Y9:3@H#4>5SAB5 M7)42RDO,5W"RP/F-RC(MD, $!-HPTM2 \+TAH_[PH;(@C(,P.'!@B O#U/<# MLX=H\!"->\"B1$4EVLIX0FKT4((7!VYXH-04YB?I(\F.!Z'QJ-!YLY!,8F(2 M%AMRF,2I$QTH,\2%2>0%B5E:,DA+1J5]9I3O]AB3Q%&&?VTEST2V9S8=S*;_ MJ9NFSYF"9R+;2X'K_#F G=%_O#M4#?WT&%&0QA/3>= MHRA)P\/-8XIS_=@_ MW#WVSOB@9S=UYJXJ*A"!I0(ZI[&JUNJ$1*X#E#O MEXS)^X4>4H:A-/L-4$L#!!0 ( ,*%J%C2,&V"XP( " , 9 >&PO M=V]R:W-H965TICV8Y$*B)G9F&^C^_6PGN D+42OE!6+[GI-S["-S"?:4/?($0*"G M/"-\:B5"%->VS:,$QY[1DI*RM*']7@-IY:CE($&41"46#YM8,% M9)EBDCK^5*26>:<"UI\/[!^U>6EFA3DL:/8SC44RM286BF&-MYE8TOTGJ Q= M*KZ(9EQ_HGU5ZU@HVG)!\PHL%>0I*;_Q4[41-8#D:0=X%&XV6;E*BCO%!,+F:2IP(OS$< YI%$=T2P=$2(DAW M>)7!!?HJ0_0.+2B)@ B&]:[3=:V$H[,;$#C-^+DJU&*!'2&6*7^4JRUO"&PA M#2@9=E2)G9=BO1-B?71'B4@X^D!BB%OPBV[\J -ORXTSN^<==F_N=1+>839 MOGN!/,<;MNGIAG_>$@EW--SOD..;P_0UW_ $GSF"6=O>=F+5=7'-"QS!U)+W M 0>V RM\^\8=.>_;C/5$UK Y-#:'FMT_9?/_@/WZ(FO0K8"<_V[S/NS3>T]D M#>^7QOME]Q$WO#/E_:P IN;.VXR7;!/-IJ[T7>@,?"^P=W5#;45#4]/0.3(Z M1R^+XKQ-52?VMC"9M8UN33G274_9CIE9T_[.=--G/Y>7O;/L*C8IX2B# MM80Z@[&\GUG9CI8#00O=T:VHD,'6CXELX8&I KF^IE0&ULK55=3]LP%/TK5H8F)C'RG5#61H)6:#QL0@7&P[0'-[EM+1P[L]T& M_OVNDQ"5$KH]["7QQSW'YUS;U^-:JD>]!C#DJ>1"3YRU,=6YZ^I\#275I[(" M@3-+J4IJL*M6KJX4T*(!E=P-/"]Q2\J$DXV;L1N5C>7&<";@1A&]*4NJGB^! MRWKB^,[+P)RMUL8.N-FXHBNX!7-?W2CLN3U+P4H0FDE!%"PGSH5_/DUL?!/P M@T&M=]K$.EE(^6@[U\7$\:P@X) ;RT#QMX4I<&Z)4,;OCM/IE[3 W?8+^U7C M';TLJ(:IY ^L,.N)<^:0 I9TP\UV,'!]](D>$"7*WEAM-1:''KD&!=ADW[\1PT/LV9S6>,P, M*$;YX$ZV\*2!VU*QS?Q1DH;IV-WN>G@;%OAI&D5]V"MU4:\N.JCN 4N#/6N5 MDCGH07TM0;RS<)R.@FA/WD#4*$["875QKRX^J.Z*"88WLB K*8>O0?QFV="/ M1Z-@3]U F!=Y:3HL+^GE)0?EW4E#.6:OO]Q#"I,W^Q:G7A*'>PH'PL[\\&Q_ M>]V= F4?![SH*R8TX;!$H'>:HD?5%MRV8V35U*R%-%@!F^8:WRA0-@#GEU*: MEXXM@_VKE_T!4$L#!!0 ( ,*%J%A\.6C : , + * 9 >&PO=V]R M:W-H965TL5X, M#9IVNQAV04O'%A%*U$C*3O?K1TJRJEBT$6"[L47IO(?/>?FY.'+Q)$L A9XK M5LNE4RK5W+FNS$NHB+SE#=3ZRXZ+BBC=%'M7-@)(T8DJYOJ>%[L5H;6S6G3O M'L1JP5O%: T/ LFVJHCX]AX8/RX=[)Q>?*;[4ID7[FK1D#T\@OK:/ C= M-3!F,FF.OX>DSMBG$4Z?3]D_=,7K8K9$PIJS/VBARJ63.JB '6F9^LR/O\)0 M4&3RY9S)[A<=AUC/07DK%:\&L2:H:-W_D^?!B(D AQ<$_B#P7RL(!D'0%=J3 M=65MB"*KA>!')$RTSF8>.F\ZM:Z&UF88'Y707ZG6J=6#@(;0 OWRK">&!(E( M7:!/J@2!UJT04"MT+R4HB7Y"CWH.%2T#Q'?H];JW&U"$,OE.9_CZN$%OW[Q# M;Q"MT9>2MU++Y,)5NA+#X^8#]?N>VK] _1L1MRC -\CW_- B7U^7;R ?Y<%+ MN:O]&TWT1Q/]+E]P,=\.=,T%6G.IY U:DX8JPN@_4-RS_;K/F?DKTP M*AB-"JYEUT8U7%+5SQ92'$B=@W7X^S1QE\;L1(<5SH)HX1ZFE)K7M-;C8O!L='V*:-)QF*3>&=T\* V"T$X7C731J^@$[%M&%!?? MT [L#D9S1A]G9XSSH#@(L)TQ'AGCJXP?ZYQ7T(TP[V:[(L\:. =Z(%MFAXUG M'%C#IF>TEJ@ QZD=-QEQDU=9JBGM;,FLU\SWSJ?B/ CC-,OL:.F(EOXWM-1B M6^KY9VSSJ"SS+Z!E(UIV%6U=$K&'+5;:(M M$/WUJ&\HWG0WC"U7^K[2/9;Z2@G"!.CO.\[5J6$N+>,E=?4O4$L#!!0 ( M ,*%J%CT *N%MP( &4' 9 >&PO=V]R:W-H965TE>.JE:U:S;AVD?'+B 56,SVX3VW\\V MA*4=8YVT+^"S[WG\W/E\CALN[F0!H-!]29F<.X52U9GKRK2 $LL37@'3*QLN M2JRT*7)75@)P9D$E=7W/B]P2$^8DL9V[%DG,:T4)@VN!9%V66#PL@/)F[DR< MW<0-R0ME)MPDKG .*U"WU;70EMNS9*0$)@EG2,!F[IQ/SI:1\;<.7P@TQK+&$ M):=?2::*N3-S4 8;7%-UPYL/T,43&KZ44VF_J.E\/0>EM52\[,!:04E8^\?W M71[V )IG&.!W /^Y@* #!#;05ID-ZP(KG,2"-T@8;\UF!C8W%JVC(Q8>C,@) M^O,*+%_PM_/Z=L/U5Y=R@T7V?2C1+=%TF,ATAS-9X13FCK[^$L06G.3EBTGD MO1F*\C^1/8IYVL<\'6-/%IABEL(16D-.&",L-V58@2!\J$(6+5MDV4P7VR;A MZ2SR3V-WNQ_2H-LL#'JW1V+#7FPX*G99"P$L?4!*8"8I-LUJ2&3+$N[M?CSS MGB@,?U-X[)LB'-(7]?JBYR43](4?36,TE)]P^C2-H]O]:V6X>YVL!)';!B]1 MRFNFVJ;6S_9OR+EMG>XO]_8!TA=75XM$%#8:ZIV\UMD4;5-O#<4KVQ?77.DN M:X>%?@=!& >]ON%<[0RS0?^R)C\!4$L#!!0 ( ,*%J%@)<1O#\0, #<7 M 9 >&PO=V]R:W-H965TO&>"B M 56E&WA>XE:8U,YLTLP]LMF$;D1):GADB&^J"K,OMU#2W=3QG=>))[)<"37A MSB9KO(1G$!_7CTR.W)ZE(!74G- :,5A,G;E_D_FQ C0[_B2PXP?/2!WEA=)/ M:G!?3!U/>00EY$)18/FUA3LH2\4D_?BW(W5ZFPIX^/S*_DMS>'F8%\SACI9_ MD4*LIL[(004L\*843W3W&W0':AS,: YNAN>_9&N!0+/)LPND-,[99L MZJ%1OT%+O4BM7I1GP>0JD3@Q^Y728D?*$N&Z0'^(%3!T7PM<+\E+"6C..0B. MWJ-Y41 56%S*Y?;U5&%^DX+ I'PK=WQ\3M&;']].7"&]4MQNWGEPVWH0?,.# M$#W06JPXRNH"BB'>E:?ICQ2\'NDV,!(^8':%0O\="KP@TOAS=SX\U,!3,SR% MW C/SH<'!C'"/KYAPQ?^7WS__EVNH'L!%?]'%Z26)M+3J'1UP]ZRJT=5+5;5$-E#U MNE?UVJCJ\QIR@DOQ1:>4$7II[K1)EMHDRRR1#?0?]?J/[-QC(YNQL$F6VB3+ M+)$-8C'N8S'^[GML?)J8DR3496:CC4NU/=ML9LGL0#C?V__;]LS200V,Y-H[ MS0R]]-6URI9:9RK>O\7QCV3*;;S_,GS*M>%;+.JMLJ56V MS!;;, 3[TLZ/+.44F_7;G56VU"I;9HMM&)%]6>F;ZTIC3CDM"Y-QK$TI-NO" M]&R[F2V[K7CN08.P ED"JLXL1SG=U*)MK/6S??=WWO0\C^9O_9N[MH>[IVE; MR@^RLB0U1R4L)*5W=2T/P-HN;3L0=-VT(5^H$+1J'E> "V!J@UQ?4"I>!\I MWRN??0502P,$% @ PH6H6. H8%%$! /1( !D !X;"]W;W)K&ULM5A=;]LV%/TKA%8,"5!'(O6=V092!^T"M)O1K.O# ML =&HFVADNB1M-WLUY>4%,F2*18NW#S$^KCGZ-QK\IYK30^4?>$;0@3X6N0E MGUD;(;:WMLV3#2DPOZ%;4LH[*\H*+.0I6]M\RPA.*U"1V\AQ KO 66G-I]6U M)9M/Z4[D64F6#/!=46#V_(;D]#"SH/5RX6.VW@AUP9Y/MWA-'HGXM%TR>6:W M+&E6D))GM 2,K&;6';Q=($%WTB3D*[Z$YKSZ#PY-K&.!9,<%+1JP5%!D9?V)OS:%. (@?P2 &@ : * W M G ;@%LE6BNKTKK' L^GC!X 4]&231U4M:G0,INL5%_CHV#R;B9Q8OZ.TO20 MY3G 90K^%!O"P$,I<+G.GG("[C@G@H.)YMK5/1$XR_FUO/OI\1YKK-44X%_WLMX\"!(P?_5Y5J3>WIRM3UO^18G M9&;)_<<)VQ-K_NLO,'!^TV5^(;)>'=RV#JZ)?;Z@7.@2K%%!A5+M8C^'+HQ1 M$$_M_;%V;9P3AK"-Z\GR6EF>4=9=DNR*78Z%_';N"LI$]C]6K4$GM6;RCR1, M(NA''AI(U<2%80!C5R_5;Z7Z1JE_$&T!_9.G^8[KH7 @2A/F>GX8Z34%K:; MJ.FAG&P930CG0"T9S))-U012LI?-?2M;M59S<"+&]64A_8'F[X;U-(>MYO [ MFMM-B*M-^!HD(XLS/!$ @]"'T!L(U<7)/QCHE4:MTNA) $RYG;9C&_'G=K$+D?52A4YG=<[/[.<- M^X5*<2FV?BV.;!\:O_C/U7Q#TLG=GC YK_4Z*%@2EM$47$D[?Y:=@5]KZV%^ M0E!# 0(%+<6& XA BI]UBVQAIOK18G0^#XWV.6IP#:SG7,@)O1.':P)[703& M43QF<;"S7FCVWG-,KJ'JNY<;NSX/&%V#.BZD%T00 M1D-AI_[KQ7X0>B.Z.O^%9@.N)]MLV)2U6HU,9V_S"['U\^X\'@8_M>491XBS M:W$AMGXMNMD!FH>'2[0\\Q/GT\@@KB^L&T>@>1XYJ]W%FBX6>/%)M]/%H2@>F?!0-T\@HT>/-;L& M=5Q$UW>=H6?HPM1(-U!E'_VV5R]6Y&_D=59RD).5Q#DWH\JZA-!M]7/ M_23M0;A/:-T?P;4$L#!!0 ( ,*%J%BVE)SX M$0, (4* 9 >&PO=V]R:W-H965T@,QB!NE_<".R9M4O,4L@DXQD1,.T;Y_;9P+:TH!CQG<%*KK6)#F7, M^8/N7,5]P])$D,!$:0N*?TL80))H)^3X79D:]9Q:N-Y^=K\L@L=@QE3"@"<_ M6*SF?2,T2 Q3FB?JEJ\^0Q60K_TF/)'%+UE58RV#3'*I>%J)D2!E6?E/'ZM$ MK EL[PV!4PFP MKJDX):Y]3!S+\1KD@W;Y$":UW'TM-S%!=9:<.DM.X>>^X7?),J;@Y NNN'@[ M/\>->3DFUQ23QM03&>'FBW,<__-\+)7 I?NK*24E@]?,H/?SF5S0"?0-W+ 2 MQ!*,Z/T[.[ ^-"7H/YF]2I=;I\MM&PO M=V]R:W-H965TP8_R/6 !+= M96DNIM9:RN+2MD6\AHR("U9 KGJ6C&=$JB9?V:+@0)(2E*6VZSBAG1&:6[-) M>>^&SR9L(U.:PPU'8I-EA-^_AY3MIA:V'FY\I:NUU#?LV:0@*UB _%[<<-6R M&Y:$9I +RG+$83FUWN'+*SS2@#+B!X6=V+M&6LHM8W]TXSJ96H[."%*(I:8@ MZF\+5Y"FFDGE\;(YJC;VNV$21/Q,26*A_- M:L?UL]]7SW9///LSX1?(PZ^1Z[A^#_QJ&#Z'N(%[7;BM1J$9"K<9"K?D\YXR M%+\^J5YT+2$3O_N4551^/Y5^]RY%06*86NKE$L"W8,U>/,.A\[9/IR&RCFJO M4>T-L=>J2:FZ3VB%#DNT7A.VL\B+_&AB;_<5'$<%08#;J$YJ?I.:/YC:=2Y! M"9:($PE([$C1E^ @Q[DS88BL(S=HY ;F_!>85&V(K*,Z;%2'_^6_"AWL.\L- M/?? ?\=17N2,QOW^BYK4HL'4%A!O.)7W:ELHF*#]^0U2G#L1AL@Z:D>-VI$Y M^XU,JC9$UE$];E2/_\M^XV-CA3@\<%]?D./VFP\[[<[L#*;VB>6K-VH%S)#2 M71":(+A3U9N _JUVD.S<*3'%UI6^5Y1@*F,F M3B0^2'WV+!EBZPY$6YA@WZ _C58HIMBZRML:!0\6 X_[,SARGN\XA^5B7Y3O MGB@7<5M*X*?4$JE:-U&Y;@ZD.4AT]IP88NO*;LL4'!ETH]&"Q11;5WE;LN#! MVN!Q-XZ.SB78\<;>H1V/PR+LA@=VM/=.V?H3ASJ^KF@N4 I+!7,N]#7!^Y9)=8PO+]= $N Z0/4O&9,/#7V6;[[=S/X!4$L#!!0 ( ,*% MJ%A\0T#ADP, )\, 9 >&PO=V]R:W-H965T)[)*RRII/FWM+,9_RK2I8!4M!Y+8LJ7AZ#P7? MS2S7>KYQRS:YTC?L^;2F&[@#]:5>"ES9O4K&2J@DXQ41L)Y9[]SKA>MKA\;B M'P8[>7!-="@KSN_UXD,VLQQ-! 6D2DM0_'J !12%5D*._SI1JW^G=CR\?E;_ MLPD>@UE1"0M>_,LRE<^LB44R6--MH6[Y[B_H @JU7LH+V7R276?K6"3=2L7+ MSAD)2E:UW_2Q2\2!@QN<Z&O'[UAKPBK"*?<[Z5Z"6G MML(@-(J==L#O6V#O!/ G*JZ([_Y&/,<+#.Z+\^XWD/;N_K&[C:GK\^?U^?,: M/?^$WBT45&'82RK4$_DL:"5I6Z!?/Z(I^:"@E-],8;:Z@5E7=^^UK&D*,PO; M4X)X &O^ZR]NY+PU!?U"8D1IKS4G4=U(9D@P]';@V#B1 /&L57LNMZ)9$8]8G01XB?( M6$I9UC0_\I8@4D8+3/(*&\+8V-&()XF0:$!ML'*BQ#%3QSUU?%D)\"=:Z+W) MQ!>/?],DCI,!W]C*\_W@1%8G/=_D+-]BG\ TIV*#24SO99/;,PF=C($=SQN6 MP?>LCH"3'CBY**&UX&N0>J@C^AK,G,F8( B384L9K%S'"1FS,)Z283@)W6$_F>S\((J& M6Y5]<'K41W<\86T8CLD"UNCH7,58\J(]#;<+Q>OF0+GB"H^GS66._R! : -\ MON9R1+PD1 MX"G/"CZTED*L^K;-DR7),;^@*U+(*W/*YCEFSYK/""3(AX6-TR MN;)KEEF:DX*GM ",S(?6-]B_@JX"Z(B?*=GPQC%05J:4/JK%]6QH.4H1R4@B M% 66?VMR1;),,4D=?[>D5GU/!6P>O[!_U^:EF2GFY(IFO]*96 ZMG@5F9([+ M3-S1S0^R->0KOH1F7/^"314;R."DY(+F6[!4D*=%]8^?MHEH *#W!@!M >A8 M@+L%Z,S9E3)M:X0%C@>,;@!3T9)-'>C<:+1TDQ;J,4X$DU=3B1/QB$P%. >3 MZBD".@=C6BS.!6$YT-=.1T3@-.-?9-3#9 1.3[Z $Y 6X'Y)2XZ+&1_80@I1 M=':RO>EE=5/TQDUO,+L +CP#R$&> 7YUଠ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 98 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 100 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 344 322 1 false 141 0 false 14 false false R1.htm 0000001 - Document - Cover Sheet http://www.amneal.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Consolidated Statements of Operations Sheet http://www.amneal.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals) Sheet http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals Consolidated Statements of Comprehensive Loss (Parentheticals) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets Sheet http://www.amneal.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.amneal.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Deficiency) Sheet http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency Consolidated Statements of Changes in Stockholders??? Equity (Deficiency) Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Deficiency) (Parenthetical) Sheet http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiencyParenthetical Consolidated Statements of Changes in Stockholders??? Equity (Deficiency) (Parenthetical) Statements 9 false false R10.htm 0000010 - Disclosure - Nature of Operations Sheet http://www.amneal.com/role/NatureofOperations Nature of Operations Notes 10 false false R11.htm 0000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.amneal.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Revenue Recognition Sheet http://www.amneal.com/role/RevenueRecognition Revenue Recognition Notes 12 false false R13.htm 0000013 - Disclosure - Alliance and Collaboration Sheet http://www.amneal.com/role/AllianceandCollaboration Alliance and Collaboration Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.amneal.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Loss per Share Sheet http://www.amneal.com/role/LossperShare Loss per Share Notes 15 false false R16.htm 0000016 - Disclosure - Trade Accounts Receivable, Net Sheet http://www.amneal.com/role/TradeAccountsReceivableNet Trade Accounts Receivable, Net Notes 16 false false R17.htm 0000017 - Disclosure - Inventories Sheet http://www.amneal.com/role/Inventories Inventories Notes 17 false false R18.htm 0000018 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 18 false false R19.htm 0000019 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.amneal.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 19 false false R20.htm 0000020 - Disclosure - Other Assets Sheet http://www.amneal.com/role/OtherAssets Other Assets Notes 20 false false R21.htm 0000021 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.amneal.com/role/AccountsPayableandAccruedExpenses Accounts Payable and Accrued Expenses Notes 21 false false R22.htm 0000022 - Disclosure - Debt Sheet http://www.amneal.com/role/Debt Debt Notes 22 false false R23.htm 0000023 - Disclosure - Other Long-Term Liabilities Sheet http://www.amneal.com/role/OtherLongTermLiabilities Other Long-Term Liabilities Notes 23 false false R24.htm 0000024 - Disclosure - Fair Value Measurements Sheet http://www.amneal.com/role/FairValueMeasurements Fair Value Measurements Notes 24 false false R25.htm 0000025 - Disclosure - Financial Instruments Sheet http://www.amneal.com/role/FinancialInstruments Financial Instruments Notes 25 false false R26.htm 0000026 - Disclosure - Commitments and Contingencies Sheet http://www.amneal.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 26 false false R27.htm 0000027 - Disclosure - Stockholders??? Equity and Redeemable Non-Controlling Interests Sheet http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterests Stockholders??? Equity and Redeemable Non-Controlling Interests Notes 27 false false R28.htm 0000028 - Disclosure - Related Party Transactions Sheet http://www.amneal.com/role/RelatedPartyTransactions Related Party Transactions Notes 28 false false R29.htm 0000029 - Disclosure - Segment Information Sheet http://www.amneal.com/role/SegmentInformation Segment Information Notes 29 false false R30.htm 0000030 - Disclosure - Subsequent Events Sheet http://www.amneal.com/role/SubsequentEvents Subsequent Events Notes 30 false false R31.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.amneal.com/role/SummaryofSignificantAccountingPolicies 31 false false R32.htm 9954472 - Disclosure - Revenue Recognition (Tables) Sheet http://www.amneal.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.amneal.com/role/RevenueRecognition 32 false false R33.htm 9954473 - Disclosure - Loss per Share (Tables) Sheet http://www.amneal.com/role/LossperShareTables Loss per Share (Tables) Tables http://www.amneal.com/role/LossperShare 33 false false R34.htm 9954474 - Disclosure - Trade Accounts Receivable, Net (Tables) Sheet http://www.amneal.com/role/TradeAccountsReceivableNetTables Trade Accounts Receivable, Net (Tables) Tables http://www.amneal.com/role/TradeAccountsReceivableNet 34 false false R35.htm 9954475 - Disclosure - Inventories (Tables) Sheet http://www.amneal.com/role/InventoriesTables Inventories (Tables) Tables http://www.amneal.com/role/Inventories 35 false false R36.htm 9954476 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssets 36 false false R37.htm 9954477 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.amneal.com/role/GoodwillandOtherIntangibleAssets 37 false false R38.htm 9954478 - Disclosure - Other Assets (Tables) Sheet http://www.amneal.com/role/OtherAssetsTables Other Assets (Tables) Tables http://www.amneal.com/role/OtherAssets 38 false false R39.htm 9954479 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.amneal.com/role/AccountsPayableandAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://www.amneal.com/role/AccountsPayableandAccruedExpenses 39 false false R40.htm 9954480 - Disclosure - Debt (Tables) Sheet http://www.amneal.com/role/DebtTables Debt (Tables) Tables http://www.amneal.com/role/Debt 40 false false R41.htm 9954481 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.amneal.com/role/OtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.amneal.com/role/OtherLongTermLiabilities 41 false false R42.htm 9954482 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.amneal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.amneal.com/role/FairValueMeasurements 42 false false R43.htm 9954483 - Disclosure - Financial Instruments (Tables) Sheet http://www.amneal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.amneal.com/role/FinancialInstruments 43 false false R44.htm 9954484 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.amneal.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.amneal.com/role/CommitmentsandContingencies 44 false false R45.htm 9954485 - Disclosure - Stockholders??? Equity and Redeemable Non-Controlling Interests (Tables) Sheet http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsTables Stockholders??? Equity and Redeemable Non-Controlling Interests (Tables) Tables http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterests 45 false false R46.htm 9954486 - Disclosure - Related Party Transactions (Tables) Sheet http://www.amneal.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.amneal.com/role/RelatedPartyTransactions 46 false false R47.htm 9954487 - Disclosure - Segment Information (Tables) Sheet http://www.amneal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.amneal.com/role/SegmentInformation 47 false false R48.htm 9954488 - Disclosure - Nature of Operations - Additional Information (Details) Sheet http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails Nature of Operations - Additional Information (Details) Details 48 false false R49.htm 9954489 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies 49 false false R50.htm 9954490 - Disclosure - Revenue Recognition - Concentration of Revenue (Details) Sheet http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails Revenue Recognition - Concentration of Revenue (Details) Details 50 false false R51.htm 9954491 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue (Details) Sheet http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails Revenue Recognition - Schedule of Disaggregated Revenue (Details) Details 51 false false R52.htm 9954492 - Disclosure - Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details) Sheet http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details) Details 52 false false R53.htm 9954493 - Disclosure - Alliance and Collaboration - Additional Information (Details) Sheet http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails Alliance and Collaboration - Additional Information (Details) Details 53 false false R54.htm 9954494 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 54 false false R55.htm 9954495 - Disclosure - Loss per Share - Computation of Basic and Diluted Loss per Share (Details) Sheet http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails Loss per Share - Computation of Basic and Diluted Loss per Share (Details) Details 55 false false R56.htm 9954496 - Disclosure - Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details) Sheet http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details) Details 56 false false R57.htm 9954497 - Disclosure - Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) Sheet http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) Details 57 false false R58.htm 9954498 - Disclosure - Trade Accounts Receivable, Net - Concentration of Receivables (Details) Sheet http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails Trade Accounts Receivable, Net - Concentration of Receivables (Details) Details 58 false false R59.htm 9954499 - Disclosure - Inventories - Components of Inventories, Net of Reserves (Details) Sheet http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails Inventories - Components of Inventories, Net of Reserves (Details) Details 59 false false R60.htm 9954500 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 60 false false R61.htm 9954501 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) Sheet http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) Details 61 false false R62.htm 9954502 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Detail) Sheet http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail Goodwill and Other Intangible Assets - Additional Information (Detail) Details 62 false false R63.htm 9954503 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details) Sheet http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails Goodwill and Other Intangible Assets - Intangible Assets (Details) Details 63 false false R64.htm 9954504 - Disclosure - Goodwill and Other Intangible Assets - Future Amortization Expense (Details) Sheet http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails Goodwill and Other Intangible Assets - Future Amortization Expense (Details) Details 64 false false R65.htm 9954505 - Disclosure - Other Assets - Schedule of Other Assets (Details) Sheet http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails Other Assets - Schedule of Other Assets (Details) Details 65 false false R66.htm 9954506 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) Sheet http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) Details 66 false false R67.htm 9954507 - Disclosure - Debt - Summary of Long-term Debt (Details) Sheet http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails Debt - Summary of Long-term Debt (Details) Details 67 false false R68.htm 9954508 - Disclosure - Debt - Narrative (Details) Sheet http://www.amneal.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 68 false false R69.htm 9954509 - Disclosure - Other Long-Term Liabilities (Details) Sheet http://www.amneal.com/role/OtherLongTermLiabilitiesDetails Other Long-Term Liabilities (Details) Details http://www.amneal.com/role/OtherLongTermLiabilitiesTables 69 false false R70.htm 9954510 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 70 false false R71.htm 9954511 - Disclosure - Fair Value Measurements - Summary of the Company???s Indebtedness at Fair Value (Details) Sheet http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails Fair Value Measurements - Summary of the Company???s Indebtedness at Fair Value (Details) Details 71 false false R72.htm 9954512 - Disclosure - Financial Instruments - Additional Information (Details) Sheet http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails Financial Instruments - Additional Information (Details) Details 72 false false R73.htm 9954513 - Disclosure - Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) Sheet http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) Details 73 false false R74.htm 9954514 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 74 false false R75.htm 9954515 - Disclosure - Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) Sheet http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) Details 75 false false R76.htm 9954516 - Disclosure - Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details) Sheet http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details) Details 76 false false R77.htm 9954517 - Disclosure - Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) Sheet http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) Details 77 false false R78.htm 9954518 - Disclosure - Related Party Transactions - Related Party Agreements (Details) Sheet http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails Related Party Transactions - Related Party Agreements (Details) Details 78 false false R79.htm 9954519 - Disclosure - Related Party Transactions - Narrative (Details) Sheet http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions - Narrative (Details) Details 79 false false R80.htm 9954520 - Disclosure - Segment Information - Additional Information (Details) Sheet http://www.amneal.com/role/SegmentInformationAdditionalInformationDetails Segment Information - Additional Information (Details) Details 80 false false R81.htm 9954521 - Disclosure - Segment Information - Schedules of Segment Information (Details) Sheet http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails Segment Information - Schedules of Segment Information (Details) Details 81 false false R82.htm 9954522 - Disclosure - Subsequent Events (Details) Sheet http://www.amneal.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.amneal.com/role/SubsequentEvents 82 false false All Reports Book All Reports amrx-20240331.htm amrx-20240331.xsd amrx-20240331_cal.xml amrx-20240331_def.xml amrx-20240331_lab.xml amrx-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 102 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "amrx-20240331.htm": { "nsprefix": "amrx", "nsuri": "http://www.amneal.com/20240331", "dts": { "inline": { "local": [ "amrx-20240331.htm" ] }, "schema": { "local": [ "amrx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "amrx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "amrx-20240331_def.xml" ] }, "labelLink": { "local": [ "amrx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "amrx-20240331_pre.xml" ] } }, "keyStandard": 260, "keyCustom": 62, "axisStandard": 29, "axisCustom": 2, "memberStandard": 39, "memberCustom": 100, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 344, "entityCount": 1, "segmentCount": 141, "elementCount": 618, "unitCount": 14, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 877, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.amneal.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "longName": "0000002 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeExpenseNonoperatingNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R3": { "role": "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Loss", "shortName": "Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R4": { "role": "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)", "shortName": "Consolidated Statements of Comprehensive Loss (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R5": { "role": "http://www.amneal.com/role/ConsolidatedBalanceSheets", "longName": "0000005 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R6": { "role": "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "amrx:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R8": { "role": "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "longName": "0000008 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficiency)", "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficiency)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-32", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-32", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiencyParenthetical", "longName": "0000009 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficiency) (Parenthetical)", "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficiency) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R10": { "role": "http://www.amneal.com/role/NatureofOperations", "longName": "0000010 - Disclosure - Nature of Operations", "shortName": "Nature of Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.amneal.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.amneal.com/role/RevenueRecognition", "longName": "0000012 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.amneal.com/role/AllianceandCollaboration", "longName": "0000013 - Disclosure - Alliance and Collaboration", "shortName": "Alliance and Collaboration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.amneal.com/role/IncomeTaxes", "longName": "0000014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.amneal.com/role/LossperShare", "longName": "0000015 - Disclosure - Loss per Share", "shortName": "Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.amneal.com/role/TradeAccountsReceivableNet", "longName": "0000016 - Disclosure - Trade Accounts Receivable, Net", "shortName": "Trade Accounts Receivable, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.amneal.com/role/Inventories", "longName": "0000017 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssets", "longName": "0000018 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.amneal.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000019 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.amneal.com/role/OtherAssets", "longName": "0000020 - Disclosure - Other Assets", "shortName": "Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.amneal.com/role/AccountsPayableandAccruedExpenses", "longName": "0000021 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.amneal.com/role/Debt", "longName": "0000022 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.amneal.com/role/OtherLongTermLiabilities", "longName": "0000023 - Disclosure - Other Long-Term Liabilities", "shortName": "Other Long-Term Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.amneal.com/role/FairValueMeasurements", "longName": "0000024 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.amneal.com/role/FinancialInstruments", "longName": "0000025 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.amneal.com/role/CommitmentsandContingencies", "longName": "0000026 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterests", "longName": "0000027 - Disclosure - Stockholders\u2019 Equity and Redeemable Non-Controlling Interests", "shortName": "Stockholders\u2019 Equity and Redeemable Non-Controlling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.amneal.com/role/RelatedPartyTransactions", "longName": "0000028 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.amneal.com/role/SegmentInformation", "longName": "0000029 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.amneal.com/role/SubsequentEvents", "longName": "0000030 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.amneal.com/role/RevenueRecognitionTables", "longName": "9954472 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.amneal.com/role/LossperShareTables", "longName": "9954473 - Disclosure - Loss per Share (Tables)", "shortName": "Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.amneal.com/role/TradeAccountsReceivableNetTables", "longName": "9954474 - Disclosure - Trade Accounts Receivable, Net (Tables)", "shortName": "Trade Accounts Receivable, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.amneal.com/role/InventoriesTables", "longName": "9954475 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "longName": "9954476 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsTables", "longName": "9954477 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.amneal.com/role/OtherAssetsTables", "longName": "9954478 - Disclosure - Other Assets (Tables)", "shortName": "Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.amneal.com/role/AccountsPayableandAccruedExpensesTables", "longName": "9954479 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.amneal.com/role/DebtTables", "longName": "9954480 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.amneal.com/role/OtherLongTermLiabilitiesTables", "longName": "9954481 - Disclosure - Other Long-Term Liabilities (Tables)", "shortName": "Other Long-Term Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.amneal.com/role/FairValueMeasurementsTables", "longName": "9954482 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.amneal.com/role/FinancialInstrumentsTables", "longName": "9954483 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.amneal.com/role/CommitmentsandContingenciesTables", "longName": "9954484 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsTables", "longName": "9954485 - Disclosure - Stockholders\u2019 Equity and Redeemable Non-Controlling Interests (Tables)", "shortName": "Stockholders\u2019 Equity and Redeemable Non-Controlling Interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.amneal.com/role/RelatedPartyTransactionsTables", "longName": "9954486 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.amneal.com/role/SegmentInformationTables", "longName": "9954487 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails", "longName": "9954488 - Disclosure - Nature of Operations - Additional Information (Details)", "shortName": "Nature of Operations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-49", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954489 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "amrx:IncreaseDecreaseInTaxReceivableAgreementLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "longName": "9954490 - Disclosure - Revenue Recognition - Concentration of Revenue (Details)", "shortName": "Revenue Recognition - Concentration of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-50", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails", "longName": "9954491 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue (Details)", "shortName": "Revenue Recognition - Schedule of Disaggregated Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R52": { "role": "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails", "longName": "9954492 - Disclosure - Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details)", "shortName": "Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-104", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "longName": "9954493 - Disclosure - Alliance and Collaboration - Additional Information (Details)", "shortName": "Alliance and Collaboration - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-116", "name": "amrx:CollaborativeArrangementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "amrx:CollaborativeArrangementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails", "longName": "9954494 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R55": { "role": "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails", "longName": "9954495 - Disclosure - Loss per Share - Computation of Basic and Diluted Loss per Share (Details)", "shortName": "Loss per Share - Computation of Basic and Diluted Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails", "longName": "9954496 - Disclosure - Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details)", "shortName": "Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-150", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails", "longName": "9954497 - Disclosure - Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details)", "shortName": "Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails", "longName": "9954498 - Disclosure - Trade Accounts Receivable, Net - Concentration of Receivables (Details)", "shortName": "Trade Accounts Receivable, Net - Concentration of Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-152", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails", "longName": "9954499 - Disclosure - Inventories - Components of Inventories, Net of Reserves (Details)", "shortName": "Inventories - Components of Inventories, Net of Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "longName": "9954500 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails", "longName": "9954501 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Goodwill (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R62": { "role": "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "longName": "9954502 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Detail)", "shortName": "Goodwill and Other Intangible Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R63": { "role": "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails", "longName": "9954503 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails", "longName": "9954504 - Disclosure - Goodwill and Other Intangible Assets - Future Amortization Expense (Details)", "shortName": "Goodwill and Other Intangible Assets - Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails", "longName": "9954505 - Disclosure - Other Assets - Schedule of Other Assets (Details)", "shortName": "Other Assets - Schedule of Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherAssetsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-169", "name": "us-gaap:OtherAssetsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R66": { "role": "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "longName": "9954506 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails", "longName": "9954507 - Disclosure - Debt - Summary of Long-term Debt (Details)", "shortName": "Debt - Summary of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.amneal.com/role/DebtNarrativeDetails", "longName": "9954508 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-183", "name": "us-gaap:ProceedsFromLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:RepaymentsOfLongTermDebt", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R69": { "role": "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails", "longName": "9954509 - Disclosure - Other Long-Term Liabilities (Details)", "shortName": "Other Long-Term Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-187", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R70": { "role": "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954510 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:InterestRateCashFlowHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "amrx:DeferredCompensationPlanLiabilitiesFairValueDisclosures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R71": { "role": "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails", "longName": "9954511 - Disclosure - Fair Value Measurements - Summary of the Company\u2019s Indebtedness at Fair Value (Details)", "shortName": "Fair Value Measurements - Summary of the Company\u2019s Indebtedness at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-204", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-204", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "longName": "9954512 - Disclosure - Financial Instruments - Additional Information (Details)", "shortName": "Financial Instruments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:InterestRateCashFlowHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R73": { "role": "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails", "longName": "9954513 - Disclosure - Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details)", "shortName": "Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-211", "name": "us-gaap:InterestRateCashFlowHedgeLiabilityAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-211", "name": "us-gaap:InterestRateCashFlowHedgeLiabilityAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "longName": "9954514 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R75": { "role": "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails", "longName": "9954515 - Disclosure - Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details)", "shortName": "Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LitigationReserveCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:LitigationReserveCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R76": { "role": "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails", "longName": "9954516 - Disclosure - Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details)", "shortName": "Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails", "longName": "9954517 - Disclosure - Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details)", "shortName": "Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-253", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R78": { "role": "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "longName": "9954518 - Disclosure - Related Party Transactions - Related Party Agreements (Details)", "shortName": "Related Party Transactions - Related Party Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-307", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-307", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "longName": "9954519 - Disclosure - Related Party Transactions - Narrative (Details)", "shortName": "Related Party Transactions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-328", "name": "amrx:CollaborativeArrangementUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-328", "name": "amrx:CollaborativeArrangementUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.amneal.com/role/SegmentInformationAdditionalInformationDetails", "longName": "9954520 - Disclosure - Segment Information - Additional Information (Details)", "shortName": "Segment Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails", "longName": "9954521 - Disclosure - Segment Information - Schedules of Segment Information (Details)", "shortName": "Segment Information - Schedules of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-335", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "unique": true } }, "R82": { "role": "http://www.amneal.com/role/SubsequentEventsDetails", "longName": "9954522 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-343", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "inr", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-343", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "inr", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "amrx-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r27" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r783" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r199", "r308", "r309", "r745" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r725" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net", "totalLabel": "Trade accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r308", "r309" ] }, "amrx_AccruedMedicaidAndCommercialRebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AccruedMedicaidAndCommercialRebatesMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Medicaid and Commercial Rebates", "label": "Accrued Medicaid And Commercial Rebates [Member]", "documentation": "Accrued Medicaid And Commercial Rebates [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28", "r748" ] }, "amrx_AccruedSalesRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AccruedSalesRebatesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Medicaid and commercial rebates", "label": "Accrued Sales Rebates Current", "documentation": "Accrued sales rebates current." } } }, "auth_ref": [] }, "amrx_AccruedSalesReturnsAllowanceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AccruedSalesReturnsAllowanceCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued returns allowance", "label": "Accrued Sales Returns Allowance Current", "documentation": "Accrued sales returns allowance current." } } }, "auth_ref": [] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow hedge, net of tax", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r207", "r215", "r216", "r490", "r755", "r816" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r38", "r39", "r131", "r200", "r575", "r609", "r610" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "verboseLabel": "Accumulated other comprehensive (loss) income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r13", "r39", "r498", "r501", "r534", "r605", "r606", "r816", "r817", "r818", "r827", "r828", "r829" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r4", "r13", "r39", "r215", "r216", "r524", "r525", "r526", "r527", "r528", "r816" ] }, "amrx_AchievementOfAnnualCommercialMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AchievementOfAnnualCommercialMilestoneMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement Of Annual Commercial Milestone", "label": "Achievement Of Annual Commercial Milestone [Member]", "documentation": "Achievement Of Annual Commercial Milestone" } } }, "auth_ref": [] }, "amrx_AchievementOfCumulativeNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AchievementOfCumulativeNetSalesMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Cumulative Net Sales", "label": "Achievement Of Cumulative Net Sales [Member]", "documentation": "Achievement Of Cumulative Net Sales [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r123", "r783", "r891" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r463", "r464", "r465", "r626", "r827", "r828", "r829", "r868", "r893" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r73", "r74", "r436" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r670", "r736", "r789", "r865", "r874", "r875", "r876" ] }, "amrx_AlkermesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AlkermesMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alkermes", "label": "Alkermes [Member]", "documentation": "Alkermes" } } }, "auth_ref": [] }, "amrx_AlkermesPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AlkermesPlcMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alkermes Plc", "label": "Alkermes Plc [Member]", "documentation": "Alkermes Plc" } } }, "auth_ref": [] }, "amrx_AllowanceForAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AllowanceForAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Subtotal", "label": "Allowance For Accounts Receivable Current", "documentation": "Allowance For Accounts Receivable, Current" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails": { "parentTag": "amrx_AllowanceForAccountsReceivableCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r201", "r310", "r314" ] }, "amrx_AmendedNewRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AmendedNewRevolvingCreditFacilityMember", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended New Revolving Credit Facility", "label": "Amended New Revolving Credit Facility [Member]", "documentation": "Amended New Revolving Credit Facility" } } }, "auth_ref": [] }, "amrx_AmendedOctober2019SwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AmendedOctober2019SwapMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended October 2019 Swap", "label": "Amended October 2019 Swap [Member]", "documentation": "Amended October 2019 Swap" } } }, "auth_ref": [] }, "amrx_AmendedRondoCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AmendedRondoCreditFacilityMember", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Rondo Credit Facility", "label": "Amended Rondo Credit Facility [Member]", "documentation": "Amended Rondo Credit Facility" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "amrx_AmnealPharmaceuticalsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AmnealPharmaceuticalsLLCMember", "presentation": [ "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amneal Pharmaceuticals, LLC", "label": "Amneal Pharmaceuticals, LLC [Member]", "documentation": "Amneal Pharmaceuticals, LLC" } } }, "auth_ref": [] }, "amrx_AmnealSpecialtyPharmaSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AmnealSpecialtyPharmaSegmentMember", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty", "label": "Amneal Specialty Pharma Segment [Member]", "documentation": "Amneal Specialty Pharma Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs and discount", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r381", "r530", "r765", "r766", "r820" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r60", "r64" ] }, "amrx_AntiInfectiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AntiInfectiveMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-infective", "label": "Anti Infective [Member]", "documentation": "Anti infective." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities excluded from earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r267" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "amrx_AntiviralMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AntiviralMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antiviral", "label": "Antiviral [Member]", "documentation": "Antiviral." } } }, "auth_ref": [] }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net of income taxes, recognized in accumulated other comprehensive income", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r205" ] }, "amrx_ApaceKYLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ApaceKYLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Apace Packaging, LLC - packaging agreement", "label": "Apace K Y L L C [Member]", "documentation": "Apace KY, LLC." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r484" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r163", "r193", "r230", "r278", "r293", "r299", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r486", "r491", "r514", "r571", "r663", "r783", "r798", "r859", "r860", "r877" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets", "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r187", "r203", "r230", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r486", "r491", "r514", "r783", "r859", "r860", "r877" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "amrx_AvKARESegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AvKARESegmentMember", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AvKARE", "label": "AvKARE Segment [Member]", "documentation": "AvKARE segment." } } }, "auth_ref": [] }, "amrx_AvKareIncorporationAndRAndSNortheastLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AvKareIncorporationAndRAndSNortheastLLCMember", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Av Kare Incorporation And R And S Northeast L L C", "label": "Av Kare Incorporation And R And S Northeast L L C [Member]", "documentation": "Av Kare Incorporation And R And S Northeast L L C" } } }, "auth_ref": [] }, "amrx_AvPropLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AvPropLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AvPROP, LLC - operating lease", "label": "Av Prop L L C [Member]", "documentation": "AvProp, LLC." } } }, "auth_ref": [] }, "amrx_AvtarInvestmentsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AvtarInvestmentsLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avtar Investments LLC - consulting services", "label": "Avtar Investments, LLC [Member]", "documentation": "Avtar Investments, LLC" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ] }, "amrx_AzaTechPharmaLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "AzaTechPharmaLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AzaTech Pharma LLC - supply agreement", "label": "Aza Tech Pharma L L C [Member]", "documentation": "AzaTech Pharma LLC." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails", "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails", "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r91", "r95" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "amrx_BiosimilarLicensingAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "BiosimilarLicensingAndSupplyAgreementMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biosimilar Licensing and Supply Agreement", "label": "Biosimilar Licensing And Supply Agreement [Member]", "documentation": "Biosimilar Licensing And Supply Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r481", "r778", "r779" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r76", "r78", "r481", "r778", "r779" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Voting interest acquired (percent)", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r77" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r483", "r819" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "netLabel": "Contingent consideration liabilities", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r81", "r482" ] }, "amrx_CardiovascularSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CardiovascularSystemMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular system", "label": "Cardiovascular System [Member]", "documentation": "Cardiovascular system." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents - end of period", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r44", "r189", "r743" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period", "totalLabel": "Cash, cash equivalents, and restricted cash - end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r44", "r142", "r226" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r142" ] }, "amrx_CashDiscountAllowancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CashDiscountAllowancesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails": { "parentTag": "amrx_AllowanceForAccountsReceivableCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash discount allowances", "label": "Cash Discount Allowances Current", "documentation": "Cash Discount Allowances, Current" } } }, "auth_ref": [] }, "amrx_CashDiscountAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CashDiscountAllowancesMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Discount Allowances", "label": "Cash Discount Allowances [Member]", "documentation": "Cash Discount Allowances [Member]" } } }, "auth_ref": [] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge gain (loss) to be reclassified within 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r102" ] }, "amrx_CentralNervousSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CentralNervousSystemMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Central nervous system", "label": "Central Nervous System [Member]", "documentation": "Central nervous system." } } }, "auth_ref": [] }, "amrx_ChangesInReallocationOfOwnershipInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ChangesInReallocationOfOwnershipInterests", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reallocation of ownership interests", "label": "Changes In Reallocation Of Ownership Interests", "documentation": "Changes in reallocation of ownership interests." } } }, "auth_ref": [] }, "amrx_ChargebacksReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ChargebacksReceivableCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chargebacks receivable", "label": "Chargebacks Receivable, Current", "documentation": "Chargebacks Receivable, Current" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "amrx_CivilPrescriptionOpioidLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CivilPrescriptionOpioidLitigationMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Civil prescription opioid litigation", "label": "Civil Prescription Opioid Litigation [Member]", "documentation": "Civil Prescription Opioid Litigation" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/Cover", "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r181", "r196", "r197", "r198", "r230", "r260", "r261", "r264", "r266", "r272", "r273", "r311", "r346", "r349", "r350", "r351", "r357", "r358", "r389", "r390", "r393", "r396", "r403", "r514", "r615", "r616", "r617", "r618", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r651", "r673", "r696", "r717", "r718", "r719", "r720", "r721", "r805", "r821", "r830" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r196", "r197", "r198", "r272", "r389", "r390", "r391", "r393", "r396", "r401", "r403", "r615", "r616", "r617", "r618", "r767", "r805", "r821" ] }, "amrx_CollaborativeArrangementAggregateSalesBasedMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementAggregateSalesBasedMilestonePayment", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement aggregate sales-based milestone payment", "label": "Collaborative Arrangement Aggregate Sales-Based Milestone Payment", "documentation": "Collaborative Arrangement Aggregate Sales-Based Milestone Payment" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementContingentPaymentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementContingentPaymentsAmount", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement maximum contingent payments amount", "label": "Collaborative Arrangement Contingent Payments Amount", "documentation": "Collaborative Arrangement, Contingent Payments, Amount" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/AllianceandCollaboration" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance and Collaboration", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r171", "r173", "r180" ] }, "amrx_CollaborativeArrangementLicenseRevenueAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementLicenseRevenueAgreement", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement license revenue agreement", "label": "Collaborative Arrangement License Revenue Agreement", "documentation": "Collaborative Arrangement License Revenue Agreement" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementMaximumMilestonePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementMaximumMilestonePaid", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement maximum milestone paid", "label": "Collaborative Arrangement Maximum Milestone Paid", "documentation": "Collaborative Arrangement Maximum Milestone Paid" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementMedicalAndMarketingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementMedicalAndMarketingActivities", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, medical and marketing activities", "label": "Collaborative Arrangement, Medical And Marketing Activities", "documentation": "Collaborative Arrangement, Medical And Marketing Activities" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementNetRevenueAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementNetRevenueAgreement", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement net revenue agreement", "label": "Collaborative Arrangement Net Revenue Agreement", "documentation": "Collaborative Arrangement Net Revenue Agreement" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementNonRefundableLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementNonRefundableLicenseFee", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement non-refundable license fee", "label": "Collaborative Arrangement, Non-Refundable License Fee", "documentation": "Collaborative Arrangement, Non-Refundable License Fee" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementNonRefundableLicenseFeeAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementNonRefundableLicenseFeeAmortizationPeriod", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement non-refundable license fee, amortization period", "label": "Collaborative Arrangement, Non-Refundable License Fee, Amortization Period", "documentation": "Collaborative Arrangement, Non-Refundable License Fee, Amortization Period" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementNonrefundableLicenseFeeReceivedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementNonrefundableLicenseFeeReceivedAmount", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrefundable license fee received, amount", "label": "Collaborative Arrangement, Nonrefundable License Fee Received, Amount", "documentation": "Collaborative Arrangement, Nonrefundable License Fee Received, Amount" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementNumberOfProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementNumberOfProducts", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, number of products", "label": "Collaborative Arrangement, Number Of Products", "documentation": "Collaborative Arrangement, Number Of Products" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementOtherLongTermLiabilities", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long term liabilities", "label": "Collaborative Arrangement Other Long Term Liabilities", "documentation": "Collaborative Arrangement Other Long Term Liabilities" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementProfitSharePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementProfitSharePercentage", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, profit share (percent)", "label": "Collaborative Arrangement Profit Share Percentage", "documentation": "Collaborative Arrangement, Profit Share, Percentage" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementRenewForSuccessiveTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementRenewForSuccessiveTerm", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement renew for successive term", "label": "Collaborative Arrangement Renew for Successive Term", "documentation": "Collaborative Arrangement Renew for Successive Term" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementRenewalDeclineNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementRenewalDeclineNoticePeriod", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notice period", "label": "Collaborative Arrangement, Renewal Decline Notice Period", "documentation": "Collaborative Arrangement, Renewal Decline Notice Period" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementTerm", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement term", "label": "Collaborative Arrangement Term", "documentation": "Collaborative Arrangement, Term" } } }, "auth_ref": [] }, "amrx_CollaborativeArrangementUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CollaborativeArrangementUpfrontPayment", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement upfront payment", "label": "Collaborative Arrangement Upfront Payment", "documentation": "Collaborative arrangement, up-front payment." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r484" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Notes 4 and 17)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r33", "r111", "r572", "r650" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r152", "r338", "r339", "r726", "r851" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r893" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B", "verboseLabel": "Shares of Old PubCo Class B common stock", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r893" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r786", "r787", "r788", "r790", "r791", "r792", "r795", "r827", "r828", "r868", "r890", "r893" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r122" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r122", "r651" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r122" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares beginning balance (in shares)", "periodEndLabel": "Shares ending balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r122", "r651", "r669", "r893", "r894" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r122", "r574", "r783" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Amneal Pharmaceuticals, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r40", "r211", "r213", "r217", "r567", "r584" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r48", "r50", "r103", "r104", "r307", "r725" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r48", "r50", "r103", "r104", "r307", "r611", "r725" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r48", "r50", "r103", "r104", "r307", "r725", "r809" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r725" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r48", "r50", "r103", "r104", "r307" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r47", "r48", "r50", "r51", "r103", "r162", "r725" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r48", "r50", "r103", "r104", "r307", "r725" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r236", "r280", "r291", "r292", "r293", "r294", "r295", "r297", "r301", "r346", "r347", "r348", "r349", "r351", "r352", "r354", "r356", "r357", "r859", "r860" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r236", "r280", "r291", "r292", "r293", "r294", "r295", "r297", "r301", "r346", "r347", "r348", "r349", "r351", "r352", "r354", "r356", "r357", "r859", "r860" ] }, "amrx_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration" } } }, "auth_ref": [] }, "amrx_ContractChargeBacksAndSalesVolumeAllowancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ContractChargeBacksAndSalesVolumeAllowancesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails": { "parentTag": "amrx_AllowanceForAccountsReceivableCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract charge-backs and sales volume allowances", "label": "Contract Charge Backs And Sales Volume Allowances Current", "documentation": "Contract Charge-Backs And Sales Volume Allowances, Current" } } }, "auth_ref": [] }, "amrx_ContractChargebacksAndSalesVolumeAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ContractChargebacksAndSalesVolumeAllowancesMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Charge - Backs and Sales Volume Allowances", "label": "Contract Chargebacks And Sales Volume Allowances [Member]", "documentation": "Contract Charge-backs And Sales Volume Allowances [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits and advances", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r405", "r406", "r425" ] }, "us-gaap_ContractualRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualRightsMember", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product rights", "label": "Contractual Rights [Member]", "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements)." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate and Other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r20", "r292", "r293", "r294", "r295", "r301", "r833" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "verboseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r136", "r551" ] }, "amrx_CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim", "label": "Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim [Member]", "documentation": "Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r234", "r235", "r363", "r391", "r541", "r752", "r754" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "amrx_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CustomerAMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer A", "verboseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "amrx_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CustomerBMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer B", "verboseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "amrx_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CustomerCMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer C", "verboseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Customer C [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r49", "r307" ] }, "amrx_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "CustomerDMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer D", "label": "Customer D [Member]", "documentation": "Customer D [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r153", "r228", "r359", "r365", "r366", "r367", "r368", "r369", "r370", "r375", "r382", "r383", "r385" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails", "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails", "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r118", "r119", "r164", "r165", "r236", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r531", "r762", "r763", "r764", "r765", "r766", "r822" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r22", "r165", "r386" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails", "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r531", "r762", "r763", "r764", "r765", "r766", "r822" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails", "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails", "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r31", "r236", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r531", "r762", "r763", "r764", "r765", "r766", "r822" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails", "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r69", "r72", "r105", "r106", "r108", "r112", "r155", "r156", "r236", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r531", "r762", "r763", "r764", "r765", "r766", "r822" ] }, "amrx_DeferredCompensationPlanLiabilitiesFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DeferredCompensationPlanLiabilitiesFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred compensation plan liabilities", "label": "Deferred Compensation Plan Liabilities Fair Value Disclosures", "documentation": "Deferred Compensation Plan Liabilities, Fair Value Disclosures" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r107", "r862" ] }, "us-gaap_DeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncome", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Deferred Income", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r807", "r887", "r889" ] }, "amrx_DeferredRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DeferredRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income", "label": "Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income [Member]", "documentation": "Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income" } } }, "auth_ref": [] }, "amrx_DeferredRevolvingCreditFacilityCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DeferredRevolvingCreditFacilityCostsMember", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revolving credit facility costs", "label": "Deferred Revolving Credit Facility Costs [Member]", "documentation": "Deferred revolving credit facility costs." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r472" ] }, "amrx_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs", "documentation": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r641", "r643", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r683", "r684", "r685", "r686", "r689", "r690", "r691", "r692", "r711", "r712", "r713", "r714", "r786", "r788" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, fixed interest rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r92", "r94", "r96", "r97", "r641", "r643", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r683", "r684", "r685", "r686", "r689", "r690", "r691", "r692", "r711", "r712", "r713", "r714", "r754", "r786", "r788" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r503" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r866", "r867" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r15", "r87", "r88", "r89", "r90", "r93", "r96", "r98", "r99", "r101", "r503" ] }, "amrx_DermatologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DermatologyMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dermatology", "label": "Dermatology [Member]", "documentation": "Dermatology." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r15" ] }, "amrx_DevelopmentMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DevelopmentMilestonesMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development Milestones", "label": "Development Milestones [Member]", "documentation": "Development Milestones" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r424", "r768", "r769", "r770", "r771", "r772", "r773", "r774" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r424", "r768", "r769", "r770", "r771", "r772", "r773", "r774" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregated Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r863" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r185" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r10", "r18" ] }, "amrx_DisposalGroupIncludingDiscontinuedOperationAssumptionOfLoanPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationAssumptionOfLoanPayable", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumption of loan payable", "label": "Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable", "documentation": "Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable" } } }, "auth_ref": [] }, "amrx_DisposalGroupIncludingDiscontinuedOperationAssumptionOfLoanPayableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationAssumptionOfLoanPayableInterestRate", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan payable, interest rate", "label": "Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable, Interest Rate", "documentation": "Disposal Group, Including Discontinued Operation, Assumption Of Loan Payable, Interest Rate" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration on sale of subsidiary", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r778", "r779" ] }, "us-gaap_DistributionServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionServiceMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution", "label": "Distribution Service [Member]", "documentation": "Distribution assistance, including, but not limited to, marketing and selling fund shares, advertising, printing and mailing of prospectus and sale literature to investor." } } }, "auth_ref": [ "r864" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r802" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r803" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r218", "r248", "r249", "r250", "r251", "r252", "r257", "r260", "r264", "r265", "r266", "r270", "r506", "r507", "r568", "r585", "r756" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "amrx_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": [ "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to Amneal Pharmaceuticals, Inc.\u2019s Class A common stockholders:", "label": "Earnings Per Share Basic And Diluted EPS [Abstract]", "documentation": "Earnings Per Share Basic And Diluted EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r218", "r248", "r249", "r250", "r251", "r252", "r260", "r264", "r265", "r266", "r270", "r506", "r507", "r568", "r585", "r756" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.amneal.com/role/LossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r256", "r267", "r268", "r269" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r521" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r469" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r800" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r800" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r800" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r804" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r800" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r800" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r800" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r800" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r182", "r214", "r215", "r216", "r243", "r244", "r245", "r247", "r253", "r255", "r271", "r312", "r313", "r404", "r463", "r464", "r465", "r474", "r475", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r523", "r524", "r525", "r526", "r527", "r528", "r534", "r605", "r606", "r607", "r626", "r696" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r509", "r510", "r513" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r509", "r510", "r513" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r373", "r428", "r429", "r430", "r431", "r432", "r433", "r510", "r546", "r547", "r548", "r763", "r764", "r775", "r776", "r777" ] }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Company\u2019s Indebtedness at Fair Value", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value." } } }, "auth_ref": [ "r512" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.amneal.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r508" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r373", "r428", "r433", "r510", "r546", "r775", "r776", "r777" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r373", "r428", "r433", "r510", "r547", "r763", "r764", "r775", "r776", "r777" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r373", "r428", "r429", "r430", "r431", "r432", "r433", "r510", "r548", "r763", "r764", "r775", "r776", "r777" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of contingent consideration", "negatedTerseLabel": "Change in fair value during the period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r511" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r373", "r428", "r429", "r430", "r431", "r432", "r433", "r546", "r547", "r548", "r763", "r764", "r775", "r776", "r777" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of financing lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r533" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r533" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r532" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated useful life (in years)", "terseLabel": "Weighted-Average Amortization Period (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }, "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r191", "r331" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2023", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r329", "r330", "r331", "r332", "r552", "r553" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r149", "r553" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r552" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r61", "r63" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsFutureAmortizationExpenseDetails", "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r149", "r552" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange (loss) gain, net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r515", "r517", "r519", "r520", "r693" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized foreign currency loss (gain)", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r144", "r671", "r796", "r870", "r871", "r892" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Charges (credit) related to legal matters, net", "terseLabel": "(Credit) charges related to legal matters, net", "negatedTerseLabel": "(Credit) charges related to legal matters, net", "label": "Gain (Loss) Related to Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r852" ] }, "amrx_GastroenterologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "GastroenterologyMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gastroenterology", "label": "Gastroenterology [Member]", "documentation": "Gastroenterology." } } }, "auth_ref": [] }, "amrx_GenericDigoxinAndDoxycyclineAntitrustLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "GenericDigoxinAndDoxycyclineAntitrustLitigationMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Generic Digoxin and Doxycycline Antitrust Litigation", "label": "Generic Digoxin And Doxycycline Antitrust Litigation [Member]", "documentation": "Generic Digoxin and Doxycycline Antitrust Litigation." } } }, "auth_ref": [] }, "amrx_GenericsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "GenericsSegmentMember", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Generics", "label": "Generics Segment [Member]", "documentation": "Generics Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r190", "r317", "r566", "r761", "r783", "r838", "r845" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r148" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r324" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r761" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "amrx_GovernmentLabelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "GovernmentLabelMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government label", "label": "Government Label [Member]", "documentation": "Government label." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r134", "r230", "r278", "r292", "r298", "r301", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r514", "r757", "r859" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r15", "r495" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r15" ] }, "amrx_HormonalAllergyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "HormonalAllergyMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hormonal / allergy", "label": "Hormonal Allergy [Member]", "documentation": "Hormonal allergy." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charges", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r9", "r19" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charges, indefinite-lived", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r820", "r848" ] }, "amrx_IncomeAndOtherTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "IncomeAndOtherTaxesReceivable", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income and other tax receivables", "label": "Income And Other Taxes Receivable", "documentation": "Income and other taxes receivable." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r132", "r168", "r278", "r292", "r298", "r301", "r569", "r580", "r757" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r778", "r779" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r231", "r467", "r470", "r471", "r473", "r476", "r478", "r479", "r480", "r620" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "verboseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r170", "r178", "r254", "r255", "r286", "r468", "r477", "r586" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash (paid) received, net for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r45" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDueFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueFromRelatedParties", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Related party receivables", "label": "Increase (Decrease) in Due from Related Parties", "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Related party payables", "label": "Increase (Decrease) in Due to Related Parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses, other current assets and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "amrx_IncreaseDecreaseInTaxReceivableAgreementLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "IncreaseDecreaseInTaxReceivableAgreementLiability", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in tax receivable agreement liability", "negatedTerseLabel": "Increase in tax receivable agreement liability", "label": "Increase (Decrease) in Tax Receivable Agreement Liability", "documentation": "Increase (Decrease) in Tax Receivable Agreement Liability" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r151" ] }, "amrx_InitialCommercialLaunchMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "InitialCommercialLaunchMilestonesMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Commercial Launch Milestones", "label": "Initial Commercial Launch Milestones [Member]", "documentation": "Initial Commercial Launch Milestones" } } }, "auth_ref": [] }, "amrx_InstitutionalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "InstitutionalMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Institutional", "label": "Institutional [Member]", "documentation": "Institutional." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, cost", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r190" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r59", "r62" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating, Net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r221", "r224", "r225" ] }, "us-gaap_InterestRateCashFlowHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Interest Rate Cash Flow Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all interest rate derivative assets designated as cash flow hedging instruments." } } }, "auth_ref": [ "r94" ] }, "us-gaap_InterestRateCashFlowHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeLiabilityAtFairValue", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "label": "Interest Rate Cash Flow Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all interest rate derivative liabilities designated as cash flow hedging instruments." } } }, "auth_ref": [ "r94" ] }, "amrx_InterestRateLockAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "InterestRateLockAgreementMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Lock Agreement", "label": "Interest Rate Lock Agreement [Member]", "documentation": "Interest rate lock agreement." } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r740", "r793", "r794" ] }, "amrx_InventoryAndCostOfGoodsSoldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "InventoryAndCostOfGoodsSoldMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory and Cost of Goods Sold", "label": "Inventory and Cost of Goods Sold [Member]", "documentation": "Inventory and Cost of Goods Sold" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r315" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r147", "r749" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r202", "r744", "r783" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r147", "r751" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/InventoriesComponentsofInventoriesNetofReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r147", "r750" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory provision", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r316" ] }, "amrx_KananLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "KananLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kanan, LLC - operating lease", "label": "Kanan L L C [Member]", "documentation": "Kanan, LLC [Member]" } } }, "auth_ref": [] }, "amrx_KashivBioSciencesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "KashivBioSciencesLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kashiv Biosciences LLC", "label": "Kashiv Bio Sciences L L C [Member]", "documentation": "Kashiv BioSciences LLC [Member]" } } }, "auth_ref": [] }, "amrx_KashivBioSciencesLicenseAndCommercializationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "KashivBioSciencesLicenseAndCommercializationAgreementMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kashiv Bio Sciences License and Commercialization Agreement", "label": "Kashiv Bio Sciences License And Commercialization Agreement [Member]", "documentation": "Kashiv Bio Sciences license and commercialization agreement." } } }, "auth_ref": [] }, "amrx_KashivSpecialtyPharmaceuticalsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "KashivSpecialtyPharmaceuticalsLLCMember", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kashiv Specialty Pharmaceuticals, LLC", "label": "Kashiv Specialty Pharmaceuticals, LLC [Member]", "documentation": "Kashiv Specialty Pharmaceuticals, LLC" } } }, "auth_ref": [] }, "amrx_KnightTherapeuticsInternationalS.A.LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "KnightTherapeuticsInternationalS.A.LicenseAgreementMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Knight Therapeutics International S.A. License Agreement", "label": "Knight Therapeutics International S.A. License Agreement [Member]", "documentation": "Knight Therapeutics International S.A. License Agreement" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' (deficiency) equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r127", "r167", "r578", "r783", "r823", "r835", "r869" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' (Deficiency) Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r30", "r188", "r230", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r487", "r491", "r492", "r514", "r783", "r859", "r877", "r878" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r22", "r115", "r116", "r117", "r120", "r230", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r487", "r491", "r492", "r514", "r859", "r877", "r878" ] }, "amrx_LiabilitiesUnderTaxReceivableAgreementNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LiabilitiesUnderTaxReceivableAgreementNoncurrent", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities recorded under tax receivable agreement", "label": "Liabilities Under Tax Receivable Agreement Noncurrent", "documentation": "Liabilities Under Tax Receivable Agreement, Noncurrent" } } }, "auth_ref": [] }, "amrx_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LicenseAgreementMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License agreement", "label": "License Agreement [Member]", "documentation": "License Agreement" } } }, "auth_ref": [] }, "amrx_LicenseAgreementWithOrionCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LicenseAgreementWithOrionCorporationMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement with Orion Corporation", "label": "License Agreement with Orion Corporation [Member]", "documentation": "License Agreement with Orion Corporation" } } }, "auth_ref": [] }, "amrx_LicenseAgreementWithZambonBiotechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LicenseAgreementWithZambonBiotechMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement with Zambon Biotech", "label": "License Agreement with Zambon Biotech [Member]", "documentation": "License Agreement with Zambon Biotech" } } }, "auth_ref": [] }, "amrx_LicenseSupplyAgreementPotentialFutureMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LicenseSupplyAgreementPotentialFutureMilestonePayments", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License supply agreement, potential future milestone payments", "label": "License Supply Agreement, Potential Future Milestone Payments", "documentation": "License Supply Agreement, Potential Future Milestone Payments" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r22", "r165", "r886" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r118", "r164" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated litigation liability", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r33", "r852" ] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails", "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of liabilities for legal matters", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r33", "r852" ] }, "us-gaap_LitigationReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities for legal matters - long term", "label": "Estimated Litigation Liability, Noncurrent", "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r33", "r852" ] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement amount", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement expense", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "amrx_LitigationSettlementInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementInterestRate", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, interest rate", "label": "Litigation Settlement, Interest Rate", "documentation": "Litigation Settlement, Interest Rate" } } }, "auth_ref": [] }, "amrx_LitigationSettlementOptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementOptionAxis", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Option [Axis]", "label": "Litigation Settlement, Option [Axis]", "documentation": "Litigation Settlement, Option" } } }, "auth_ref": [] }, "amrx_LitigationSettlementOptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementOptionDomain", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Option [Domain]", "label": "Litigation Settlement, Option [Domain]", "documentation": "Litigation Settlement, Option [Domain]" } } }, "auth_ref": [] }, "amrx_LitigationSettlementOptionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementOptionOneMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Option One", "label": "Litigation Settlement, Option One [Member]", "documentation": "Litigation Settlement, Option One" } } }, "auth_ref": [] }, "amrx_LitigationSettlementOptionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementOptionTwoMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Option Two", "label": "Litigation Settlement, Option Two [Member]", "documentation": "Litigation Settlement, Option Two" } } }, "auth_ref": [] }, "amrx_LitigationSettlementPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementPaymentTerms", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement agreement terms", "label": "Litigation Settlement, Payment Terms", "documentation": "Litigation Settlement, Payment Terms" } } }, "auth_ref": [] }, "amrx_LitigationSettlementPercentageOfProductValue": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementPercentageOfProductValue", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, percentage of product value", "label": "Litigation Settlement, Percentage Of Product Value", "documentation": "Litigation Settlement, Percentage Of Product Value" } } }, "auth_ref": [] }, "amrx_LitigationSettlementProductSupplyAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementProductSupplyAmount", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, product supply amount", "label": "Litigation Settlement, Product Supply Amount", "documentation": "Litigation Settlement, Product Supply Amount" } } }, "auth_ref": [] }, "amrx_LitigationSettlementProductSupplyPrice": { "xbrltype": "perUnitItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LitigationSettlementProductSupplyPrice", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, product supply price (in USD per twin pack)", "label": "Litigation Settlement, Product Supply Price", "documentation": "Litigation Settlement, Product Supply Price" } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNet" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Accounts Receivable, Net", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r834" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "amrx_LongTermCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LongTermCompensationMember", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term compensation", "label": "Long Term Compensation [Member]", "documentation": "Long-term compensation." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt, net of debt issuance costs", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r165", "r372", "r387", "r763", "r764", "r886" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt, net", "negatedLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net", "verboseLabel": "Total long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r195" ] }, "amrx_LongTermPortionOfLiabilitiesForLegalMattersIncludedInOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LongTermPortionOfLiabilitiesForLegalMattersIncludedInOtherLongTermLiabilities", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Civil prescription opioid litigation (Liabilities for legal matters - long term)", "label": "Long-Term Portion of Liabilities For Legal Matters (Included In Other Long-Term Liabilities)", "documentation": "Long-Term Portion of Liabilities For Legal Matters (Included In Other Long-Term Liabilities)" } } }, "auth_ref": [] }, "amrx_LongTermPrepaidExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LongTermPrepaidExpensesMember", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term prepaid expenses", "label": "Long Term Prepaid Expenses [Member]", "documentation": "Long-term prepaid expenses." } } }, "auth_ref": [] }, "amrx_LongTermPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LongTermPromissoryNotesMember", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sellers Notes", "label": "Long Term Promissory Notes [Member]", "documentation": "Long term promissory notes." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r31" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r65" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r340", "r341", "r342", "r345", "r853", "r855" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r340", "r341", "r342", "r345", "r853", "r855" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r340", "r806" ] }, "amrx_LossContingencyCivilLawsuitFiledNumberOfAdditionalStates": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LossContingencyCivilLawsuitFiledNumberOfAdditionalStates", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency civil lawsuit filed number of additional states", "label": "Loss Contingency Civil Lawsuit Filed Number Of Additional States", "documentation": "Loss contingency civil lawsuit filed number of additional states." } } }, "auth_ref": [] }, "amrx_LossContingencyCivilLawsuitFiledNumberOfStates": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LossContingencyCivilLawsuitFiledNumberOfStates", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states, filed civil lawsuit", "label": "Loss Contingency Civil Lawsuit Filed Number Of States", "documentation": "Loss Contingency, Civil Lawsuit Filed, Number Of States" } } }, "auth_ref": [] }, "us-gaap_LossContingencyClaimsDismissedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyClaimsDismissedNumber", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of claims dismissed", "label": "Loss Contingency, Claims Dismissed, Number", "documentation": "Number of claims dismissed." } } }, "auth_ref": [ "r853", "r855" ] }, "amrx_LossContingencyDeadlinePeriodForDefendantsToRespondToComplaint": { "xbrltype": "durationItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LossContingencyDeadlinePeriodForDefendantsToRespondToComplaint", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deadline period for defendants", "label": "Loss Contingency, Deadline Period For Defendants To Respond To Complaint", "documentation": "Loss Contingency, Deadline Period For Defendants To Respond To Complaint" } } }, "auth_ref": [] }, "amrx_LossContingencyNumberOfCases": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LossContingencyNumberOfCases", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of cases filed", "label": "Loss Contingency, Number Of Cases", "documentation": "Loss Contingency, Number Of Cases" } } }, "auth_ref": [] }, "amrx_LossContingencyNumberOfLegalActions": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LossContingencyNumberOfLegalActions", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of actions", "label": "Loss Contingency, Number of Legal Actions", "documentation": "Loss Contingency, Number of Legal Actions" } } }, "auth_ref": [] }, "amrx_LossContingencyNumberOfStatesWithCases": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "LossContingencyNumberOfStatesWithCases", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states with cases", "label": "Loss Contingency, Number Of States with Cases", "documentation": "Loss Contingency, Number Of States with Cases" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Axis]" } } }, "auth_ref": [ "r307", "r770", "r863", "r887", "r888" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r435", "r550", "r604", "r642", "r643", "r704", "r706", "r708", "r709", "r715", "r737", "r738", "r758", "r767", "r780", "r785", "r861", "r879", "r880", "r881", "r882", "r883", "r884" ] }, "amrx_MembersTaxReceivableAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "MembersTaxReceivableAgreementMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Members - tax receivable agreement", "label": "Members - Tax Receivable Agreement [Member]", "documentation": "Members - Tax Receivable Agreement" } } }, "auth_ref": [] }, "amrx_MetabolicDiseaseEndocrineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "MetabolicDiseaseEndocrineMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Metabolic disease / endocrine", "label": "Metabolic Disease Endocrine [Member]", "documentation": "Metabolic disease endocrine." } } }, "auth_ref": [] }, "amrx_MetforminLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "MetforminLitigationMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Metformin Litigation", "label": "Metformin Litigation [Member]", "documentation": "Metformin Litigation" } } }, "auth_ref": [] }, "amrx_MilestonePaymentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "MilestonePaymentAxis", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payment", "label": "Milestone Payment [Axis]", "documentation": "Milestone Payment [Axis]" } } }, "auth_ref": [] }, "amrx_MilestonePaymentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "MilestonePaymentDomain", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payment", "label": "Milestone Payment [Domain]", "documentation": "[Domain] for Milestone Payment [Axis]" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r37", "r166", "r230", "r311", "r346", "r349", "r350", "r351", "r357", "r358", "r514", "r577", "r653" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax distribution", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r157" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage by noncontrolling owners (percent)", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership by parent (percent)", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r37", "r83", "r84", "r135" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetConcentrationofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Domain]" } } }, "auth_ref": [ "r307", "r770", "r863", "r887", "r888" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r223" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r223" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r142", "r143", "r144" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Amneal Pharmaceuticals, Inc.", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r133", "r144", "r169", "r186", "r209", "r212", "r216", "r230", "r246", "r248", "r249", "r250", "r251", "r254", "r255", "r262", "r278", "r292", "r298", "r301", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r507", "r514", "r583", "r672", "r694", "r695", "r757", "r796", "r859" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Net (income) loss attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r86", "r160", "r209", "r212", "r254", "r255", "r582", "r818" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to Amneal Pharmaceuticals, Inc.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r219", "r248", "r249", "r250", "r251", "r257", "r258", "r263", "r266", "r278", "r292", "r298", "r301", "r757" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity." } } }, "auth_ref": [ "r23", "r160", "r161" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International and other", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r895", "r896", "r897", "r898" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activity:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "amrx_NoncashOrPartNoncashAcquisitionTaxDistributionsToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "NoncashOrPartNoncashAcquisitionTaxDistributionsToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Tax distributions to non-controlling interests", "label": "Noncash or Part Noncash Acquisition, Tax Distributions to Noncontrolling Interests", "documentation": "Noncash or Part Noncash Acquisition, Tax Distributions to Noncontrolling Interests" } } }, "auth_ref": [] }, "amrx_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersTaxDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersTaxDistribution", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax distributions, net", "label": "Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders Tax Distribution", "documentation": "Noncontrolling interest, decrease from distributions to noncontrolling interest holders, tax distribution." } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Non- Controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r82", "r404", "r827", "r828", "r829", "r893" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r824", "r825" ] }, "amrx_November2023SwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "November2023SwapMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2023 Swap", "label": "November 2023 Swap [Member]", "documentation": "November 2023 Swap" } } }, "auth_ref": [] }, "amrx_NumberOfGenericPrescriptionMedications": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "NumberOfGenericPrescriptionMedications", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of generic prescription medications", "label": "Number of Generic Prescription Medications", "documentation": "Number of Generic Prescription Medications" } } }, "auth_ref": [] }, "amrx_NumberOfProductsFamilies": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "NumberOfProductsFamilies", "presentation": [ "http://www.amneal.com/role/SegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of products families", "label": "Number Of Products Families", "documentation": "Number Of Products Families" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.amneal.com/role/SegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r832" ] }, "amrx_NumberOfSalesRepresentatives": { "xbrltype": "integerItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "NumberOfSalesRepresentatives", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of sales representatives", "label": "Number of Sales Representatives", "documentation": "Number of Sales Representatives" } } }, "auth_ref": [] }, "amrx_ONGENTYSLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ONGENTYSLicenseAgreementMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ONGENTYS\u00ae License Agreement", "label": "ONGENTYS\u00ae License Agreement [Member]", "documentation": "ONGENTYS\u00ae License Agreement" } } }, "auth_ref": [] }, "amrx_OldPubCoCommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OldPubCoCommonClassAMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Old PubCo, Common Class A", "label": "Old PubCo, Common Class A [Member]", "documentation": "Old PubCo, Common Class A" } } }, "auth_ref": [] }, "amrx_OldPubCoCommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OldPubCoCommonClassBMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Old PubCo, Common Class B", "label": "Old PubCo, Common Class B [Member]", "documentation": "Old PubCo, Common Class B" } } }, "auth_ref": [] }, "amrx_OncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OncologyMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oncology", "label": "Oncology [Member]", "documentation": "Oncology." } } }, "auth_ref": [] }, "amrx_OpanaERAccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OpanaERAccruedInterestMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opana ER\u00ae antitrust litigation-accrued interest", "label": "Opana ER Accrued Interest [Member]", "documentation": "Opana ER Accrued Interest" } } }, "auth_ref": [] }, "amrx_OpanaERAntitrustLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OpanaERAntitrustLitigationMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opana ER\u00ae antitrust litigation", "label": "Opana ER Antitrust Litigation [Member]", "documentation": "Opana ER Antitrust Litigation" } } }, "auth_ref": [] }, "amrx_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities - related party", "label": "Operating And Finance Lease Liability Current", "documentation": "Operating And Finance Lease, Liability, Current" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating (loss) income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r278", "r292", "r298", "r301", "r757" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r533" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r533" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r532" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r301" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/NatureofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Operations", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r114", "r158", "r612", "r613" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Assets [Abstract]", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/OtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "amrx_OtherAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherAssetsLineItems", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets [Line Items]", "label": "Other Assets [Line Items]", "documentation": "Other assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r91", "r100" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r192" ] }, "amrx_OtherAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherAssetsTable", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets [Table]", "label": "Other Assets [Table]", "documentation": "Other assets." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income:", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments arising during the period", "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r131", "r516", "r518", "r522" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss before reclassification", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r21", "r39", "r215", "r523", "r525", "r528", "r816" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized gain (loss) on cash flow hedge, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r204", "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiencyParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of cash flow hedge to earnings, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow hedge, net of tax of $0", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r204", "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain recorded within accumulated other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r204", "r205", "r493", "r494", "r496" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiencyParenthetical", "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow hedge, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of cash flow hedge to earnings, net of tax of $0", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r205", "r208" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative gain reclassified from accumulated OCI into income (loss)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r177", "r205", "r208" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of cash flow hedge to earnings, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Other comprehensive loss attributable to non-controlling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r7", "r12", "r159", "r210", "r213" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r159", "r210", "r213" ] }, "amrx_OtherExpenseTaxReceivableAgreementTRALiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherExpenseTaxReceivableAgreementTRALiabilityMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Expense", "label": "Other Expense Tax Receivable Agreement T R A Liability [Member]", "documentation": "Other Expense Tax Receivable Agreement T R A Liability" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-Term Liabilities", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r29" ] }, "amrx_OtherLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherLiabilitiesLineItems", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities [Line Items]", "label": "Other Liabilities [Line Items]", "documentation": "Other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "amrx_OtherLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherLiabilitiesTable", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities [Table]", "label": "Other Liabilities [Table]", "documentation": "Other liabilities." } } }, "auth_ref": [] }, "amrx_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesScheduleofLiabilitiesForLegalMattersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other [Member]", "documentation": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other operating charges and credits, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long term assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Long-Term Liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r140" ] }, "us-gaap_OtherNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNotesPayable", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable - related party", "label": "Other Notes Payable", "documentation": "Amount of long-term notes payable classified as other." } } }, "auth_ref": [ "r22", "r165", "r886" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other operating income", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other prepaid assets", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r814", "r836" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "amrx_OtherTherapeuticClassesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "OtherTherapeuticClassesMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other therapeutic classes", "label": "Other Therapeutic Classes [Member]", "documentation": "Other therapeutic classes." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.amneal.com/role/NatureofOperationsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee payroll tax withholding on restricted stock unit vesting", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r220" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r141" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r141" ] }, "amrx_PaymentsToAcquirePropertyPlantAndEquipmentDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "PaymentsToAcquirePropertyPlantAndEquipmentDeposits", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deposits for future acquisition of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment, Deposits", "documentation": "Payments to Acquire Property, Plant, and Equipment, Deposits" } } }, "auth_ref": [] }, "amrx_PercentageOfOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "PercentageOfOwnershipInterest", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest (percent)", "label": "Percentage Of Ownership Interest", "documentation": "Percentage of ownership interest." } } }, "auth_ref": [] }, "amrx_PercentageOfPrescribedLabel": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "PercentageOfPrescribedLabel", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage Of Prescribed Label", "label": "Percentage Of Prescribed Label", "documentation": "Percentage Of Prescribed Label" } } }, "auth_ref": [] }, "amrx_PercentageOfTaxBenefitsUnderTaxReceivableAgreement": { "xbrltype": "percentItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "PercentageOfTaxBenefitsUnderTaxReceivableAgreement", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of tax receivable agreement paid to other holders of Amneal common units (percent)", "label": "Percentage Of Tax Benefits Under Tax Receivable Agreement", "documentation": "Percentage of tax benefits under tax receivable agreement." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance stock units", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r121", "r389" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r121", "r651" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r121", "r389" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r121", "r573", "r783" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r815" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r746", "r759", "r836" ] }, "amrx_PrepaidRegulatoryFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "PrepaidRegulatoryFeesCurrent", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid regulatory fees", "label": "Prepaid Regulatory Fees Current", "documentation": "Prepaid Regulatory Fees, Current" } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r747", "r760", "r836" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r811" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of businesses", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows", "http://www.amneal.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings on revolving credit facilities", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r42", "r822" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r17" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r864" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r303", "r551", "r598", "r599", "r600", "r601", "r602", "r603", "r741", "r768", "r784", "r810", "r856", "r857", "r863", "r887" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r303", "r551", "r598", "r599", "r600", "r601", "r602", "r603", "r741", "r768", "r784", "r810", "r856", "r857", "r863", "r887" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows", "http://www.amneal.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r186", "r209", "r212", "r222", "r230", "r246", "r254", "r255", "r278", "r292", "r298", "r301", "r311", "r346", "r347", "r349", "r350", "r351", "r353", "r355", "r357", "r358", "r485", "r488", "r489", "r507", "r514", "r569", "r581", "r625", "r672", "r694", "r695", "r757", "r781", "r782", "r797", "r818", "r859" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r570", "r579", "r783" ] }, "amrx_RSSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RSSolutionsMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&S Solutions - logistics services", "label": "R&S Solutions [Member]", "documentation": "R&S Solutions" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r427", "r435", "r459", "r460", "r461", "r549", "r550", "r604", "r642", "r643", "r704", "r706", "r708", "r709", "r715", "r737", "r738", "r758", "r767", "r780", "r785", "r788", "r849", "r861", "r880", "r881", "r882", "r883", "r884" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r427", "r435", "r459", "r460", "r461", "r549", "r550", "r604", "r642", "r643", "r704", "r706", "r708", "r709", "r715", "r737", "r738", "r758", "r767", "r780", "r785", "r788", "r849", "r861", "r880", "r881", "r882", "r883", "r884" ] }, "amrx_RanitidineLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RanitidineLitigationMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranitidine Litigation", "label": "Ranitidine Litigation [Member]", "documentation": "Ranitidine Litigation" } } }, "auth_ref": [] }, "amrx_RebatesAndChargebacks": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RebatesAndChargebacks", "crdr": "credit", "calculation": { "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial chargebacks and rebates", "label": "Rebates And Chargebacks", "documentation": "Rebates and chargebacks." } } }, "auth_ref": [] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Receivables [Abstract]", "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of cash flow hedge to earnings, net of tax of $0", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r21", "r39", "r215", "r523", "r527", "r528", "r816" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "amrx_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax distribution recorded as a reduction to redeemable non-controlling interest", "label": "Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders", "documentation": "Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders" } } }, "auth_ref": [] }, "amrx_RegulatoryApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RegulatoryApprovalMember", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory Approval", "label": "Regulatory Approval [Member]", "documentation": "Regulatory Approval [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r434", "r538", "r539", "r645", "r646", "r647", "r648", "r649", "r668", "r670", "r703" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r232", "r233", "r538", "r539", "r540", "r541", "r645", "r646", "r647", "r648", "r649", "r668", "r670", "r703" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts of transaction with related party", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r110", "r538" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r538", "r539", "r876" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r676", "r677", "r680" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r434", "r538", "r539", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r645", "r646", "r647", "r648", "r649", "r668", "r670", "r703", "r876" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r535", "r536", "r537", "r539", "r542", "r621", "r622", "r623", "r678", "r679", "r680", "r700", "r702" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of outstanding principal", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r43", "r618" ] }, "amrx_RepaymentsOfLongTermDebtRevolvingCreditFacilityAndFinancingLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RepaymentsOfLongTermDebtRevolvingCreditFacilityAndFinancingLeaseObligations", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of principal on debt, revolving credit facilities, financing leases and other", "label": "Repayments Of Long Term Debt, Revolving Credit Facility And Financing Lease Obligations", "documentation": "Repayments of long term debt and financing lease obligations." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r234", "r235", "r363", "r391", "r541", "r753", "r754" ] }, "amrx_ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate", "label": "Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate [Member]", "documentation": "Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r113", "r466", "r885" ] }, "amrx_ResearchAndDevelopmentGenericDevelopmentSupplyAgreementResearchAndDevelopmentMaterialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ResearchAndDevelopmentGenericDevelopmentSupplyAgreementResearchAndDevelopmentMaterialMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development - Generic Development Supply Agreement - Research and Development Material", "label": "Research and Development - Generic Development Supply Agreement - Research and Development Material [Member]", "documentation": "Research and Development - Generic Development Supply Agreement - Research and Development Material" } } }, "auth_ref": [] }, "amrx_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development [Member]", "documentation": "Research and Development" } } }, "auth_ref": [] }, "amrx_ResearchAndDevelopmentParkingSpaceLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ResearchAndDevelopmentParkingSpaceLeaseMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development - Parking Space Lease", "label": "Research and development - Parking Space Lease [Member]", "documentation": "Research and development - Parking Space Lease" } } }, "auth_ref": [] }, "amrx_ResearchAndDevelopmentReimbursementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ResearchAndDevelopmentReimbursementMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Reimbursement", "label": "Research And Development Reimbursement [Member]", "documentation": "Research And Development Reimbursement [Member]" } } }, "auth_ref": [] }, "amrx_ResearchAndDevelopmentStorageIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ResearchAndDevelopmentStorageIncomeMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Storage Income", "label": "Research and Development Storage Income [Member]", "documentation": "Research and Development Storage Income" } } }, "auth_ref": [] }, "amrx_RespiratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RespiratoryMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Respiratory", "label": "Respiratory [Member]", "documentation": "Respiratory." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "periodEndLabel": "Restricted cash - end of period", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r44", "r189", "r226" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit vesting, net of shares withheld to cover payroll taxes", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and other charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r335", "r336", "r850" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r124", "r157", "r576", "r608", "r610", "r619", "r652", "r783" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r182", "r243", "r244", "r245", "r247", "r253", "r255", "r312", "r313", "r463", "r464", "r465", "r474", "r475", "r497", "r499", "r500", "r502", "r505", "r605", "r607", "r626", "r893" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r279", "r280", "r291", "r296", "r297", "r303", "r305", "r307", "r423", "r424", "r551" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionConcentrationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r307", "r808" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Obligations", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r179", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r739" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.amneal.com/role/RevenueRecognition" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r179", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r426" ] }, "amrx_ReversalOfAccruedTaxReceivableAgreementLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "ReversalOfAccruedTaxReceivableAgreementLiability", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal of accrued tax receivable agreement liability", "label": "Reversal Of Accrued Tax Receivable Agreement Liability", "documentation": "Reversal of accrued tax receivable agreement liability." } } }, "auth_ref": [] }, "amrx_RondoClassBUnitHoldersTaxDistributionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RondoClassBUnitHoldersTaxDistributionsMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rondo Class B unit holders - tax distributions", "label": "Rondo Class B Unit Holders - Tax Distributions [Member]", "documentation": "Rondo Class B Unit Holders - Tax Distributions" } } }, "auth_ref": [] }, "amrx_RondoPartnersLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "RondoPartnersLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes", "label": "Rondo Partners L L C [Member]", "documentation": "Rondo Partners, LLC." } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual property legal development expenses", "verboseLabel": "Intellectual property legal development expenses", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r137" ] }, "us-gaap_SalesReturnsAndAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesReturnsAndAllowancesMember", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Returns Allowance", "label": "Sales Returns and Allowances [Member]", "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Trade Accounts Receivable, Net", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Expenses", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive (Loss) Income by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r39", "r872", "r873" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.amneal.com/role/LossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.amneal.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r31", "r69", "r72", "r105", "r106", "r108", "r112", "r155", "r156", "r763", "r765", "r826" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.amneal.com/role/LossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r831" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r509", "r510" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r61", "r63", "r552" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r61", "r63" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r761" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r761", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.amneal.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r24", "r128", "r129", "r130" ] }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Charges and Liabilities Related to Legal Matters", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date." } } }, "auth_ref": [ "r852", "r854", "r856", "r858" ] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": [ "http://www.amneal.com/role/OtherAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": [ "r813" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.amneal.com/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedLiabilitiesDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails", "http://www.amneal.com/role/TradeAccountsReceivableNetScheduleofTradeAccountsReceivableNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r109", "r110", "r676", "r677", "r680" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue by Major Customers by Reporting Segments", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r55", "r56", "r57", "r58" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.amneal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r55", "r56", "r57", "r58" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r155", "r156", "r157", "r196", "r197", "r198", "r272", "r389", "r390", "r391", "r393", "r396", "r401", "r403", "r615", "r616", "r617", "r618", "r767", "r805", "r821" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r63" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.amneal.com/role/TradeAccountsReceivableNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules of Percent of Gross Trade Receivables", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r47", "r48", "r50", "r51", "r103", "r162" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r799" ] }, "amrx_SecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SecurityDepositsMember", "presentation": [ "http://www.amneal.com/role/OtherAssetsScheduleofOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposits", "label": "Security Deposits [Member]", "documentation": "Security deposits." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r801" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r307", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r334", "r337", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r761", "r810", "r887" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r305", "r306", "r638", "r639", "r640", "r705", "r707", "r710", "r716", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r742", "r769", "r788", "r863", "r887" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r290", "r295", "r299", "r300", "r301", "r302", "r303", "r304", "r307" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "amrx_SellersOfAvKARELLCAndRSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SellersOfAvKARELLCAndRSMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes", "label": "Sellers of AvKARE LLC and R&S [Member]", "documentation": "Sellers of AvKARE LLC and R&S" } } }, "auth_ref": [] }, "amrx_SellersOfKSPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SellersOfKSPMember", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sellers of KSP", "label": "Sellers of KSP [Member]", "documentation": "Sellers of KSP" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r138" ] }, "amrx_SellingGeneralAndAdministrativeLogisticsServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SellingGeneralAndAdministrativeLogisticsServicesMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative - Logistics Services", "label": "Selling, General and Administrative - Logistics Services [Member]", "documentation": "Selling, General and Administrative - Logistics Services" } } }, "auth_ref": [] }, "amrx_SellingGeneralAndAdministrativeOperatingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SellingGeneralAndAdministrativeOperatingLeaseMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative - Operating Lease", "label": "Selling, General and Administrative - Operating Lease [Member]", "documentation": "Selling, General and Administrative - Operating Lease" } } }, "auth_ref": [] }, "amrx_SeniorSecuredCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SeniorSecuredCreditFacilityMember", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Secured Credit Facility", "label": "Senior Secured Credit Facility [Member]", "documentation": "Senior Secured Credit Facility [Member]" } } }, "auth_ref": [] }, "amrx_SeniorSecuredCreditFacilityTermLoanDueMay2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SeniorSecuredCreditFacilityTermLoanDueMay2025Member", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Due 2025", "label": "Senior Secured Credit Facility, Term Loan Due May 2025 [Member]", "documentation": "Senior Secured Credit Facility, Term Loan Due May 2025" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.amneal.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r145", "r227" ] }, "amrx_SpecialtySegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SpecialtySegmentMember", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty", "label": "Specialty Segment [Member]", "documentation": "Specialty Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetail", "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails", "http://www.amneal.com/role/SegmentInformationSchedulesofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r184", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r307", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r333", "r334", "r337", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r761", "r810", "r887" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/Cover", "http://www.amneal.com/role/LossperShareSecuritiesExcludedfromDilutedEarningsperShareComputationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r181", "r196", "r197", "r198", "r230", "r260", "r261", "r264", "r266", "r272", "r273", "r311", "r346", "r349", "r350", "r351", "r357", "r358", "r389", "r390", "r393", "r396", "r403", "r514", "r615", "r616", "r617", "r618", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r651", "r673", "r696", "r717", "r718", "r719", "r720", "r721", "r805", "r821", "r830" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/FinancialInstrumentsAdditionalInformationDetails", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r35", "r182", "r214", "r215", "r216", "r243", "r244", "r245", "r247", "r253", "r255", "r271", "r312", "r313", "r404", "r463", "r464", "r465", "r474", "r475", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r523", "r524", "r525", "r526", "r527", "r528", "r534", "r605", "r606", "r607", "r626", "r696" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r305", "r306", "r638", "r639", "r640", "r705", "r707", "r710", "r716", "r724", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r742", "r769", "r788", "r863", "r887" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r243", "r244", "r245", "r271", "r551", "r614", "r637", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r670", "r674", "r675", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r696", "r789" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfOtherComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Other Comprehensive Income [Abstract]", "label": "Statement of Other Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r243", "r244", "r245", "r271", "r551", "r614", "r637", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r670", "r674", "r675", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r696", "r789" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r121", "r122", "r157", "r445" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r14", "r35", "r157" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r122", "r125", "r126", "r146", "r653", "r669", "r697", "r698", "r783", "r798", "r823", "r835", "r869", "r893" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency", "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterestsScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' (deficiency) equity", "periodStartLabel": "Stockholders' equity beginning balance", "periodEndLabel": "Stockholders' equity ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r82", "r83", "r85", "r182", "r183", "r215", "r243", "r244", "r245", "r247", "r253", "r312", "r313", "r404", "r463", "r464", "r465", "r474", "r475", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r523", "r524", "r528", "r534", "r606", "r607", "r624", "r653", "r669", "r697", "r698", "r722", "r797", "r823", "r835", "r869", "r893" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' (Deficiency) Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.amneal.com/role/StockholdersEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity and Redeemable Non-Controlling Interests", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r154", "r229", "r388", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r402", "r404", "r504", "r699", "r701", "r723" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r529", "r544" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r529", "r544" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r529", "r544" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r529", "r544" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r529", "r544" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.amneal.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r543", "r545" ] }, "amrx_SubsidiaryInIndiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SubsidiaryInIndiaMember", "presentation": [ "http://www.amneal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary In India", "label": "Subsidiary In India [Member]", "documentation": "Subsidiary In India" } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Major Categories of Sales-Related Deductions", "label": "Summary of Valuation Allowance [Table Text Block]", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r75" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.amneal.com/role/PrepaidExpensesandOtherCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r812" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "amrx_SutariaFamilyRealtyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "SutariaFamilyRealtyLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sutaria Family Realty, LLC - operating lease", "label": "Sutaria Family Realty, LLC [Member]", "documentation": "Sutaria Family Realty, LLC" } } }, "auth_ref": [] }, "amrx_TaxDistributionToNoncontrollingInterestFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TaxDistributionToNoncontrollingInterestFinancingActivities", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax distributions to non-controlling interests", "label": "Tax Distribution To Noncontrolling Interest Financing Activities", "documentation": "Tax Distribution To Non-controlling Interest, Financing Activities" } } }, "auth_ref": [] }, "amrx_TaxReceivableAgreementLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TaxReceivableAgreementLiability", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax receivable agreement liability", "label": "Tax Receivable Agreement Liability", "documentation": "Tax Receivable Agreement Liability" } } }, "auth_ref": [] }, "amrx_TaxReceivableAgreementPaymentRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TaxReceivableAgreementPaymentRatio", "presentation": [ "http://www.amneal.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax receivable agreement, payment ratio", "label": "Tax Receivable Agreement, Payment Ratio", "documentation": "Tax Receivable Agreement, Payment Ratio" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.amneal.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amneal.com/role/ConsolidatedBalanceSheets", "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable non-controlling interests", "periodStartLabel": "Redeemable Non-Controlling Interests, beginning balance", "periodEndLabel": "Redeemable Non-Controlling Interests, ending balance", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r34", "r230", "r311", "r514" ] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income", "label": "Temporary Equity, Net Income", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "amrx_TemporaryEquityTaxDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TemporaryEquityTaxDistribution", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficiency" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax distributions, net", "label": "Temporary Equity, Tax Distribution", "documentation": "Temporary Equity, Tax Distribution" } } }, "auth_ref": [] }, "amrx_TermLoanDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TermLoanDue2025Member", "presentation": [ "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Due May 2025", "label": "Term Loan Due 2025 [Member]", "documentation": "Term Loan Due 2025" } } }, "auth_ref": [] }, "amrx_TermLoanDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TermLoanDue2028Member", "presentation": [ "http://www.amneal.com/role/DebtSummaryofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Due May 2028", "label": "Term Loan Due 2028 [Member]", "documentation": "Term Loan Due 2028" } } }, "auth_ref": [] }, "amrx_TermLoanDueMay2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TermLoanDueMay2028Member", "presentation": [ "http://www.amneal.com/role/FairValueMeasurementsSummaryoftheCompanysIndebtednessatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Due 2028", "label": "Term Loan Due May 2028 [Member]", "documentation": "Term Loan Due May 2028" } } }, "auth_ref": [] }, "amrx_TracyPropertiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "TracyPropertiesLLCMember", "presentation": [ "http://www.amneal.com/role/RelatedPartyTransactionsRelatedPartyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tracy Properties LLC - operating lease", "label": "Tracy Properties L L C [Member]", "documentation": "Tracy Properties LLC." } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.amneal.com/role/GoodwillandOtherIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Other intangible assets", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r79" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.amneal.com/role/AllianceandCollaborationAdditionalInformationDetails", "http://www.amneal.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r484" ] }, "amrx_UFCWLocal1500WelfareFundV.TakedaPharmaceuticalsU.S.A.Inc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "UFCWLocal1500WelfareFundV.TakedaPharmaceuticalsU.S.A.Inc.Member", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.", "label": "UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. [Member]", "documentation": "UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US", "label": "UNITED STATES" } } }, "auth_ref": [] }, "amrx_UncertainTaxPositionNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "UncertainTaxPositionNoncurrentMember", "presentation": [ "http://www.amneal.com/role/OtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "label": "Uncertain Tax Position Noncurrent [Member]", "documentation": "Uncertain tax position noncurrent." } } }, "auth_ref": [] }, "amrx_UnitedStatesDepartmentOfJusticeInvestigationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "UnitedStatesDepartmentOfJusticeInvestigationsMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States Department of Justice Investigations", "label": "United States Department of Justice Investigations [Member]", "documentation": "United States Department of Justice Investigations" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.amneal.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r52", "r53", "r54", "r172", "r174", "r175", "r176" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r237", "r242" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision related to sales recorded in the period", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r240" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Credits/payments issued during the period", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r237", "r238", "r239", "r241", "r242" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r237", "r238", "r239", "r241", "r242" ] }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "auth_ref": [ "r237", "r238", "r239", "r241", "r242" ] }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": [ "http://www.amneal.com/role/RevenueRecognitionScheduleofMajorCategoriesofSalesRelatedDeductionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "auth_ref": [ "r237", "r238", "r239", "r241", "r242" ] }, "amrx_VariableToFixedInterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "VariableToFixedInterestRateSwapMember", "presentation": [ "http://www.amneal.com/role/FinancialInstrumentsSummaryofFairValuesofDerivativeInstrumentsinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable to Fixed Interest Rate Swap", "label": "Variable To Fixed Interest Rate Swap [Member]", "documentation": "Variable-to-fixed interest rate swap." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in shares)", "terseLabel": "Weighted-average shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r259", "r266" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations", "http://www.amneal.com/role/LossperShareComputationofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted-average shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r257", "r266" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.amneal.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "amrx_XyremSodiumOxybateAntitrustLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amneal.com/20240331", "localname": "XyremSodiumOxybateAntitrustLitigationMember", "presentation": [ "http://www.amneal.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Xyrem\u00ae (Sodium Oxybate) Antitrust Litigation", "label": "Xyrem\u00ae (Sodium Oxybate) Antitrust Litigation [Member]", "documentation": "Xyrem\u00ae (Sodium Oxybate) Antitrust Litigation" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(3)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.27(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r805": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r806": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 103 0001723128-24-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001723128-24-000021-xbrl.zip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end XML 105 amrx-20240331_htm.xml IDEA: XBRL DOCUMENT 0001723128 2024-01-01 2024-03-31 0001723128 2024-04-30 0001723128 2023-01-01 2023-03-31 0001723128 amrx:OpanaERAntitrustLitigationMember 2023-01-01 2023-03-31 0001723128 2024-03-31 0001723128 2023-12-31 0001723128 us-gaap:NonrelatedPartyMember 2024-03-31 0001723128 us-gaap:NonrelatedPartyMember 2023-12-31 0001723128 us-gaap:RelatedPartyMember 2024-03-31 0001723128 us-gaap:RelatedPartyMember 2023-12-31 0001723128 us-gaap:CommonClassAMember 2023-12-31 0001723128 us-gaap:CommonClassAMember 2024-03-31 0001723128 us-gaap:CommonClassBMember 2024-03-31 0001723128 us-gaap:CommonClassBMember 2023-12-31 0001723128 2022-12-31 0001723128 2023-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001723128 us-gaap:RetainedEarningsMember 2023-12-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001723128 us-gaap:NoncontrollingInterestMember 2023-12-31 0001723128 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001723128 us-gaap:RetainedEarningsMember 2024-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2024-03-31 0001723128 amrx:OldPubCoCommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001723128 amrx:OldPubCoCommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001723128 us-gaap:RetainedEarningsMember 2022-12-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001723128 us-gaap:NoncontrollingInterestMember 2022-12-31 0001723128 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001723128 amrx:OldPubCoCommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001723128 amrx:OldPubCoCommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001723128 amrx:OldPubCoCommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001723128 us-gaap:RetainedEarningsMember 2023-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2023-03-31 0001723128 amrx:AmnealPharmaceuticalsLLCMember 2024-03-31 0001723128 amrx:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001723128 amrx:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001723128 amrx:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001723128 amrx:CustomerDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001723128 amrx:AntiInfectiveMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:AntiInfectiveMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:HormonalAllergyMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:HormonalAllergyMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:AntiviralMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:AntiviralMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:CentralNervousSystemMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:CentralNervousSystemMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:CardiovascularSystemMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:CardiovascularSystemMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:GastroenterologyMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:GastroenterologyMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:OncologyMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:OncologyMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:MetabolicDiseaseEndocrineMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:MetabolicDiseaseEndocrineMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:RespiratoryMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:RespiratoryMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:DermatologyMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:DermatologyMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:OtherTherapeuticClassesMember country:US amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:OtherTherapeuticClassesMember country:US amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:NonUsMember amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:NonUsMember amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 amrx:HormonalAllergyMember country:US amrx:SpecialtySegmentMember 2024-01-01 2024-03-31 0001723128 amrx:HormonalAllergyMember country:US amrx:SpecialtySegmentMember 2023-01-01 2023-03-31 0001723128 amrx:CentralNervousSystemMember country:US amrx:SpecialtySegmentMember 2024-01-01 2024-03-31 0001723128 amrx:CentralNervousSystemMember country:US amrx:SpecialtySegmentMember 2023-01-01 2023-03-31 0001723128 amrx:LicenseAgreementMember country:US amrx:SpecialtySegmentMember 2024-01-01 2024-03-31 0001723128 amrx:LicenseAgreementMember country:US amrx:SpecialtySegmentMember 2023-01-01 2023-03-31 0001723128 amrx:OtherTherapeuticClassesMember country:US amrx:SpecialtySegmentMember 2024-01-01 2024-03-31 0001723128 amrx:OtherTherapeuticClassesMember country:US amrx:SpecialtySegmentMember 2023-01-01 2023-03-31 0001723128 amrx:SpecialtySegmentMember 2024-01-01 2024-03-31 0001723128 amrx:SpecialtySegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:DistributionServiceMember country:US amrx:AvKARESegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:DistributionServiceMember country:US amrx:AvKARESegmentMember 2023-01-01 2023-03-31 0001723128 amrx:GovernmentLabelMember country:US amrx:AvKARESegmentMember 2024-01-01 2024-03-31 0001723128 amrx:GovernmentLabelMember country:US amrx:AvKARESegmentMember 2023-01-01 2023-03-31 0001723128 amrx:InstitutionalMember country:US amrx:AvKARESegmentMember 2024-01-01 2024-03-31 0001723128 amrx:InstitutionalMember country:US amrx:AvKARESegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:ProductAndServiceOtherMember country:US amrx:AvKARESegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:ProductAndServiceOtherMember country:US amrx:AvKARESegmentMember 2023-01-01 2023-03-31 0001723128 amrx:AvKARESegmentMember 2024-01-01 2024-03-31 0001723128 amrx:AvKARESegmentMember 2023-01-01 2023-03-31 0001723128 amrx:ContractChargebacksAndSalesVolumeAllowancesMember 2023-12-31 0001723128 amrx:CashDiscountAllowancesMember 2023-12-31 0001723128 us-gaap:SalesReturnsAndAllowancesMember 2023-12-31 0001723128 amrx:AccruedMedicaidAndCommercialRebatesMember 2023-12-31 0001723128 amrx:ContractChargebacksAndSalesVolumeAllowancesMember 2024-01-01 2024-03-31 0001723128 amrx:CashDiscountAllowancesMember 2024-01-01 2024-03-31 0001723128 us-gaap:SalesReturnsAndAllowancesMember 2024-01-01 2024-03-31 0001723128 amrx:AccruedMedicaidAndCommercialRebatesMember 2024-01-01 2024-03-31 0001723128 amrx:ContractChargebacksAndSalesVolumeAllowancesMember 2024-03-31 0001723128 amrx:CashDiscountAllowancesMember 2024-03-31 0001723128 us-gaap:SalesReturnsAndAllowancesMember 2024-03-31 0001723128 amrx:AccruedMedicaidAndCommercialRebatesMember 2024-03-31 0001723128 amrx:LicenseAgreementWithOrionCorporationMember 2022-12-28 2022-12-28 0001723128 amrx:LicenseAgreementWithOrionCorporationMember 2023-01-01 2023-03-31 0001723128 amrx:LicenseAgreementWithOrionCorporationMember 2024-01-01 2024-03-31 0001723128 us-gaap:AccountsPayableAndAccruedLiabilitiesMember amrx:LicenseAgreementWithOrionCorporationMember 2024-03-31 0001723128 us-gaap:OtherNoncurrentLiabilitiesMember amrx:LicenseAgreementWithOrionCorporationMember 2024-03-31 0001723128 us-gaap:AccountsPayableAndAccruedLiabilitiesMember amrx:LicenseAgreementWithOrionCorporationMember 2023-12-31 0001723128 us-gaap:OtherNoncurrentLiabilitiesMember amrx:LicenseAgreementWithOrionCorporationMember 2023-12-31 0001723128 amrx:ONGENTYSLicenseAgreementMember 2023-12-05 0001723128 amrx:ONGENTYSLicenseAgreementMember 2023-12-01 2023-12-31 0001723128 amrx:KnightTherapeuticsInternationalS.A.LicenseAgreementMember 2024-01-24 2024-01-24 0001723128 amrx:KnightTherapeuticsInternationalS.A.LicenseAgreementMember 2024-02-26 0001723128 amrx:KnightTherapeuticsInternationalS.A.LicenseAgreementMember 2024-02-26 2024-02-26 0001723128 amrx:LicenseAgreementWithZambonBiotechMember 2024-02-23 2024-02-23 0001723128 amrx:LicenseAgreementWithZambonBiotechMember 2024-02-23 0001723128 amrx:LicenseAgreementWithZambonBiotechMember 2024-01-01 2024-03-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember 2018-05-07 2018-05-07 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember 2022-01-01 2022-12-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember 2022-12-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember 2024-01-01 2024-03-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember 2023-10-12 2023-10-12 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember 2023-01-01 2023-12-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember amrx:DevelopmentMilestonesMember 2023-01-01 2023-12-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember amrx:RegulatoryApprovalMember 2023-01-01 2023-12-31 0001723128 amrx:BiosimilarLicensingAndSupplyAgreementMember amrx:AchievementOfCumulativeNetSalesMember 2023-01-01 2023-03-31 0001723128 2018-01-01 2018-12-31 0001723128 2019-01-01 2019-12-31 0001723128 2023-01-01 2023-11-06 0001723128 2023-11-07 2023-11-07 0001723128 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001723128 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001723128 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001723128 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001723128 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001723128 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001723128 us-gaap:CommonClassBMember 2024-01-01 2024-03-31 0001723128 us-gaap:CommonClassBMember 2023-01-01 2023-03-31 0001723128 amrx:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001723128 amrx:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001723128 amrx:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001723128 amrx:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001723128 2023-01-01 2023-06-30 0001723128 amrx:SpecialtySegmentMember 2024-03-31 0001723128 amrx:GenericsSegmentMember 2024-03-31 0001723128 amrx:AvKARESegmentMember 2024-03-31 0001723128 amrx:SpecialtySegmentMember 2023-12-31 0001723128 amrx:GenericsSegmentMember 2023-12-31 0001723128 amrx:AvKARESegmentMember 2023-12-31 0001723128 us-gaap:ContractualRightsMember 2024-03-31 0001723128 us-gaap:ContractualRightsMember 2023-12-31 0001723128 us-gaap:TradeNamesMember 2024-03-31 0001723128 us-gaap:TradeNamesMember 2023-12-31 0001723128 us-gaap:InterestRateSwapMember 2024-03-31 0001723128 us-gaap:InterestRateSwapMember 2023-12-31 0001723128 amrx:SecurityDepositsMember 2024-03-31 0001723128 amrx:SecurityDepositsMember 2023-12-31 0001723128 amrx:LongTermPrepaidExpensesMember 2024-03-31 0001723128 amrx:LongTermPrepaidExpensesMember 2023-12-31 0001723128 amrx:DeferredRevolvingCreditFacilityCostsMember 2024-03-31 0001723128 amrx:DeferredRevolvingCreditFacilityCostsMember 2023-12-31 0001723128 us-gaap:OtherNoncurrentAssetsMember 2024-03-31 0001723128 us-gaap:OtherNoncurrentAssetsMember 2023-12-31 0001723128 amrx:TermLoanDue2025Member 2024-03-31 0001723128 amrx:TermLoanDue2025Member 2023-12-31 0001723128 amrx:TermLoanDue2028Member 2024-03-31 0001723128 amrx:TermLoanDue2028Member 2023-12-31 0001723128 amrx:AmendedNewRevolvingCreditFacilityMember 2024-01-01 2024-03-31 0001723128 amrx:AmendedRondoCreditFacilityMember 2024-01-01 2024-03-31 0001723128 amrx:AmendedNewRevolvingCreditFacilityMember 2023-12-31 0001723128 amrx:AmendedRondoCreditFacilityMember 2024-03-31 0001723128 amrx:UncertainTaxPositionNoncurrentMember 2024-03-31 0001723128 amrx:UncertainTaxPositionNoncurrentMember 2023-12-31 0001723128 amrx:LongTermCompensationMember 2024-03-31 0001723128 amrx:LongTermCompensationMember 2023-12-31 0001723128 amrx:ContingentConsiderationMember 2024-03-31 0001723128 amrx:ContingentConsiderationMember 2023-12-31 0001723128 us-gaap:OtherNoncurrentLiabilitiesMember 2024-03-31 0001723128 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001723128 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001723128 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001723128 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001723128 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001723128 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001723128 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001723128 amrx:SeniorSecuredCreditFacilityTermLoanDueMay2025Member us-gaap:FairValueInputsLevel2Member amrx:SeniorSecuredCreditFacilityMember 2024-03-31 0001723128 amrx:SeniorSecuredCreditFacilityTermLoanDueMay2025Member us-gaap:FairValueInputsLevel2Member amrx:SeniorSecuredCreditFacilityMember 2023-12-31 0001723128 amrx:TermLoanDueMay2028Member us-gaap:FairValueInputsLevel2Member amrx:SeniorSecuredCreditFacilityMember 2024-03-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:SeniorSecuredCreditFacilityMember 2023-12-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:LongTermPromissoryNotesMember 2024-03-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:LongTermPromissoryNotesMember 2023-12-31 0001723128 amrx:InterestRateLockAgreementMember 2019-10-31 0001723128 amrx:AmendedOctober2019SwapMember 2023-11-14 0001723128 amrx:November2023SwapMember 2023-11-14 0001723128 amrx:AmendedOctober2019SwapMember 2023-11-14 2023-11-14 0001723128 us-gaap:OtherAssetsMember amrx:VariableToFixedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001723128 us-gaap:OtherAssetsMember amrx:VariableToFixedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001723128 amrx:OpanaERAntitrustLitigationMember 2024-03-31 0001723128 amrx:OpanaERAntitrustLitigationMember 2023-12-31 0001723128 amrx:OpanaERAccruedInterestMember 2024-03-31 0001723128 amrx:OpanaERAccruedInterestMember 2023-12-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2024-03-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2023-12-31 0001723128 amrx:OtherMember 2024-03-31 0001723128 amrx:OtherMember 2023-12-31 0001723128 amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember 2014-11-06 2014-11-06 0001723128 amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember 2015-03-13 2015-03-13 0001723128 amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember 2023-05-15 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2019-05-10 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2019-11-01 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2020-06-10 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2020-06-10 2020-06-10 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2023-05-31 2023-05-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember us-gaap:SubsequentEventMember 2024-04-30 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionOneMember 2024-04-30 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionOneMember 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionTwoMember 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionTwoMember 2024-04-30 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember srt:MaximumMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionOneMember 2024-04-30 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2024-01-01 2024-03-31 0001723128 amrx:RanitidineLitigationMember 2023-12-31 0001723128 amrx:MetforminLitigationMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionOneMember 2024-05-02 2024-05-02 0001723128 amrx:MetforminLitigationMember us-gaap:SubsequentEventMember amrx:LitigationSettlementOptionTwoMember 2024-05-02 2024-05-02 0001723128 amrx:XyremSodiumOxybateAntitrustLitigationMember 2023-02-28 2023-02-28 0001723128 amrx:XyremSodiumOxybateAntitrustLitigationMember 2023-12-18 2023-12-18 0001723128 amrx:XyremSodiumOxybateAntitrustLitigationMember 2023-12-01 2023-12-31 0001723128 amrx:XyremSodiumOxybateAntitrustLitigationMember 2023-12-31 0001723128 amrx:UFCWLocal1500WelfareFundV.TakedaPharmaceuticalsU.S.A.Inc.Member 2024-02-28 2024-02-28 0001723128 amrx:AmnealPharmaceuticalsLLCMember 2023-11-07 0001723128 us-gaap:CommonClassBMember 2023-11-07 0001723128 amrx:KashivSpecialtyPharmaceuticalsLLCMember 2021-04-02 0001723128 amrx:SellersOfKSPMember amrx:KashivSpecialtyPharmaceuticalsLLCMember 2021-04-02 0001723128 amrx:AvKareIncorporationAndRAndSNortheastLLCMember 2021-12-31 0001723128 amrx:RondoPartnersLLCMember amrx:AvKareIncorporationAndRAndSNortheastLLCMember 2020-01-31 0001723128 amrx:RondoPartnersLLCMember amrx:AvKareIncorporationAndRAndSNortheastLLCMember 2024-03-31 0001723128 amrx:AvKareIncorporationAndRAndSNortheastLLCMember 2024-01-01 2024-03-31 0001723128 amrx:AvKareIncorporationAndRAndSNortheastLLCMember 2023-01-01 2023-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentParkingSpaceLeaseMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentParkingSpaceLeaseMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentStorageIncomeMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentStorageIncomeMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentGenericDevelopmentSupplyAgreementResearchAndDevelopmentMaterialMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentGenericDevelopmentSupplyAgreementResearchAndDevelopmentMaterialMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:DeferredRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMember 2024-01-01 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:DeferredRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMember 2023-01-01 2023-03-31 0001723128 amrx:ResearchAndDevelopmentMember 2024-01-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001723128 amrx:KananLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2024-01-01 2024-03-31 0001723128 amrx:KananLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723128 amrx:SutariaFamilyRealtyLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2024-01-01 2024-03-31 0001723128 amrx:SutariaFamilyRealtyLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723128 amrx:ApaceKYLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2024-01-01 2024-03-31 0001723128 amrx:ApaceKYLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723128 amrx:TracyPropertiesLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2024-01-01 2024-03-31 0001723128 amrx:TracyPropertiesLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2023-01-01 2023-03-31 0001723128 amrx:AzaTechPharmaLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2024-01-01 2024-03-31 0001723128 amrx:AzaTechPharmaLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723128 amrx:AvPropLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2024-01-01 2024-03-31 0001723128 amrx:AvPropLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2023-01-01 2023-03-31 0001723128 amrx:AvtarInvestmentsLLCMember amrx:ResearchAndDevelopmentMember 2024-01-01 2024-03-31 0001723128 amrx:AvtarInvestmentsLLCMember amrx:ResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001723128 amrx:AlkermesMember amrx:InventoryAndCostOfGoodsSoldMember 2024-01-01 2024-03-31 0001723128 amrx:AlkermesMember amrx:InventoryAndCostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723128 amrx:RSSolutionsMember amrx:SellingGeneralAndAdministrativeLogisticsServicesMember 2024-01-01 2024-03-31 0001723128 amrx:RSSolutionsMember amrx:SellingGeneralAndAdministrativeLogisticsServicesMember 2023-01-01 2023-03-31 0001723128 amrx:MembersTaxReceivableAgreementMember amrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember 2024-01-01 2024-03-31 0001723128 amrx:MembersTaxReceivableAgreementMember amrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember 2023-01-01 2023-03-31 0001723128 amrx:KashivBioSciencesLLCMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:KashivBioSciencesLLCMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:ApaceKYLLCMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:ApaceKYLLCMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:AlkermesMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:AlkermesMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:AzaTechPharmaLLCMember 2024-03-31 0001723128 amrx:AzaTechPharmaLLCMember 2023-12-31 0001723128 amrx:AzaTechPharmaLLCMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:AzaTechPharmaLLCMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:AvtarInvestmentsLLCMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:AvtarInvestmentsLLCMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:SellersOfAvKARELLCAndRSMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:SellersOfAvKARELLCAndRSMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:MembersTaxReceivableAgreementMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:MembersTaxReceivableAgreementMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:RondoClassBUnitHoldersTaxDistributionsMember 2024-03-31 0001723128 amrx:RondoClassBUnitHoldersTaxDistributionsMember 2023-12-31 0001723128 amrx:AlkermesPlcMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:AlkermesPlcMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:RondoPartnersLLCMember us-gaap:RelatedPartyMember 2024-03-31 0001723128 amrx:RondoPartnersLLCMember us-gaap:RelatedPartyMember 2023-12-31 0001723128 amrx:KashivBioSciencesLLCMember 2024-03-01 2024-03-31 0001723128 amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember amrx:DevelopmentMilestonesMember 2024-03-01 2024-03-31 0001723128 amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember amrx:RegulatoryApprovalMember 2024-03-01 2024-03-31 0001723128 amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember 2024-03-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember 2022-12-01 2022-12-31 0001723128 amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember 2024-01-01 2024-03-31 0001723128 srt:MaximumMember amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember 2024-01-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember amrx:DevelopmentMilestonesMember 2024-01-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember amrx:RegulatoryApprovalMember 2024-01-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember amrx:InitialCommercialLaunchMilestonesMember 2024-01-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember amrx:AchievementOfAnnualCommercialMilestoneMember 2024-01-01 2024-03-31 0001723128 amrx:ResearchAndDevelopmentReimbursementMember srt:AffiliatedEntityMember amrx:KashivBioSciencesLicenseAndCommercializationAgreementMember 2024-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:GenericsSegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AmnealSpecialtyPharmaSegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AvKARESegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:GenericsSegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AmnealSpecialtyPharmaSegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AvKARESegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0001723128 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember amrx:SubsidiaryInIndiaMember us-gaap:SubsequentEventMember 2024-04-30 0001723128 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember amrx:SubsidiaryInIndiaMember us-gaap:SubsequentEventMember 2024-04-30 2024-04-30 shares iso4217:USD iso4217:USD shares pure iso4217:EUR amrx:product amrx:representative amrx:medication amrx:state amrx:action amrx:case iso4217:USD amrx:twinPack amrx:segment iso4217:INR 0001723128 --12-31 2024 Q1 false 10-Q true 2024-03-31 false 001-38485 Amneal Pharmaceuticals, Inc. DE 93-4225266 400 Crossing Boulevard, Bridgewater NJ 08807 908 947-3120 Class A Common Stock, par value $0.01 per share AMRX NASDAQ Yes Yes Accelerated Filer false false false 308651373 659191000 557540000 421131000 379354000 238060000 178186000 112595000 102096000 39298000 38690000 984000 1644000 1470000 510000 -100000 -2457000 -94359000 436000 0 1224000 -10746000 34449000 -65703000 -49315000 -1197000 1901000 -1948000 -826000 4072000 4365000 -64776000 -43875000 -75522000 -9426000 6156000 668000 -81678000 -10094000 9965000 -3151000 -91643000 -6943000 -0.30 -0.05 307279000 152109000 -81678000 -10094000 9965000 -3151000 -91643000 -6943000 -390000 1797000 0 0 15543000 -14270000 0 0 6515000 0 0 -6236000 8638000 -6237000 -83005000 -13180000 46520000 91542000 5097000 7565000 668955000 613732000 570653000 581384000 87298000 82685000 1521000 955000 1380044000 1377863000 439815000 447574000 598549000 598629000 859272000 890423000 32970000 30329000 12468000 12954000 59532000 59280000 73747000 55517000 3456397000 3472569000 558518000 534662000 30130000 76988000 179000000 179000000 33660000 34125000 9508000 9207000 3192000 2825000 3305000 2467000 17075000 7321000 834388000 846595000 2377707000 2386004000 41893000 41447000 26786000 24095000 11969000 12787000 58809000 58566000 11394000 11776000 85479000 316000 24579000 29679000 2638616000 2564670000 47022000 41293000 0.01 0.01 2000000 2000000 0 0 0 0 0.01 0.01 900000000 900000000 308623000 306565000 3086000 3066000 0.01 0.01 300000000 300000000 0 0 0 0 538720000 539240000 -581819000 -490176000 -23711000 -32349000 -63724000 19781000 95000 230000 -63629000 20011000 3456397000 3472569000 -81678000 -10094000 55528000 58150000 -1511000 1987000 288000 2058000 920000 0 100000 2457000 6722000 7596000 22923000 25204000 -1250000 -2047000 55173000 -195970000 12200000 22508000 11708000 -29160000 562000 -470000 62174000 -150483000 5495000 1672000 -4410000 139712000 9198000 9688000 9700000 338000 862000 1711000 -19760000 -11737000 63377000 72659000 48000000 80000000 28000 0 7212000 2022000 594000 18219000 -23155000 -12900000 -165000 767000 -47490000 115842000 99107000 35227000 51617000 151069000 46520000 144674000 5097000 6395000 51617000 151069000 64514000 41066000 -4567000 3421000 3777000 11548000 306565000 3066000 539240000 -490176000 -32349000 230000 20011000 41293000 -91643000 -135000 -91778000 10100000 -390000 -390000 6722000 6722000 10000 28000 28000 2048000 20000 -7270000 -7250000 0 15543000 15543000 4371000 0 6515000 6515000 308623000 3086000 538720000 -581819000 -23711000 95000 -63629000 47022000 151490000 1514000 152117000 1522000 691629000 -406183000 9939000 -114442000 183979000 24949000 -6943000 -8688000 -15631000 5537000 898000 899000 1797000 7596000 7596000 1831000 18000 1497000 62000 -3572000 -1995000 0 -7135000 -7135000 -14270000 26808000 26808000 2959000 153321000 1532000 152117000 1522000 700722000 -413126000 3764000 -159746000 134668000 27527000 Nature of Operations<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, and biosimilars in our Generics segment and specialty branded pharmaceuticals. The Company operates principally in the United States (“U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company whose principal assets are 100% of the common units of Amneal Pharmaceuticals, LLC (“Amneal”).</span></div> 1 Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the updates included in this note, the accounting policies of the Company are set forth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contained in the Company’s 2023 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:106%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior period balance related to the TRA (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior period balance related to long-term liabilities for legal matters of $0.3 million, formerly included in other long-term liabilities as of December 31, 2023, has been reclassified to the balance sheet caption “liabilities for legal matters - long term” to conform to the current period presentation in the consolidated balance sheets. This reclassification did not impact total long-term liabilities or total liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the updates included in this note, the accounting policies of the Company are set forth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contained in the Company’s 2023 Annual Report on Form 10-K.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:106%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior period balance related to the TRA (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss.</span></div>The prior period balance related to long-term liabilities for legal matters of $0.3 million, formerly included in other long-term liabilities as of December 31, 2023, has been reclassified to the balance sheet caption “liabilities for legal matters - long term” to conform to the current period presentation in the consolidated balance sheets. This reclassification did not impact total long-term liabilities or total liabilities -800000 300000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div> Revenue Recognition<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Alliance and Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information related to revenue recognition associated with license agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregated Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-infective</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hormonal / allergy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antiviral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central nervous system</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular system</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gastroenterology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabolic disease / endocrine</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other therapeutic classes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Generics net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,294 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,806 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Specialty</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hormonal / allergy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central nervous system</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other therapeutic classes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Specialty net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,234 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,678 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">AvKARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government label</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Institutional</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total AvKARE net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,663 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,540 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:16.44pt">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Alliance and Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for information on revenue recognized under a license agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract<br/>Charge - Backs<br/>and Sales<br/>Volume<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Discount<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Returns<br/>Allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Medicaid and<br/>Commercial<br/>Rebates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,690 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales recorded in the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments issued during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,711 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.21 0.22 0.15 0.14 0.23 0.20 0.10 0.09 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-infective</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hormonal / allergy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antiviral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central nervous system</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular system</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gastroenterology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabolic disease / endocrine</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other therapeutic classes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Generics net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,294 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,806 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Specialty</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hormonal / allergy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central nervous system</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other therapeutic classes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Specialty net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,234 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,678 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">AvKARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government label</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Institutional</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total AvKARE net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,663 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,540 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:16.44pt">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Alliance and Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for information on revenue recognized under a license agreement.</span></div> 6110000 5174000 107714000 104851000 3866000 25474000 109456000 84582000 45878000 32503000 18197000 14364000 38533000 10578000 11185000 9265000 11136000 12815000 18975000 18004000 18523000 25895000 1721000 301000 391294000 343806000 29375000 24763000 66276000 60139000 4479000 0 5104000 6776000 105234000 91678000 109713000 83230000 34952000 24516000 10858000 8862000 7140000 5448000 162663000 122056000 659191000 557540000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract<br/>Charge - Backs<br/>and Sales<br/>Volume<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Discount<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Returns<br/>Allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Medicaid and<br/>Commercial<br/>Rebates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,690 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales recorded in the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments issued during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,711 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 559334000 23892000 136486000 90690000 885322000 30073000 16220000 61271000 987202000 26550000 15598000 55250000 457454000 27415000 137108000 96711000 Alliance and Collaboration<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which generally obligate the Company to provide R&amp;D services over multiple periods. The Company’s significant arrangements are discussed below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orion Corporation License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of its complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During both the three months ended March 31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the Company recognized $0.6 million as a reduction to R&amp;D expense related to services performed under the Orion Agreement. As of March 31, 2024, deferred income of $10.7 million and $1.2 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, deferred income of $7.8 million and $4.7 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of March 31, 2024, no products have been supplied by Amneal under the Orion Agreement. Refer to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 5. Alliance and Collaboration</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in our 2023 Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ONGENTYS® License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2023, the Company entered into a license agreement with BIAL-Portela &amp; Ca., S.A. (“BIAL”) for the exclusive royalty-free right to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023 and ending at such time when generic opicapone sales reach certain predetermined thresholds (the “BIAL License Agreement”). ONGENTYS® is BIAL’s proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes. Under the BIAL Agreement, the Company is responsible for commercialization and marketing of ONGENTYS® in the U.S. and BIAL is responsible for manufacturing and supply. The BIAL Agreement also requires the Company to spend a minimum of $6.0 million in medical and marketing activities directly related to ONGENTYS®. The Company commenced distribution of ONGENTYS® during the three months ended March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2023, the Company paid a nonrefundable license fee of $12.5 million to BIAL, which was capitalized as an intangible asset and will be amortized to cost of sales over a period of eight years. The BIAL License Agreement provides for potential future milestone payments totaling $22.5 million, depending on cumulative net sales of ONGENTYS®.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Knight Therapeutics International S.A. License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. (“Knight”) granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the “Knight License Agreement”). The Knight License Agreement will automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Knight will be responsible for the performance of all R&amp;D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2024, the Company received a nonrefundable license fee of $1.0 million from Knight, which was recorded as net revenue for the three months ended March 31, 2024. The Knight License Agreement provides for potential future milestone payments totaling $10.5 million, contingent upon regulatory approval, launch dates and cumulative net sales targets by Knight. The agreement also includes low-double digit royalty payments based on net sales of IPX203.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">License Agreement with Zambon Biotech</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2024, the Company entered into a license, distribution and supply agreement with Zambon Biotech S.A. (“Zambon”) granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the “Zambon License Agreement”). The term for the Zambon License Agreement is 15 years commencing from the commercial launch of the product, which can automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Zambon will be responsible for the performance of all R&amp;D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Zambon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the agreement, the Company was entitled to a non-refundable license fee of €5.0 million, or $5.4 million, which was received in April 2024. Of the license fee, the Company allocated €3.2 million, or $3.5 million, to the delivery of a functional license, which was recorded as net revenue during the three months ended March 31, 2024. In addition, the Company is eligible to receive future milestone payments totaling €71.5 million, or $77.2 million, from Zambon, contingent upon regulatory approval of the product, and achievement of certain annual net sales targets by Zambon. The Zambon License Agreement also includes single-digit to low-double digit royalty payments based on net sales of IPX203.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilar Licensing and Supply Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bevacizumab</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2018, the Company entered into a licensing and supply agreement with mAbxience S.L. (“mAbxience”), for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. Pursuant to the agreement, the Company will be the exclusive partner in the U.S. market and pay up-front, development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to mAbxience, up to $78.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2022, the FDA approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million during the year ended December 31, 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of seven years. During the three months ended March 31, 2024, the Company paid a sales-based milestone of $9.5 million, which was capitalized as a product rights intangible asset and is being amortized to cost of sales. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Denosumab</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, the Company entered into a licensing and supply agreement with mAbxience to be the exclusive U.S. partner for two denosumab biosimilars referencing both Prolia® and XGEVA®. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. mAbxience is responsible for the clinical and regulatory approval for the two products and regulatory fees will be shared by the parties. Upon approval of each product, mAbxience will be responsible for supply and the Company will be responsible for commercialization. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded R&amp;D expense for a $2.5 million payment made upon execution of the agreement and an additional $2.5 million for a developmental milestone. During the three months ended March 31, 2024, the Company recorded R&amp;D expense for a $3.0 million payment made for a clinical milestone. The agreement provides for potential future milestone payments to mAbxience of up to $66.0 million as follows: (i) up to $3.5 million relating to clinical and developmental milestones; (ii) up to $15.0 million for regulatory approval and initial commercial launch milestones; and (iii) up to $47.5 million for the achievement of annual commercial milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Agreements with K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">ashiv Biosciences, LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details on the Company’s related party agreements with Kashiv Biosciences, LLC (“Kashiv”), refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19. Related Party Transactions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in this Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24. Related Party Transactions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company’s 2023 Annual Report on Form 10-K.</span></div> P8Y P2Y 600000 600000 10700000 1200000 7800000 4700000 6000000 12500000 P8Y 22500000 P15Y P2Y P1Y 1000000 10500000 P15Y P2Y P1Y 5000000 5400000 3200000 3500000 71500000 77200000 78300000 26500000 P7Y 9500000 2 2 2 2500000 2500000 3000000 66000000 3500000 15000000 47500000 Income Taxes<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three months ended March 31, 2024, the Company’s provision for income taxes and effective tax rate were $6.2 million and (8.2)%, respectively, as compared to $0.7 million and (7.1)%, respectively, for the three months ended March 31, 2023. For the three months ended March 31, 2024, the period-over-period change in the provision for income taxes was primarily related to changes in the jurisdictional mix of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded deferred tax assets for (i) its outside basis difference in its investment in Amneal on May 4, 2018, (ii) the net operating loss of Impax Laboratories, Inc., which was acquired by the Company in 2018, from January 1, 2018 through May 4, 2018, (iii) certain federal and state credits, and (iv) interest carryforwards of Impax that were attributable to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company established a valuation allowance on its DTAs based upon all available objective and verifiable evidence, both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three-year pre-tax losses through March 31, 2024. As a result of the losses through March 31, 2024, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of March 31, 2024 and December 31, 2023, this valuation allowance was $566.0 million and $566.5 million, respectively, and reduced the carrying value of these gross DTAs to zero.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a tax receivable agreement (“TRA”) for which it was generally required to pay the holders of Amneal common units on a one-to-one basis, 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal common units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal common units for shares of Class A common stock of the Company prior to the Reorganization (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Nature of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Annual Report on Form 10-K) and (ii) tax benefits attributable to payments made under the TRA. In conjunction with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million during 2019. As part of the Reorganization, the TRA was amended to reduce the Company’s future obligation to pay 85% of the tax benefits subject to the TRA to 75% of such realized benefits. This agreement will not cause the acceleration of payments under the TRA. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize its DTAs subject to the TRA; therefore, as of March 31, 2024 and December 31, 2023, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more-likely-than-not in the future, at such time, these TRA liabilities (which amounted to approximately $185.0 million at March 31, 2024 and December 31, 2023) will be recorded through charges in the Company’s consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and amount of any payments under the TRA may vary depending on the timing of the Company’s taxable income and the tax rate in effect at the time of realization of the Company’s taxable income. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. Payments could also be in excess of the tax savings that the Company may ultimately realize.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the DTAs were not determined to be realizable as of March 31, 2024 and December 31, 2023, the Company assessed that a TRA liability of $5.7 million and $3.8 million at those dates, respectively, had become probable. For the three months ended March 31, 2024 and 2023, the Company recorded expenses associated with the TRA of $1.9 million and $0.8 million, respectively. In future periods, the Company will continue to evaluate whether any future TRA payments become probable and can be estimated and, if so, an estimate of payment will be accrued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any future recognition of these TRA liabilities will be recorded through charges in the Company’s consolidated statements of operations. However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA in excess of the $5.7 million accrued as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Should the Company determine that a DTA with a </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">valuation allowance is realizable in a subsequent period, the related valuation allowance will be reversed and, if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously monitors government proposals to make changes to tax laws, including proposed legislation in certain foreign jurisdictions resulting from the adoption of the Organization for Economic Cooperation and Development (“OECD”) policies (refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company’s 2023 Annual Report on Form 10-K). The OECD has issued a two-pillar approach to global taxation, focusing on global profit allocation and a global minimum tax rate of at least 15%. Legislation for the “Pillar Two” proposal, applying to the Company, has been enacted in Ireland, and it is effective with the financial year beginning on January 1, 2024. As the tax rates the other jurisdictions in which the Company operates exceed 15%, the Company does not believe there is any potential additional exposure besides in Ireland. </span></div>Since Pillar Two taxes are an alternative minimum tax, deferred taxes will not need to be recorded or remeasured as a result of Pillar Two taxes. Instead, Pillar Two taxes will be expensed as incurred. For interim tax provision purposes, the Pillar Two tax related to Ireland taxes is included in the calculation of the Company’s provision for income taxes. 6200000 -0.082 700000 -0.071 566000000 566500000 0.01 0.85 192800000 0.85 0.75 185000000 185000000 5700000 3800000 -1900000 -800000 5700000 Loss per Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the implementation of the Reorganization on November 7, 2023, all outstanding shares of Old PubCo Class A common stock and Old PubCo Class B common stock were exchanged for an equivalent number of shares of Class A common stock of the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of the Company’s Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share of Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding, adjusted to give effect to potentially dilutive securities. The weighted-average number of shares of Class A common stock for all periods prior to the Reorganization includes shares of Old PubCo Class A common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Amneal Pharmaceuticals, Inc.</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Reorganization, shares of Old PubCo Class B common stock did not share in the losses of the Company and, therefore, were not participating securities. As such, separate presentation of basic and diluted loss per share of Old PubCo Class B common stock under the two-class method was not presented. Effective with the Reorganization, all outstanding shares of Old PubCo Class B common stock were surrendered and canceled.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Old PubCo Class B common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span>Shares of Old PubCo Class B common stock were considered potentially dilutive shares of Old PubCo Class A common stock. Shares of Old PubCo Class B common stock were excluded from the computations of diluted loss per share of Class A common stock for the three months ended March 31, 2023 because the effect of their inclusion would have been anti-dilutive under the if-converted method. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Amneal Pharmaceuticals, Inc.</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -91643000 -6943000 307279000 307279000 152109000 152109000 -0.30 -0.30 -0.05 -0.05 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Old PubCo Class B common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span>Shares of Old PubCo Class B common stock were considered potentially dilutive shares of Old PubCo Class A common stock. Shares of Old PubCo Class B common stock were excluded from the computations of diluted loss per share of Class A common stock for the three months ended March 31, 2023 because the effect of their inclusion would have been anti-dilutive under the if-converted method. 2406000 2632000 10837000 11576000 7827000 7018000 0 152117000 Trade Accounts Receivable, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable, net was comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract charge-backs and sales volume allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash discount allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,906)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,732 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Receivables</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable, net was comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract charge-backs and sales volume allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash discount allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,906)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,732 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1156861000 1199980000 3037000 3022000 457454000 559334000 27415000 23892000 487906000 586248000 668955000 613732000 <div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Receivables</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.32 0.40 0.29 0.24 0.23 0.22 Inventories<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,737 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,744 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,924 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,992 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,077 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,653 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,384 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,737 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,744 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,924 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,992 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,077 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,653 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,384 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 196737000 217744000 57924000 59563000 315992000 304077000 570653000 581384000 Prepaid Expenses and Other Current Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits and advances</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid regulatory fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,298 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,685 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits and advances</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid regulatory fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,298 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,685 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.</span></div> 1935000 2200000 4780000 8334000 4219000 6331000 12198000 13168000 9205000 11899000 12802000 9929000 8575000 7876000 33584000 22948000 87298000 82685000 Goodwill and Other Intangible Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,549 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,629 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, $366.3 million, $162.7 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2023, $366.3 million, $162.8 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Amortization Period<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(739,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,800 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,491)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,309 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,800 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,896)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,904 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319,269 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815,842)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,427 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310,771 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776,193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,578 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675,114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815,842)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,272 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,616 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776,193)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,423 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for the three months ended March 31, 2024 and 2023 was $39.9 million and $41.1 million, respectively.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&amp;D”) intangible assets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,432 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,115 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,263 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,427 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews intangible assets with finite lives for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Indefinite-lived intangible assets, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. Intangible asset impairments were immaterial for the three months ended March 31, 2024 (none for the three months ended March 31, 2023).</span></div><div style="margin-top:7pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, the Company received a complete response letter (“CRL”) from the FDA regarding its new drug application (“NDA”) for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that, although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. During October 2023, the Company met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked the Company to perform a QT study, a routine cardiac safety study that is required for new drugs. On February 7, 2024, the Company provided a complete response resubmission to the FDA for IPX203. IPX203 has a Prescription Drug User Fee Act (PDUFA) decision date of August 7, 2024.</span></div><div style="margin-top:7pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No indicators of impairment of the Company’s IPX203 IPR&amp;D intangible asset were identified during 2024. Additionally, there was no impairment recorded during 2023. While management believes the assumptions used in the Company’s 2023 annual impairment test of its IPX203 IPR&amp;D intangible asset were reasonable and continue to be commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin, delaying the potential launch date, and lowering the probability of technical and regulatory success, could result in material future impairments of the Company’s IPX203 IPR&amp;D intangible asset. Refer to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13. Goodwill and Other Intangible Assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Company’s Annual Report on Form 10-K for additional information.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,549 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,629 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 598629000 598853000 -80000 -224000 598549000 598629000 366300000 162700000 69500000 366300000 162800000 69500000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Amortization Period<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(739,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,800 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,491)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,309 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,800 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,896)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,904 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319,269 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815,842)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,427 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310,771 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776,193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,578 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,845 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675,114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815,842)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,272 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,616 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776,193)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,423 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P6Y2M12D 1207469000 739351000 468118000 1198971000 703297000 495674000 P3Y1M6D 111800000 76491000 35309000 111800000 72896000 38904000 1319269000 815842000 503427000 1310771000 776193000 534578000 355845000 355845000 355845000 355845000 1675114000 815842000 859272000 1666616000 776193000 890423000 39900000 41100000 <div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&amp;D”) intangible assets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,432 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,115 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,263 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,427 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 355800000 119432000 121638000 73115000 52606000 33263000 26484000 76889000 503427000 0 0 Other Assets <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets were comprised of the following (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposits </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revolving credit facility costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,747 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,517 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.2pt">Refer to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Note 15. Fair Value Measurements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 16. Financial Instruments</span> for information about the Company’s interest rate swap. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets were comprised of the following (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposits </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revolving credit facility costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,747 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,517 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.2pt">Refer to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Note 15. Fair Value Measurements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 16. Financial Instruments</span> for information about the Company’s interest rate swap. 52632000 37089000 3616000 3602000 3099000 3273000 4007000 4427000 10393000 7126000 73747000 55517000 Accounts Payable and Accrued Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses were comprised of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Medicaid and commercial rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial chargebacks and rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,518 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,662 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.43pt">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a rollforward of the balance from December 31, 2023 to March 31, 2024.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses were comprised of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Medicaid and commercial rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial chargebacks and rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,518 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,662 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.43pt">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a rollforward of the balance from December 31, 2023 to March 31, 2024.</span></div> 175325000 143572000 137108000 136486000 44806000 71122000 96711000 90690000 19779000 23342000 10226000 10226000 14598000 11005000 59965000 48219000 558518000 534662000 Debt<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the Company’s long-term debt since December 31, 2023, except as disclosed below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16. Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Company’s 2023 Annual Report on Form 10-K for additional information and definitions of terms used in this note. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s indebtedness under its term loans (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due May 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due May 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company (i) borrowed and repaid $20.0 million under the Amended New Revolving Credit Facility and (ii) borrowed and repaid $28.0 million under the Amended Rondo Revolving Credit Facility. As of each of March 31, 2024 and December 31, 2023, $179.0 million was outstanding on the Amended New Revolving Credit Facility.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s indebtedness under its term loans (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due May 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due May 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 191979000 191979000 2336949000 2351647000 2528928000 2543626000 117561000 123497000 2411367000 2420129000 33660000 34125000 2377707000 2386004000 20000000 20000000 28000000 28000000 179000000 179000000 Other Long-Term Liabilities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were comprised of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,466 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,679 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 15. Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were comprised of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,466 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,679 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 15. Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div> 504000 497000 18073000 21283000 433000 433000 5569000 7466000 24579000 29679000 Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 – </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</span></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16. Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on the Company's interest rate swap. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. For the three months ended March 31, 2024, there was no material activity or payments related to the contingent consideration liabilities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels in the fair value hierarchy during the three months ended March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s indebtedness at fair value (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:61.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan Due 2025 and Term Loan Due 2028 are in the Level 2 category within the fair value level hierarchy. The fair values were determined using market data for valuation. The Sellers Notes are in the Level 2 category within the fair value level hierarchy. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Company’s 2023 Annual Report on Form 10-K for detailed information about its indebtedness, including definitions of terms. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no non-recurring fair value measurements during the three months ended March 31, 2024 and 2023.</span></div> The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16. Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on the Company's interest rate swap. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span>The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. For the three months ended March 31, 2024, there was no material activity or payments related to the contingent consideration liabilities. 52632000 0 52632000 0 9668000 0 9668000 0 1021000 0 0 1021000 37089000 0 37089000 0 9100000 0 9100000 0 921000 0 0 921000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s indebtedness at fair value (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:61.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Due 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 192099000 190779000 2339870000 2328130000 41944000 41033000 Financial Instruments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company’s debt obligations consist of variable-rate and fixed-rate debt instruments. The Company’s primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. To achieve this objective, the Company initially entered into an interest rate swap on the Term Loan Due 2025. On November 14, 2023, in connection with the refinancing of the Term Loan Due 2025, the Company novated its swap agreement to another counterparty and, in connection with such novation, amended the interest rate swap agreement. Refer to the section “Interest Rate Derivative - Cash Flow Hedge” below and in </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20. Financial Instruments </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company’s 2023 Annual Report on Form 10-K for additional information and the definition of certain terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivative – Cash Flow Hedge</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inte</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month London interbank offered rate (“LIBOR”) associated with the Term Loan Due 2025 (the “October 2019 Swap”). On May 31, 2023,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company executed an amendment to the October 2019 Swap that, among other things, changed the variable reference rate from LIBOR to the one-month secured overnight financing rate (“SOFR”) (the “Amended October 2019 Swap”). </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2023, in connection with the Company’s refinancing of the Term Loan Due 2025 and the New Credit Facility </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(refer to Note 16. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company’s 2023 Annual Report on Form 10-K </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for definitions and additional information), the Company novated the Amended October 2019 Swap to another counterparty and subsequently amended the interest rate agreement. Specifically, the amendments modified (i) the fixed rate payable by the counterparty from 1.3660% to a new fixed rate of 2.7877% and (ii) extended the termination date through May 4, 2027 (i.e., one year before the Term Loan Due 2028 matures) (the “November 2023 Swap”). The amendments did not change the notional amount of $1.3 billion. The purpose of the November 2023 Swap is to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month SOFR associated with the Term Loan Due 2028. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used a strategy commonly referred to as “blend and extend,” which allows the existing asset position of the swap agreement to be effectively blended into the new interest rate swap agreement. As a result of this transaction, on November 14, 2023, the Amended October 2019 Swap was de-designated and the unrealized gain of $66.7 million was recorded within accumulated other comprehensive (loss) income and will be amortized as a reduction of interest expense, net, over the original term of the of the Amended October 2019 Swap (until May 2025), as the hedged transactions affect earnings. Additionally, the November 2023 Swap had a fair value of $66.7 million at inception and will be ratably recorded to accumulated other comprehensive (loss) income and reclassified to interest expense, net, over the term of the November 2023 Swap, as the hedged transactions affect earnings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended March 31, 2024, the Company reclassified a gain of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.5 million</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from accumulated other comprehensive loss to interest expense, net. Approximately $26.1 million of net gains included in accumulated other comprehensive loss as of March 31, 2024 are expected to be reclassified into earnings within the next 12 months as interest payments are made on the Company’s Term Loan Due 2028 and amortization of the amounts included in accumulated other comprehensive loss occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the total gain, net of income taxes, related to the Company’s cash flow hedge of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.8 million</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was recognized in accumulated other comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable-to-fixed interest rate swap</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1300000000 0.013660 0.027877 1300000000 66700000 66700000 6500000 26100000 42800000 <div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable-to-fixed interest rate swap</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,632 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 52632000 37089000 Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Manufacturing, Collaboration, License, and Distribution Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered with third parties. The Company has also licensed certain technologies or IP from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Alliance and Collaboration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these arrangements are with related parties. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19. Related Party Transactions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, how</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ever, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, charges related to legal matters, net of $94.4 million were associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. (refer to the section </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Prescription Opioid Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). For the three months ended March 31, 2023, credit related to legal matters, net of $0.4 million was comprised of a litigation settlement gain, partially offset by charges for legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for legal matters were comprised of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Opana ER® antitrust litigation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Opana ER® antitrust litigation-accrued interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Civil prescription opioid litigation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of liabilities for legal matters</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Civil prescription opioid litigation (Liabilities for legal matters - long term)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the respective discussions below for additional information about the significant matters in the tables above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our Annual Report on Form 10-K for a general discussion of Medicaid Reimbursement and Price Reporting Matters and Patent Litigation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Litigation Related to the Company’s Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opana ER® Antitrust Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiffs”) of Opana ER® were filed against Endo Pharmaceuticals Inc. and Impax Laboratories, Inc. (“Impax”) and consolidated into multi-district litigation (“MDL”) in the U.S. District Court for the Northern District of Illinois.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impax subsequently entered into settlement agreements with all of the plaintiffs that were subsequently approved by the court. Pursuant to the settlement agreements, the Company agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all of the plaintiffs’ claims. As of December 31, 2023, the liability for the final settlement payment of $50.0 million, plus 3% stated interest thereon, was included in the current portion of liabilities for legal matters and was paid in January 2024 with cash on hand. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">United States Department of Justice Investigations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, Amneal received a CID from the Civil Division requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only” after the reference listed drug’s label was converted to over-the-counter. The Company is cooperating with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Re Generic Pharmaceuticals Pricing Antitrust Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Generic Pharmaceuticals Pricing Antitrust Litigation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 2724, (E.D. Pa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)) (“MDL No. 2724”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original plaintiff states. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the May 10, 2019 and June 10, 2020 lawsuits seek unspecified monetary damages and penalties and equitable relief including disgorgement and restitution, and both were incorporated into MDL No. 2724. The June 10, 2020 lawsuit was selected for bellwether status. The States of Alabama, Hawaii and Arkansas, and the Territory of Guam voluntarily dismissed all of their claims in the two actions against all defendants, including the Company. American Samoa voluntarily dismissed its claims in the May 10, 2019 action and was not named as a plaintiff in the June 10, 2020 action. On February 27, 2023, the Court addressed defendants’ motions to dismiss the June 10, 2020 action, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. On November 1, 2023, the Attorneys </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General filed a Motion to Remand their cases to the State of Connecticut. On January 21, 2024, the Joint Panel on Multidistrict Litigation (“JPML”) granted the motion, and these cases were formally remanded in April 2024. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Connecticut, et al. v. Teva Pharmaceuticals USA, Inc., et al., 3:19-cv-00710-MPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Connecticut, et al. v. Sandoz, Inc. et al., 3:20-cv-00803-MPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fact discovery in MDL No. 2724 is proceeding as to both bellwether and non-bellwether cases, and expert discovery as to bellwether cases is also underway. No trial date has been set. No schedule has yet been issued in the May 10, 2019 and June 10, 2020 actions brought by the State Attorneys General, which have now been remanded to the District of Connecticut.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kathryn Eaton v. Teva Canada Limited, et. al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, the plaintiff filed a second amended complaint. On May 30, 2023, the plaintiff served materials for their motion to certify the action as a class proceeding, define the class and certify the common questions to be decided, among other things. The certification hearing date is scheduled for December 2024, but subject to court approval, the hearing date may be rescheduled on consent to May 2025. The Company is preparing a response to the motion to certify in advance of that date. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Prescription Opioid Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain of its affiliates are named as defendants in over 900 cases filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors, and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act, state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors, and retail pharmacies as defendants, and there have been numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors, and retail pharmacies in which the Company and its affiliates are not named. Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804) (the “Opioid MDL”). The Company is also named in various state court cases pending in seven states. No firm trial dates have been set except in Texas (January 31, 2025, trial-ready date (Dallas County)).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reached a settlement agreement with the New Mexico Attorney General to resolve its claims against the Company, which was finalized on April 24, 2023. A Consent Judgment dismissing the case was entered on May 15, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company reached a settlement agreement to resolve all pending litigation brought by West Virginia political subdivisions, which was signed on May 25, 2023. The two neonatal abstinence syndrome cases in West Virginia state court were dismissed on May 31, 2023 and were subsequently appealed by the plaintiffs. These appeals remain pending. The hospital cases pending in West Virginia state court were dismissed on May 2, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company reached a preliminary settlement with a group of private hospitals in Alabama in June 2023 to resolve the hospitals’ claims against the Company. The Company anticipates a final determination approving the settlement by the end of the second quarter of 2024. On February 7, 2024, the Company was dismissed from the Mobile County Board of Health case. The Company previously reported an August 12, 2024 trial date for that case.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 13, 2023, the Company re</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ceived a subpoena from the New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information. On January 4, 2024, the Company received a CID issued by the Alaska Attorney General seeking information regarding its business concerning opioid-containing products. The Company is evaluating the CID. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In late April 2024, the Company reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. The settlement in principle is subject to the negotiation and execution of a definitive settlement agreement between the parties. The settlement would be payable over ten years. Under the settlement in principle, the Company would agree to pay $92.5 million in cash and provide $180.0 million (valued at $125/ twin pack) in naloxone nasal spray to help treat opioid overdoses. In lieu of receiving product, the settling parties can opt to receive 25% of the naloxone nasal spray’s value (up to $45.0 million) in cash during the last four years of the ten years payment term, which could increase the total amount of cash the Company would agree to pay up to $137.5 million. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2024, the Company concluded the loss related to the opioid litigation was probable, and the related loss was reasonably estimable considering the settlement in principle. As a result, the Company recorded a charge of $94.4 million associated with the settlement in principle during the three months ended March 31, 2024 to increase the liability as of March 31, 2024, to $115.6 million, of which $85.5 million was classified as long-term. While this liability has been deemed reasonable by the Company’s management, it could significantly change as the definitive settlement agreement is finalized. As of December 31, 2023, the Company had a liability of $21.5 million related to its prescription opioid litigation, of which $0.3 million was classified as long-term. For the remaining cases not covered by the settlement in principle, primarily brought by other hospitals, schools and individuals, the Company has not recorded a liability as of March 31, 2024 or December 31, 2023, because it concluded that a loss was not probable and estimable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">United States Department of Justice / Drug Enforcement Administration Subpoenas </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered civil and criminal tolling agreements with the USAO through May 15, 2024. It is not possible to determine the exact outcome of these investigations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, Amneal received a subpoena from an Assistant U.S. Attorney for the Southern District of Florida (the “AUSA”). The subpoena requested information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2019, Amneal received a subpoena from the New York State Department of Financial Services seeking documents and information related to sales of opioid products in the state of New York. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact outcome of this investigation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ranitidine Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">re Zantac/Ranitidine NDMA Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MDL No. 2924), in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers, including the Company, without leave to file further amended complaints, holding all claims were preempted. Plaintiffs appealed the MDL Court’s dismissals to the 11th Circuit Court of Appeals. On November 7, 2022, the 11th Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The 11th Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Plaintiffs filed their merits brief on April 10, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates have also been named as defendants in various state lawsuits in five states in which the Company has filed motions to dismiss or plans to file motions to dismiss in the future. On August 17, 2023, the judge in the consolidated Illinois state court cases granted a motion to dismiss all such cases in which the Company and affiliates had been named, holding all claims preempted. There are no trial dates involving the Company in any of the state court cases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metformin Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amneal and AvKARE, LLC (improperly named as AvKARE, Inc.) were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey, consolidated as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Re Metformin Marketing and Sales Practices Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(No. 2:20-cv-02324-MCA-MAH) (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Metformin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The lawsuits allege economic loss in connection with their purchase or reimbursements due to the alleged contamination of generic metformin products with NDMA. Plaintiffs have voluntarily dismissed their claims seeking medical monitoring or evaluation due to their consummation of allegedly contaminated metformin. The parties are currently engaged in discovery. On October 17, 2023, co-defendant Rite-Aid filed a suggestion of bankruptcy and automatic stay of proceeding. AvKARE, LLC has been dismissed from this action. Three additional similar putative class action lawsuits filed against Amneal and AvKARE, LLC have been consolidated for discovery and pretrial purposes only, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marcia E. Brice v. Amneal Pharmaceuticals, Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 2:20-cv-13728 (D.N.J.), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael Hann v. Amneal </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceuticals of New York, LLC et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 2:23-cv-22902 (D.N.J.), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Metformin:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of Monmouth, et al. v. Apotex Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:23-cv-21001-MAC-MAH (D.N.J.) (“County of Monmouth”).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a Stipulation and Order entered on the docket on May 2, 2024, plaintiffs will file a third amended complaint in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Metformin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which includes the claims and parties in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of Monmouth. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third amended complaint must be filed within three days of entry of the Stipulation and Order. Immediately preceding the filing of the third amended complaint, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of Monmouth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First Amended Complaint will be voluntarily dismissed without prejudice. Defendants may file a motion to dismiss the third amended complaint within thirty days of the filing of the third amended complaint.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of valsartan, losartan, and metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern metformin (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Davis v. Camber Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation transferred the Davis Action into the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multi-district litigation for pretrial proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Xyrem® (Sodium Oxybate) Antitrust Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amneal was named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with the settlement of patent litigation related to Xyrem®. The actions were consolidated in the United States District Court for the Northern District of California for pretrial proceedings (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Xyrem (Sodium Oxybate) Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 5:20-md-02966-LHK (N.D. Cal.)). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amneal was also named as a defendant in a similar action filed by Aetna Inc. (“Aetna”) in California state court </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Aetna Inc. v. Jazz Pharms., Inc. et. al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 22CV010951 (Cal. Super. Ct.). The California state court held that it lacks jurisdiction over several defendants, including Amneal, on December 27, 2022, and later issued an order dismissing Amneal without prejudice. On August 25, 2023, Aetna filed a motion seeking leave to file a second amended complaint adding Amneal as a defendant, which the Court tentatively granted on October 20, 2023. Aetna filed a second amended complaint naming Amneal on November 17, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, Amneal executed a $1.9 million settlement agreement with class plaintiffs in the federal litigation. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class plaintiffs filed a motion for final approval of the settlement on November 10, 2023, and entered an order granting final approval, certifying settlement class, and dismissing class plaintiffs’ against Amneal with prejudice on April 17, 2024. On December 18, 2023, Amneal executed a $4.0 million settlement with Aetna, United Healthcare Services, Inc. (“United”), Humana Inc. (“Humana”), Molina Healthcare Inc. (“Molina”), and Health Care Service Corporation (“HCSC”). Pursuant to that settlement, the federal court dismissed United, Humana, Molina and HCSC’s claims against Amneal, with prejudice, on February 26, 2024, and the California state court dismissed Aetna’s claims against Amneal, with prejudice, on February 29, 2024. Thus, all claims against Amneal in the federal and state court have been voluntarily dismissed with prejudice pursuant to settlements. In December 2023, the Company recorded $3.0 million for the settlement of claims associated with Xyrem® antitrust litigation. As of December 31, 2023, the Company had a liability of $2.0 million associated with this settlement, which was paid in January 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 14, 2023, UFCW Local 1500 Welfare Fund and other health plans filed a purported class action lawsuit in the United States District Court for the Southern District of New York against Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) and other manufacturers of generic versions of Takeda’s Colcrys® (colchicine), including Amneal (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">UFCW Local 1500 Welfare Fund et al. v. Takeda Pharma. U.S.A., Inc. et al, No. 1:23-cv-10030 (S.D.N.Y.). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The plaintiff health plans seek to represent a class of third party payers and alleging that the generic manufacturers conspired with Takeda to restrict output of generic Colcrys® to maintain higher prices, in violation of the antitrust laws. On February 28, 2024, Takeda filed a motion to transfer the case to the United States District Court for the Eastern District of Pennsylvania. On March 13, 2024 and March 27, 2024, Amneal submitted a letter and brief, respectively, informing the Court of its position that the Eastern District of Pennsylvania lacks personal jurisdiction over Amneal. The deadline for defendants to respond to the complaint is 45 days after the date on which the motion to transfer is resolved.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Indian Tax Authority Matters</span></div>Amneal Pharmaceuticals Pvt. Ltd., RAKS Pharmaceuticals Pvt. Ltd., and Puniska Healthcare Pvt. Ltd., which are subsidiaries of the Company, are currently involved in litigations with Indian tax authorities concerning Central Excise Tax, Service Tax, Goods &amp; Services Tax, and Value Added Tax for various periods of time between 2014 and 2017. These subsidiaries have contested certain of these assessments, which are at various stages of the administrative process. The Company strongly believes its Indian subsidiaries have meritorious defenses in the matter. -94400000 400000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for legal matters were comprised of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Opana ER® antitrust litigation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Opana ER® antitrust litigation-accrued interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Civil prescription opioid litigation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of liabilities for legal matters</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Civil prescription opioid litigation (Liabilities for legal matters - long term)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 50000000 0 2347000 30130000 21189000 0 3452000 30130000 76988000 85479000 316000 265000000 50000000 0.03 1 4 0.01 43 9 46 2 900 7 2 P10Y 92500000 180000000 125 0.25 45000000 P4Y P10Y 137500000 -94400000 115600000 85500000 21500000 300000 5 P3D P30D 1900000 4000000 3000000 2000000 P45D Stockholders’ Equity and Redeemable Non-Controlling Interests<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective with the Reorganization on November 7, 2023, the Company holds 100% of the Amneal Common Units. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Reorganization, the Company amended and restated its certificate of incorporation. The voting rights, dividend rights and participation rights of holders of Class A common stock of the Company did not materially change as a result of the amendment. There were no shares of Class B common stock of the Company outstanding as of December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold. Prior to the Reorganization, non-controlling interests were adjusted for capital transactions that impact the non-publicly held economic interests in Amneal.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Reorganization, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”).</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2023, the Company recorded net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax distributions to the Members of $26.8 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acquired a 98% interest in KSP on April 2, 2021. The sellers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KSP</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a related party, hold the remaining interests. The Company attributes 2% of the net income or loss of KSP to non-controlling interests. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Non-Controlling Interests</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&amp;S Northeast LLC, a Kentucky limited liability company (“R&amp;S”), in 2020.  The sellers of AvKARE, LLC and R&amp;S hold the remaining 34.9% interest (“Rondo Class B Units”) in the holding company that directly owns the acquired companies (“Rondo”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. Because the redemption of the Rondo Class B Units is outside of the Company’s control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company attributes 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption probable. For </span><span style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended March 31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, the Company recorded tax distributions of $4.4 million and $3.0 million, respectively, as a reduction of redeemable non-controlling interests, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">flow hedge, net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">comprehensive (loss) income</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,072)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,723 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,349)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cash flow hedge to earnings, net of tax of $0</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,751 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,711)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reallocation of ownership interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,679)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1 0 26800000 0.98 0.02 0.651 0.349 0.349 4400000 3000000 <div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">flow hedge, net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">comprehensive (loss) income</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,072)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,723 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,349)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cash flow hedge to earnings, net of tax of $0</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,751 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,711)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reallocation of ownership interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,679)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -66072000 33723000 -32349000 -390000 15543000 15153000 0 0 0 6515000 6515000 -66462000 42751000 -23711000 -32382000 42321000 9939000 898000 -7135000 -6237000 -195000 257000 62000 -31679000 35443000 3764000 Related Party Transactions <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various business agreements with certain parties in which there is some common ownership. However, the Company does not directly own or manage any of such related parties. Except as disclosed below, as of and for the three months ended March 31, 2024, there were no material changes to our related party agreements or relationships as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24. Related Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 22. Stockholders’ Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the Company’s related party transactions (in thousands): </span></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Party and Nature of Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Caption in Balance Sheet and Statement of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Kashiv Biosciences LLC</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Parking space lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Storage agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Generic development supply agreement - research and development material</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Generic development supply agreement - development activity deferred income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue and net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development and commercialization agreement - Long-acting injectable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Related Parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kanan, LLC - operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sutaria Family Realty, LLC - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tracy Properties LLC - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AzaTech Pharma LLC - supply agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AvPROP, LLC - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Avtar Investments, LLC - consulting services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alkermes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;S Solutions - logistics services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Members - tax receivable agreement (TRA liability)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts due to or from the Company for related party transa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ctions (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kashiv - various agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apace Packaging, LLC - packaging agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alkermes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AzaTech Pharma LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Related party receivables - short term </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kashiv - various agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apace Packaging, LLC - packaging agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AzaTech Pharma LLC - supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avtar Investments LLC - consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers of AvKARE LLC and R&amp;S - accrued interest on Sellers Notes </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members - tax receivable agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rondo Class B unit holders - tax distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alkermes Plc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Related party payables - short term </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,075 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kashiv - contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers of AvKARE LLC and R&amp;S - accrued interest on Sellers Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members - tax receivable agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Related party payables - long term </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,776 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kashiv Biosciences</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Amendment to Biosimilar License Agreement</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company amended the Kashiv Biosimilar Agreement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 24. Related Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the Company’s 2023 Annual Report on Form 10-K) to include two additional in-development products, a pre-filled auto-injector delivery system for peg-filgrastim and a pre-filled on-body injector (OBI) delivery system for peg-filgrastim. Consistent with the existing terms, Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling, and pricing activities of these product candidates. The amendment did not change the contractual terms related to existing commercialized biosimilar products.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The amendment provides an incremental $14.5 million in potential future milestone payments specific to these in-development products, including $7.0 million for clinical and developmental milestones and $7.5 million for regulatory approval and first commercial-sales milestones. In addition, the amendment clarifies that future net sales milestones payments of up to $37.5 million, which did not change, shall be contingent upon reaching certain commercial sales volume objectives for the aggregate of all products under the amended agreement. The agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs. </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No amounts were paid or recognized during the three months ended March 31, 2024 pursuant to this amendment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Long-Acting Injectable License and Supply Agreement</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal is responsible for manufacturing batch products and performing certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, is responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the development supply agreement, Amneal maintained a right of first offer and negotiation to the licensing of each generic product candidate. In March 2024, Amneal and Kashiv entered into a license and supply agreement for the development and commercialization of a long-acting injectable (the “Injectable License and Supply Agreement"). The existing development supply agreement remains effective for the remaining three generic product candidates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms of the Injectable License and Supply Agreement, Amneal is responsible for development, regulatory approval, and commercialization of the product candidate in the U.S., whereas Kashiv is responsible for development and regulatory approval of the product candidate for all other territories outside the U.S. Contingent upon Kashiv obtaining regulatory approval outside the U.S., Amneal shall manufacture the commercial supply for Kashiv at a stated price. The term of the agreement is 10 years from the respective product’s launch date in the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2024, the Company recorded R&amp;D expense for a $0.5 million payment made upon execution of the license and supply agreement. The agreement provides for potential future milestone payments to Kashiv of up to $35.0 million as follows: (i) up to $10.0 million relating to developmental milestones; (ii) up to $20.0 million for U.S. regulatory approval and initial commercial launch milestones; and (iii) up to $5.0 million for the achievement of annual commercial milestones. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 3. Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 24. Related Party Transactions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the Company’s 2023 Annual Report on Form 10-K for information on the Company’s agreements with Kashiv.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the Company’s related party transactions (in thousands): </span></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Party and Nature of Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Caption in Balance Sheet and Statement of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Kashiv Biosciences LLC</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Parking space lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Storage agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Generic development supply agreement - research and development material</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Generic development supply agreement - development activity deferred income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue and net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development and commercialization agreement - Long-acting injectable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Related Parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kanan, LLC - operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sutaria Family Realty, LLC - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tracy Properties LLC - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AzaTech Pharma LLC - supply agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AvPROP, LLC - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Avtar Investments, LLC - consulting services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alkermes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory and cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;S Solutions - logistics services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Members - tax receivable agreement (TRA liability)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts due to or from the Company for related party transa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ctions (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kashiv - various agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apace Packaging, LLC - packaging agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alkermes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AzaTech Pharma LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Related party receivables - short term </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kashiv - various agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apace Packaging, LLC - packaging agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AzaTech Pharma LLC - supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avtar Investments LLC - consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers of AvKARE LLC and R&amp;S - accrued interest on Sellers Notes </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members - tax receivable agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rondo Class B unit holders - tax distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alkermes Plc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Related party payables - short term </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,075 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kashiv - contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers of AvKARE LLC and R&amp;S - accrued interest on Sellers Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members - tax receivable agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Related party payables - long term </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,776 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25000 17000 0 50000 4526000 144000 -77000 -48000 1216000 0 -48000 0 -422000 0 500000 0 592000 566000 314000 305000 5001000 1836000 143000 169000 2312000 575000 44000 47000 69000 188000 12000 2000 0 20000 1948000 826000 1434000 954000 9000 0 0 1000 78000 0 1521000 955000 5773000 3179000 1863000 1091000 1650000 1958000 22000 100000 442000 442000 3532000 549000 3777000 0 16000 2000 17075000 7321000 530000 430000 8691000 8139000 2173000 3207000 11394000 11776000 14500000 7000000 7500000 37500000 0.50 2400000 P10Y 500000 35000000 10000000 20000000 20000000 5000000 0.50 Segment Information<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reportable segments: Generics, Specialty, and AvKARE. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Generics segment includes a retail and institutional portfolio of over 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Specialty</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AvKARE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Operating Decision Makers</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, because they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment because it is not reviewed by the Company’s chief operating decision makers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):</span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AvKARE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,060 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,085 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,407 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property legal development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and other charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges related to legal matters, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,403)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,241 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,347 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,931)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,746)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Generics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">AvKARE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate<br/>and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,940 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,177 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,096 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property legal development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and other charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credit) charges related to legal matters, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,241 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,596)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:29.94pt">Operating results for the sale of Amneal products by AvKARE are included in Generics.</span></div> 3 270 <div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AvKARE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,060 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,085 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,407 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property legal development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and other charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges related to legal matters, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,403)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,241 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,347 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,931)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,746)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Generics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">AvKARE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate<br/>and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,940 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,177 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,096 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property legal development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and other charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credit) charges related to legal matters, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,241 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,596)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:29.94pt">Operating results for the sale of Amneal products by AvKARE are included in Generics.</span></div> 391294000 105234000 162663000 0 659191000 239922000 44800000 136409000 0 421131000 151372000 60434000 26254000 0 238060000 33085000 25196000 14907000 39407000 112595000 34371000 4927000 0 0 39298000 960000 24000 0 0 984000 0 946000 0 524000 1470000 0 -100000 0 0 -100000 -94359000 0 0 0 -94359000 -11403000 29241000 11347000 -39931000 -10746000 343806000 91678000 122056000 0 557540000 230551000 43191000 105612000 0 379354000 113255000 48487000 16444000 0 178186000 27600000 22379000 12940000 39177000 102096000 32359000 6331000 0 0 38690000 1624000 20000 0 0 1644000 99000 0 0 411000 510000 0 -2457000 0 0 -2457000 2444000 0 0 -2008000 436000 1224000 0 0 0 1224000 55241000 17300000 3504000 -41596000 34449000 Subsequent EventOn April 30, 2024, Amneal closed on the sale of a wholly owned subsidiary in India to Kashiv for total consideration of ₹1 billion, or approximately $12 million. Total consideration consisted of a ₹416 million, or approximately $5 million, cash payment at closing and the assumption of a loan payable of approximately ₹600 million, or approximately $7 million, payable to another subsidiary of Amneal in India. The loan payable bears interest of 11% on the unpaid principal and is due on or before December 31, 2024. The Company is permitted to offset royalties or other amounts payable to Kashiv with any overdue principal on the loan payable. The subsidiary’s assets and liabilities were primarily comprised of a building under construction and a note payable, respectively. The subsidiary had no business activity, other than the construction of the building. 1000000000 12000000 416000000 5000000 600000000 7000000 0.11